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Abstract 
Chronic myeloid leukaemia (CML) is a haematological malignancy that is identified 
by the presence of a fusion oncogene, BCR-ABL1, which is a constitutive tyrosine 
kinase. The discovery of tyrosine kinase inhibitors (TKIs) over that past decade 
has resulted in significantly improved survival rates and disease management in 
CML patients. However, a subpopulation of BCR-ABL1+ cells in the niche are 
found which exhibit stem cell-like features, such as self-renewal and quiescence. 
These CML stem cells (LSCs) are shown to be insensitive to TKI treatment and 
are capable of deriving the disease during the relapse. Consequently, the 
elimination of LSCs is a primary goal of current research. Therefore, the aim of this 
thesis was to obtain a global view of the cellular processes that maintain stem cell 
identity in CD34+ CD38- LSCs as well as identify those processes which initiate the 
transition to proliferative CD34+ CD38+ CML progenitor cells (LPCs). A combined 
approach was exploited to investigate genome-wide gene expression profiles and 
histone modification signatures of normal HSCs and committed progenitors 
(HPCs), and their LSC and LPC counterparts. Despite having increased activity in 
pathways involved in cell division and proliferation, expression levels of the 
pathways involved in stem cell identity were not significantly different in LSCs to 
those found in HSCs. These pathways included Wnt, TGF-β   signalling,   and  
several novel neurotransmitter signalling pathways. By examining genome-wide 
histone modification patterns using ChIP-sequencing it was shown that the stem 
cell identities of HSCs and LSCs are programmed at the epigenetic level. All of the 
pathways which confer stem cell identity to both HSCs and LSCs are significantly 
enriched for bivalent gene promoters having both the H3K4me3 and H3K27me3 
marks. These similarities were most evident in neurotransmitter signalling and it 
was demonstrated that these pathways are capable of promoting LSC 
maintenance in vitro. Intriguingly, although the stem cell entry into the proliferative 
state occurs through the repression of many of the same stem cell identity 
pathways in both HSCs and LSCs, it was shown that epigenetic reprogramming in 
CML mediates this repression via a different mechanism than in normal HSCs. 
Furthermore, abnormalities in levels of several chromatin enzymes were identified 
that are likely to be responsible for the epigenetic reprogramming of CML cells. 
The work presented in this thesis defines the chromatin landscape of a cancer 
stem cell for the first time and provides new therapeutic targets for the eradication 
of TKI resistant CML stem cells. 
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1. Introduction 
Haemopoiesis is a complex and hierarchical biological process that is responsible 
for generating one trillion blood cells daily, and therefore, is tightly regulated to 
maintain general homeostasis. However, abnormalities in the regulation of this 
process are responsible for the development of many haematological disorders 
and malignancies, such as leukaemias and lymphomas, which can significantly 
reduce life expectancy. Therefore, a better understanding of normal and malignant 
haemopoiesis from the biological point of view will provide opportunities to find 
new therapeutics that can rescue the normal phenotype and increase the survival 
rates of cancer sufferers. A comprehensive understanding of biology cannot be 
possible without studying the genome which consists of all the genetic material 
contained in a cell of an organism and contains all of the information necessary for 
life. The genome is comprised of three types of features - genes, regulatory 
elements and maintenance elements. Genes are the coding entities for the cellular 
proteome, while the spatial and temporal production of proteins are controlled by 
the regulatory elements, which include promoters, enhancers, insulators, as well 
as non-coding regulatory RNAs. Nevertheless, the epigenome regulates the 
function of the genome in an additional layer mediated by methylation of DNA and 
biochemical modifications of chromatin. DNA repair, replication and recombination 
are controlled by maintenance elements, such as centromeres, telomeres, origins 
of replication and recombination hotspots. After sequencing of the human genome 
was completed in 2004 (IHGS, 2004), the next challenge in the post-genome era 
is to elucidate the role of genomic and epigenomic regulation during normal 
development and disease states. Thus, this Chapter is going to review the knowns 
and unknowns of normal and malignant haemopoiesis and the role of epigenetics 
in these processes. 
1.1 Systems biology approach 
The complexity of eukaryotic systems and the rapid development of new 
technologies over the past decade to study the biology of cells and organisms 
have formed a new research territory, known as systems biology. The systems 
biology approach is, therefore, based on collecting all the information presented at 
the single cell or multicellular levels in order to understand various functions of the 
system and their regulation. In other words, the regulatory mechanisms and 
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biological pathways are so intensively interconnected that make the understanding 
of the whole system impossible without studying all the biological pathways and 
mechanisms involved. The systems biology research has been mainly driven by 
the information collected by genomics, epigenomics, transcriptomics, proteomics 
and metabolomics. Furthermore, sophisticated computational modelling is required 
to integrate the datasets collected by these five components (Alon, 2007). 
The proteome is defined as the library of expressed proteins in an organism or a 
cell type under a defined condition. Thus, the proteomics task is to detect and 
quantify the levels, modifications, cellular localisation, and interactions of all 
expressed proteins. The characterisation of interacting partners of a single protein 
is by far the most challenging task of proteomics since such interactions are 
extremely fragile and transient. However, recent advances in the mass 
spectrometry technology has revolutionised the field of proteomics by allowing the 
analysis of protein-protein interactions as well identification of post-translational 
modifications, such as phosphorylation. The identification of cellular localisation is 
another important aspect of protein characterisation which can be achieved by cell 
imaging or fractionation approaches (Lovric, 2011).  
Proteomics are closely interconnected with the transcriptomics that is the science 
of defining and quantifying all the various transcripts present in a cell, or 
population of cells, including mRNAs, non-coding RNAs (ncRNAs) and small 
RNAs. Transcriptomics allows to better understand the structure of genes and 
their transcripts; for instance their transcriptional start sites (TSSs), splicing 
patterns, 5′   and   3′   ends,   and   post-transcriptional modifications, in addition to 
measuring the expression changes of each transcript under various conditions. 
Nevertheless, the changes in mRNA levels are not always associated with 
changes at the level of proteomics as a result of splicing, post-transcriptional 
regulation and mRNA stability. However, transcriptomics approaches are more 
sensitive in the identification of less abundant transcripts and therefore, more 
sensitive tools for gene expression analysis, than proteomics approaches 
(Latchman, 2005, Lovric, 2011). Transcriptomics approaches are described in 
Table 1.1. As mentioned earlier, the transcriptomics studies are part of the 
systems biology approach which are closely interconnected with genomics and 
epigenomics in the control of gene regulation, which are discussed below.  
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Table   1.1: Various technologies used for gene expression profiling. 
The summary of various transcriptomic technologies developed to date with their advantages and 
disadvantages is listed (Russell et al., 2009, Wang et al., 2009). IVT, in vitro transcription; SAGE, 
serial analysis of gene expression; CAGE, cap analysis of gene expression; MPSS; massively 
parallel signature sequencing; RT-PCR, real-time polymerase chain reaction 
1.2 Transcribed regions of the human genome 
By using comparative genomic and computational approaches after the 
completion of Human Genome Project, ~20,000-25,000 protein-coding genes were 
identified (IHGS, 2004). These protein-coding regions make up to less than 2% of 
the human genome. Nevertheless, it is believed that the majority of the genome is 
transcribed which is far beyond the scope of annotated genes. This phenomenon 
is known as pervasive transcription. This phenomenon was supported by 
hybridisation of the RNA content of various human tissues and cell lines on whole 
chromosome tiling arrays which identified 93% of the genomic bases in the 
transcripts of one cell type or another (Bertone et al., 2004, Cheng et al., 2005, 
Kapranov et al., 2002, Rinn et al., 2003). Therefore, it is suggested that a large 
proportion of the transcriptome contains novel ncRNAs.  
The human transcriptomics analysis was part of the Encyclopaedia of DNA 
Elements (ENCODE) project which intended to identify and characterise the 
functional genomic elements within the human genome sequence (ENCODE, 
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2004). The pilot phase of study, which investigated 1% of the human genome, 
identified pervasive transcription in both gene-rich and gene-poor regions (Birney 
et al., 2007). Furthermore, in the second phase of the project, in which the 
complete human genome was examined across 15 cell lines, 62.1% and 74.7% of 
the human genome were found to be associated with either processed or primary 
transcripts, respectively (Djebali et al., 2012). This study also showed that genes 
have a tendency to express multiple isoforms simultaneously with an average of 
10-12 isoforms per gene per cell type. Furthermore, coding transcripts were found 
to be significantly enriched in the cytoplasm, whereas the ncRNAs were 
predominantly found in the nucleus (Djebali et al., 2012). The expression of 
mRNAs and potentially ncRNAs are regulated by the non-transcribed regulatory 
elements in the genome, which provide sophisticated control for gene regulation. 
1.3 Transcriptional regulatory elements 
1.3.1 Core and proximal promoters 
The core promoter is the region that is situated at the 5′-end of the gene that binds 
to the transcriptional machinery and includes the TSS. Many core promoters are 
characterised by the presence of the TATA box, which is the docking site for the 
TATA box binding protein (TBP) that is a subunit of the pre-initiation complex 
(PIC). The other less common genomic elements within the core promoters are 
the initiator element (Inr), downstream promoter element (DPE), downstream core 
element (DCE), general transcription factor IIB (GTF2B)-recognition element 
(BRE), and motif ten element (MTE), which serve as docking sites for various 
transcription machinery subunits (Gershenzon and Ioshikhes, 2005, Maston et al., 
2006). Moreover, the proximal promoter is the upstream region adjacent to the 
core promoter. There is no universal consensus to distinguish the proximal 
promoters based on their length as they exhibit a huge degree of variation. These 
promoters serve as docking sites for various transcription factors (Maston et al., 
2006). 
The mammalian promoters are classified based on their sequence composition 
into promoters with high CpG dinucleotide frequency, also known as CpG-rich, 
and promoters with low CpG dinucleotide frequency, also known as CpG-poor 
(Carninci et al., 2006). The CpG-rich promoters contain multiple TSSs which are 
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referred  to  as  ‘broad’  promoters.  These  promoters  are  typically  found  at  the  start  of  
ubiquitously expressed and developmentally regulated loci (Carninci et al., 2006, 
Yamashita et al., 2005). On the contrary, the CpG-poor promoters are associated 
with a single TSS which are referred  to  as  ‘sharp’  promoters.  These  promoters  are  
associated with tissue-specific genes. Furthermore, the tissue-specific promoters 
harbour a TATA box, whereas the CpG-rich promoters lack TATA box (Carninci et 
al., 2006). Two subcategories of CpG-rich promoters have been identified: the 
promoters with one short CpG island that encompasses the TSS and the 
promoters with multiple large and gene body-extended CpG islands. The former 
class is associated with the ubiquitously expressed genes, while the latter is linked 
to the developmentally regulated genes (Akalin et al., 2009).  
1.3.2 Enhancers 
The discovery of enhancers was made by the observations that some genomic 
regions of SV40 tumour virus are capable of increasing the transcriptional activity 
of a human gene with a promoter (Banerji et al., 1981). The immunoglobulin heavy 
chain locus was the first human locus for which an enhancer was identified 
(Banerji et al., 1983). Enhancers typically contain transcription factor binding sites 
and therefore, are capable of transcriptional regulation which is independent of 
their orientation and distance with respect to promoter. A single promoter can be 
regulated by multiple enhancers which may operate at different cell types, in 
response to different external cues or at different times in the course of 
development (Maston et al., 2006, Remenyi et al., 2004). The functions of 
enhancers and proximal promoters are very similar, although the former can be 
located several hundred kilobase pairs upstream or downstream of the promoter 
or within the gene body (Blackwood and Kadonaga, 1998). The distally located 
enhancer is believed to be brought into the close proximity of the core promoter by 
forming a loop that is referred to as the DNA-looping model (Vilar and Saiz, 2005). 
1.3.3 Silencers  
Silencers are genomic elements that highly resemble the enhancers which induce 
transcriptional repression in their controlled locus. Silencers are also distally 
located and can function irrespective of their orientation or distance from promoter 
(Ogbourne and Antalis, 1998). Silencers serve as docking sites for a subset of 
transcription factors and cofactors that are referred to as repressors and 
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corepressors, respectively (Privalsky, 2004). Repressors can mediate their 
function in multiple ways; for instance by blocking the assembly of PIC (Chen and 
Widom, 2005), by inhibiting the binding of an activator to an adjacent enhancer 
(Harris et al., 2005) or by competing for the same site (Li et al., 2004).  
1.3.4 Insulators 
Insulators or boundary elements are important in blocking the function of 
neighbouring transcriptional regulatory elements which results in partitioning the 
genome into discreet transcriptional domains. Insulators may exhibit their function 
by blocking the enhancer-promoter interaction or the spread of repressive 
chromatin conformation. The activity of insulators is position-dependent, but 
orientation-independent (Maston et al., 2006, Recillas-Targa et al., 2002). The 
number of insulator elements in the human genome is not established, but the 
most well-studied insulator is the β-globin insulator in the human and chicken 
genomes (Felsenfeld et al., 2004, Li et al., 1999). Insulators serve as docking sites 
for the CCCTC-binding factor (CTCF) (Bell and Felsenfeld, 2000, Bell et al., 1999). 
It is believed that the insulators function as physical barriers between enhancers 
and promoters by forming chromatin loops as a result of interaction with other 
insulator elements in the genome which generates distinct domains of 
transcriptional activity (Maston et al., 2006). 
1.3.5 Locus control regions (LCRs) 
LCRs are responsible for controlling the transcriptional activity of a cluster of 
genes. LCRs consist of multiple genomic elements which include enhancers, 
silencers, insulators, and scaffold/matrix attachment regions (S/MAR). LCRs are 
key players in tissue specific transcriptional regulation which are copy number-
dependent, but position- and distance-independent. LCRs act as binding sites for 
many transcription factors, repressors, coactivators and/or chromatin modifiers. 
Nevertheless, predominantly LCRs are associated with enhancer (Li et al., 2002, 
Maston et al., 2006). It is believed that LCRs also function via long-range looping 
mechanisms that bring them together with the core promoter (Tolhuis et al., 2002). 
The summary of above transcriptional regulatory elements is schematically 
illustrated in Figure 1.1.  
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Figure   1.1: Transcriptional regulatory elements. 
A schematic representation of the transcriptional regulatory elements. The binding of various 
transcriptional activators and repressors to the enhancers, silencers and LCRs regulate the 
assembly of PIC to the core promoter. The proximal promoter which is located adjacent to core 
promoter harbours transcriptional factor binding sites (TFBSs) which also induce PIC assembly 
upon transcription factor binding. The TFBSs can also be found downstream of the TSS.  
1.4 Proteins involved in transcriptional regulation 
As mentioned above, the transcriptional regulatory elements serve as docking 
sites for various trans-acting factors that induce the transcriptional activation or 
repression of the controlled locus. The proteins involved in transcriptional 
regulation can be classified into the following categories: (i) general transcription 
factors (GTFs) which are part of the basic transcriptional machinery and PIC; (ii) 
sequence-specific transcription factors; (iii) coactivators which are not sequence-
specific and mediate the interaction between the sequence-specific transcription 
factors and the basic transcriptional machinery; and (iv) chromatin remodelling 
enzymes (discussed in Section 1.5). 
1.4.1 GTFs 
The GTFs are essential for the initiation of transcription from the core promoters. 
These factors include RNA polymerase II (RNAPII) and the GTF2 (also known as 
TFII) family of accessory proteins TBP, GTF2A, GTF2B, , GTF2E, GTF2F, and 
GF2H. The ordered assembly of these accessory subunits at the core promoters 
results in the formation of PIC which guides RNAPII to the TSS. PIC assembly 
initiates with the binding of TBP to the TATA box and interaction with a subset of 
TBP-associated factors (TAFs) which form a complex that is known as TFIID. 
Subsequently, RNAPII is recruited to the core complex and its carboxyl-terminal 
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domain undergoes phosphorylation that marks transcriptional elongation process. 
During transcriptional elongation, TFIID, GTF2E, GTF2H and a multi-subunit 
complex known as Mediator form a scaffold at the core promoter. In order to 
reinitiate transcription, GTF2F and GTF2B are required to recruit RNAPII to the 
core promoter (Hahn, 2004). The binding of general transcription factors can only 
induce low transcriptional activity or basal transcription, and requires the binding of 
sequence-specific transcription factors to the proximal promoter in order to 
stimulate transcription and also to mediate the recruitment and stabilisation of 
basic transcriptional machinery.  
1.4.2 Sequence-specific transcription factors 
It is estimated that there are ~1,400 genes coding for sequence-specific 
transcription factors (~6% of the protein coding genes) which are expressed in 
either all cell types or specific tissues (Vaquerizas et al., 2009). These sequence-
specific factors are not part of the basic transcription machinery and also lack 
enzymatic activity, but can recruit or stabilise PIC and the subsequent initiation, 
elongation or reinitiation of transcription. Furthermore, these transcription factors 
can be important in recruiting the chromatin modifying machinery, as discussed 
below (de la Serna et al., 2005). The Gene Ontology (GO) analysis of the 
characterised transcription factors revealed that they are mainly associated with 
developmental regulation, cellular processes such as signalling, and response to 
stimulus such as immune response (Vaquerizas et al., 2009). Nevertheless, these 
GO classifications are fairly general and do not elucidate the precise function of 
these transcription factors. The classification can also be based on the structure of 
their DNA-binding domain which leads to the characterisation of unknown 
transcription factors based on their homology with the known transcription factors. 
This method of classification would allow understanding of DNA interaction and 
the binding site sequence of different clusters of transcription factors (Luscombe et 
al., 2000). The majority of sequence-specific transcription factors in human 
genome belong to the C2H2 zinc-finger, homeodomain, and helix-loop-helix 
families (Gray et al., 2004, Vaquerizas et al., 2009).  
The comparison between the promoter sequences that are known to be bound by 
a specific transcription factor has resulted in the identification of consensus 
binding sites, which are referred to as motifs, for some transcription factors. The 
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consensus motifs are typically in the range of 6-12 basepairs (bp) (Wright and 
Funk, 1993). These consensus motifs are used in genome-wide bioinformatics 
approaches to identify all the potential binding sites for the transcription factor of 
interest (Elnitski et al., 2006, Morgan et al., 2007). However, the number of 
consensus motifs that can be identified by this approach is higher than the real 
binding sites for a transcription factor (Rabinovich et al., 2008). This study also 
suggested that despite the presence of motifs for some transcription factors such 
as RE1-silencing transcription factor (REST) and signal transducer and activator of 
transcription 1 (STAT1), the recruitment of some others is independent of a 
consensus motif such as the E2F family (Rabinovich et al., 2008, Robertson et al., 
2007, Valouev et al., 2008). The transcription factors that are not linked to a 
consensus motif are suggested to bind DNA using alternative mechanisms such 
as forming a loop from a distal location to interact with another protein that is 
bound to its consensus motif which could be mediated by coactivators, binding to 
DNA through interactions with the DNA binding domain of another protein which is 
known   as   ‘piggyback’   binding,   binding   to   the close proximity of another factor 
which binds to a consensus motif, or binding to a histone modification which can 
also be facilitated by coactivators, which is discussed in Section 1.5.3 (Farnham, 
2009). Thus, the presence of consensus motifs is not a rule for DNA binding of 
transcription factors, and even the usage of consensus motifs at hypothetical 
binding sites should be verified in in vitro or in vivo assays.  
1.5 The role of chromatin structure and modifications in 
transcriptional regulation 
Human DNA is approximately 2 meters in length which has been packaged in a 
nucleus with only a few microns in diameter. This could only be achieved by the 
formation of a highly condensed and compact structure called chromatin. The 
chromatin structure is, therefore, responsible for providing access to the DNA-
binding proteins such as transcription factors. As a result, all the metabolic 
activities involved in the maintenance of DNA and gene regulation, such as DNA 
replication, transcription, repair, recombination and chromosome maintenance, are 
regulated at the chromatin level. Therefore, the term epigenetics was first defined 
as the changes of gene function that can be heritably transmitted during mitosis 
and/or meiosis which are not associated with changes of DNA sequence (Russo et 
al., 1996, Turner, 1993). The significant technological advancements over the 
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recent years have enabled genome-wide analysis of changes in chromatin 
conformation and signature in different cell types and in the course of development 
and disease formation to better understand their role in gene regulation. 
Therefore, the roles of key chromatin modifiers and modifications are reviewed in 
this section (Figure 1.2).  
 
Figure   1.2: Different layers of chromatin modifications and organisation.  
Different features of chromatin organisation are schematically illustrated. DNA methylation is 
associated with CpG dinucleotides and the histone modifications are biochemically added to the 
histone tails projecting out of the nucleosomes. The nucleosomes can be repositioned by the action 
of ATP-dependent chromatin remodelling complexes which provides accessibility for the binding of 
RNAPII and transcription factors. Bottom: the major histone H3 amino acid residues associated 
with methylation (Me), acetylation (Ac), and phosphorylation (P) marks are represented. The 
residues are also numbered. Some residues such as lysine 4 (K4) and lysine 27 (K27) can be 
associated with more than one type of modifications, but not simultaneously.   
1.5.1 The structure of chromatin and nucleosomes 
Nucleosomes are the primary units of chromatin structure which are composed of 
an octamer core of histone proteins that include H2A, H2B, H3, and H4, around 
which ~147 bp of left-handed DNA are wrapped in 1.65 turns (Luger et al., 1997). 
The core histones are highly conserved and are packed with positively charged 
arginine and lysine residues which enables them to favourably bind the negatively 
charged DNA template. Another histone protein, H1, is also present in the context 
of chromatin which serves as a linker histone that facilitates the compaction of 
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nucleosomes and chromatin structure. Core histones are composed of three major 
domains, which include the histone fold, the histone fold extension, and the 
histone tails. Nucleosomes are formed as a result of heterodimerisation of 
histones H2A/H2B and H3/H4 which is mediated by the hydrophobic interactions 
between the histone fold domains. The octamer core is, therefore, formed from a 
H3-H4 tetramer adjoined by two H2A-H2B dimers. On the other hand, the N-
terminal tails of histones are not associated with a secondary structure and are 
found to be projected out of the nucleosome core and chromatin structure. The 
histone tails are between 16 to 44 amino acids in length and in some cases a C-
terminal tail is also noticeable such as histone H2A (Luger et al., 1997). The 
projection of histone tails makes them accessible to a range of histone modifying 
enzymes that add post-translational modifications to various amino acid residues 
(Allfrey et al., 1964, Jenuwein and Allis, 2001, Kouzarides, 2007).  
The chromatin structure comprises two major functional domains: euchromatin 
and heterochromatin (Henikoff, 2000, Felsenfeld and Groudine, 2003). Previous 
biochemical, cytological, and genetic studies have demonstrated that euchromatin 
is involved in active DNA processes, whereas heterochromatin is associated with 
repression or silencing as a result of blocking DNA accessiblity to transcription 
factors. The properties of heterochromatin are defined as compact and 
inaccessible, gene poor, late replicating, associated with large regions of repetitive 
DNA, and poorly associated with recombination events (Katan-Khaykovich and 
Struhl, 2005). The heterochromatic regions are mainly found at centromere, 
pericentromeric regions, and telomere (Karpen and Allshire, 1997). 
Heterochromatin formation is implied in various biological phenomena such as X 
chromosome inactivation in mammals (Lee and Jaenisch, 1997). 
The chromatin accessibility can be studied by two major techniques: DNase I 
treatment and formaldehyde-assisted isolation of regulatory elements (FAIRE). It 
has been shown that the less compact euchromatin and the genomic regions that 
were subjected to nucleosomal remodelling and displacement can be digested by 
small amounts of DNase I (Stalder et al., 1980). DNase I-treated chromatin can be 
analysed by hybridisation to tiling microarrays (DNase-chip) or high throughput 
DNA sequencing (DNase-seq) which will identify genome-wide DNase I 
hypersensitive sites (Crawford et al., 2006b, Crawford et al., 2006a, Boyle et al., 
2008). On the contrary, the FAIRE approach requires formaldehyde crosslinking of 
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the cells followed by sonication and phenol/chloroform extraction that would 
release the protein-unbound DNA fragments which can be further analysed by 
sequencing or microarray analysis (Giresi et al., 2007). Both of these methods are 
demonstrated to be efficient in identifying the open chromatin regions.  
1.5.1.1 DNase I hypersensitive sites  
DNase I hypersensitive sites are associated with transcriptional regulatory 
elements such as promoters, enhancers, silencers, insulators, and LCRs 
(Felsenfeld and Groudine, 2003, Gross and Garrard, 1988, Keene et al., 1981, 
McGhee et al., 1981). The pilot phase of ENOCDE project also revealed that 
TSSs, TFBSs, histone modification sites, and regions of early replication are 
associated with these hypersensitive sites (Birney et al., 2007). The above results 
indicate that the transcriptional regulatory elements are depleted from nucleosoms 
which therefore, can be used as markers for identifying such elements. The 
incorporation of the genome-wide analysis of hypersensitive sites and the histone 
modification signatures of the flanking nucleosomes could further elucidate the 
function of the identified regulatory elements. The completion of second phase of 
ENCODE project, which investigated the entire human genome, has identified 
approximately 2.89 million DNase I hypersensitive sites across 125 human cell 
and tissue types using DNase I-seq approach. The majority of these 
hypersensitive sites (95%) are located in intergenic or intronic locations and only 
3% were found at the annotated TSSs (Thurman et al., 2012). The results also 
indicated that 95% of the bases in the human genome are in 8 kb proximity of 
DNase I hypersensitive sites, which was also shown to contain 99% of the known 
transcription factor binding motifs, as opposed to 1.2% of bases in the genome 
that are found within the protein-coding exons (Dunham et al., 2012). This data 
suggested that more genomic information is required for gene regulation than for 
biochemical activities. 
1.5.2 Chromatin remodelling complexes 
The access of transcription factors and basic transcription machinery to the 
regulatory elements requires conformational changes in chromatin structure, which 
can be achieved by physical repositioning, exclusion or inclusion of nucleosomes. 
This is achieved by the function of ATP-dependent chromatin remodelling 
complexes (Almer et al., 1986, Narlikar et al., 2001).  
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Five classes of remodelers have been identified which have differences in their 
mechanism of action and composition, which include the SWI/SNF complex, the 
ISWI complex, Mi-2/NURD complex, the INO80 complex and the SWR1 complex 
(Laurent, 2006). The SWI/SNF complex was first identified in yeast which was 
shown to be associated with gene activation (Winston and Carlson, 1992). This 
complex was also demonstrated to be important in human chromatin remodelling 
as well as being involved in transcriptional elongation, DNA repair and 
chromosome stability (Chai et al., 2005, Martens and Winston, 2003). These 
remodelers are capable of repositioning DNA around the nucleosome which in turn 
provides accessibility for transcription factors to bind DNA, as verified by the 
changes in the pattern of DNase I hypersensitivity (Cote et al., 1994, Kwon et al., 
1994). The ISWI complex is composed of NURF (nucleosome remodelling factor), 
CHRAC (chromatin accessibility complex), and ACF (ATP-dependent chromatin 
assembly and remodelling factor) (Ito et al., 1997, Tsukiyama and Wu, 1995). 
ISWI family is involved predominantly in chromatin assembly as well as 
transcriptional elongation (Corona and Tamkun, 2004). Similar to SWI/SNF 
complex, the pattern of DNase I hypersensitivity can be altered by the function of 
ISWI complex which is indicative of chromatin accessibility; however, an increase 
in the frequency of transcription factor binding could not be established (Langst et 
al., 1999). Both SWI/SNF and ISWI complexes function by sliding nucleosomes 
along DNA instead of complete dissociation/reassociation of nucleosomes (Langst 
et al., 1999, Whitehouse et al., 1999). 
1.5.3  DNA methylation 
The methylation of DNA at cytosine C5 residues was first reported in vertebrates 
(Holliday and Pugh, 1975, Riggs, 1975), which brought the focus of research to 
understand the role of DNA methylation in biological processes and the 
mechanisms of maintenance and regulation of these marks. The mammalian DNA 
methylation has been mainly studied in the context of 5-methylcytosines (5mC) 
which are predominantly found within CpG sequences, although recent studies 
have confirmed the presence of non-CpG methylation with an unknown function 
(Lister et al., 2009).  
CpG sequences are not evenly distributed in mammalian genomes. There are ~1 
kb CpG-rich domains, also known as the CpG islands, which are associated with 
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more than half of the genes in the genome, while the rest of the genome is not 
associated with CpGs, also known as the CpG-poor regions. The role of DNA 
methylation in transcriptional regulation has been extensively investigated and it is 
believed that their position relative to transcriptional regulatory elements is key in 
determining their role in gene regulation (Jones, 2012). Except its essential role in 
transcriptional regulation, DNA methylation is also involved in genomic stability, 
the suppression of transposons, and DNA repair (Karpf and Matsui, 2005, Walsh 
et al., 1998, Walsh and Xu, 2006).  
The analysis of DNA methylation at TSSs, which has been the primary focus of 
DNA methylation studies, showed that the methylated CpG islands suppress 
transcriptional initiation and therefore, DNA methylation can be regarded as a 
silencing epigenetic mechanism at the promoters (Hashimshony et al., 2003, Kass 
et al., 1997, Venolia and Gartler, 1983). With respect to the structure of promoters 
that was described earlier, most of the promoters associated with CpG islands are 
unmethylated in somatic cells and it was suggested that the transcriptional 
repression at these promoters are mediated by the Polycomb complex (Section 
1.5.4.8) (Illingworth and Bird, 2009, Taberlay et al., 2011). Less than 10% of these 
promoters can become DNA methylated to confer a stable silenced state to the 
repressed genes such as imprinted and germline loci (Illingworth and Bird, 2009). 
However, tissue-specific changes of DNA methylation have been observed at the 
DNA  sequences  surrounding   these  CpG   islands,  also  known  as   ‘shores’   (Irizarry 
et al., 2009). On the other hand, the CpG-poor promoters which are associated 
with tissue-specific genes are found to be methylated in the tissues and cell types 
that do not require their expression (Han et al., 2011). 
Despite the extensive investigation of DNA methylation patterns at the TSSs, they 
can also be found at the gene bodies, which are predominantly CpG-poor. The 
DNA methylation patterns over gene bodies is known to be associated with active 
transcription (Hellman and Chess, 2007, Wolf et al., 1984). Therefore, promoter 
DNA methylation is inversely correlated with transcriptional activity, while the 
methylation over gene bodies is positively correlated with gene expression (Jones, 
1999). Thus, as mentioned earlier, the position of DNA methylation with respect to 
the transcriptional regulatory elements is the key factor in determining the outcome 
of gene regulation.   
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DNA methylation is added and maintained by DNA methyltransferases (DNMTs), 
which include DNMT1, DNMT3A, and DNMT3B. The initial DNA methylation 
pattern during development is established by the de novo activity of DNMT3A and 
DNMT3B. DNMT1, on the other hand, favours hemi-methylated DNA which is an 
outcome of DNA replication and repair and therefore, is suggested to be involved 
in the maintenance of DNA methylation. However, it is now believed that the 
function of DNMT3A and DNMT3B is also crucial for the maintenance of DNA 
methyalation (Jones and Liang, 2009). The function of all three DNMTs is 
essential for embryonic development (Okano et al., 1999, Li et al., 1992) and the 
function of somatic cells (Jackson-Grusby et al., 2001); however, the absence of 
DNMTs in ES cells does not affect their self-renewal capacities (Tsumura et al., 
2006). It is now understood that the mechanism of de novo methylation requires 
the presence of two molecules each of DNMT3-like protein (DMNT3L), DNMT3A 
and a nucleosome (Ooi et al., 2007). This study explained the reason behind why 
DNA methylation is not the initial silencing mechanism and normally confers a 
more stable silencing to a repressed promoter. Active TSSs are not occupied by a 
nucleosome, as described earlier, and therefore, cannot be targeted for de novo 
methylation. This observation was also supported by a recent study on the 
mechanism of DNA methylation at NANOG promoter in the course of embryonic 
differentiation (You et al., 2011).  
The removal of DNA methylation from CpG dinucleotides is mediated by active or 
passive mechanisms. Active DNA demethylation is often associated with DNA 
base excision repair mechanisms to remove the 5mC residue. Demethylation 
enzymes are found in three major classes: ten-eleven translocation (TET) 
methylcytosine dioxygenase, activation-induced cytidine deaminase (AID), and 
thymine DNA glycosylase (TDG) (Cortellino et al., 2011, He et al., 2011, Popp et 
al., 2010). DNA demethylation by TET1 enzyme involves the formation of 
intermediate oxidation substrates, including 5-hydroxymethylcytosine (5hmC), 5-
formylcytosince (5-fC), and 5 carboxylcytosine (5-caC). The importance of these 
demethylation derivatives in biological processes is largely unknown, except 5hmC 
which is shown to be associated with both transcriptional activating and silencing 
mechanisms. 5hmC is found at the promoters of transcriptionally poised genes, 
enhancers, and insulators (Wu and Zhang, 2011).  
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Several methods have been developed for the analysis of DNA methylation such 
as sodium bisulphite sequencing, methylated DNA immunoprecipitation (MeDIP), 
MBD-affinity column (MAC), and methylated CpG island recovery assay (MIRA). 
However, bisulphite sequencing and MeDIP are the two most frequently used 
methods. Sodium bisulphite treatment deaminates cytosine to uracil, unless the 
cytosine residue is methylated (Clark et al., 1994, Frommer et al., 1992). The 
combination of bisuphite treatment and deep sequencing has enabled genome-
wide analysis of DNA methylations at single base resolution (Lister et al., 2009). 
MeDIP method, on the other hand, is an immunoprecipitation (IP) based method 
that uses an antibody which specifically identifies 5mC residues on the sonicated 
DNA fragments (Weber et al., 2005). MeDIP-purified DNA fragments can be 
subsequently coupled to microarray hybridisation (MeDIP-chip) or deep 
sequencing (MeDIP-seq), although single base resolution cannot be achieved.   
1.5.4 Histone modifications 
The histone tails are the main target of histone modifying enzymes which 
covalently add biochemical groups to the amino acid residues. 130 amino acid 
residues in the core histones are found to be associated with a histone 
modification (Tan et al., 2011). There are 14 known histone modifications, 10 of 
which have been further investigated to elucidate their biological function (Table 
1.2) (Dawson and Kouzarides, 2012). Chromatin immunoprecipitation (ChIP) is the 
major method for the analysis of histone modification patterns that uses an 
antibody which specifically identifies the histone modification of interest. The ChIP-
purified DNA fragments can then be subjected to microarray hybridisation (ChIP-
chip) or deep sequencing (ChIP-seq), which are discussed in more details in 
Chapters 4 and 5. In this section, the biological role of 5 histone modifications in 
gene regulation will be discussed, which include acetylation, methylation, 
phosphorylation, ubiquitylation, and sumoylation.  
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Table   1.2: Histone modifications and their biological function. 
14 different types of histone modifications are listed with their attributed biological functions 
(Dawson and Kouzarides, 2012, Tan et al., 2011). Me1, monomethylation; me2: dimethylation; 
me3, trimethylation; me2s, symmetrical dimethylation; me2a, asymmetrical dimethylation; Cit, 
citrulline. 
Histone modifications can affect gene regulation via two major mechanisms: (i) 
through affecting the nucleosome-DNA and the nucleosome-nucleosome 
interactions as a result of altering histone charges or their physical entity that may 
cause spatial hindrance, and/or (ii) serve as docking sites for histone binding 
proteins   or   the   ‘readers’   that   orchestrate   various   biological   outcomes.  
Nevertheless, transcriptional regulation is not the only biological implication of 
histone modifications, but also a variety of DNA-associated mechanisms such as 
replication, repair and condensation can also be regulated by these epigenetic 
marks (Kouzarides, 2007). Histone modifications are dynamic epigenetic marks 
which can represent different patterns in different cell types or in response to 
various stimuli and external conditions which therefore, provide a complex picture 
for their regulation and function. Histone modifications can be interpreted in a 
combinatorial manner  in which the presence of different histone modifications is 
required for implementing a biological outcome such as transcriptional regulation. 
Furthermore, some histone modifications can affect the deposition and removal of 
other modifications or induce the activity of chromatin remodelling complexes. This 
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phenomenon   is   known   as   “histone   crosstalk”,   also   referred   to   as   the   “histone  
code”,  which  has  a  significant  biological   implication  on  gene  regulation  and  other  
biological processes (Jenuwein and Allis, 2001, Lee et al., 2010).   
1.5.4.1 Sumoylation 
Small ubiquitin-related modifier (SUMO) protein can covalently attach to the lysine 
residues of histone tails. It has been reported that the binding of SUMO will result 
in the recruitment of histone deacetylases (HDACs) as well as heterochromain 
protein 1 (HP1) which in turn results in the removal of acetylation and 
ubiquitylation marks that are associated with transcriptional activation (described 
below). Thus, sumoylation confers a repressed chromatin state and transcriptional 
suppression (Nathan et al., 2006, Shiio and Eisenman, 2003).  
1.5.4.2 Ubiquitylation  
Similar to sumoylation, ubiquitylation is also involved in the covalent attachment of 
ubiquitin protein to the lysine residues of histones. Monoubiquitylation results in 
changes of protein function, whereas polyubiquitylation targets the protein for 
degradation. Histones H2A, H2B, H3 and H1 are found to be monoubiquitylated 
(Goldknopf et al., 1975, West and Bonner, 1980). H2A ubiquitylation is well-
characterised in the context of transcriptional regulation. Polycomb repressive 
complex 1 (PRC1) is responsible for mediating the ubiquitylation of H2A in 
response to the methylation of H3 lysine 27 (H3K27), which is a repressive mark 
(discussed below), to stably silence gene expression (Cao et al., 2005, Wang et 
al., 2004). On the other hand, the ubiquitylation of H2B is shown to be associated 
with gene activation (Minsky et al., 2008, Nickel et al., 1989). H2B ubiquitylation is 
associated with both TSSs and gene bodies and therefore, its role in 
transcriptional elongation is more profound than transcriptional initiation. The 
ubiquitylation of H2B is believed to be important in the recruitment of H3K4 and 
H3K79 methylases, which are associated with active transcription (discussed 
below) (Dover et al., 2002, McGinty et al., 2008). Thus, dependent on the position 
of ubiquitylated residues, this histone modification can be associated with both 
transcriptional activation and repression.  
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1.5.4.3 Phosphorylation 
The phosphorylation of histones is catalysed by protein kinases which add a 
phosphate group (PO4) to a serine, threonine, or tyrosine. The removal of 
phosphorylation is mediated by protein phosphatases. One of the well-
characterised histone phosphorylations occurs at the histone H3 serine 10 
(H3S10) residue which is linked to transcriptional activation (Nowak and Corces, 
2000), whereas the removal of this mark by protein phosphatase 2A (PP2A) is 
associated with transcriptional repression (Nowak and Corces, 2004). The kinase 
signal transduction is therefore, not only important in post-translationally modifying 
the cytoplasmic proteins, but can also affect histone proteins, which indicates an 
important role for the signalling pathways that function via kinase activation 
cascades in regulating chromatin structure at the promoters and subsequently 
activating gene expression. The serine and threonine phosphorylations are bound 
by 14-3-3 family of proteins (Macdonald et al., 2005).  
1.5.4.4 Acetylation 
Histone acetylation is mediated by the addition of an acetyl group from acetyl 
coenzyme A (Acetyl-CoA) to the lysine residues of histone tails. This modification 
is catalysed by histone acetyltransferases (HATs) and can be removed by the 
function of HDACs. Lysine acetylation has been detected on the tails of all core 
histones. Histone acetylation is positively correlated with gene expression and 
recent genome-wide screenings have identified histone acetylation enrichments at 
the promoters and enhancers of transcribed genes (Heintzman et al., 2007, Wang 
et al., 2008).  
One of the mechanisms through which histone acetylation can induce 
transcriptional activation is mediated by the changes of chromatin structure. The 
deposition of acetyl group on histone tails results in the neutralisation of histone 
charge that in turn weakens the interaction between histone and DNA template. As 
a result, the chromatin structure becomes less condensed and provides 
accessibility for the transcription factors and transcriptional machinery (Workman 
and Kingston, 1998). Additionally, histone acetylation can act as docking sites for 
transcriptional regulators that contain a bromodomain or tandem plant 
homeodomain (PHD) fingers, which include transcriptional coactivators, HATs, 
histone methylatransferases (HMTs), and chromatin remodelers (Chung and 
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Witherington, 2011, Taverna et al., 2007). The association of various histone 
modifiers with histone acetylation is indicative of their role in histone crosstalk 
which can be used as an additional mechanism of transcriptional regulation. two 
examples of this crosstalk are reported between phosphorylated H3S10 which 
recruits lysine acetyltransferase 2A (KAT2A/GCN5) in order to acetylate the 
H3K14 residue (Cheung et al., 2000, Lo et al., 2000), and between H3K14 
acetylation and H3K4 trimethylation (H3K4me3), which is also an activating 
histone mark (discussed below) (Nakanishi et al., 2008).  
HATs are classified based on their structure, which include GCN5-related 
acetyltransferases (GNATs), MYST, and E1A binding protein p300 (EP300)/CREB 
binding protein (CBP) (Sterner and Berger, 2000). EP300 and CBP are also two 
well-characterised transcription factors that are associated with the regulation of 
apoptosis and G1 arrest, induction of cell cycle inhibitors cyclin-dependent kinase 
inhibitor 1A (CDKN1A/p21) and CDKN1B/p27, and controlling differentiation 
(Kawasaki et al., 1998, Yuan et al., 1999). EP300 and CBP are linked to the 
acetylation of several histone residues, which include H2BK12, H2BK15, H3K14, 
H3K18, H3K56, H4K5, and H4K8 (Schiltz et al., 1999). The Cbp+/- mice were 
deficient in haemopoietic lineage differentiation, which indicated the essential role 
of CBP is haemopoietic development (Kung et al., 2000). It can be, therefore, 
proposed that abnormalities in the deposition of histone acetylation marks impair 
transcriptional activation of the genes that are required for lineage development 
and differentiation as was observed in haemopoietic development. 
1.5.4.5 Methylation 
Histone methylation is the result of covalently adding a methyl group from S-
adenosylmethionine (SAM) substrates to the nitrogen atoms on the side chains of 
lysine and arginine residues. Lysine residues can be mono- (me1), di- (me2) or 
trimethylated (me3), whereas ariginine residues can only be mono- or 
dimethylated (Kouzarides, 2007). Histone lysine methylations can be associated 
with both transcriptional activation, such as H3K4, H3K36 and H3K79 
methylations, and repression, such as H3K9, H3K27 and H4K20 methylations, in a 
context-dependent manner. Similarly, arginine monomethylation can be 
associated with both transcriptional activation and repression, whereas symmetric 
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arginine dimethylation is linked to repression and asymmetric arginine 
dimethylation is associated with activation (Di Lorenzo and Bedford, 2011).    
The enzymes that catalyse histone methylations are referred to as HMTs which 
are classified into three categories: (i) SET domain-containing HMTs which 
specifically methylate lysine residues K4, K9, K27 and K36 of histone H3 as well 
as K20 of histone H4; (ii) HMTs that do not contain a SET domain which are linked 
to the methylation of H3K79 residue; (iii) arginine methylating HMTs which target 
R2, R17 and R26 residues of histone H3 as well as the R3 residue of histone H4 
(Fyodorov and Kadonaga, 2001, Marmorstein, 2001). The histone methylations 
can be removed by the function of histone demethylases. Lysine demethylase 1A 
(KDM1A/LSD1) was the first identified lysine demethylase which can demethylate 
H3K4 and H3K9 (Shi et al., 2004). Other lysine demethylases are classified into 
two categories of Jumonji AT rich interactive domain 1 (JARID1) and Jumonji C-
domain containing proteins (JMD2) families. The latter group consists of KDM4A 
and KDM4C, which demethylate H3K9 and H3K36; KDM4B and KDM4D, which 
demethylate H3K9; KDM2A, which demethylates H3K36; KDM2B, which 
demethylates H3K4 and H3K36; KDM6A/UTX and KDM6B, which demethylate 
H3K27 (Tsukada et al., 2006, Whetstine et al., 2006, Agger et al., 2007). The 
JARID1 family is composed of KDM5A, KDM5B, KDM5C and KDM5D, which are 
specific H3K4 demethylases (Christensen et al., 2007, Iwase et al., 2007). On the 
other hand, the demethylation of arginine residues is facilitated by histone 
deimination (Table 1.2), which is mediated by PADI4 deiminase (Cuthbert et al., 
2004).  
H3K36 methylation – H3K36me2/me3 are predominantly linked to active 
transcription and the levels of H3K36me3 marks are positively correlated with 
gene expression levels. The pattern of H3K36 methylation enrichment is found to 
be progressively moving from monomethylation at the promoter to trimethylation at 
the 3′-end of the gene with noticeable H3K36me3 enrichments over the expressed 
exons (Bannister et al., 2005, Kolasinska-Zwierz et al., 2009). H3K36me3 is 
demonstrated to be significantly associated with transcriptional elongation and the 
observations in yeast and human demonstrated an association between the 
H3K36 methylase, Set2, and elongating RNAPII (Kizer et al., 2005).  
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H3K79 methylation – H3K79me2/me3 are also enriched over the gene bodies of 
transcribed genes. H3K79 methylation distribution pattern over the active gene 
bodies shows significant enrichments at the 5′-end of the gene which is 
progressively reduced towards the 3′-end, as opposed to the H3K36me3 
methylation pattern. H3K79 methylation is catalysed by DOT1L HMT (Barski et al., 
2007, Steger et al., 2008). 
H3K9 methylation – H3K9me3 marks have been linked to the formation of 
heterochromatin regions and therefore gene silencing (Richards and Elgin, 2002). 
This methylation is deposited by suppressor of variegation 3-9 homolog 1 
(SUV39H1) and SUV39H2 enzymes (Tschiersch et al., 1994). The formation of 
heterochromatin is thought to be mediated by the binding of HP1 protein to 
H3K9me2/me3 marks. In addition to the formation of heterochromatin domains, 
the H3K9me3 enrichments at the gene level can be interpreted in a context-
dependent manner in which the promoter enrichments are associated with 
transcriptional repression, whereas the gene body enrichments are linked to 
transcriptional activities (Vakoc et al., 2005). Furthermore, H3K9me1 marks are 
found at the promoters of active genes (Barski et al., 2007).    
H3K4 methylation – The early studies of histone methylation distributions 
identified H3K4me3 marks at the promoter regions and TSSs of transcribed genes 
(Barski et al., 2007, Kim et al., 2005, Santos-Rosa et al., 2002). Moreover, 
H3K4me2 marks were mainly identified within the active gene bodies (Barski et al., 
2007, Bernstein et al., 2002), and H3K4me1 marks were detected on active 
enhancers and active gene bodies (Barski et al., 2007, Heintzman et al., 2009). 
However, a more stringent analysis of H3K4me3 distribution at the genome-wide 
level indicated that this mark is associated with CpG-rich promoters regardless of 
their transcriptional activity (Guenther et al., 2007, Mikkelsen et al., 2007). 
H3K4me3 sites were also marked with histone acetylation and DNase I 
hypersensitive sites, which are involved in chromatin accessibility and 
transcriptional regulatory elements (Ernst and Kellis, 2010, Wang et al., 2008). 
Furthermore, H3K4me2/me3 sites were found to be inversely correlated with DNA 
methylation at the promoters (Meissner et al., 2008, Ooi et al., 2007).  
Although the precise role of H3K4 methylation marks in transcriptional activation is 
not fully established, it has been proposed that GTFs, such as TAF3, which 
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contain a PHD domain can recognise H3K4 methylation at the promoters that in 
turn serve as a docking site for the assembly of PIC (Vermeulen et al., 2007). This 
has been further supported by the observation of RNAPII binding at the H3K4me3-
asscoiated promoters (Guenther et al., 2007). Therefore, the H3K4me3-marked 
CpG-rich promoters are positively correlated with transcriptional initiation, but not 
necessarily with transcriptional elongation. Recent studies have demonstrated that 
the RNAPII at some H3K4me3-promoters are kept at a paused state which are 
released in response to activation signals that in turn results in transcriptional 
elongation (Hargreaves et al., 2009, Rahl et al., 2010). Thus, the H3K4me3-
marked promoters can be classified as actively transcribed, which are associated 
with elongating RNAPII, or primed to be activated, which are associated with a 
stalled RNAPII at their TSSs (Zhou et al., 2011). H3K4me2 enrichments, on the 
other hand, have been found at the CpG-poor promoters of haemopoietic lineage-
specific genes (Orford et al., 2008). These lineage-specific genes are repressed in 
HSCs and early progenitor cells, but can become activated in the course of 
differentiation which is associated with a switch from H3K4me2 to H3K4me3 at 
their promoters. Thus, H3K4me2 marks are suggested to be important in marking 
the CpG-poor tissue-specific promoters that can be induced in terminally 
differentiated cell types. 
H3K4 methyltransferases – H3K4 methylation marks are deposited by the 
Trithorax group (TrxG) proteins. The TrxG complex responsible for H3K4 
methylation in mammals is known as the complex proteins associated with Set1 
(COMPASS)-like complex. Six non-redundant and essential COMPASS-related 
H3K4 methylases have been identified in mammals, which include SETD1A, 
SETD1B, mixed-lineage leukaemia (MLL), MLL2, MLL3, and MLL4 (Shilatifard, 
2008). SETD1A and SETD1B proteins are associated with the majority of H3K4 
methylation activity in the genome and therefore, they have an important role in 
global gene activation (Wu et al., 2008). In addition to the role of H3K4me3 in 
recruiting GTFs and inducing transcriptional initiation, the COMPASS-like complex 
can affect transcriptional regulation by recruiting other histone modifying enzymes 
that deposit the activating histone marks or remove the repressive modifications. 
For instance, MLL/MLL2 can recruit a HAT, lysine acetyltransferase 8 (KAT8), 
which acetylates H4K16 and induces open chromatin conformation (Dou et al., 
2005). Moreover, MLL3/MLL4 can recruit KDM6A/UTX H3K27 demethylase to 
counteract with the repressive H3K27 methylation marks and induce 
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transcriptional activation (Agger et al., 2007). The above examples are therefore 
indicative of a histone crosstalk as an additional mechanisms of transcriptional 
activation by H3K4me3 marks (Figure 1.3). 
The recruitment of TrxG complexes to chromatin in mammals is mediated by the 
CXXC domain of MLL family proteins or the CXXC1 subunit, which is associated 
with SETD1A and SETD1B HMTs (Thomson et al., 2010). The CXXC DNA binding 
domain identifies the unmethylated CpG dinucleotides which explains the 
association between H3K4me3 marks and the CpG-rich promoters.  
TrxG proteins and ES cells – Several members of TrxG complex have been 
implicated in the maintenance of embryonic stem (ES) cells and during embryonic 
development, although it has been a challenging task to fully elucidate the role of 
six H3K4 methyltransferases in ES cells due to their partial redundancies. 
Nevertheless, the role of MLL has been widely investigated in embryonic and adult 
stem cells. MLL-knockout mice are embryonic lethal and are associated with 
reduced numbers of haemopoietic stem cells (HSCs) in their foetal livers (Gan et 
al., 2010, McMahon et al., 2007). Furthermore, MLL is essential for the self-
renewal of haemopoiesis (Ernst et al., 2004) and its abnormal expression as a 
result of chromosomal translocations is associated with increased HSC self-
renewal which in turn results in the formation of leukaemia (Krivtsov et al., 2006). 
A core component of the COMPASS-like complex, WDR5, has also been reported 
to have an essential role in ES cell self-renewal (Ang et al., 2011). WDR5 interacts 
with POU5F1/OCT4 in ES cells and targets the promoters of self-renewal genes. 
Thus, TrxG proteins have an essential role in stem cell maintenance through H3K4 
methylation activities and/or engaging in a crosstalk with other histone 
modifications such as acetylation and H3K27 methylation, which is discussed 
below.     
H3K27 methylation – H3K27me2/me3 marks are linked to transcriptional 
repression (Lee et al., 2006, Boyer et al., 2006). H3K27me3 marks are found at 
the promoters of repressed genes and are absent from the active promoters and 
transcribed gene bodies. On the contrary, H3K27me1 marks are found over the 
body of active genes with higher enrichments towards the 5′-end (Barski et al., 
2007).  
Chapter 1  40 
H3K27 methyltransferases – H3K27 methylations are deposited by the activity of 
Polycomb group (PcG) proteins that were first characterised in Drosophila as 
transcriptional factors involved in the suppression of Hox genes (Struhl, 1981). 
The PcG proteins are classified into two complexes known as PRC1 and PRC2. 
The H3K27 methylation is mediated by PRC2 complex, while PRC1 is important in 
the maintenance of repression in the target genes, which are mainly the 
developmentally regulated loci and transcription factors (Boyer et al., 2006, 
Bracken et al., 2006, Lee et al., 2006). The catalytic SET domain-containing 
subunits of PRC2 complex are enhancer of zeste homolog 1 (EZH1) and EZH2 
which are activated through interactions with suppressor of zeste 12 homolog 
(SUZ12) and embryonic ectoderm development (EED) proteins (Cao and Zhang, 
2004, Pasini et al., 2004). EZH1 and EZH2 subunits are not found in the same 
PRC2 complex. The PRC2-EZH1 complex is mainly expressed in adult stem cells 
and non-dividing cells, whereas the PRC2-EZH2 complex is predominantly 
expressed in proliferative cells and in the course of embryogenesis (Margueron et 
al., 2008, Shen et al., 2008). Furthermore, the PRC2-EZH1 complex possesses 
less H3K27 methyltransferase activity than the PRC2-EZH2 complex and can 
mediate transcriptional repression mainly by compacting the nucleosomes and 
altering chromatin conformation (Margueron et al., 2008). The PRC2 complex also 
contains other subunits which are involved in PRC2 stimulation, such as the 
Polycomb-like proteins (PCLs) (Nekrasov et al., 2007, Sarma et al., 2008), and 
histone binding, such as retinoblastoma binding protein 4 (RBBP4) and RBBP7 
(Song et al., 2008).  
The mechanism of PcG targeting in mammals is not fully understood; however, 
previous studies in Drosophila have reported the presence of Polycomb response 
elements (PREs) and recruiters that recognise PREs and subsequently recruit 
PcG complexes (Ringrose and Paro, 2007). PREs have not been identified in 
mammalian genomes, although several candidate recruiters have been proposed, 
such as yin and yang 1 (YY1) (Caretti et al., 2004) and POU5F1/OCT4 in 
embryonic stem cells (Endoh et al., 2008). Further investigation of the PRC1 and 
PRC2 binding sites identified 97% of the PcG targets to be located within the CpG-
rich sequences (Ku et al., 2008), which are mainly associated with 
developmentally regulated promoters (Section 1.3.1). The identification of an 
EZH2 interacting partner, JARID2, and its association with CpG-rich domains 
suggested a potential role for JARID2 in the recruitment of PRC2 complex to the 
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CpG-rich promoters (Li et al., 2010). This hypothesis was further strengthened by 
the observation of significant overlap between the genome-wide binding regions of 
JARID2 and PRC2 complex (Pasini et al., 2010). 
PRC2 roles in transcriptional repression – In addition to the methyltransferase 
activity, the PRC2 complex can also recruit a H3K4 demethylase, KDM5A (Pasini 
et al., 2008). This would in turn combine H3K4 demethylation with H3K27 
methylation to confer a more repressed chromatin state. Additionally, the PRC2 
complex is capable of recruiting DNMTs which can confer a more stable silencing 
to certain targets (Vire et al., 2006). HDAC enzymes have also been purified with 
PRC complexes that facilitate the removal of acetylation marks (Sparmann and 
van Lohuizen, 2006). Overall, the above observations demonstrate different 
mechanisms that the H3K27 methylation and PcG complexes exploit to confer 
transcriptional repression (Figure 1.3). 
PRC1 roles in gene silencing – The PRC1 complex in mammals is associated with 
a significant diversity in terms of its composition and function. However, two core 
proteins have been identified in all human PRC1 complexes, which include BMI1 
and ring finger protein 2 (RNF2). These core proteins are associated with histone 
H2A monoubiquitylation which is believed to be the major mechanism of 
suppression conferred by the PRC1 complex (Cao et al., 2005, Wang et al., 2004). 
This H2A monoubiquitylating complex comprised of other subunits, which include 
ring finger protein 1 (RING1), BCL6 corepressor (BCOR), Polycomb group ring 
finger 1 (PCGF1), and KDM2B (Gearhart et al., 2006, Sanchez et al., 2007). The 
PRC1-bound and H2A monoubiquitylated loci are associated with a paused 
RNAPII over the gene bodies, which indicate a block on transcriptional elongation. 
However, upon RING1 and RNF2 knockdown in ES cells, the H2A 
monoubiquitylation sites were depleted and the stalled RNAPII molecules resumed 
transcription (Stock et al., 2007).  
The H3K27me3 marks provide docking sites for the PRC1 complex (Fischle et al., 
2003, Min et al., 2003). Studies in Drosophila have suggested a PRC1-dependent 
mechanism for the maintenance and expansion of H3K27me3 marks which in turn 
results in transcriptional repression. In this model, the PRC1 interactions between 
both H3K27me3 marks and the PRE-bound PRC2 complex form a loop that brings 
the gene body and the promoter of the repressed gene to a close proximity which 
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in turn induces chromatin compaction (Schwartz and Pirrotta, 2007). The 
association of PRC1 and H3K27me3 marks in mammalian cells have also been 
demonstrated in vivo (Lee et al., 2007b, Mujtaba et al., 2008). These studies, 
therefore, indicate a mechanism of H3K27me3 repression via recruitment of PRC1 
complex in vivo. Nevertheless, the PRC1 recruitment to chromatin is not 
dependent on PRC2 or H3K27 methylation (Schoeftner et al., 2006) and not all 
H3K27me3 domains recruit the PRC1 complex (Ku et al., 2008). Thus, the PRC1 
interaction with H3K27me3 marks in maintaining a stable repression is target-
dependent. 
PcG proteins and ES cells – The role of PRC2 in the maintenance of ES cells is 
proposed in two different models. PRC2 complex can be required for the 
maintenance of pluripotency through suppressing developmentally regulated 
genes (Boyer et al., 2006), or it can promote differentiation by suppressing the 
pluripotency genes (Chamberlain et al., 2008, Pasini et al., 2007, Shen et al., 
2008). There have been more evidence favouring the second model by 
demonstrating that the knockdown of PRC2 subunits does not affect the 
pluripotent state (Chamberlain et al., 2008, Pasini et al., 2007), whereas the 
knockdown of SUZ12 or JARID2 is linked to inefficient repression of pluripotency 
genes, NANOG and POU5F1/OCT4 (Landeira et al., 2010, Pasini et al., 2007). 
The Eed-/- and Ezh2-/- mouse ES (mES) cells displayed impaired mesoendodermal 
differentiation, while Suz12-/- mES cells could not establish an endodermal layer 
upon differentiation (Pasini et al., 2007, Shen et al., 2008). Therefore, it is 
plausible that the PRC2 complex is required for lineage commitment and terminal 
differentiation. Furthermore, the knockdown of RNF2 and RING1 in ES cells was 
reported to impair ES cell maintenance and differentiation (Endoh et al., 2008). 
This data indicates that PRC1 also has an essential role in the maintenance of 
pluripotency and lineage commitment which can be independent of PRC2 function. 
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Figure   1.3: The composition of PcG and TrxG complexes and the mechanisms of 
transcriptional regulation by these complexes.  
(A) The subunits of TrxG COMPASS and COMPASS-like and the PcG PRC2 complexes. The 
SET-domain containing catalytic subunits are illustrated in red. The common subunits between the 
COMPASS-like complexes are illustrated in blue. The mechanisms of gene regulation at the 
promoters by the PRC2 and TrxG complexes mediated via direct and indirect changes of chromatin 
modifications are illustrated. These mechanisms are not mutually exclusive. (B) Direct H3K27 
methylation by EZH2, and direct H3K4 methylation by  MLL; (C) the indirect regulation of histone 
acetylation by recruiting HDACs and HATs; (D) the indirect removal of H3K4 and H3K27 
methylations by recruiting KDMs; (E) direct recruitment of DNMTs by PRC2 to DNA methylate 
certain targets, whereas TrxG targets and DNA methylation are antagonising.       
Chapter 1  44 
1.5.4.6 The bivalent chromatin state 
The genome-wide analyses of histone modifications in ES cells have identified 
H3K27me3-enriched gene promoters that are also associated with H3K4me3 
marks and are, therefore, called bivalent domains (Azuara et al., 2006, Bernstein 
et al., 2006). The genes that have bivalent promoters in ES cells are associated 
with the developmentally regulated loci which are kept repressed in the pluripotent 
cells, but their fates are determined in the course of development. This can be 
achieved by resolving into a monovalent structure in the course of differentiation in 
which the resolution to H3K4me3 mark results in transcriptional activation and the 
resolution to H3K27me3 mark results in a more stable repression. Therefore, the 
chromatin conformation of bivalent promoters keeps them poised for fate 
determination at the later stages of differentiation (Bernstein et al., 2006, 
Mikkelsen et al., 2007). Intriguingly, the bivalent promoters are CpG-rich which can 
be explained by the preferential recruitment of TrxG and PRC2 complexes to the 
CpG-rich sequences, as discussed above (Mikkelsen et al., 2007, Pan et al., 2007, 
Zhao et al., 2007b). Bivalent promoters are found to be associated with RNAPII 
despite being transcriptionally inactive or expressed at very low levels which is 
indicative of transcriptional initiation block (Guenther et al., 2007, Stock et al., 
2007). The expression of bivalent promoters is, therefore, under a balanced 
regulation mediated by both TrxG and PRC2 complexes, although the exact 
mechanisms of fate determination at these loci are not fully understood.  
The analysis of chromatin conformation changes during in vitro neural 
differentiation from ES cells demonstrated a significant association between neural 
gene promoters and bivalent domains in ES cells. However, in neural progenitor 
cells the bivalent promoters of neural genes lost their H3K27me3 marks, but 
maintained their H3K4me3 marks which resulted in their transcriptional activation 
(Mikkelsen et al., 2007). This was proposed to be linked to KDM6B-mediated 
H3K27me3 demethylation at the bivalent loci, downregulation of EZH2 and 
changes of PRC2 targets in neural progenitor cells (Burgold et al., 2008, Lee et al., 
2007a, Mohn et al., 2008). Furthermore, two accessory subunits of COMPASS-like 
complexes, RBBP5 and DPY30, were shown to be required for the bivalency 
resolution in the course of ES cell differentiation, whose knockdown abolished 
neural differentiation as a result of significant H3K4me3 reduction at the bivalent 
loci (Jiang et al., 2011). Therefore, in addition to the important role of PRC2 
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complex, TrxG complex also have an essential role in bivalency resolution via their 
core subunits during differentiation. 
The different mechanisms of epigenetic regulation of transcription at the promoters 
that have been reviewed are schematically illustrated in Figure 1.4. 
 
Figure   1.4: The epigenetic regulation CpG-rich and CpG-poor promoters. 
A large subset of the CpG-rich promoters are ubiquitously expressed that are in open chromatin 
conformation at all times, which is defined by the presence of H3K4me3 marks and RNAPII at the 
TSS. Poised CpG-rich promoters are characterised by bivalent chromatin. RNAPII can be found 
paused at these promoters with basal transcriptional activity. Silenced CpG-rich promoters are 
marked with repressive H3K27me3 marks and are inaccessible to transcriptional machinery. The 
CpG-poor promoters can be activated in a cell type-specific manner and are marked with 
H3K4me3, whereas their poised promoters are inactive and marked with H3K4me2. The inactive 
CpG-poor promoters are marked with DNA methylation in the absence of histone marks.  
1.6 Normal haemopoiesis 
The systems biology approach can be applied to better elucidate the functional 
network of complex biological processes such as haemopoiesis. Haemopoiesis, 
the process of blood formation, is a hierarchical process that includes a defined 
origin, which is the HSC, and multiple intermediate levels of lineage potency. This 
process is precisely programmed to generate terminally differentiated lineage cells 
when needed. Thus, understanding of the molecular mechanisms that underlie the 
loss of pluripotency and subsequent lineage commitment and differentiation has 
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been the goal of ongoing studies in the field of haemopoiesis. The incorporation of 
genome-wide transcriptomics, proteomics and, recently, epigenomics have 
identified a series of key biological pathways and developmental regulators in 
haemopoiesis which are discussed below. 
1.6.1 The haemopoietic hierarchy  
The adult human bone marrow (BM) is capable of producing approximately 1012 
cells daily and is therefore, one of the most regenerative tissues found in the 
human body. It has long been established that BM haemopoiesis is initiated from a 
common precursor, known as HSC, which gives rise to a hierarchy of various cell 
types. The existence of multipotent HSCs was initially reported by clonal in vivo 
repopulation assays (Becker et al., 1963, Till and Mc, 1961). HSCs are 
characterised by their long-term self-renewal capacities, but can also undergo 
differentiating cell divisions which give rise to the hierarchy of blood lineages. By 
this process a series of progenitor cells are formed in the intermediate stages 
before committing fate decisions in becoming mature blood cells. The 
haemopoietic hierarchy is comprised of two major branches: lymphoid and 
myeloid. The former is composed of T, B, natural killer (NK) and dendritic cells that 
possess adaptive and innate immune functions. Granulocytes (neutrophils, 
basophils, eosinophils, and mast cells), monocytes, megakaryocytes and 
erythrocytes are the short-lived terminally differentiated cells of the myeloid 
lineage. The earliest commitment decisions are made downstream of multipotent 
progenitors (MPPs), which only possess limited repopulation capacities (Adolfsson 
et al., 2001, Morrison et al., 1997). The commitment of MPPs results in the 
formation of common myeloid progenitors (CMPs) that initiate the myeloid branch 
and multilymphoid progenitors (MLPs) which initiate the lymphoid branch. MLPs 
have recently been defined as progenitors that can differentiate to all lymphoid 
lineages but may or may not exhibit other myeloid potentials (Doulatov et al., 
2010), as opposed to the previously assigned common lymphoid progenitors 
(CLPs). CMPs then give rise to granulocyte/monocyte progenitors (GMPs), which 
in turn differentiate to granulocytes and monocytes and megakaryocyte/erythroid 
progenitors (MEPs), which give rise to erythrocytes and megakaryocytes that 
produce platelets. In the lymphoid branch, MLPs give rise to early thymic 
progenitors (ETPs) and B- and NK-cell precursors. This model is known as the 
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classical model of haemopoiesis (Figure 1.5) (Akashi et al., 2000, Kondo et al., 
1997).    
 
Figure   1.5: The lineage determination model in the adult human haemopoietic hierarchy.  
The major subsets of haemopoietic cells in the adult human hierarchy are schematically illustrated. 
HSCs are the common precursors of haemopoiesis which are capable of self-renewal as well as 
giving rise to intermediate progenitors which drive the terminally differentiated mature blood cells, 
as listed on the right. HSCs, MPPs, and MLPs are characterised as lineage- (Lin-) CD34+ CD38- in 
addition to the other listed cell-specific surface markers (Doulatov et al., 2010, Doulatov et al., 
2012). CMPs, GMPs, MEPs, pre-B and pre-T cells are characterised as Lin- CD34+ CD38+ in 
addition to other listed cell-specific markers. The terminally differentiated cells are defined as Lin+ 
subsets. B/NK, B- and NK-cells precursor.  
1.6.2 The origin of HSCs 
In order to better understand the hierarchical model of haemopoiesis, it is essential 
to elucidate the origin of adult HSCs. During embryonic development, 
haemangioblasts act as the common precursors of blood and endothelium 
development (Choi et al., 1998). These cells are located within the mesodermal 
region of yolk sac, which is the first site of haemopoiesis in embryo (Huber et al., 
2004). Intriguingly, although the haemopoiesis hierarchy in embryo is different 
from the adult mechanism, they are both originated from an FLK1+ mesodermal 
population, which indicates common developmental mechanisms (Lugus et al., 
2009). Upon transferring the haemopoiesis site to the aortic-gonado-
mesonephrons (AGM) region in early embryogenesis, the haemogenic 
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endothelium cells, which express vascular endothelial (VE)-cadherin, become the 
new cellular origin of haemopoiesis (Boisset et al., 2010, de Bruijn et al., 2002). 
The haemogenic endothelial cells migrate to the foetal liver and subsequently to 
the BM where they repopulate and exhibit self-renewal and multilineage 
differentiation capacities (Zovein et al., 2008). This AGM origin of adult HSCs is 
confirmed by cell-fate tracing experiments in a murine model (Ivanovs et al., 
2011). However, a recent report demonstrated both mesenchymal and endothelial 
origins for HSCs (Rybtsov et al., 2011). These observations, therefore, 
hypothesise two models of origin for HSCs. The first model suggests that 
mesenchymal cells migrate through the endothelial layer of AGM in order to form 
haemopoietic clusters, whereas the second model proposes that mesenchymal 
cells undergo an intermediate endothelial phase before developing HSCs (Lancrin 
et al., 2009). Thus, the embryonic origin of adult HSCs is the underlying reason for 
their multipotential capacities which can give rise to different haemopoietic 
lineages upon receiving external cues.     
1.6.3 Characterisation and isolation of HSCs 
The current knowledge of haemopoiesis is largely drawn from functional 
repopulation assays performed in mice due to the obvious limitations of analysing 
human HSCs. Nevertheless, the development of in vitro clonal assays, 
xenotransplantation methods and precise sorting strategies have significantly 
improved the understanding of human haemopoiesis (Doulatov et al., 2012). 
1.6.3.1 Characterisation of HSCs 
The initial studies in understanding haemopoiesis were directed towards the 
generation of colony-forming progenitors in vitro by colony-forming unit in culture 
(CFU-C) assays, in which stromal feeder layers were used to promote the 
formation of CFU-C colonies from BM cells (Sutherland et al., 1989). The 
precursor of CFU-Cs was identified as long-term culture-initiating cells (LTC-ICs). 
By using cytokine-producing stroma, the LTC-IC assays could promote 
multilineage differentiation over longer periods (Sutherland et al., 1991). Although 
LTC-ICs were multipotent precursors, they exhibited differences repopulation 
potential in comparison with HSCs.  
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The requirement for a more robust in vivo model to study haemopoiesis resulted in 
the development of immune-deficient mice that could be used for human 
haemopoietic cell engraftment assays. Severe combined immune-deficient (Scid) 
mice were the first humanised mouse models that were immune-compromised due 
to the absence of B and T cells (Bosma et al., 1983, Fulop and Phillips, 1990). The 
sublethally irradiated Scid mice were transplanted with human BM in the presence 
of interleukin (IL)-3, granulocyte-monocyte colony-stimulating factor (GM-CSF) 
and stem cell factor (SCF) (Kamel-Reid and Dick, 1988, Lapidot et al., 1992). The 
generation of myeloid progenitors and the production of B cells revealed 
successful long-term and multipotent engraftment of HSCs. This technique was 
the first quantitative in vivo assay that could prove that human HSC had been 
isolated and measure their activity. Further advancements in the success rate of 
engraftment assays were achieved by developing nonobese diabetic (NOD)-scid 
mice that were defective in their innate immunity (Shultz et al., 1995). In recent 
years, a new generation of in vivo models have been introduced which are 
mutated in their  IL-2 receptor (IL-2R) gene that in turn results in complete loss of 
adaptive and innate immunity  and, consequently, a 5-fold increase in CD34+ cell 
engraftment (Ito et al., 2002, Shultz et al., 2005). Overall, the development of 
robust in vivo models has improved the characterisation of human HSCs in the 
recent years. 
1.6.3.2 Isolation of murine HSCs 
Murine HSCs were initially characterised as a lineage-negative (Lin-), Sca-1+, c-
Kit+ (LSK) population (Ikuta and Weissman, 1992, Spangrude et al., 1988). The 
CD34- subset of this population is associated with long-term self-renewal and 
multilineage development (Osawa et al., 1996). One in three CD34- LSK cells is 
identified as a Long-term HSC (LT-HSC) which is characterised by the expression 
of CD150+ CD48- signalling lymphocytic activation molecule (SLAM) phenotype 
(Kiel et al., 2005). 
1.6.3.3 Isolation of human HSCs 
The isolation and purification of human HSCs is another obstacle in the path of 
their characterisation. In human BM only 1 in 106 cells is a transplantable HSC, 
which is surrounded by a pool of differentiated cells (Wang et al., 1997). LT-HSCs 
are defined as the cells that are capable of repopulation beyond 12 weeks in the 
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mouse model, whereas short-term HSCs (ST-HSCs) and MPPs are defined as the 
populations that can give rise to all lineages but possess transient engraftment 
capacities (Doulatov et al., 2012).  
CD34 was identified as a key marker of human HSCs and progenitors, which is 
expressed in less than 5% of all blood cells (Civin et al., 1984, Vogel et al., 2000). 
Human HSCs do not express CD150, unlike their murine counterparts, but 
express the Fms-like tyrosine kinase-3 (FLT3) receptor which is absent in mouse 
(Larochelle et al., 2011, Sitnicka et al., 2003); thus, suggesting a fundamental 
difference between the haemopoietic markers in humans and mice. Since the 
CD34 antigen was also found on the surface of proliferating cells,  more primitive 
HSCs were further characterised as CD34+CD38-CD90+CD45RA- (Bhatia et al., 
1997, Lansdorp et al., 1990, Murray et al., 1995). The loss of CD90 expression in 
HSCs was shown to be associated with cells involved in short-term engraftment or 
MPPs (Majeti et al., 2007), although they were still capable of serial 
transplantation and thus, were not fully resolved from HSCs. The cell-anchoring 
integrin molecules have recently been used as additional markers to distinguish 
true HSCs from their less primitive progeny. The CD49f integrin marker is found on 
50% of the CD90+ and 25% of the CD90- cells. Moreover, the CD49f+ cells in both 
subsets were demonstrated as the population with long-term stem cell function, 
while the CD49f- cells represented transiently repopulating MPPs (Notta et al., 
2011).  
1.6.4 The intra- and extracellular regulators of HSCs self-renewal 
and quiescence 
An HSC can undergo symmetrical or asymmetrical cell divisions with potentially 
three outcomes: two stem cells (self-renewal), a stem cell and a differentiated cell 
(homeostasis), or two differentiated cells (stem cell depletion). Such cell fate 
decisions are generally driven by gene expression changes which are regulated by 
transcription factors in response to external signals; however, the fate of early 
divisions in stem cells may be determined simply by the asymmetric distribution of 
fate determinants in the absence of transcriptional changes (Neumuller and 
Knoblich, 2009).  
By using bromodeoxyuridine (BrdU) labelling in mice, it was estimated that LT-
HSCs divide once every 30-50 days and are therefore, very quiescent (Cheshier et 
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al., 1999, Kiel et al., 2007). Nevertheless, even more quiescent HSCs have been 
identified in mice that only divide approximately five times in their lifetime (Foudi et 
al., 2009). These quiescent cells were identified by tracking cell divisions for long 
periods using green fluorescence protein (GFP)-tagged histone H2B as a 
chromatin marker, which revealed that the highest repopulation capacity resides 
with the cells that did not divide for over 200 days. Nevertheless, the highly 
quiescent cells, which constitute ~15% of the LT-HSC population, are believed to 
supply haemopoiesis in the case of injury, but are not thought to be involved in the 
daily production of blood lineages (Wilson et al., 2008). The presence of such 
dormant HSC populations in human BM could not be verified directly due to 
limitations in the application of label-retaining-cell methods, but flow cytometry 
analysis has demonstrated that the bulk of human HSCs reside in G0 (Doulatov et 
al., 2012). The evaluation of mean telomere length or X chromosome inactivation 
ratios in mature blood cells has been used to estimate the cell division rate of 
human HSCs as once in every 175-350 days (Catlin et al., 2011, Shepherd et al., 
2004). These observations in humans and mice have revealed less frequent HSC 
divisions in human BM, whereas the total number of cell divisions throughout the 
lifespan of both organisms appears to be similar. Therefore, HSCs reduce the risk 
of accumulating DNA damage as a result of oxidative and replicative stress by 
infrequent cycling (Doulatov et al., 2012). Therefore, in this section the role of 
various intrinsic and extrinsic factors in the maintenance of self-renewal and 
quiescence of HSCs will be reviewed.  
1.6.4.1 Cyclin-dependent kinase inhibitors  
The most intrinsic regulators of quiescence are the cyclin dependent kinase 
inhibitors (CDKIs) which act as checkpoints that monitor the passage of cells 
through different stages of the cell cycle. The two major subgroups of CDKIs are 
known as the Cip/Kip and the Ink4 families. The former consists of CDKN1A/p21, 
CDKN1B/p27, and CDKN1C/p57 proteins, whereas the latter comprises 
CDKN2A/p16, CDKN2B/p15, CDKN2C/p18 and CDKN2D/p19. The subfamilies 
are distinguished as a result of specific preferences for certain cyclin-dependent 
kinases (CDKs) they suppress. Cip/Kip family specifically target CDK2, whereas 
CDK4 and CDK6 are inhibited by the Ink4 family (Harper et al., 1995, Sherr and 
Roberts, 1995). Although the CDKIs are regulated at the post-transcriptional level, 
CDKN1A/p21 and CDKN1B/p27 are also under transcriptional regulation (Bloom 
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et al., 2003, Gartel and Tyner, 1999, Pagano et al., 1995). Elevated levels of 
CDKN1A/p21 are specifically associated with primitive, quiescent HSCs and 
deletion of CDKN1A/p21 in murine BM results in the proliferation of HSCs (Cheng 
et al., 2000). Similarly, the knockdown of CDKN1A/p21 in CD34+ and CD34+ 
CD38- cord blood cells resulted in their release from the quiescent state and 
subsequent expansion, both in vitro and in vivo (Stier et al., 2003). Similar 
outcomes are observed with the knockdown of CDKN1B/p27 (Dao et al., 1998). 
Moreover, two recent studies provided evidence for the involvement of 
CDKN1C/p57 in the maintenance of HSCs and their quiescence as the knockout 
mice showed reduced number of HSCs with impaired repopulation capacities upon 
transplantation, as well as a reduction in the G0 population. The CDKN1A/p21 and 
CDKN1C/p57 double-knockout mice displayed more severely affected 
haemopoiesis than the CDKN1C/p57 knockout alone. The abnormalities in 
CDKN1C/p57 knockout mice could be corrected by the overexpression of 
CDKN1B/p27; thus, proposing functional similarities between CDKN1A/p21, 
CDKN1B/p27 and CDKN1C/p57 and the importance of the Cip/Kip CDKIs in the 
maintenance of HSCs self-renewal and quiescence (Matsumoto et al., 2011, Zou 
et al., 2011).   
1.6.4.2 Cytokine growth factors 
The intracellular activities of CDKIs and other transcriptional regulators are 
controlled by cell surface molecules responsible for transferring external signals. 
Cytokines, such as erythropoietin (EPO), granulocyte colony-stimulating factor (G-
CSF), and GM-CSF were the very first group of external signals that were 
identified to stimulate the colony-formation potentials of haemopoietic cells 
(Bernstein et al., 1991, Haylock et al., 1992, Ozer et al., 2000). Nevertheless, 
cytokines displayed a pleiotropic effect on HSCs, largely in favour of differentiation 
rather than self-renewal and even in the presence of IL-11, SCF, and FLT3 ligand 
cocktail only a small expansion of murine HSCs was achievable (Attar and 
Scadden, 2004, Miller and Eaves, 1997). 
Repopulating murine HSCs express the receptors for SCF and thrombopoietin 
(TPO), c-Mpl and c-Kit, respectively (Ikuta and Weissman, 1992, Kimura et al., 
1998). Mice with genetic abnormalities in TPO and c-Mpl showed a significant 
decrease in their HSC numbers (Solar et al., 1998, Kimura et al., 1998). 
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Furthermore, TPO increased the survival of HSCs through reduction of apoptosis 
(Pestina et al., 2001). Overall, TPO and SCF are believed to be the most important 
of the classic haemopoietic cytokines in the regulation of stem cell features in 
HSCs.  
1.6.4.3 Notch signalling pathway 
Notch signalling is crucial in the fate determination of HSCs and in lymphopoiesis 
where it promotes the development of T cells (Radtke et al., 1999). Notch is 
cleaved upon binding to its extracellular ligands, Delta and Jagged, and its 
intracellular domain translocates to the nucleus where it functions as a 
transcription factor (Figure 1.6A) (Pajcini et al., 2011). Primitive HSCs and the 
surrounding niche cells express both Notch and Jagged (Karanu et al., 2000, 
Milner et al., 1994). The presence of Delta and Jagged resulted in the increased 
expansion of HSCs in vitro (Karanu et al., 2000, Karanu et al., 2001).  One of the 
Notch targets, hairy and enhancer of split 1 (HES1), was found to be expressed in 
the CD34+ CD38- population (Shojaei et al., 2005) and its overexpression was 
associated with increased repopulation capacities of HSCs. An extracellular ligand 
of Notch, nephroblastoma overexpressed gene (NOV), was shown to increase the 
expression of HES1, which in turn enhanced the stem cell activities of HSCs 
(Sakamoto et al., 2002).  
Osteoblasts are reported to increase the expression of Jagged in response to 
activation of parathyroid hormone (PTH) receptor and subsequently induce the 
self-renewal capacities of HSCs as measured by the LTC-IC and repopulation 
assays (Calvi et al., 2003). Thus, indicating an important role for the Jagged/Notch 
signalling pathway in the regulation of HSC self-renewal. However, the normal 
repopulation of Notch1-/- HSCs into a Jagged1-/- microenvironment suggested a 
dispensable role for Notch signalling in vivo (Mancini et al., 2005), perhaps due to 
redundancy between the various Notch receptors and ligands.    
1.6.4.4 Wnt signalling pathway 
The action of canonical Wnt signalling is mediated by activation of its G protein-
coupled receptor (GPCR), frizzled, which subsequently stabilises its intracellular 
effector, β-catenin, causing the nuclear translocation of β-catenin that forms a 
transcriptional complex with T cell-specific transcription factors (TCFs) and 
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lymphoid enhancer-binding factor 1 (LEF1) to target certain genes (Figure 1.6B) 
(Bienz, 1998). Canonical Wnt signalling was identified in LSK cells and β-catenin-
transduced LSKs showed improved survival and 100-1,000-fold expansion in vitro 
(Reya et al., 2003). The same study also demonstrated elevated levels of self-
renewal regulators Notch1 and HoxB4. Furthermore, through downregulation of 
Wnt signalling by using the soluble form of frizzled that competes with the 
membrane-bound receptor or by the overexpression of axin, which degrades β-
catenin, HSC growth was significantly affected both in vitro and in vivo, indicating 
an essential role for Wnt signalling in the maintenance of HSCs (Reya et al., 
2003). Nevertheless, it was reported that the overexpression or deletion of β-
catenin in vivo did not result in a significant change of phenotype with regard to 
HSC number and function (Cobas et al., 2004, Kirstetter et al., 2006). The 
controversial findings may propose a redundancy between canonical and non-
canonical Wnt signalling pathways in the maintenance of HSCs in vivo.  
The self-renewal and repopulation potential of adult murine HSCs can be induced 
upon Wnt3a treatment, both in vitro and in vivo (Willert et al., 2003). This 
observation was further supported by showing that the Wnt3a stimulation can 
transcriptionally activate Notch target genes. Therefore, it is plausible to propose a 
synergistic mechanism of action between Wnt and Notch signalling pathways 
(Duncan et al., 2005). Both signalling pathways induce self-renewal of HSCs, but 
through different mechanisms, in which Wnt ligands induce the survival and 
expansion of LSK cells and Notch signalling maintains the immature state of stem 
cells. Finally, blocking the activity of Wnt intracellular effector, glycogen synthase 
kinase (GSK) 3β, impaired HSC self-renewal through misregulation of both Notch 
and Wnt target genes (Trowbridge et al., 2006).  
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Figure   1.6: Notch and Wnt signalling pathways. 
(A) Schematic mechanism of action in the Notch signalling pathway. The membrane-bound Notch 
receptor is cleaved by γ-secretase upon binding to its membrane-bound ligands, Delta (Delta 1-3) 
and Jagged (Jagged 1-2), which releases the intracellular domain of Notch that can translocate to 
the nucleus and activate target genes in the presence of Mastermind-like (MAML) cofactors and 
RBPJ transcription factor (Blank et al., 2008). (B) Schematic mechanism of action in the canonical 
Wnt signalling pathway. In the absence of Wnt-frizzled interaction intracellular β-catenin signalling 
is inactive due to its degradation by a complex of proteins including axin, GSK3β, adenomatous 
polyposis coli (APC), and casein kinase 1-α1 (CK1α).  The  binding  of  Wnt  ligands  to  frizzled  results  
in the recruitment of lipoprotein receptor-related protein (LRP) and subsequent recruitment of axin 
and dishevelled (DSH) to the cell membrane. Consequently, β-catenin is no longer degraded and 
can activate target genes in the presence of TCFs and LEF1 (Clevers, 2006). P indicates 
phosphorylation.       
1.6.4.5 Transforming growth factor-beta (TGF-β) and Smad signalling 
pathways 
The Smad pathway is an intracellular signal transduction network downstream of 
TGF-β, bone morphogenetic proteins (BMPs), activins, and Nodal superfamily of 
ligands and receptors (Figure 1.7), which regulate many biological processes 
during development. TGF-β is the master regulator of HSC quiescence (Batard et 
al., 2000, Sitnicka et al., 1996) and inhibition of TGF-β signalling triggers 
proliferation of HSCs (Hatzfeld et al., 1991). Nevertheless, the deletion of TGF-β  
receptor type I (TGFBR1) did not impair HSC self-renewal and repopulation 
capacities in vivo, even under stress conditions (Larsson et al., 2003, Larsson et 
al., 2005). This observation might be explained by the existing redundancy 
between the ligands and receptors of the TGF-β   superfamily,   all   of   which   can  
activate the downstream Smad signalling pathway. 
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The activated type I receptor phosphorylate and activate SMAD2/SMAD3 
intracellular effectors that can make a complex with SMAD4 proteins. 
Subsequently, this complex translocates to the nucleus and act as a transcription 
factor that regulates the expression of certain target genes (Heldin et al., 1997). 
The growth inhibitory function of TGF-β  is  mediated  by  the  upregulation  of  CDKIs,  
such as CDKN1A/p21 and CDKN1C/p57, or by changing the expression of 
cytokine receptors (Dubois et al., 1994, Ducos et al., 2000, Jacobsen et al., 1991, 
Scandura et al., 2004). A novel mechanism of action for TGF-β/Smad  signalling  
has   been   recently   suggested   involving   transcriptional   intermediary   factor   1γ  
(TIF1γ)   that   can   compete   with   Smad4   for   binding   Smad2/Smad3.   Upon   TGF-β  
stimulation  of  progenitors,  the  TIF1γ/Smad2/Smad3  complex  can  induce  erythroid  
differentiation, while the Smad4/Smad2/Smad3 complex causes growth arrest, 
suggesting   the   balance   between  Smad4   and  TIF1γ  may   predict   the   outcome  of  
TGF-β  stimulation  (He et al., 2006).   
 
Figure   1.7: TGF-β and Smad signalling pathways. 
The schematic diagram depicts the mechanism of signal transduction from the TGF-β  superfamily  
of ligands and receptors to the nucleus via the intracellular Smad signalling pathway. Three major 
subclasses of TGF-β  ligands  are  identified  as  activins  and  Nodal,  TGF-β,  and  BMPs.  Upon  binding  
of ligands to type 2 receptors, a heterodimer of type 1/type 2 receptors is formed. Type 1 receptors 
subsequently phosphorylate receptor-activated Smads (R-Smads), which form a complex with co-
Smad, Smad4, and translocate to the nucleus to activate or suppress target genes in the presence 
of coactivators or corepressors (Heldin et al., 1997). Inhibitory Smads (I-Smads) are capable of 
blocking R-Smads and therefore, act in a negative feedback loop (Nakao et al., 1997). Overall, 
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TGF-β,   activins   and   Nodal   use   Smad2/Smad3   as   their   R-Smads, while BMPs activate 
Smad1/Smad5/Smad8 R-Smads. P indicates phosphorylation. ACVR1, activin A receptor type 1; 
ACVR1B, activin A receptor type 1B; ACVR1C, activin A receptor type 1C; ACVR2A, activin A 
receptor type 2A; ACVR2B, activin A receptor type 2B; ACVRL1, activin A receptor type 2-like 1; 
TGFBR2, TGF-β  receptor  type  2;;  BMPR2,  BMP  receptor  type  2.       
In addition to TGF-β,  BMP4  can  also  maintain  the  self-renewal capacity of HSCs in 
vitro, whilst at lower concentrations it favours the proliferation of early progenitors 
in adult human haemopoiesis (Bhatia et al., 1999). BMP4 functions via activation 
of intracellular Smad5 protein. The deletion of Smad5 protein in the cells derived 
from yolk sac or embryoid bodies resulted in enhanced proliferation and colony 
forming potential (Liu et al., 2003); however, similar results could not be achieved 
in adult mouse HSCs (Singbrant et al., 2006). Thus, it is plausible to propose a 
role for BMP4/Smad5 signalling in early haemopoiesis. Nonetheless, the 
observation of normal phenotype upon Smad5 deletion in adult HSCs could be 
due to redundancy between the Smad signalling proteins.  
It has been proposed that Smad signalling is a negative regulator of self-renewal, 
since the overexpression of inhibitory Smad protein, Smad7, in murine HSCs 
significantly induced self-renewal (Blank et al., 2006). Furthermore, Smad 
signalling may have a role during fate determination. The SMAD7 overexpressing 
HSCs favour myeloid differentiation significantly more than lymphoid. Thus, the 
activation of Smad signalling results in the reduction of myeloid differentiation and 
a shift towards lymphoid commitment (Chadwick et al., 2005). Overall, TGF-β  
ligands maintain the quiescence of HSCs through the activation of intracellular 
Smad signalling which in turn may inhibit self-renewal or induce lymphopoiesis in 
early progenitors. Thus, the biological outcome of TGF-β  stimulation  is  dependent 
on the differentiation state of the haemopoietic cells (Ruscetti et al., 2005).   
1.6.4.6 Hedgehog signalling pathway 
The hedgehog signalling pathway has been demonstrated to have an important 
role in the development of the early mesoderm layer through the morphogenic 
activity of its ligands, Sonic hedgehog (SHH), Indian hedgehog (IHH), and desert 
hedgehog (DHH), which are cell surface proteins that can bind directly to their 
receptor Patched (PTC) on neighbouring cells or can be cleaved and diffuse to 
distal locations. The ligand-receptor interaction results in the activation of another 
transmembrane protein Smoothened (SMO) and subsequent activation of 
downstream effectors (Ruiz i Altaba, 1997). Human HSCs express SHH, PTC, and 
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SMO, while the inhibition of SHH by blocking antibodies resulted in reduced HSC 
expansion that was rescued by the addition of soluble SHH in NOD-scid mice. 
Furthermore, the SHH effect was blocked in the presence of Noggin, which is an 
inhibitor of bone BMP4, therefore, suggesting a potential link between SHH and 
BMP4 in the survival of HSCs (Bhardwaj et al., 2001).  
1.6.4.7 HSC niche: acellular factors versus cellular support 
Hypoxia and reactive oxygen species (ROS) – HSCs are believed to be located 
in a hypoxic compartment of the BM niche as confirmed by pimonidazole staining, 
which is a hypoxia marker (Parmar et al., 2007). Furthermore, Hoechst staining of 
the niche revealed that LT-HSCs and osteoblasts co-reside in hypoxia, whereas 
mesenchymal stem cells (MSCs) and vascular endothelial cells are located in 
normoxia (Winkler et al., 2010). Overall, these observations indicated that LT-
HSCs and osteoblasts reside relatively far from the oxygenated circulation. 
However, recent observations indicate that the apparent hypoxic behaviour of 
HSCs could be regulated intrinsically, rather than dictated by the niche, as hypoxic 
HSCs could also be located in close proximity to the vasculature and to other non-
hypoxic haemopoietic cells (Wang and Wagers, 2011). The regulation of hypoxia 
has been shown to be essential for HSC maintenance and can be tracked by the 
elevated levels of hypoxia inducible factor 1α (HIF1α) under low-oxygen level 
conditions (Takubo et al., 2010). This upregulation of HIF1 results in a switch 
from mitochondrial oxidative phosphorylation to glycolysis, which in turn is a pro-
survival mechanism for HSCs in hypoxic conditions (Simsek et al., 2010). HIF1α-
deficient HSCs were shown to be highly proliferative which resulted in their 
exhaustion in repopulation assays, especially under haemopoietic stress (Takubo 
et al., 2010). The same study also showed that the overexpression of HIF1α  was  
associated with loss of HSCs, indicating a tight range of activity for the optimum 
functionality of this factor.  
ROS can also lead to HSC exhaustion as a result of activating the p38/mitogen 
activated protein kinase (MAPK) pathway which induces proliferation (Ito et al., 
2006). The forkhead box O (FoxO) family of transcription factors are important in 
protecting HSCs from oxidative stress by activating genes involved in the 
detoxification process. Murine HSCs with triple knockouts of FoxO1, FoxO3 and 
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FoxO4 displayed impaired repopulation potential, increased cell division and 
apoptosis, in addition to elevated levels of ROS (Tothova et al., 2007).  
Osteoblasts – They are the best characterised cells that reside in contact with 
HSCs in the BM niche. An increase in their number was directly associated with an 
increase in the number of HSCs (Calvi et al., 2003) and the loss of osteoblasts 
from the niche resulted in the loss of HSCs (Visnjic et al., 2004). Osteoblasts 
express and secrete G-CSF, GM-CSF, IL-6, angiopoietin, TPO, Wnt, Notch, N-
cadherin, and osteopontin, which have impact on both HSC maintenance and 
proliferation (Fleming et al., 2008, Haug et al., 2008, Nilsson et al., 2005, 
Taichman et al., 1996). Recent visualisation of the niche by confocal microscopy 
has revealed the close proximity of LT-HSCs and osteoblasts, while the more 
mature progenitor cells are distally located (Lo Celso et al., 2009).  
The perivascular niche – A proportion of the BM niche is in close proximity of 
vasculature and is therefore known as the perivascular space. The perivascular 
space provides the means for migration, homing and engraftment of haemopoietic 
cells and for them to receive differentiation signals and various other stimuli. 
MSCs, endothelial cells, chemokine (C-X-C motif) ligand 12 (CXCL12)-abundant 
reticular (CAR) cells and neural cells are the major types of cells in this niche 
(Wang and Wagers, 2011). MSCs are required for the maintenance of LT-HSCs 
and their loss resulted in reduction of LT-HSCs by 50% (Mendez-Ferrer et al., 
2010). MSCs also express CXCL12 that is involved in HSC migration (Tzeng et 
al., 2011). The influence of MSCs on haemopoiesis can be altered through change 
of global gene expression signatures as a result of physiological stimuli. A 50% 
loss of LT-HSCs was also observed with the loss of CAR cells (Omatsu et al., 
2010). CAR cells are characterised by expressing N-cadherin and Jagged ligand 
on their cell surface. Moreover, endothelial cells are characterised by the 
expression of vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, 
platelet endothelial cell adhesion molecule 1 (PECAM1) and cadherin 5 type 2 
(CDH5), which are required for the maintenance of self-renewal and repopulation 
capacities of HSCs (Butler et al., 2010). Thus, the above observations indicate a 
crucial role for the cells in the BM niche in the maintenance of HSCs.        
Neural regulation – BM is noticeably innervated by sympathetic and 
parasympathetic nerves in close proximity of bones and arterial smooth muscle 
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cells (Mignini et al., 2003). The neural cells in the BM niche can regulate HSC 
function directly and indirectly. Several neurotransmitter receptors are identified on 
the surface of HSCs, such as dopaminergic, adrenergic, serotonin, adenosine, 
opioids, orexin, vasoactive intestinal peptide (VIP) and corticotropin-releasing 
hormone (CRH) (Steidl et al., 2004). Norepinephrine signalling was demonstrated 
to cause G-CSF-mediated mobilisation of murine HSCs, suppression of 
osteoblasts and downregulation of CXCL12 (Katayama et al., 2006). Furthermore, 
dopamine and norepinephrine signalling were shown to regulate the motility of 
human HSCs as well as inducing BM repopulation through the activation of Wnt 
signalling (Spiegel et al., 2007). A recent report also suggested that 
norepinephrine induces the production of HSCs from their haemogenic 
endothelium precursors in AGM; thus, providing compelling evidence on the role of 
neurotransmitters in the formation of HSCs (Fitch et al., 2012). Additionally, the 
nonmyelinating Schwann cells, which are a subset of the neural cells in BM niche, 
were shown to be required for the activation of the latent form of TGF-β and 
therefore, indirectly maintain the quiescence of HSCs (Yamazaki et al., 2011).       
1.6.5 Transcription factors in haemopoietic development 
Transcription factors are key intrinsic players in cell fate determination during HSC 
development from AGM and during haemopoietic lineage differentiation (Orkin, 
2000). Mutations or chromosomal translocations of haemopoietic transcription 
factors are the main cause of developing haematological malignancies; therefore, 
it is required to understand their role during normal haemopoiesis. Conventional 
and conditional gene knockouts in mice, zebrafish, chicken, Drosophila and 
Xenopus have provided thorough insights into the function and role of key 
haemopoietic transcription factors (Iwasaki and Akashi, 2007, Orkin and Zon, 
2008, Rothenberg, 2007).   
The transcription factors that are crucially linked to the formation of HSCs during 
embryogenesis are MLL, runt-related transcription factor 1 (RUNX1), T cell acute 
lymphocytic leukaemia 1 (TAL1/SCL), LIM domain only 2 (LMO2), and ETS variant 
6 (ETV6/TEL); the absence of which results in the abolishment of haemopoiesis 
(Orkin, 2000, Orkin and Zon, 2008). Chromosomal translocations of these genes 
are found in the majority of leukaemic events; for example TAL1/SCL and LMO2 
translocations in T-cell acute lymphoblastic leukaemia (T-ALL) and translocations 
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of MLL, RUNX1, and ETV6/TEL that result in the formation of fusion oncogenes in 
the cases of various myeloid and lymphoid leukaemias (Orkin and Zon, 2008). On 
the other hand, the major transcription factors that are associated with lineage 
differentiation are GATA binding protein 1 (GATA1), CCAAT/enhancer binding 
protein-alpha (CEBPA), SPI1/PU.1, growth factor independent 1 transcription 
repressor (GFI1), and IFN consensus sequence binding protein (ICSBP) (Figure 
1.8) (Orkin and Zon, 2008, Rosenbauer and Tenen, 2007). Nevertheless, it is 
suggested that all lineage-specific transcription factors are expressed at low levels 
in HSCs and MPPs at a single-cell level, which is referred to as the lineage 
priming model (Akashi, 2005, Orkin, 2003). The lineage priming model proposes a 
gradual fate determination route that is open to switch between lineages at all 
times. This phenomenon is associated with open chromatin configurations at the 
promoters of haemopoietic regulators to enable accessible transcription when 
needed, which offers plasticity to the multipotent precursors. The open chromatin 
regions can be transiently repressed upon early fate determinations and 
subsequently permanently silenced in mature blood cells (Orkin and Zon, 2008). 
 
Figure   1.8: Essential transcription factors in haemopoiesis. 
Schematic illustration of the transcription factors (grey boxes) that are required for the formation of 
HSCs from mesoderm and haemopoietic lineage differentiation. TAL1/SCL and RUNX1 are 
essential for the generation of foetal liver HSCs and subsequently adult HSCs, whose levels are 
gradually diminished in the course of lineage commitment. SPI1/PU.1 is required for the formation 
of GMPs as well as lymphoid progenitors. CEBPA is essential for granulocytosis whereas ICSBP is 
required in the monocytes development. On the other hand, the development of megakaryoctes 
and erythrocytes require the expression of GATA1. The development of T cells require the activity 
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of Notch signalling, whereas B cell development is mediated by the function of early B-cell factors 
(EBFs), PAX5 and TCF3/E2A transcription factors. Some of the transcription factors required for 
the HSC maintenance, such as GFI1, are also essential in the formation of terminally differentiated 
cells, such as neutrophils and megakaryocytes (Orkin and Zon, 2008, Rosenbauer and Tenen, 
2007).   
A global analysis of gene expression signatures in human HSCs, intermediate 
progenitors and terminally differentiated haemopoietic cells has discovered a 
complex interconnected network of transcription factors which significantly overlap 
with the above findings (Novershtern et al., 2011). This report has identified 
modules of transcription factors which are coregulated at different stages of 
haemopoiesis. Furthermore, this study has provided supporting evidence for the 
lineage priming model by showing the binding of lineage-specific transcription 
factors to their target genes in HSCs, which has been referred to as anticipatory 
regulation. The global gene expression analysis of HSCs and haemopoietic 
progenitors are reviewed in Chapter 3. 
1.6.6 Epigenetics of haemopoietic development 
The importance of epigenetic in transcriptional regulation was discussed in Section 
1.5. Therefore, it is important to review the genome-wide studies of chromatin 
changes during haemopoietic development which provide a better understanding 
of the lineage priming model.  
1.6.6.1 Role of DNA methylation in lineage commitment 
The genome-wide studies of DNA methylation has been recently performed on 
several mouse haemopoietic progenitors, which include MPPs, CMPs, GMPs and 
CLPs, as well terminally differentiated granulocytes, monocytes and T cells (Ji et 
al., 2010). This study showed that a number of myeloid- and lymphoid-lineage-
specific genes were subjected to differential DNA methylation in the course of 
haemopoietic development from MPPs. The lymphoid- and myeloid-specific  
genes showed a significant DNA demethylation during lymphopoiesis and 
myelopoiesis, respectively, which was associated with transcriptional upregulation. 
DNA methylation patterns during haemopoiesis demonstrated significant 
epigenetic plasticity. Lymphopoiesis was significantly linked to the gain of 
methylation, whereas myelopoiesis showed a higher tendency towards the loss of 
DNA methylation. Thus, the observation indicated that the lymphopoiesis is more 
dependent on DNA methylation than myelopoiesis (Ji et al., 2010). In addition to 
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the identification of many novel loci that were differentially methylated in the 
course of myelopoiesis and lymphopoiesis, a subset of genes was also identified 
which showed a progressive hypermethylation in both myeloid and lymphoid 
lineages which was subsequently linked to the maintenance of multipotent state, 
such as MEIS1, hepatic leukaemia factor (HLF), HOXA9, and PR domain 
containing 16 (PRDM16) which have been previously reported to be important 
during haemopoiesis (Ji et al., 2010). Thus, overall this study showed a significant 
difference in DNA methylation programming between myelopoiesis and 
lymphopoiesis, which suggested a DNA-methylation-dependent mechanism of 
differentiation for the latter.  
DNA methylation has also been directly linked to the maintenance of HSC self-
renewal and fate determination upon the loss of multipotency (Broske et al., 2009, 
Trowbridge et al., 2009). These studies demonstrated that by reducing the 
expression of DNMT1 in HSCs, their self-renewal capacities were impaired and 
their differentiation was skewed towards the myeloid lineage. The latter could be 
explained by the above observation which showed a less DNA-methylation-
dependent mechanism of differentiation during myelopoiesis. On the contrary, the 
loss of DNMT3A was associated with failed differentiation, but did not affect the 
HSCs self-renewal capacities (Challen et al., 2012). Thus, de novo DNA 
methylation by DNMT3A is essential to block the HSC-specific transcription factors 
which in turn induces lineage commitment and differentiation. 
1.6.6.2 Role of histone modifications in lineage priming 
The analysis of genome-wide histone modification patterns in HSCs have 
demonstrated large numbers of bivalent promoters which are noticeably reduced 
during lineage differentiation in both murine and human haemopoiesis (Cui et al., 
2009, Weishaupt et al., 2010). The tracking of CD133+ human haemopoietic stem 
and progenitor cells during differentiation to CD36+ erythroblasts identified a 
subset of CD133+ bivalent genes that lost H3K27me3 and became activated in 
CD36+ cells. These genes were also associated with paused RNAPII, H3K4me1 
and H3K9me1 at their promoters and basal level transcription in CD133+ cells. On 
the contrary, the bivalent genes that lost H3K4me3 during differentiation were not 
associated with RNAPII, H3K4me1 or H3K9me1 at their promoters in CD133+ cells 
(Cui et al., 2009). Therefore, the results indicated that genes were primed for 
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activation or permanent repression in HSCs and progenitor cells and, thus, 
providing further evidence for the lineage priming model that was discussed 
above. This study also demonstrated that the majority of bivalent genes in CD133+ 
cells (53%) lost their H3K4me3 in CD36+ cells and only 24% of the bivalent 
promoters remained bivalent after differentiation, although they exhibited higher 
levels of H3K27me3 than H3K4me3. Therefore, the differentiation was associated 
predominantly with the silencing of the developmentally regulated and other 
lineages-specific loci (Cui et al., 2009). Similar observations was made in the 
genome-wide analysis of murine haemopoiesis (Weishaupt et al., 2010). 
Nevertheless, the bivalent promoters in murine HSCs were shown to be 
significantly associated with the repressive H3K9me3 marks more frequently than 
the bivalent promoters in T cells, which may propose a unique epigenetic 
suppression mechanism in HSCs that may be required for  blocking immature 
lineage commitment. Furthermore, the results suggested that T cell maturation is 
also associated with a global silencing mechanism, as observed in the case of 
human CD36+ cells (Weishaupt et al., 2010). The above observations were further 
supported by a recent study in murine LSK cell population which showed a 
positive correlation between the levels of H3K4me3 in bivalent promoters in LSK 
cells and the related gene expression levels in differentiated cell types (Adli et al., 
2010). Overall, the genome-wide histone modification analyses provided 
compelling evidence for the lineage priming model and the role of epigenetics in 
anticipatory regulation. 
In addition to the changes of histone modification signatures during haemopoiesis 
development, several studies have also investigated the role of PcG proteins in 
this process. These reports demonstrated negative correlation between the PRC2 
expression and long term HSC repopulating capacities (Majewski et al., 2008, 
Majewski et al., 2010). In other words, these studies showed that EZH2, SUZ12 
and EED subunits restrict the function of HSCs, whereas the PRC1 complex and 
in particular BMI1 are essential for the maintenance of HSC niche (Lessard et al., 
1999).  
Overall, the above observations indicate an important role for the epigenetic 
mechanisms of gene regulation in the maintenance of HSC self-renewal as well as 
lineage differentiation through inducing the lineage priming model.  
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1.7 Chronic myeloid leukaemia (CML) 
CML is a rare haematological disorder affecting of 1 or 2 cases per 100,000 
individuals per year with the median age onset of around 65 years. Women are 
less frequently affected and show higher survival rates compared to men (Berger 
et al., 2005, Hehlmann et al., 2007). CML is a bi- or triphasic disorder which 
initiates in the chronic phase (CP) that is a more stable stage of disease and can 
typically last 3-8 years. CP CML patients can progress to the more advanced 
phases of disease, known as accelerated phase and blast crisis (BC) (Mughal and 
Goldman, 1999).    
This disease is identified by the presence of Philadelphia (Ph) chromosome which 
is the outcome of a reciprocal chromosomal translocation t(9;22)(q34;q11) in 
haemopoietic cells (Rowley, 1973). This translocation brings a proto-oncogene, c-
abl oncogene 1 (ABL1), from chromosome 9 to the juxtaposition of breakpoint 
cluster region (BCR) gene on chromosome 22 (Bartram et al., 1983, Groffen et al., 
1984). ABL1 is a non-receptor tyrosine kinase which becomes constitutively active 
under the control of the BCR promoter (Laneuville, 1995); thus, the BCR-ABL1 
fusion oncogene functions as a constitutive tyrosine kinase (Lugo et al., 1990). 
The underlying mechanisms leading to this translocation are currently unknown. 
CML can be diagnosed by excessive granulocytosis in the differential blood count 
analysis. A white buffy coat is noticeable upon sedimentation that consists of white 
blood cells. The full diagnosis is confirmed by identifying the presence of the BCR-
ABL1 fusion oncogene and/or transcripts in peripheral blood (PB) and/or BM cells 
by cytogenetic analysis, fluorescence in situ hybridisation (FISH) or real time-
polymerase chain reaction (RT-PCR), respectively (Hehlmann et al., 2007, 
Hughes et al., 2006). The entry to BC is diagnosed by the presence of the blast 
cells with 70% of patients show a shift towards the myeloid lineage and the rest 
towards the lymphoid lineage or show a mixed leukaemia (Mughal and Goldman, 
1999).  
1.7.1 The anatomy of BCR-ABL1 oncogene 
The relationship between the BCR-ABL1 protein and CML was initially elucidated 
in BCR-ABL1-transduced mouse cells in vivo (Daley et al., 1990, Heisterkamp et 
al., 1990). Furthermore, BCR-ABL1-expressing murine HSC cells bearing a 
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mutation in the ATP-binding pocket, which has the kinase activity, of ABL1 did not 
develop CML-like disease (Zhang and Ren, 1998). Additionally, through 
ectopically expressing BCR-ABL1 in human CD34+ cells in vitro CML-like 
characteristics could be induced (Ramaraj et al., 2004, Zhao et al., 2001). 
Therefore, these observations suggest that high levels of BCR-ABL1 expression is 
sufficient to induce CP CML disease and additional mutations are not required for 
developing CP characteristics in haemopoietic subclones.  
The ABL1 breakpoints are typically located upstream of exon 1b, or downstream 
of exon 1a, or between exon 1b and 1a (Melo, 1996). On the other hand, the 
breakpoints in the BCR gene typically occur in a 5.8 kilobase (kb) window 
spanning exons 12-16 (b1-b5), known as the major breakpoint cluster region (M-
bcr). Fusion transcripts of two main forms can be found due to alternative splicing, 
which present either b2a2 or b3a2 junctions, that translate into a 210-kDa protein 
(p210BCR-ABL1) (Faderl et al., 1999).  
1.7.2 Signalling pathways downstream of BCR-ABL1 
The constitutive tyrosine activity of BCR-ABL1 results in the activation of several 
downstream pathways. The active BCR-ABL1 is phosphorylated at BCR tyrosine 
177 (Zhang et al., 2001). The growth factor receptor-bound protein 2 (GRB2) binds 
to this phosphorylation site and recruits son of sevenless (SOS) that in turn 
activates RAS and the scaffold protein GRB2-associated binding protein 2 (GAB2) 
(Ren, 2005). BCR-ABL1-mediated phosphorylation of GAB2 is responsible for the 
constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT and 
extracellular signal-regulated kinase (ERK) pathways (Sattler et al., 2002, Skorski 
et al., 1995). Activation of the PI3K/AKT pathway is thought to block the activity of 
ICSBP, a negative regulator of granulocytosis (Section 1.6.5), by inhibiting its DNA 
binding capacity that results is subsequent activation of its target genes, such as 
the antiapoptotic B-cell CLL/lymphoma 2 (BCL2) gene (Middleton et al., 2006).  
Furthermore, three SRC family kinases, haemopoietic cell kinase (HCK), LYN and 
FGR, are phosphorylated by BCR-ABL1. The transcription factor STAT5 is 
recruited by phosphorylated HCK (Ilaria and Van Etten, 1996, Ren, 2005), which 
subsequently upregulates cyclin D1 (CCND1) that causes G1 to S progression and 
increased proliferation (Nosaka et al., 1999). STAT5 knockdown in primary CML 
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cells blocked the formation of Ph+ myeloid lineage and Stat5a-/- Stat5b-/- mice 
foetal liver cells failed to develop leukaemia upon retroviral transduction of BCR-
ABL1 (Hoelbl et al., 2006). Furthermore, STAT5 activates the antiapoptotic protein 
BCL2L1/BCLX that leads to the inhibition of apoptosis (Gesbert and Griffin, 2000).  
Another intracellular signalling pathway mediated by the RAC family of guanosine 
triphosphatases (GTPases), which include RAC1, RAC2 and RAC3, is also 
demonstrated to be active in CML cells (Thomas et al., 2007). The knockdown of 
RAC1 and RAC2 genes in murine cells expressing p210BCR-ABL1 caused a delay in 
developing a myeloproliferative disorder which was associated with reduced 
phosphorylation of BCR-ABL1 downstream effectors CRK-like (CRKL), ERK, c-
Jun N-terminal kinase (JNK) and p38; proposing a RAC-dependent mechanism of 
function for the BCR-ABL1 oncoprotein (Thomas et al., 2007).  
Thus, the overall net effect of BCR-ABL kinase activity is increased proliferation 
and survival as well as reduced apoptosis (Figure 1.9).  
 
Figure   1.9: The downstream signalling mediators of BCR-ABL1 tyrosine kinase. 
GRB2 binds to the phosphorylated tyrosine 177 residue of BCR and recruits SOS, an activator of 
RAS-MAPK pathway, and GAB2, which activates p85 and p110 subunits of PI3K pathway. 
Activation of PI3K pathway leads to downstream activation of AKT that induces the expression of 
MYC oncogene, through NFκB signalling, and its stabilisation by inhibiting GSK3β. Activated AKT 
also induces the expression of the antiapoptotic factors BCL2 and BCL2L1/BCLX by inhibiting 
ICSBP function. On the contrary, the activation of phosphatase and tensin homolog (PTEN) blocks 
the activity of AKT by inhibiting its phosphorylation that in turn block the activation of AKT 
downstream targets. Activation of Janus kinase 2 (JAK2) by ABL1 and subsequent activation of 
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downstream HCK and LYN SRC kinases result in the phosphorylation and activation of STAT5, 
which can also be activated by the RAC family proteins. STAT5 activity can also cause MYC 
expression. The overall outcome of BCR-ABL1 oncogenic function is increased proliferation and 
survival. P indicates phosphorylation. PIK3CD, PI3K catalytic delta polypeptide. 
1.7.3 CML stem cells (LSCs) 
The early evidence regarding the clonality and HSC origins of CML came from the 
observations in which cells isolated from the BM of CML patients were associated 
with increased proliferation and the capacity to differentiate into different myeloid 
lineages (Dameshek, 1951). The identification of Ph chromosome and BCR-ABL1 
oncogene in multiple myeloid lineages (Tough et al., 1963, Whang et al., 1963) 
and similar X-chromosome inactivation patterns in the granulomonocytic lineages, 
platelets and B cells (Fialkow et al., 1967, Fialkow et al., 1977) further elucidated 
the clonality of CML and self-renewing, multipotent HSCs as the origin of the 
disease. The initial evidence for the presence of repopulating LSCs came from the 
observations that the white blood cells obtained from CML patients were capable 
of repopulating in severely neutropenic recipients and generate Ph+ progeny 
(Levin et al., 1963), which was later explained to be due to the presence of high 
numbers of mobilised LSCs into PB in CML patients (Dazzi et al., 2000, Petzer et 
al., 1996). Furthermore, the CMP or GMP origin of CML was ruled out as the 
ectopic expression of BCR-ABL1 in murine haemopoietic progenitor cells failed to 
induce self-renewal capacities; therefore, the results provided further evidence to 
support the HSC origin of CML (Huntly et al., 2004).     
The isolation of LSCs from their normal counterparts is one of the major 
challenges in studying LSCs. LSCs display similar cell surface markers that define 
HSCs, which include CD34, CD90, and aldehyde dehydrogenase in the absence 
of Lin and CD38 markers (Florian et al., 2006, Jiang et al., 2008, Petzer et al., 
1996). Despite the similarities between HSCs and LSCs in terms of cell surface 
markers, LSCs exhibit a higher proportion of cells in cycle which can be used for 
their isolation (Holyoake et al., 1999).  Nonetheless, recent studies have 
demonstrated novel cell surface markers, including IL-1 receptor accessory protein 
(IL1RAP) and dipeptidyl peptidase 4 (DPP4/CD26), to distinguish between LSCs 
and HSCs (Herrmann et al., 2012, Jaras et al., 2010). Ultimately, the genotyping 
approaches are applied to characterise the sorted cell populations. 
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LSCs are characterised with the highest levels of BCR-ABL1 transcripts (Jamieson 
et al., 2004, Jiang et al., 1999, Jiang et al., 2007). The expression of BCR-ABL1 in 
LSCs has been linked to the secretion of autocrine IL-3 and G-CSF that results in 
stem cell differentiation and inhibition of self-renewal (Holyoake et al., 2001, Jiang 
et al., 1999). In line with these findings, LSCs were shown to have reduced self-
renewal capacities than their normal counterparts as observed with their limited 
potential to compete with HSCs in in vitro and in vivo assays (Petzer et al., 1997, 
Udomsakdi et al., 1992). Furthermore, LSCs are associated with increased 
proliferative activities in comparison to HSCs (Holyoake et al., 1999) which could 
be explained by the autocrine loop of IL-3 and G-CSF that induces the proliferation 
and survival of CML progenitors. The increased sensitivity of LSCs to the stromal-
secreted chemokines such as CXCL12, chemokine (C-C motif) ligand 2 (CCL2), 
and CCL3/MIP-1α may decrease the quiescence of LSCs relative to HSCs and 
can increase their mobilisation (Cashman et al., 2002, Eaves et al., 1993). 
However, several reports suggested a more profound role for TGF-β in the 
maintenance of quiescence of LSCs similar to their role in HSCs (Section 1.7.6) 
(Cashman et al., 1992, Naka et al., 2010). LSCs, unlike HSCs, are not dependent 
on the external growth factors to inhibit apoptosis and therefore, are associated 
with significantly reduced apoptosis which could be also linked to the autocrine 
secretion of IL-3 and G-CSF (Jiang et al., 1999, Maguer-Satta et al., 1998). 
Overall, LSCs demonstrate increased proliferation potential and reduced 
quiescence, self-renewal and apoptotic capacities in comparison to HSCs. 
The identification of LSCs hypothesised two models which could explain the 
progression of CP CML to BC. First, LSCs in CP may acquire further mutations 
that would in turn skew their differentiation towards myeloid lineage or the second 
model which suggests the acquisition of further mutations by the GMPs or other 
lineage-restricted progenitors which cause them to abnormally self-renew and 
block differentiation. Recent studies have provided compelling evidence in favour 
of the second model which show abnormal activation of β-catenin in GMPs that in 
turn results in the formation of undifferentiated blasts (Jamieson et al., 2004, 
Neering et al., 2007). 
Based on the above observations, a hypothetical model of LSC formation during 
CP and BC is proposed (Figure 1.10) (Quintas-Cardama and Cortes, 2009). 
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Figure   1.10: The hypothetical model of LSC formation during CP and BC. 
Several lines of evidence indicate that LSCs are originated from multipotent self-renewing HSCs. 
The reciprocal translocation and BCR-ABL1 expression are the first preleukaemic events that occur 
in an HSC. Subsequently by activation of antiapoptotic genes such as BCL2 and the activity of 
proliferative genes such as MYC, a progressive acquisition of proliferative potential and loss of 
apoptotic abilities occur. Further loss of control on self-renewal due to the inactivity of tumour 
suppressor genes such as p53 and CDKN2A/p16 results in the formation of LSCs. The reduction of 
differentiation capacities as a result of Ikaros family zinc finger 1 (IKZF1) or CEBPA suppression in 
LSCs and re-activation of self-renewal genes such as β-catenin in the leukaemic GMPs in addition 
to accumulation of further genetic and/or epigenetic abnormalities can give rise BC (Quintas-
Cardama and Cortes, 2009).                
1.7.4 Tyrosine kinase inhibitors (TKIs) in CML therapy 
The small molecule TKIs are the central line of treatment against CML. Over the 
past decade the development of TKIs that directly target the constitutive tyrosine 
kinase activity of BCR-ABL1 has resulted in significantly improved survival rates 
and disease management in CP CML patients. Nevertheless, it has to be noted 
that allogeneic transplantation remains the most effective long-term therapy for 
CML, particularly in the more aggressive stages of the disease.  
The first TKI to be discovered was imatinib which could specifically discriminate 
CML cells from their normal counterparts by directly targeting BCR-ABL1 (Druker 
et al., 1996). Imatinib treatment of CML in CP is associated with an overall survival 
rate of 89% over a five-year clinical evaluation and a progression-free survival rate 
of 93%, which was much higher than earlier treatment strategies involving 
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interferon-alpha (IFN-α) (Druker et al., 2006). However, resistance to imatinib can 
arise as a result of mutations in the kinase domain that either make direct 
interactions with imatinib or are important in formation of the inactive BCR-ABL1 
conformation that is required for drug interaction (Gorre et al., 2001).  
Therefore, two second generation TKIs were designed to overcome the observed 
imatinib resistance, which included nilotinib (Weisberg et al., 2005), a derivative of 
imatinib with ~30-fold higher strength, and dasatinib (Shah et al., 2004), with ~300-
fold higher potency than imatinib. The administration of second generation TKIs 
resulted in achieving a quicker response, significantly reduced progression to the 
later stages of the disease and increased overall survival (Jabbour et al., 2011). 
Nevertheless, BCR-ABL1T315I is the most TKI-insensitive mutation which is 
referred to as the gatekeeper mutation that could not be targeted by second 
generation TKIs (Azam et al., 2008). Therefore, there have been increased efforts 
to develop third generation TKIs that can target BCR-ABL1T315I mutant, such as 
ponatinib (O'Hare et al., 2009)and DCC-2036 (Chan et al., 2011).  
CML patients who have responded to therapy and are in a state of remission 
harbour a very suppressed clone of CML cells which is referred to as minimal 
residual disease (MRD) or LSCs (Chomel et al., 2011). LSCs are responsible for 
the relapse of CP CML after the withdrawal of TKIs and therefore, patients are 
kept on lifelong TKI treatment after achieving remission. The survival of LSCs in 
the presence of TKIs is the current challenge in CML management and treatment 
strategies. Thus, understanding of the LSC biology is essential for developing 
effective chemotherapies that can completely eradicate CML. 
1.7.5 Targeting CML stem cells 
The TKI-insensitivity of LSCs raised the question of whether resistance is 
conferred in a BCR-ABL1-dependent or independent manner. TKIs have been 
shown to block the kinase activity of BCR-ABL1 in LSCs (Corbin et al., 2011, 
Hamilton et al., 2012); however, the rate of apoptosis in LSCs upon TKI treatments 
is significantly lower than in progenitors. Thus, LSCs are believed not to be BCR-
ABL1-kinase addicted (Hamilton et al., 2012).   
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It was mentioned above that TKI treatment can inhibit BCR-ABL1 function in 
LSCs, but cannot eliminate them. Therefore, an LSC with suppressed BCR-ABL1 
activity upon TKI treatment could be associated with a loss-of-function, gain-of-
function, or neutral status relative to an untreated LSC harbouring fully functional 
BCR-ABL1 proteins. The loss-of-function LSCs are therefore, in a dominant-
negative state which are cytokine-dependent and their myeloid cells express only 
very low levels of BCR-ABL1 (Corbin et al., 2011, Kumari et al., 2012). The neutral 
variants, on the other hand, are indistinguishable from HSCs and are suggested to 
be more dependent on HIF1α and promyelocytic leukaemia (PML) proteins (Ito et 
al., 2008, Zhang et al., 2012). In the gain-of-function variants the pathways 
downstream of BCR-ABL1 exhibit high activity despite the inhibition of the kinase 
domain, which subsequently enhance migration and minimise adhesion capacities 
(Ramaraj et al., 2004). It is also suggested that the gain-of-function variants can 
represent epigenetic alterations as a result of initial BCR-ABL1 activity which still 
persist after TKI-induced suppression. Thus, blocking kinase-independent or 
epigenetically active pathways may be required in order to eliminate LSCs. These 
reports indicate that there are multiple subclones of LSCs, which could exist 
simultaneously, and potentially a combinatorial treatment strategy is required to 
eliminate LSCs (Kaelin, 2005). Therefore, it is required to dissect the role of key 
biological pathways in the maintenance of LSCs, as discussed below. 
1.7.6 Major biological pathways involved in the survival of LSCs   
1.7.6.1 Wnt signalling pathway  
It was demonstrated in a murine CML model that the absence of β-catenin 
reduced the severity of the disease as a result of impaired self-renewal capacities 
of LSCs (Zhao et al., 2007a). However, contradictory observations suggested that 
the inhibition of GSK3β,   a   negative   regulator   of   β-catenin, in combination with 
imatinib caused apoptosis in LSCs (Reddiconto et al., 2012). Thus, it is plausible 
that  β-catenin levels should be tightly regulated in LSCs to act as a pro-survival 
factor.  
1.7.6.2 TGF-β  signalling  pathway  and  the  role  of FOXO3A and BCL-6 
BCR-ABL1 induces the cytoplasmic translocation and subsequent degradation of 
FOXO3A, which is phosphorylated by the activated AKT, in CML progenitor cells. 
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Imatinib treatment, therefore, results in the nuclear stabilisation of FOXO3A which 
causes cell cycle arrest and apoptosis through upregulation of CDKN1B/p27 and 
BCL2L11/BIM genes (Essafi et al., 2005). A recent study on the role of TGF-β in 
the maintenance of LSCs, demonstrated inhibition of AKT phosphorylation in the 
presence of TGF-β  ligand  that  resulted in nuclear localisation of FOXO3A in LSCs, 
which was independent of TKI treatment (Naka et al., 2010). The murine 
FOXO3A-deficient CML model developed leukaemia in the first engraftment, but 
failed to promote leukaemia in later engraftments; thus, implying an important 
function for TGF-β-FOXO3A signalling in the maintenance of LSCs. Through 
inhibition of TGF-β   signalling   by   LY364947,   a   TGFBR1 inhibitor, and in 
combination with imatinib, the CML mice demonstrated better prognosis than the 
imatinib-treated controls (Naka et al., 2010). This was mediated by the activation 
of AKT which caused cytoplasmic translocation and degradation of FOXO3A. This 
study provided substantial evidence on the role of TGF-β  signalling  in  maintaining  
LSC quiescence despite the expression of BCR-ABL1. However it remains unclear 
whether TGF-β  signalling  is  regulated  by  autocrine  or  paracrine  means  in  CML.   
FOXO3A also targets BCL6 in CML (Hurtz et al., 2011). The nuclear localisation 
and activity of FOXO3A in the presence of TKIs or TGF-β  stimulation  may  result  in  
upregulation of BCL6 which in turn protects LSCs by suppressing p53 and 
CDKN2A/p16 tumour suppressors. Therefore, the administration of retro-inverso 
BCL6 peptide inhibitor (RI-BPI) resulted in increased survival of mice transplanted 
with CML cells (Hurtz et al., 2011). Thus, a specific LSC survival mechanism can 
be proposed in which the TGF-β-FOXO3A signalling suppresses LSC apoptosis 
by activating BCL6.   
1.7.6.3 Hedgehog signalling pathway  
The hedgehog pathway is implied in conferring self-renewal capacities to LSCs 
through the function of SMO (Dierks et al., 2008). TKIs are unable to inhibit the 
hedgehog signalling, but hedgehog-blocking antibodies can successfully impair 
the pathway (Zhao et al., 2009); therefore, indicating a BCR-ABL1-independent 
mechanism for hedgehog activation. Cyclopamine, a potent antagonist of 
hedgehog signalling by inducing an inactive conformation in SMO, was shown to 
target LSCs specifically over HSCs; therefore, it can be used as a potent 
chemotherapeutic in combination with TKIs (Zhao et al., 2009). 
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1.8 Epigenetic origins of  cancer  
There has been a growing interest over the past decade to understand the role of 
epigenetic abnormalities as an equally important factor as genetic abnormalities in 
cancer development (Herman and Baylin, 2003; Jones and Baylin, 2007). In fact, 
the first evidence of epigenetic involvement in cancer came from the observations 
of abnormal changes in DNA methylation patterns in cancer genome (Riggs and 
Jones, 1983). Therefore, the understanding of underlying epigenetic mechanisms 
and abnormalities that give rise to the gene expression signatures of cancer cells 
is crucial for a better understanding of the cancer biology. Tumours often form as a 
result of the stress responses such as exposure to DNA damaging agents. 
Therefore, under these circumstances predisposition to epigenetic abnormalities 
can result in the induction of cell survival mechanisms instead of apoptosis or 
senescence (Ohm and Baylin, 2007). Nevertheless, it can be argued that the 
genetic mutations in key developmental and cell signalling pathways, such as Wnt, 
hedgehog and Myc, are sufficient for tumourigenesis (Taipale and Beachy, 2001; 
Hanahan and Weinberg, 2000), but it has been demonstrated that the induction of 
such genetic mutations in mature cells results in apoptosis and senescence (Lowe 
et al, 2004). Thus, other cellular changes are required for the cells to survive and 
initiate cancer in the presence of these mutations. These key players can be the 
epigenetic modifications such as DNA methylation or histone modifications whose 
roles during early stages of cancer formation are discussed below. 
1.8.1 Role of DNA methylation in the formation of cancer stem 
cells 
Abnormal promoter DNA hypermethylation which results in abnormal gene 
silencing has been reported as one of the key epigenetic changes that confers 
advantage to cancer cell survival (Jones and Baylin, 2007). The promoter 
hypermethylation is identified in association with the genes that regulate stem and 
progenitor cells maintenance, such as CDKN2A/p16, GATA4, GATA5 and several 
regulators of Wnt signalling pathway. These epigenetic abnormalities are believed 
to occur during early neoplastic transformation (Jones and Baylin, 2007). This 
model has been investigated in colon cancers with respect to the Wnt signalling 
regulators. An inhibitor of Wnt signalling, SOX17, which promotes the degradation 
of β-catenin, was found to be abnormally hypermethylated and silenced in benign 
colon neoplasams (Zhang et al., 2008). This epigenetic abnormality can, therefore, 
Chapter 1  75 
result in the formation of cancer stem cells by maintaining the constitutive activity 
of Wnt signalling pathway which is important in stem cell self-renewal and 
maintenance. 
1.8.2 Role of histone modifications in the formation of cancer 
stem cells 
The genome-wide studies of histone modifications and DNA methylation in colon 
cancer showed that 50% of abnormally hypermethylated genes in cancer cells 
were associated with PRC2 complex and bivalent domains at their promoters in 
ES cells or embryonic mesenchymal cells (Schlesinger et al., 2007, 
Widschwendter et al., 2007). DNA demethylation of these genes by 5-aza-2′-
deoxycytidine treatment or as a result of DNMT knockout in colon cancer cells did 
not result in the resolution of bivalency, but was associated with increased levels 
of H3K27me3 at these promoters (McGarvey et al., 2006). The bivalent genes in 
adult stem cells are poised as their fate will be determined upon lineage 
differentiation. However, as discussed earlier, the lineage priming model indicates 
very low expression levels of the bivalent genes whose activities are required 
subsequently during differentiation. Therefore, the observation of hypermethylated 
bivalent genes in cancer cells suggests a permanent blockage on transcriptional 
activation of lineage-specific transcription factors that consequently confers a less 
mature phenotype to cancer cells. The maintenance of stem cell-like epigenetic 
signature at early stages of tumourigenesis would in turn promote the expansion of 
immature pre-malignant cancer cells. These pre-malignant clones can provide 
foundations for further genetic or epigenetic abnormalities that lead to a 
malignancy. GATA4, which is a transcription factor required for development of 
mature epithelial cells in colon, is found to be bivalent and expressed at very low 
levels in ES cells. Furthermore, upon in vitro induction of differentiation, GATA4 
promoter predominantly retains H3K4me3 marks that is associated with 
transcriptional activation (Tiwari et al., 2008). GATA4 promoter retains its 
bivalency but becomes significantly hypermethylated in colon cancer cells which 
results in the permanent silencing of this loci (Tiwari et al., 2008). Thus, 
hypermethylation completely abolishes the poised state and eliminates the 
accessibility of promoter for activation during differentiation. 
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1.9 Aims of this thesis 
CML is a stem-cell driven and clonal haematological malignancy that has played a 
significant role in the understanding of cancer stem cell biology. A systems biology 
approach was implemented to investigate the epigenetic programming that defines 
stem cell identity and entry into the proliferative compartment in CML. The aims of 
the work presented in this thesis were: 
1. To elucidate the gene expression signatures of LSCs and CML progenitor cells 
(LPCs) to identify biological pathways important in maintenance of stem cell 
features as well as exit from the stem cell programme. 
2. To develop a ChIP method that can reliably be coupled to high throughput DNA 
sequencing for small primary stem cell populations in order to study and 
compare histone modification patterns of HSCs and LSCs. 
3. To establish global histone modification maps of HSCs, LSCs and LPCs to 
identify the relationship between the epigenetic programming and the observed 
gene expression signatures. 
4. To functionally validate the novel biological pathways that are identified by 
global gene expression and epigenetics analyses to be important in the 
maintenance of LSCs. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Composition of molecular biology solutions 
Sterile high-performance liquid chromatography (HPLC)-grade water (VWR 
International, UK) was used to prepare all solutions. 
Cell lysis buffer (CLB): 
• 10 mM Tris-hydrochloric acid (HCl) (pH 8.0)  
• 10 mM sodium chloride (NaCl) (VWR International) 
• 0.2% Igepal (Sigma-Aldrich, Dorset, UK) 
• 10 mM sodium butyrate (NaBu) (Sigma-Aldrich) 
• 50  μg/ml  phenylmethanesulfonyl  fluoride  (PMSF)  (Sigma-Aldrich) 
• 1  μg/ml  Leupeptin  (MP  Biomedicals,  California, USA) 
Nuclear lysis buffer (NLB): 
• 50 mM Tris-HCl (pH 8.1) 
• 10 mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) 
• 1% sodium dodecyl sulphate (SDS) (Sigma-Aldrich) 
• 10 mM NaBu 
• 50  μg/ml  PMSF 
• 1  μg/ml  Leupeptin 
Immunoprecipitation (IP) dilution buffer (IPDB): 
• 20 mM Tris-HCl (pH 8.1) 
• 150 mM NaCl 
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• 2 mM EDTA 
• 1% Triton X-100 (VWR International) 
• 0.01% SDS 
• 10 mM NaBu 
• 50  μg/ml  PMSF 
• 1  μg/ml  Leupeptin 
IP wash buffer 1 (IPWB1): 
• 20 mM Tris-HCl (pH 8.1) 
• 50 mM NaCl 
• 2 mM EDTA 
• 1% Triton X-100 
• 0.1% SDS 
IP wash buffer 2 (IPWB2): 
• 10 mM Tris-HCl (pH 8.1) 
• 250 mM lithium chloride (LiCl) (Sigma-Aldrich) 
• 1 mM EDTA 
• 1% Igepal 
• 1% Deoxycholic acid (Sigma-Aldrich) 
IP elution buffer (IPEB): 
• 100 mM sodium bicarbonate (NaHCO3) (VWR International) 
• 1% SDS 
1X phosphate buffered saline (PBS): 
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1X PBS used for washing the cells in ChIP assay was prepared by dissolving one 
PBS tablet (Sigma-Aldrich) in 500 ml HPLC water. 
10X deoxyribonucleotide triphoshphate (dNTP) mix for labelling ChIP samples: 
The following mix was prepared in sterile labelling water (Invitrogen, Paisley, UK) 
and used for labelling ChIP samples prior to microarray hybridisations:  
• 1 mM deoxycitidine triphosphate (dCTP) (Scientific Laboratory Supplies, 
Hull, UK)  
• 2 mM each of deoxyadenosine triphosphate (dATP), deoxyguanosine 
triphosphate (dGTP), and deoxythymidine triphosphate (dTTP) (Scientific 
Laboratory Supplies) 
20X saline-sodium citrate (SSC) buffer: 
The following were dissolved in 800 ml HPLC water: 
• 175.3 g NaCl 
• 88.2 g sodium citrate (VWR International) 
The volume was adjusted to 1000 ml and the pH adjusted to 7.0. 
Tecan hybridisation station (HS) 4800 hybridisation buffer: 
• 50% formamide (Sigma-Aldrich)  
• 5% dextran sulphate (AppliChem) 
• 0.1% Tween 20 (Sigma-Aldrich) 
• 2X SSC 
• 10 mM Tris-HCl pH 7.4 
PBS/0.05% Tween 20 (Hybridisation wash solution 1): 
The following salts were dissolved in 1 litre of HPLC water: 
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• 7.33 g NaCl 
• 2.36 g sodium phosphate dibasic (Na2HPO4) (VWR International) 
• 1.52 g sodium phosphate monobasic monohydrate (NaH2PO4.H2O) (VWR 
International) 
• 500  μl  Tween  20 
10X polymerase chain reaction (PCR) buffer: 
• 670 mM Tris-HCl (pH 8.8) 
• 166 mM ammonium sulphate [(NH4)2SO4] (Sigma-Aldrich) 
• 67 mM magnesium chloride (MgCl2) (Sigma-Aldrich) 
10X Tris-borate-EDTA (TBE) buffer: 
The following salts were dissolved in 1 litre of HPLC water: 
• 108 g Tris base (Invitrogen) 
• 55 g boric acid (VWR International) 
• 9.3 g EDTA (VWR International) 
1X TBE buffer was prepared by mixing 100 ml 10X TBE buffer with 900 ml HPLC 
water. 
50X Tris-acetate-EDTA (TAE) buffer: 
The following salts were dissolved in 1 litre of HPLC water: 
• 242 g Tris base 
• 57.1 ml acetic acid (BDH) 
• 18.6 g EDTA 
1X TAE buffer was prepared by mixing 20 ml 10X TAE buffer with 980 ml HPLC 
water. 
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2.1.2 Composition of tissue culture solutions 
“DAMP”  solution for thawing cryopreserved CD34+ or mononuclear cells (MNCs) 
aliquots from liquid nitrogen: 
• 2 ml DNase I solution (1mg/ ml) (StemCell Technologies, Vancouver, 
Canada) 
• 1.25 ml MgCl2 (400X, 1M solution) (Sigma-Aldrich)  
• 53 ml trisodium citrate (0.155M) (Sigma-Aldrich) 
• 25 ml human serum albumin (20%) (Scottish National Blood Transfusion 
Service) 
Volume  was  adjusted  to  500  ml  with  Dulbecco’s  PBS  (Mg2+/Cl- free) (Invitrogen). 
Serum Free Medium (SFM): 
The following were made up and filter sterilised using vacuum bottle top filters: 
• 25 ml bovine serum albumin (BSA)/insulin/transferrin (BIT) (StemCell 
Technologies) 
• 1.25 ml L-glutamine (200 mM) (Invitrogen) 
• 1.25 ml penicillin/streptomycin (5000U/ ml) (Invitrogen)  
• 250 μl 2-mercaptoethanol (50 mM) (Invitrogen) 
• 500 μl low density lipoprotein (LDL) (10mg/ ml) (Sigma-Aldrich) 
• 97.25  ml  Isocove’s  modified  Dulbecco’s  medium  (IMDM)  (Sigma-Aldrich) 
SFM supplemented with physiological growth factors cocktail: 
The following growth factors were added at indicated volumes per 10 ml SFM and 
filter sterilised through 0.22μm filter: 
• 5 μl G-CSF (2 μg/ ml) (StemCell Technologies) 
• 20 μl GM-CSF (0.1 μg/ ml) (StemCell Technologies) 
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• 2 μl IL-6 (5 μg/ ml) (StemCell Technologies) 
• 5 μl LIF (0.1 μg/ ml) (Peprotech, USA) 
• 20 μl macrophage inflammatory protein (MIP)-1α (0.1 μg/ ml) (StemCell 
Technologies) 
• 4 μl SCF (0.5 μg/ ml) (StemCell Technologies) 
2.1.3 Antibodies  
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Culture of cell lines 
The mES cell line E14 (Hooper et al., 1987) was obtained from Bill Skarnes 
(Sanger Institute, Cambridge, UK). E14 cell line was established from the inbred 
mouse strain 129/Ola. E14 cells were cultured in a feeder-independent manner on 
gelatinised 6-well plates or 25 cm2 tissue culture flasks (Corning, Amsterdam, The 
Netherlands)   from   frozen   in   Dulbecco’s   modified   Eagle   medium   (DMEM)  
(Invitrogen) supplemented with 15% foetal bovine serum (FBS) (Invitrogen), 2% 
LIF-conditioned medium (CM), and 1.5X 10-4 M monothioglycerol (MTG) (Sigma-
Aldrich). Cells were maintained at 37oC, 5% CO2 and were passaged with warm 
fresh medium after reaching 70-80% confluency (approximately every 2 days). 
Cells were reseeded at 150,000 cells per well of a 6-well plate, or 1x106 cells per 
75 cm2 flask, or 3x106 per 225 cm2 flask. Since 108 cells were required for the 
conventional ChIP assays, five 225 cm2 flasks were normally cultured to obtain 
sufficient number of cells. 
GFP-tagged murine stromal cell line OP9 (Kodama et al., 1994) was received as a 
gift from Dr. Alison Michie (Institute of Cancer Sciences, University of Glasgow). 
OP9 cells were derived from newborn B6C3F2 op/op mouse calvaria with a 
mutation in the gene encoding for macrophage-colony stimulating factor (M-CSF), 
thus resulting in the lack of secretion of functional M-CSF (Yoshida et al., 1990). 
The OP9 cells were demonstrated to augment haemopoiesis and facilitate the 
differentiation of ES cells to CD34+ cells in vitro (Vodyanik et al., 2005). OP9-GFP 
cells were cultured in minimum essential medium alpha (MEM α) (Invitrogen) 
containing 20% FBS (Invitrogen), 1% penicillin/streptomycin, 1% L-glutamine, 1% 
non-essential amino acids (NEAA) (Invitrogen),   50   μM   2-mercaptoethanol 
(Invitrogen). Cells were maintained at 37oC, 5% CO2 and were passaged with 
warm fresh medium after reaching confluency (approximately every 3 days). The 
OP9-GFP co-culture systems were set-up by seeding 50,000 cells/well of 
collagen-coated 6-well plates and fresh medium was replenished after 3 days until 
reaching confluency prior to plating the primary haemopoietic cells.   
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2.2.1.2 Collection of human primary cell samples 
All samples were collected with approval from the Local Research and Ethics 
Committee and with written informed patient consent from patients at diagnosis of 
CP CML. Cells were collected by leukapheresis prior to any drug treatment. Each 
sample was determined to be Ph+ by FISH and BCR-ABL+ by PCR (Dr. Elaine 
Allan, Institute of Cancer Sciences, University of Glasgow). Further samples were 
also obtained from patients, with normal BM undergoing autologous stem cell 
collection for either non-Hodgkin’s  lymphoma  or  normal  bone  marrow  donors,  who  
had been mobilised with G-CSF and had excess CD34+ cells remaining after those 
required for clinical use had been processed. 
2.2.1.3 Purification of the MNC fraction from whole blood cell samples 
Either 6 ml of ficoll/Histopaque solution was added to a 15 ml falcon tube, or 20 ml 
of ficoll/Histopaque solution was added to a 50 ml falcon tube (depending on the 
volume of blood sample) and brought to room temperature (RTm). The whole 
blood sample was first diluted (1:2) with PBS, carefully layered drop-wise onto the 
ficoll/Histopaque solution, until it reached the top of the centrifuge tube and 
centrifuged at 1,500 rounds per minute (rpm) for 20 minutes (mins) at RTm. 
Following centrifugation, the opaque interface containing the MNCs was carefully 
aspirated with a pastette. The interface was then transferred into a sterile 
centrifuge tube with a pastette and washed twice with sterile PBS (centrifuged at 
1,000 rpm for 5 mins) (Dr. Alan Hair, Institute of Cancer Sciences, University of 
Glasgow). The resultant MNCs were either used fresh or cryopreserved according 
to Section 2.2.1.5 until required. 
2.2.1.4 Selection of CD34+ cells from MNC samples 
Enrichment for CD34+ cells was achieved using the sterile CliniMACS system 
(Miltenyi Biotec, Bisley, UK), which positively selects for CD34+ cells according to 
the   manufacturers’   instructions (Dr. Alan Hair, Institute of Cancer Sciences, 
University of Glasgow). Briefly, total MNCs were incubated with a specific anti-
CD34 monoclonal antibody (Miltenyi Biotec) to which super-paramagnetic MACS 
beads (~50 nm in diameter) had been conjugated. The cell sample was then 
passed through a high-gradient magnetic separation column, where the target 
CD34+ cells were retained in the column and the unlabelled CD34- cells flushed 
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through and discarded. The bound CD34+ cells were then eluted after removal 
from the magnetic field, collected and an aliquot was removed for flow cytometry 
assessment of CD34 purity, which confirmed that all samples were >95% CD34+ 
post-selection. All samples were stored at the indicated concentrations (Section 
2.2.1.5) in liquid nitrogen until required. 
2.2.1.5 Cryopreservation of cells 
E14 cells were frozen down in cryotubes at a density of 3-5x105 cells per ml in 
10% dimethyl sulfoxide (DMSO), 40% FBS, and 50% E14 culture medium. OP9-
GFP cells were frozen down at 1x106 cells per cryotube in 10% DMSO and 90% 
OP9 culture medium.  
For CML and non-CML cells between 4x106-2x107 CD34+-enriched cells or 108 
MNCs were cryopreserved by adding an equal volume of 20% DMSO in 4.5% 
ALBA (Human Albumin Solution, Scottish National Blood Transfusion Service) to 
each cell suspension to obtain a final concentration of 10% DMSO (Dr. Alan Hair, 
Institute of Cancer Sciences, University of Glasgow). The cryotubes were 
transferred to a cryofreezer container and first cooled at -80°C to provide a 
controlled temperature reduction and then transferred to liquid nitrogen for long-
term storage. 
2.2.1.6 Recovering frozen primary cells 
CML/non-CML CD34+-enriched cells or MNCs were removed from liquid nitrogen 
and immediately thawed at 37°C in a water bath until the ice crystals had melted. 
Using a pastette, the cells were added to a 15 ml sterile falcon tube and recovered 
by drop-wise addition of 10 ml of DAMP over a 20-minute period. This step was 
performed at RTm to enhance the activity of the DNase I, with constant agitation to 
prevent clumping of the cells. The cells were centrifuged at 1,000 rpm for 10 mins 
and after discarding the supernatant, the pellet was washed twice in DAMP (1,000 
rpm for 10 mins) and resuspended in SFM supplemented with physiological 
growth factors cocktail for counting and cell viability using the Trypan blue dye. 
The cells were then plated and cultured in SFM supplemented with physiological 
growth factors cocktail overnight in 75 cm2 hydrophobic tissue culture flasks at 
~2x106 cells/ml. 
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2.2.1.7 OP9-CD34+ CD38- cells co-culture  
The sorted CML CD34+ CD38- cells were seeded at a density of 5x103-5x104 per 
well on top of confluent OP9-GFP cultures (Section 2.2.1.1). The OP9 media was 
replaced with 2 ml Myelocult H5100 media (StemCell Technologies) supplemented 
with freshly prepared and filter-sterilised hydrocortisone sodium succinate 
(StemCell Technologies) to give a final concentration of 10-6 M. The co-culture was 
maintained for 3 days at 37oC and 5% CO2. A stromal-free condition was also set 
up in a well of a 96-well plate in the presence of 200 μl SFM supplemented with 
physiological growth factors to monitor the effect of OP9 stromal cells on the 
primitive cells. On day 3, the media in each well of the co-culture experiment was 
replaced by 1 ml collagenase IV/Myelocult (1 mg/ml) solution and incubated for 20 
min at 37oC. Subsequently, 1 ml trypsin (Invitrogen) was added and the cells were 
incubated for an extra 15 mins at 37oC. The cells were harvested by using cell 
scrapers and 1 ml FBS was added to each well to neutralise trypsin. Cells were 
centrifuged at 300 g for 5 mins and washed once with PBS/2% FBS. After passing 
through 0.7 μm filters, cells were then used for gene expression analysis (Section 
2.2.4.3), monitoring cell division progress (Section 2.2.2.2), or colony-forming cell 
(CFC) assays (Section 2.2.1.9).  
The concentration of neurotransmitters used for the treatment conditions in OP9 
co-culture assays are summarised in Table 2.1. The neurotransmitters were added 
to each well upon plating the CML CD34+ CD38- cells.  
 
Table   2.1: The concentration of the neurotransmitters used in OP9 co-culture treatment 
assays.  
Each neurotransmitter was prepared in stock solutions in the appropriate solvent. To achieve the 
final concentration levels two dilutions were performed; one with the Myelocult medium prior to 
adding to the well and the second one at the time of mixing with the medium in each well.  
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2.2.1.8 CFC and replating assays 
After harvesting the OP9-CD34+ CD38- co-culture cells on day 3, cells were 
stained for CD34-APC for 20 min in the dark followed by washing twice with 
PBS/2% FBS. The viable GFP- CD34+ cells were isolated using the FACSAria cell 
sorting system and equal number of cells (3-5x103) in each condition was used to 
set up duplicate CFC assays for each treatment condition. The appropriate volume 
of cell suspension for duplicate wells was added to 2 ml of MethoCult H4034 
Optimum (StemCell Technologies) methylcellulose-based medium and thoroughly 
mixed. 1 ml of this mixture was added to a 35 mm tissue culture dish and was 
gently swirled, so that the bottom of the dish was completely coated, and then 
incubated for 10 days at 37°C and 5% CO2 under humidified conditions. At the end 
of this time, the number of viable erythroid (CFU-E and BFU-E), granulocyte-
macrophage (CFU-GM, CFU-G, and CFU-M), and multipotential granulocyte, 
erythroid, macrophage, megakaryocyte (CFU-GEMM) colonies were counted in 
each dish. 
On day 11, individual colonies from each plate were carefully plucked under the 
microscope in the hood with a p10 pipette and were inoculated into individual wells 
in a 96-well plate, which were covered with 100 μl of MethoCult medium and 10 μl 
of SFM. Even dispersion was achieved by aspirating the SFM into the colony 
containing pipette tip and carefully mixing with the MethoCult medium by pipetting 
action without introducing air. Normally, 50 colonies were plucked at random and 
the 96-well plate was incubated at 37oC and 5% CO2 under humidified conditions 
for 10 days before measuring the replating efficiency which can be expressed as 
the total number and the types of colonies in each treatment condition.  
2.2.2 Flow cytometry  
Flow Cytometry or fluorescence-activated cell sorting (FACS) is a quantitative 
technique that permits the visualisation and sorting of cells by multiple parameters 
according to their fluorescence intensity after antibody labelling. A flow cytometer 
can also measure the size of a cell using forward scatter and the granularity of a 
cell using side scatter parameters. All the flow cytometric analyses were carried 
out employing a FACSCanto system (BD). 
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2.2.2.1 Isolation of CD34+ CD38- and CD34+ CD38+ cells from recovered 
primary samples 
The recovered primary cells were harvested after overnight culture and centrifuged 
at RTm (1,200 rpm for 5 mins). The pellet was washed once in PBS/2% FBS. After 
cell count, aliquots of cells (105 cells) were removed for appropriate isotype 
controls which were used to correctly set the detectors, so that the negative 
isotype population was placed in the first log decade for each flow cytometry 
channel. CD34-APC and CD38-FITC or CD38-PerCP (for co-culture experiments) 
single positive staining (2 μl of antibody per control) were also set up. The 
remaining cells were stained with both CD34-APC (5 μl/106 cells) and CD38-FITC 
(10 μl/106cells) or CD38-PerCP (5 μl/106 cells) antibodies and samples were 
incubated for 20 mins in the dark. Following incubation, samples were washed 
twice with PBS/2% FBS (1,200 rpm for 5 mins). The controls were resuspended in 
200 μl PBS/2% FBS and the rest of the sample was resuspended in 2 ml PBS/2% 
FBS. All samples were passed through 0.7 μm filters to remove cell clumps before 
sorting. After adjusting the isotype and positive control thresholds (gates), CD34+ 
CD38- and CD34+ CD38+ cells were then isolated using FACSAria (BD) cell sorting 
system. 
2.2.2.2 Carboxyfluorescein diacetate succinimidyl ester (CFSE) 
analysis for monitoring cell division 
2.2.2.2.1 CFSE staining 
The use of CFSE intracellular fluorescence dye was initially demonstrated to be a 
powerful flow cytometry technique to monitor cell divisions in vitro and in vivo in 
lymphocytes (Lyons and Parish, 1994). CFSE molecule is highly permeable via 
cellular membranes and once inside the cell cannot be passively lost. CFSE 
covalently binds to the intracellular amino groups and is diluted between daughter 
cells at each division. CFSE was shown to stably label intracellular molecules with 
sequential halving of fluorescence intensity at every cell division for up to eight 
divisions before the fluorescence intensity gets reduced to background level 
(Lyons and Parish, 1994). CFSE staining was also successfully reported for HSCs 
(Nordon et al., 1997).   
After isolating the CD34+ CD38- population and prior to plating for OP9-GFP co-
culture experiments, half of the cells were removed for CFSE analysis. Since we 
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were using GFP-tagged cells (FITC wavelength), the CellTrace Violet dye 
(Invitrogen) was used which could be monitored at the Pacific Blue wavelength. 
Cells were resuspended in 1 ml PBS/2% FBS and 1 μl CellTrace Violet dye (5 mM 
in DMSO) was added to give the final concentration of 5 μM. The staining 
suspension was subsequently incubated for 20 mins at 37oC and protected from 
light. The unbound dye was quenched by adding 10X the original staining volume 
of ice-cold PBS/20% FBS and washed at 300 g for 5 mins. After discarding the 
supernatant, the pellet was washed once in PBS/2% FBS. Cells were then 
resuspended in the co-culture or stromal-free media (SFM supplemented with 
physiological growth factors) and a 20 μl aliquot was removed, diluted 1:10 with 
PBS/2% FBS and used for cell counting by the CountBright Absolute Counting 
Beads   (Invitrogen)   using   flow   cytometry   according   to   the   manufacturer’s  
instructions. The efficiency of CFSE staining was also established at this stage by 
flow cytometry. Additionally, a colcemid control was set up using CFSE-stained 
cells in stromal-free conditions to determine the position of the undivided 
population (CFSEmax peak) after co-culture. The colcemid solution (100 g/ml) was 
directly added to the cultured cells to give a final concentration of 100 ng/ml. The 
cells unstained for CFSE were used to adjust the voltage settings and optimally 
compensate for spectral overlap.   
2.2.2.2.2 FACS analysis of CFSE experiments 
Following harvesting the co-culture  on  day  3,   a  20  μl  aliquot  was   removed   from  
each different condition for cell counting by the CountBright Absolute Counting 
Beads. CFSE-stained cells were washed once with PBS/2% FBS and used for 
flow cytometry. Isotype controls were used to correctly set the detectors, so that 
the negative isotype population (CFSE- cells) was placed in the first log decade for 
each flow cytometry channel. The colcemid-treated assay was used as the CFSE+ 
control and also to identify the undivided population, which was termed as the 
CFSEmax peak. The co-cultured cells were stained for CD34-APC for 20 mins in 
the dark followed by washing with PBS/2% FBS. The CFSE fluorescence was 
measured in the GFP- (FITC-) and CFSE+ (Pacific Blue+) population.   
2.2.2.2.3 Calculation of the undivided (CFSEmax) cell population 
To determine the anti-proliferative effect of different treatment conditions and 
assess the size of the non-proliferating primitive progenitor population, the 
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percentage recovery of viable CD34+ population in the undivided population 
remaining after co-culture was assessed. The number of viable cells harvested 
from each culture condition was recorded, as was the percentage of CD34+ cells 
found in the undivided fraction (CFSEmax). Percentage recovery of input cells in the 
undivided peak could then be calculated by dividing the absolute number of 
CFSEmax CD34+ cells by the total number of input CD34+ cells (day 0) and 
multiplying by 100%. This allowed direct comparison of different treatment 
conditions on the non-proliferating primitive progenitor population. 
2.2.3 Total RNA extraction for Affymetrix and TaqMan-based RT-
PCR gene expression analysis 
Total RNA was extracted by RNeasy Micro Kit (QIAGEN, Crawley, UK) for sample 
sizes smaller than 5x105 cells such as the sorted CD34+ CD38- cell populations 
according  to  the  manufacturer’s  instructions.  RNeasy  Mini  Kit  (QIAGEN)  was  used  
for sample sizes between 5x105-1x107 cells such as the sorted CD34+ CD38+ 
populations   according   to   the   manufacturer’s   instructions.   QIAshredder   columns  
(QIAGEN) were used to homogenise the cell lysates according to the 
manufacturer’s  instructions.  All  the  RNA  extraction  samples  were  DNase  I-treated 
on-column using the ribonuclease (RNase)-Free DNase Set (QIAGEN) according 
to   the  manufacturer’s   instructions.  The purity of RNA sample (A260/280) and its 
concentration were measured by NanoDrop ND-1000 spectrophotometer. The 
Agilent Bioanalyzer and Agilent RNA 6000 Nano Kit (Agilent Technologies, 
California, USA) were used to measure the integrity of the RNA samples according 
to  the  manufacturer’s  instructions. 
2.2.4 PCR-based gene expression analyses 
2.2.4.1 384-well TaqMan Micro Fluidic cards 
180 ng RNA was converted to cDNA for each sample using High Capacity RNA-
to-cDNA Kit (Applied Biosystems, Warrington, UK) according to the manufacturer’s  
instructions. A pool of RNA was used for normal CD34+ CD38- cells (60 ng of RNA 
from each individual sample), but individual RNA samples were used for CML 
CD34+ CD38- cells.  
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Custom 384-well TaqMan Micro Fluidic cards (Applied Biosystems) were designed 
for Affymetrix gene expression validation analysis. The 96a format was used which 
consists 96 TaqMan gene expression assays pre-implanted in four replicates. 
Each card uses eight sample-loading ports, each connected to 48 reaction-wells. 
Each cDNA sample was divided into triplicates; therefore, for each port 30ng 
equivalent cDNA (60 ng per replicate) was added to 100 µl of TaqMan Gene 
Expression Master Mix (Applied Biosystems), and samples run on the Applied 
Biosystems 7900HT Real-Time PCR System   according   to   the   manufacturer’s  
instructions. Data was quantified using RQ Manager Analysis and DataAssist 
softwares (Applied Biosystems). Relative gene expression was calculated using 
the 2-ΔΔCT method. The RQ ratio between target gene and endogenous controls 
were plotted as a measure of mRNA gene expression. The full list of TaqMan 
probes used to design the custom arrays can be found in the Appendix 1.  
2.2.4.2 Fluidigm Dynamic Array integrated fluidic circuits (IFCs) 
The 48.48 Dynamic Array IFCs (Fluidigm, Amsterdam, The Netherlands) were 
used to analyse the gene expression levels of primary haemopoietic cells in the 
OP9-GFP co-culture system. Cells were stained with CD34-APC and CD38-PerCP 
after harvesting on day 3 for 20 mins in the dark followed by washing twice in 
PBS/2% FBS. 300 GFP- CD34+ CD38- viable cells from each treatment condition 
were sorted directly into the pre-amplification master mix. The pre-amplification 
master mix could be made up of up to 100 TaqMan probes at 0.2X final 
concentration. Each master mix was prepared as follows: 5.0 μl CellsDirect 2X 
reaction mix (Invitrogen), 2.5 μl 0.2X probe mix, 0.2 μl SuperScript III RT/Platinum 
Taq Mix (Invitrogen), 1.3 μl Tris-EDTA (TE) buffer (pH 8.0), and 0.1 μl RNase 
inhibitor SUPERase-In (Ambion). Cells could also be sorted to the pre-
amplification master mix lacking the probe mix and the SuperScript III enzyme to 
be kept at -20oC until required. The negative control sample was also set up at this 
stage by sorting the cells into a pre-amplification master mix in the absence of 
SuperScript III enzyme. The pre-amplification mix was then placed in a thermal 
cycler using the following programme: 50oC for 15 mins (reverse transcription 
step), 95oC for 2 mins (Taq activation), and 18 cycles of 95oC for 15 secs and 
60oC for 4 mins. At the end of pre-amplification the samples were diluted 1:5 by 
the TE buffer (pH 8.0).  
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The 48.48 Dynamic Array IFCs format would allow analysis of up to 48 gene 
expression assays (45 tests + 3 housekeeping genes) for 16 samples in triplicates 
(14 tests + negative control + water). Dynamic Array IFCs were primed according 
to  the  manufacturer’s   instructions  in  the  IFC  Controller  MX  system  (Fluidigm).  48  
10X assay mixes were prepared by mixing 2.5 μl each 20X TaqMan Gene 
Expression Assay (Applied Biosystems) and 2.5 μl 2X Assay Loading Reagent 
(Fluidigm) and loaded to the probe inlets of the arrays. Each cDNA sample 
(individual replicates) was added to the samples inlet by mixing 2.5 μl 2X TaqMan 
Universal PCR Master Mix (Applied Biosystems), 0.25 μl 20X GE Sample Loading 
Reagent (Fluidigm), and 2.25 μl pre-amplified cDNA. The chip was then inserted in 
the IFC Controller MX system to complete the loading process according to the 
manufacturer’s   instructions. Finally, the chip was transferred to the BioMark HD 
system (Fluidigm) to perform the RT-PCR reactions followed by scanning and data 
collection by the BioMark Data Collection software (Fluidigm). Data analysis was 
performed in the Fluidigm Real-Time PCR Analysis software and the raw data 
were exported to Microsoft Office Excel to calculate the differential gene 
expression using the 2-ΔΔCT method. The full list of TaqMan probes used for the 
Fluidigm analysis can be found in the Appendix 2. 
2.2.4.3 Primer design for gene expression analyses  
The TaqMan assays used for the Micro Fluidic cards and Fluidigm Dynamic Array 
IFCs were selected from a catalogue of TaqMan gene expression assays available 
from Applied Biosystems website (http://bioinfo.appliedbiosystems.com/genome-
database/gene-expression.html). The selected primers could amplify all 
alternatively spliced transcripts of the genes of interest. All TaqMan probes were 
designed as FAM-conjugated. For Fluidigm gene expression analyses, in 
particular, probes were selected that amplify <100bp amplicon sizes and from 
exon-intron junctions exclusively as the pre-amplification master mix cannot be 
DNase I-treated.  
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2.2.5 Gene expression analysis using Affymetrix GeneChip 
Whole-Transcript (WT) Gene Arrays 
2.2.5.1 Preparation of labelled target DNA and array hybridisation        
After verifying the purity, integrity, and concentration of total RNA by the 
Bioanalyzer (Section 2.2.3.2), 50 ng of total RNA was used to prepare sense DNA 
targets using random priming-based Ambion WT Expression Kit (Ambion) 
according  to  the  manufacturer’s  instructions.  The  synthesised  sense  DNA  strands  
were fragmented and labelled using the GeneChip WT Terminal Labelling Kit 
(Affymetrix, High Wycombe, UK) which contains terminal deoxynucleotidyl 
transferase  (TdT),  according  to  the  manufacturer’s  instructions.  The  HuGene-1_0-
st-v1 Affymetrix arrays were hybridised, stained, and washed using GeneChip 
Hybridization, Wash, and Stain Kit (Affymetrix) on the GeneTitan Instrument 
(Affymetrix),  according  to  the  manufacturer’s  instructions.   
2.2.5.2 Preprocessing of raw image data 
The raw Affymetrix image data (.CEL) files were imported in Bioconductor 
(www.bioconductor.org), which is an R programming environment (Gentleman, 
2005). For data preprocessing, affy and aroma.affymetrix packages were used in 
Bioconductor, which perform Robust Multi-array Averages (RMA) background 
correction and quantile normalisation on the .CEL files. Aroma.affymetrix package 
uses RMA probe-level model (PLM) to obtain gene-level summaries for each gene 
(www.aroma-project.org). The array quality was assessed at this stage by the 
Normalised Unscaled Standard Error (NUSE) plot and the Relative Log 
Expression (RLE) plot. Furthermore, an extra quality control step was introduced 
by the simpleaffy package to generate the RNA degradation plots. Differential 
expression analysis was performed using the limma package which fits the 
microarray data into a linear model using an empirical Bayes method and coupled 
to the Benjamini Hochberg (BH) false discovery rate (FDR) control ((Benjamini and 
Hochberg, 1995) with an adjusted p-value of 0.05. The annotate package was 
used to annotate the significantly differentially expressed probe sets using the 
HuGene-1_0-st-v1 transcript cluster database. The made4 and rgl packages were 
used to perform three-dimensional (3D) principal component analysis (PCA). More 
information about the mentioned Bioconductor packages could be found in their 
‘vignettes’  available  from  the  Bioconductor  project  website.   
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2.2.5.3 Biological pathways analysis for gene expression differences 
Significantly differentially expressed genes in each analysis were exported to 
PANTHER database (www.pantherdb.org) (Thomas et al., 2003) to identify the 
pathways with significant numbers of changes and the pathways that show an up- 
or downregulation in a cell type relative to others. An input list of differentially 
expressed genes with their differential fold change values was provided. The 
statistical tool then created a distribution of values for the input dataset, which was 
then used as a reference for distribution. Subsequently, the input dataset was 
divided into functional categories, and the distribution of values in each group was 
then calculated and compared against the reference distribution. The probability of 
obtaining a random distribution from the reference distribution in each category 
was measured by the Mann-Whitney Rank-Sum test (U-test) (Clark et al., 2003). 
The output data was reported as p-values associated with the direction of shift for 
the distribution of values in each group relative to the reference distribution. The 
categories with non-random distribution were associated with small and significant 
p-values. 
2.2.6 ChIP 
2.2.6.1 Conventional ChIP assays 
Crosslinking 
1x108 E14 cells were collected by centrifuging at 1,200 rpm for 5 mins at RTm and 
resuspended in 50 ml serum-free DMEM media in a glass flask. Cells were 
crosslinked with 1,355   μl   formaldehyde   solution   (38%;;   final   concentration   1.0%)  
and incubated at RTm with gentle agitation for 15 mins. The crosslinking reaction 
was stopped by adding 3,425   μl   2   M   glycine   (final   concentration   of   0.125   M)  
followed by incubation for 5 mins at RTm with gentle agitation.  
Cell and nuclear lysis 
Cells were transferred to a 50 ml Falcon tube (kept on ice) and were centrifuged at 
1,200 rpm for 6-8 mins at 4ºC. The pellet was washed with 1.5 ml ice-cold PBS 
(2,000 rpm for 5 mins at 4ºC). The cell pellet was gently resuspended in 1.5X 
pellet volume of CLB and mixed well by pipetting followed by incubation on ice for 
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10 mins. Nuclei were subsequently collected by centrifuging at 2,500 rpm for 5 
mins at 4ºC. After removing the supernatant, the nuclei were resuspended in 1.2 
ml of NLB followed by incubation on ice for 10 mins. 
Sonication 
0.72 ml of IPDB was added to the nuclear lysate, which was then transferred to a 
5 ml glass falcon tube. Lysate was sonicated using the Sanyo/MES Soniprep 
sonicator to shear the crosslinked DNA into 300 – 1,000 bp fragments. The tip of 
the probe was maintained under the surface to avoid making bubbles which cause 
inefficient sonication. The samples were kept on ice at all times. Chromatin was 
sonicated for 11 mins (8 pulses of   30   secs   ‘on’   and   1  min   ‘off’)   at   14  microns  
power amplitude. The sheared chromatin was then transferred to a 2 ml eppendorf 
tube and centrifuged at 13,000 rpm for 5 mins at 4ºC. 
Pre-clearing 
The supernatant was transferred to a 15 ml falcon tube and 4.1 ml IPDB was 
added to give the NLB:IPDB ratio of 1:4. Subsequently, 100  μl  normal  rabbit   IgG  
was added to the chromatin solution and incubated for 60 mins at 4ºC on a 
rotating wheel for pre-clearing. The IgG antibodies were sequestered by adding 
200   μl   homogeneous   protein   G-agarose   beads   suspension   (100   μl   beads   bed  
volume) followed by incubation for 3 hours (hrs) at 4ºC on a rotating wheel. The 
beads were centrifuged at 3,000 rpm for 2 mins at 4ºC. The pre-cleared chromatin 
solution could be stored at -80°C at this stage until required. 
IP 
The supernatant from previous step was used to set up various IP conditions in a 
2 ml eppendorf tube. For each IP condition approximately 10% of the chromatin 
solution was used (equivalent to 107 cells). An NLB:IPDB buffer at the ratio of 1:4 
was freshly prepared and used to ensure that the final volume of all ChIP 
conditions  was  1,350  μl.  ChIP  conditions  were  set  up  as  follows: 675 μl chromatin 
+ 675 μl NLB:IPDB buffer + 10 μg of antibody raised against the histone 
modification of interest. Moreover,  270  μl  of  chromatin  was  aliquoted  and stored 
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at -20°C to be used as an input sample for array hybridisations or deep 
sequencing.  
ChIP samples were incubated overnight at 4ºC with rotation. The following day, 
samples were centrifuged at 13,000 rpm for 5 mins at 4ºC. The supernatants were 
transferred to a 1.5 ml eppendorf tubes and kept on ice whenever possible. The 
antibodies were sequestered by adding 50   μl   homogenous   protein   G-agarose 
beads   suspension   (25  μl   beads  bed   volume)   followed by incubation for 3 hrs at 
4ºC with rotation. Subsequently, protein G-agarose beads were centrifuged at 
13,000 rpm for 20 seconds at 4ºC and the supernatant was discarded. The protein 
G-agarose beads were carefully washed, for which the wash buffer was added, 
the samples were vortexed briefly, were centrifuged at 7,500 rpm for 2 mins at 4°C 
and left to stand on ice for 1 min before removing the supernatant. The washes 
were carried out in the following sequence: (i) the beads were washed twice with 
750 μl of cold IPWB1. The beads were transferred to a 1.5 ml eppendorf tube after 
the first wash; (ii) the beads were washed once with 750 μl of cold IPWB2; (iii) the 
beads were washed twice with 750 μl of cold TE buffer (pH 8.0). Finally, DNA-
protein-antibody  complexes  were  eluted  from  the  beads  by  adding  225  μl  of  IPEB 
followed by vortexing and centrifugation at 7,500 rpm for 2 mins. Subsequently, 
the supernatant was collected in a fresh 2.0 ml eppendorf tube. The bead pellet in 
the original tube was resuspended in 225 μl of IPEB again, briefly vortexed and 
centrifuged at 7,500 rpm for 2 mins. Both of the elutions were combined in the 
same tube. 
Crosslinks reversal and DNA purification 
The reversal of the crosslinks was carried out on the input sample which was 
stored at -20°C previously. This was achieved by adding 0.1   μl   RNase   A   (10  
mg/ml,  50  Kunitz  units/mg,   ICN  Biochemicals)  and  16.2  μl  5  M  NaCl  (to   the  final  
concentration of 0.3 M) to the input DNA sample. Similarly,   0.2  μl  RNase  A   (10  
mg/ml, 50 Kunitz units/mg)  and  27  μl  5  M  NaCl  (to  a  final  concentration  of  0.3  M)  
were added to each of the IP test samples. All the samples including the input 
DNA sample were incubated at 65ºC for 6 hrs to reverse the crosslinks. 
Subsequently, 9   μl   proteinase  K   (10  mg/ml,   20 U/mg, Invitrogen) was added to 
each sample to digest the proteins followed by incubation at 45ºC overnight. DNA 
was purified by adding 250   μl   phenol   (Sigma-Aldrich)   and   250   μl   chloroform   to  
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each sample. The samples were vortexed and centrifuged at 13,200 rpm for 5 
mins at RTm. The aqueous layer (top layer) was collected in fresh 2.0 ml 
eppendorf  tubes  and  500  μl  chloroform  was  added  to  each  sample.  The  samples  
were vortexed and centrifuged at 13,200 rpm for 5 mins at RTm. The aqueous 
layer was transferred to fresh 2.0  ml eppendorf tubes. DNA was precipitated by 
adding 5  μg  glycogen  (5  mg/ml;;  Roche,  UK), 70  μl  3  M  sodium  acetate  (pH  5.2), 
and 1,375   μl   100%   ethanol to each sample followed by incubation at -20°C 
overnight. After overnight precipitation, samples were centrifuged at 14,000 rpm 
for  20  mins  at  RTm.  The  DNA  pellets  were  washed  with  500  μl  of   ice-cold 70% 
ethanol and air-dried for 10-15 mins. The DNA pellets of the IP samples were 
resuspended  in  50  μl  nuclease  free  water  and  100  μl  for  the  input  DNA samples. 5 
μl  of  each  sample  was  run  on  a  1%  agarose  1X  TBE  gel  and  visualised  with  SYBR  
Safe DNA gel stain to check the DNA size. Samples were stored at -20°C. 
2.2.6.2 Low-cell ChIP assays 
Crosslinking 
1x105 cells were collected by centrifuging at 1,200 rpm for 5 min at RTm and 
resuspended in 1 ml of plain DMEM or IMDM in a 2 ml eppendorf tube. Cells were 
fixed by adding 26.3   μl   formaldehyde   solution   (38%;;   final   concentration   1.0%)  
followed by incubation at RTm with gentle agitation for 15 mins. The crosslinking 
was stopped by adding 68.5   μl   2   M   glycine   (final   concentration   of   0.125   M)  
followed by incubation for 5 mins at RTm with gentle agitation to stop the 
crosslinking reaction. 
Cell and nuclear lysis 
Cells were centrifuged at 2,200 rpm for 6-8 mins at 4ºC and the pellet was washed 
with 1.5 ml ice-cold PBS (4,000  rpm for 5 mins at 4ºC). Subsequently, cells were 
directly resuspended in 1.2 ml of NLB and incubated on ice for 10 mins. 
Sonication 
The sonication step was performed similar to the conventional ChIP. And the 
sonicated DNA was directly used to set up the IP conditions without pre-clearing. 
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IP 
The chromatin solution was used to set up various IP conditions in a 2 ml 
eppendorf tube. For each IP condition approximately 10% of the chromatin 
solution was used (equivalent to 104 cells). An NLB:IPDB buffer at the ratio of 1:4 
was freshly prepared and used to ensure that the final volume of all ChIP 
conditions  was  1,350  μl.  ChIP  conditions  were  set  up  as  follows: 675 μl chromatin 
+ 675 μl NLB:IPDB buffer + 0.5-5.0 μg of antibody raised against histone 
modification of interest. The antibody concentrations were optimised for each 
modification in the low-cell ChIP.  270  μl  of  chromatin  was  aliquoted  and  stored  at  
-20°C to be used as an input sample for array hybridisations or deep sequencing. 
The rest of IP steps, bead washes, elution, crosslinks reversal, and DNA 
purification steps were performed similar to the conventional ChIP assays. 
However, the gel electrophoresis of the purified ChIP DNA was not performed as 
the DNA concentration was lower than could be detected on the gel. The quality of 
low-cell ChIP was measured by ChIP-quantitative PCR (qPCR) instead (Section 
2.2.7). 
2.2.7 ChIP-qPCR 
ChIP-qPCR reactions were performed using SYBR green-based chemistry in a 
Stratagene Mx3000P qPCR System (Agilent Technologies) to quantify the DNA 
fragments enriched for immunoprecipitated histone modifications. Each ChIP-
qPCR reaction was set up by adding 5 μl of low-cell ChIP-purified DNA (diluted 
1:5) or ChIP-sequencing (ChIP-seq) library (dilute 1:10); 12.5 μl 2X FastStart 
Universal SYBR Green Master (Rox) (Roche) and each of the forward and reverse 
primers at the final primer concentration of 300 nm in a final volume of 25 μl. 5 ng 
of input or human genomic DNA were used as reference for determining absolute 
enrichment levels. ChIP-qPCR reactions were performed in duplicate. In order to 
determine the relative fold enrichment levels negative control primers were 
designed amplifying previously identified genomic regions that do not interact with 
the histone modification of interest. The thermal cycler programme used was as 
follows: 95°C for 10 mins, followed by 40 cycles of 95°C for 30 secs, and 60°C or 
63°C for 60 secs. Melt curve analysis was carried out between 72-95˚C  at  the  rate  
of  1˚C/second  with  continuous  measurement  of  fluorescence  to  ensure  that  there  
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was only a single product present in each reaction and to allow for detection of 
primer dimers. The relative fold enrichments were calculated as follows: 
ΔCt test primer = Ct input – Ct test primer  
ΔCt negative control = Ct input – Ct negative control 
Relative fold enrichment = 2 (ΔCt test primer – median ΔCt negative controls) 
2.2.7.1 Primer design 
Primers were designed using online primer designing tools Primer3 
(http://frodo.wi.mit.edu/; Rozen and Skaletsky, 2000) and PrimerQuest (Integrated 
DNA Technologies, Leuven, Belgium). Primer pairs were designed to amplify 
genomic regions ranging from 70-150 bp, with an optimum melting temperature of 
60°C, and an optimum length of 20 bp. The specificity of designed primers was 
checked by the BLAT and In-Silico PCR tools available from the UCSC Genome 
Browser website. Primers were made by standard desalting procedure in the stock 
solutions of 100 μM (TE pH 8.0 buffer) (Integrated DNA Technologies).   
The primers designed for the validation of low-cell ChIP efficiency were chosen 
from the known interacting and non-interacting regions with the histone 
modifications of interest. On the other hand, to monitor the mouse genomic 
contamination in the low-cell ChIP-purified DNA and low-cell ChIP-seq libraries, 
primers were designed to amplify multiple mouse genomic regions (Appendix 3).  
The primers designed for the validation of ChIP-seq profiles (Appendix 4) were 
selected from a 1 kb region spanning the TSS based on the ENSEMBL annotation 
for the major protein-coding transcript. The sequences of DNA fragments were 
obtained from the UCSC Genome Browser by entering the genomic coordinates of 
the promoter regions.  
2.2.8 ChIP-chip 
2.2.8.1 Random priming labelling of ChIP-purified DNA samples 
The hybridisation of ChIP-purified DNA samples on the mouse tiling path arrays 
(printed at the Sanger Institute, University of Cambridge) were set up on the Tecan 
Chapter 2  100 
HS 4800 (an automated hybridisation station). The DNA samples were 
fluorescently-labelled using BioPrime DNA Labelling System (Invitrogen) as 
follows:  
300-500 ng input DNA or 20% of ChIP DNA was mixed with 60 μl 2.5X random 
primers (Invitrogen) and the final volume was adjusted to 130.5 μl with labelling 
water (Invitrogen). The samples were denatured in a 100°C heat block for 10 mins 
followed by snap-chill on ice. Subsequently, 15 μl dNTPs for labelling, 1.5 μl Cy3 
(for ChIP samples) or Cy5 (for input samples) labelled dCTP (GE Healthcare), and 
3  μl  Klenow  fragment  (Invitrogen)  were  added  to  the  DNA/random  primers  solution  
and mixed gently by pipetting. The labelling reactions were incubated overnight at 
37°C and stopped by adding 15 μl of stop buffer (Invitrogen). The unlabelled 
nucleotides were removed by Micro-spin G50 columns (GE Healthcare) according 
to   the   manufacturer’s   instructions.   The   purified   labelled   DNA   samples   were  
analysed on a 1% agarose 1X TBE gel and visualised by SYBR Safe DNA gel 
stain. 
2.2.8.2 Competitive hybridisation of labelled ChIP DNAs onto 
microarrays 
The Cy3-labelled ChIP samples (~180 μl) and the Cy5-labelled input samples 
(~180 μl) were mixed and 135 μl of human or mouse Cot1 DNA, 80 μl 3 M sodium 
acetate (pH 5.2), and 1,600 μl 100% ice-cold ethanol were added and incubated 
overnight at -20°C in the dark to precipitate the labelled DNA. The precipitated 
DNA samples were centrifuged at 13,000 rpm for 20 mins at RTm. After discarding 
the supernatant, DNA pellets were washed with 500 μl 80% ice-cold ethanol 
(13,000 rpm for 5 mins at RTm). Residual levels of ethanol were aspirated and the 
pellets were resuspended in 150 μl of Tecan hybridisation buffer at 70°C with 
agitation for 2-3 mins. The samples were then denatured on a 100°C heat block 
for 10 mins followed by snap-chill on ice. The hybridisation reactions were kept at 
37°C in the dark for 60 mins.  
Prior to the hybridisation, the slide holders and the slide chambers of Tecan HS 
4800 were carefully cleaned and glass slides were loaded on the slide holder. The 
hybridisation station was washed thoroughly (automated system) by HPLC water 
and dried with blasts of nitrogen gas. The station was also primed with all wash 
buffer solutions to remove the air bubbles in the liquid channels and tubing. The 
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glass slides were subsequently replaced with the microarrays and ~150 μl of 
Tecan hybridisation buffer was injected using a positive displacement pipette to 
initiate the pre-hybridisation step, which was performed at 37°C for 60 mins. The 
microarray slides were washed with PBS/0.05% Tween 20 and dried with blasts of 
nitrogen gas. At this stage, 150 μl of hybridisation reaction was injected slowly 
onto the slide using the displacement pipette. The hybridisation step was 
performed at 37°C for 48 hrs in the dark with medium agitation. The slides were 
washed using the programme shown in Table 2.2 and dried with nitrogen gas. 
Microarray slides were stored in a dark, low temperature, low humidity 
environment until ready for scanning to prevent loss of fluorescent signal. 
 
Table   2.2: Wash steps for the hybridisations performed on Tecan HS 4800. 
The wash buffers were prepared in advance using HPLC water (Section 2.1).  
2.2.8.3 Scanning and processing of ChIP-chip data  
Cy3 and Cy5 images at 5 μm   resolution   were acquired using ScanArray 4000 
confocal laser-based scanner with a laser power of 100% a photo multiplier tube 
(PMT) value of between 70-85%. ScanArray Express (PerkinElmer) was used to 
quantitate the fluorescent intensities of the spots using the adaptive circle 
quantitation and the TOTAL normalisation methods. This software can 
automatically locate the spot position on the scanned image of the array to obtain 
the signal intensity values. Mean intensity ratios (intensity-background) were 
reported for each spot representing an array element (.csv file formats). Those 
spots  identified  as  ‘not  found’  were  removed  from  the  data  set.  Further  analysis  of  
the ChIP-chip data was carried out in a Microsoft Office Excel spreadsheet in 
which each array element was associated with its genomic sequence position 
information. The mouse tiling path array data were visualised in the UCSC 
Genome  Browser  by  uploading  a   ‘wiggle’   file  which  contained  chromosome  start  
and end coordinates and fold enrichment ratios.  
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2.2.8.4 ChIPOTle and BLOCs algorithms in ChIP-chip data analysis 
ChIPOTle is a Microsoft Office Excel-based application that performs ChIP-chip 
data analysis using a window-sliding approach (Buck et al., 2005) This method will 
identify the binding sites as peaks and a confidence value is calculated based on 
the number of array elements used to define the peak. This method is particularly 
useful to detect target sites of the proteins whose binding frequency is 
approximately less than three times the window size and therefore, was used to 
analyse histone modifications that form peaks <2 kb such as H3K4me3. The 
window size in ChIPOTle is adjusted to approximately the average sheared 
chromatin size. Larger window sizes tend to include noise from adjacent loci 
whereas smaller windows will not be able to detect data from neighbouring array 
spots. Window size is independent of the array resolution. Step size is another 
parameter which depends on both window size and the array resolution. It should 
be adjusted to less than the half of the length of array elements and less than or 
equal to a quarter of the window size. Finally, the p-value cutoff should be set to 
account for FDR. Therefore, the ChIPOTle parameters were set as 500 bp window 
size with 125 bp step size and 0.0001 p-value cutoff.  
The BLOCs algorithm was developed in Perl language to identify the broad local 
enrichments larger than 5 kb, such as H3K27me3, which are significantly above 
the background (Pauler et al., 2009). Each BLOC initiates with 10-13 consecutive 
array elements where 10 of these elements show positive log2 fold enrichments 
and ends with 6-8 successive elements where six of them show negative log2 fold 
enrichments. BLOCs larger than 5kb with a median log2 value above the 0.25X 
standard deviation of all the signals on the array were reported. A browser 
extensible data (BED) file which contained the genomic coordination of BLOCs 
enrichment domains was generated for UCSC Genome Browser visualisation. 
2.2.9 ChIP-seq 
2.2.9.1 Preparation of ChIP-seq libraries for Illumina Genome Analyzer 
The preparation of ChIP-seq DNA libraries for Illumina Genome Analyzer II 
consists of five major steps, which include end-repair of ChIP DNA fragments to 
generate blunt-ended fragments, dA-tailing, ligation of adapters, PCR amplification 
of adapter-ligated fragments, and gel size-selection. The ChIP-seq libraries were 
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prepared similarly for both low-cell and conventional ChIP assays. The ChIP-seq 
DNA Sample Prep Kit (Illumina) and the NEBNext DNA Sample Prep Reagent Set 
1 (New England BioLabs, Hitchin, UK) were used to prepare the ChIP-seq libraries 
as follows: 
End-repair 
The end repair reaction was set up as follows: 30 µl of low-cell ChIP DNA or 20 μl  
of conventional ChIP DNA, 5 µl 10X Phosphorylation Reaction Buffer, 2 µl dNTP 
mix (10 mM), 1 µl T4 DNA Polymerase, 1 µl Klenow DNA Polymerase (diluted 
1:5), 1 µl T4 Polynucleotide Kinase (PNK), and the final volume was adjusted to 50 
μl  with  ultra-pure nuclease-free water. The reaction mix was incubated in a thermal 
cycler for 30 mins at 20°C. The blunt-ended fragments were purified using 
QIAquick PCR Purification Kit (QIAGEN) in a final elution volume of 34 μl, 
according  to  the  manufacturer’s  instructions. 
Deoxyadenosine (dA)-tailing 
The 3′-dA overhang was added to the blunt-ended fragments by mixing the 
purified DNA from the previous step with 10 µl dATP (1.0 mM), 5 µl 10X Klenow 
Fragment (3′→5′  exo-) Buffer, and 1 µl Klenow Fragment (3′→5′  exo-) followed by 
30 mins incubation at 37°C. The dA-tailed fragments were then purified using 
MinElute PCR Purification Kit (QIAGEN) in a final elution volume of 10 μl,  
according  to  the  manufacturer’s  instructions.   
Ligation of adapters 
The sequencing adapters were ligated to the DNA purified in the previous step in 
the following reaction: 1 µl Illumina Adapter Oligo Mix (diluted 1:10), 15 µl 2X 
Quick Ligation Reaction Buffer, and 4 µl Quick T4 DNA Ligase. The reaction was 
incubated for 15 mins at RTm. The unligated adapters were removed by using the 
QIAquick PCR Purification Kit in a final elution volume of 36 μl, according to the 
manufacturer’s  instructions. 
PCR amplification of adapter-ligated ChIP DNA 
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The adapter-ligated DNA fragments were amplified by preparing the following PCR 
reaction mix: 10 µl 5X Phusion High-Fidelity (HF) Buffer, 1.5 µl dNTP mix (10 mM), 
1 µl Illumina PCR Primer 1.1, 1 µl Illumina PCR Primer 2.1, and 0.5 µl Phusion 
DNA Polymerase. The thermal cycler conditions were set as follows: 98ºC for 30 
secs; 18 cycles of 98ºC for 10 secs, 65ºC for 60 secs, and 72ºC for 30 secs; and 
finally 72°C for 5 mins. The PCR products were purified by MinElute PCR 
Purification Kit in a final elution volume of 10 μl, according   to   the  manufacturer’s  
instructions.  
Agarose gel size-selection of amplified libraries 
The purified PCR-amplified DNA fragments were loaded onto a 2% agarose 1X 
TAE gel in alternate wells to avoid cross-contamination of the samples. 1 kb ladder 
(New England BioLabs) was also loaded as a marker for the size-selection 
procedure. The electrophoresis was performed for 2 hrs with 60-70 voltage power. 
Subsequently, the gel was stained with 50 μl   ethidium   bromide   for   30   mins   in  
sterile water or 1X TAE buffer. After discarding the staining buffer, DNA fragments 
were visualised on the UV transilluminator and the bands corresponding to 200-
300 bp size range were excised from each sample lane using a scalpel blade. The 
excised DNA fragments were purified using QIAquick Gel Extraction Kit (QIAGEN) 
in a final elution volume of 30 μl,  according  to  the  manufacturer’s  instructions. 
At the end of this step the ChIP-seq DNA libraries were analysed by the Agilent 
Bioanalyzer to determine the average length of library fragments for flowcell 
cluster generation purposes. The quality of ChIP-seq libraries was assessed by 
qPCR as described in Section 2.2.7. 
2.2.9.2 Processing of the ChIP-seq results 
2.2.9.2.1 Sequence alignments 
Sequence reads of 76 bp were obtained from Illumina Genome Analyzer II 
platform. Using the Solexa analysis pipeline (Dr. Peter Saffrey, Institute of Cancer 
Sciences, University of Glasgow), the sequence reads were clipped back to 36 bp. 
All reads were aligned to the reference genome - human (UCSC hg18) and mouse 
(UCSC mm8) – using the Bowtie algorithm (Langmead et al., 2009) and only 
uniquely aligned reads were retained. In all analyses, reads of multiple identical 
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copies (duplicate reads) were excluded. The uniquely aligned reads were 
extended to 150 bp, which was the average length of ChIP-seq libraries (without 
the length of sequencing primers), and converted to BED files detailing the 
genomic coordinates of each tag. In order to visualise the ChIP-seq data sets on 
the UCSC Genome Browser the BED files were converted to bigWig files which 
are in an indexed binary format and therefore, faster to upload and process for the 
larger data sets. Normalised bigWig files were also generated by normalising the 
number of sequencing tags in each genomic coordinate to the total number of 
uniquely aligned reads in the relevant ChIP-seq dataset (library size) (Dr. Andrew 
Crossan, Institute of Cancer Sciences, University of Glasgow).  
Previously published ChIP-seq data sets for haemopoietic progenitor cells (HPCs) 
(Cui et al., 2009) were obtained from publicly available GEO database under the 
accession number of GSE12646. The ChIP-seq data sets for H3K4me3 and 
H3K27me3 were analysed similar to above.     
2.2.9.2.2 SICER and BayesPeak algorithms  
SICER is a spatial clustering approach which uses the enrichment context of a 
local window to determine the significance of enrichment domains (Zang et al., 
2009). This approach employs a control ChIP-seq library, normally generated from 
the input DNA to identify potential islands. This involves identifying clusters of 
windows occupied by reads that are unlikely to appear by chance. All eligible 
summary windows were first identified, with an eligible window being defined as 
those windows satisfying a required window tag-count threshold determined from 
a preset p-value based on a Poisson background model. Islands were then 
identified by grouping consecutive eligible windows allowing gaps of at most two 
ineligible windows. The resulting islands identified for each library have an 
estimated FDR of less than 1%. SICER was used for the H3K27me3 and 
H3K36me3 ChIP-seq data sets with a gap size of 1kb.   
BayesPeak algorithm (Spyrou et al., 2009) was used to identify the H3K4me3 
ChIP-seq enrichment regions using a Bayesian hidden Markov model. This 
method uses a binomial distribution as opposed to the Poisson distribution used in 
SICER and therefore, overdispersion can be taken into account in measuring the 
abundance of sequencing reads at various genomic locations. Default parameters 
were used in this study.  
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2.2.9.2.3 seqMINER clustering tool 
The extended BED files were imported into the seqMINER tool, a k-means 
clustering approach (Ye et al., 2011), for classifying all annotated transcripts in 
human hg18 build based on the histone modification enrichments at their 
promoters. The TSSs of all annotated transcripts were used as the reference 
coordinates or the middle values. Each putative promoter was defined as 2,500 bp 
upstream and downstream of the reference coordinate, also considering the 
orientation of the transcripts. Tag densities were defined as the number of tags 
present or overlapping in that 5 kb window. Data sets were linearly normalised to 
reduce the bias generated as a result of inherent ChIP-seq variations between 
samples. The number of clusters is defined by the user and the output data can be 
visualised as clusters of heatmaps based on the similarities observed between 
groups of transcripts across all analysed samples. Initially, all the annotated 
transcripts were divided into 20 clusters, from which four major classes of 
promoters could be detected including H3K4me3, bivalent, H3K27me3hi, and 
neither modifications. The genes identified in each promoter class were then 
reclustered with twice as many original clusters that were associated with each 
promoter class to identify the falsely categorised transcripts, which were 
subsequently transferred to the appropriate promoter class.  
2.2.9.3 Biological pathways analysis for epigenetic classes 
The list of genes in each cluster was exported to PANTHER database to identify 
the significantly affected pathways in each cluster. For the analysis a reference list 
was provided which contained all the annotated gene promoters in the hg18 build. 
The reference list was divided into groups based on functional classifications. An 
input list of genes associated with each promoter class was also provided, which 
was divided into similar categories as the reference. A binomial test was then 
applied to statistically determine how significantly a group of genes is over- or 
under-represented in the input list relative to the reference by taking into account 
the number of genes expected in the input list for a particular category, which was 
calculated by the number of genes in that category in the reference list and the 
size of input list, and subsequently measuring the p-value by comparing the 
number of observed genes in each category to the expected values (Mi et al., 
2010).      
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2.2.9.3.1 Composite plots for ChIP-seq data sets 
The composite plots for different promoter classes identified by the seqMINER 
were generated by dividing the defined promoters into 100 equally-sized bins and 
the maximal number of overlapping tags for each histone modification was 
averaged in each bin for each promoter class. The library-size normalised average 
tag densities of each histone modification (y-axis) were plotted over an average 
promoter length (x-axis).  
2.2.10 Statistical analysis 
Most of the statistical analysis was performed using Microsoft Office Excel. This 
included the calculation of standard deviations and confidence intervals, which 
were calculated using the STDEV and CONFIDENCE (α=0.05) functions, 
respectively. The standard error of mean (SEM) was calculated by dividing the 
standard deviation of dataset by the square root of dataset size in Excel.  
For the   Spearman’s   rank   correlation   coefficients the output of scanned and 
processed array images in .csv formats (Section 2.2.8.3) were used for  low-cell 
ChIP-chip and conventional ChIP-chip assays. The statistical correlation between 
the two datasets were analysed and   the   Spearman’s   rank   correlation   values  
between -1 and +1 were assigned, where -1 showed the highest negative 
correlation and +1 showed the highest positive correlation between two datasets. 
A p-value was also generated as a measurement for the significance of observed 
correlation (Dr. Peter Saffrey, Institute of Cancer Sciences, University of Glasgow).  
The box plots were created by GraphPad Prism 5.0. The whiskers indicate 5-95 
percentile. P-values were calculated by two-tailed unpaired t tests and 95% 
confidence intervals.  
For z-score analysis of histone modification distributions at the promoters of 
annotated genes, the total number of sequencing tags at a 2 kb window centred at 
the TSS of each promoter was computed (x). For H3K4me3 analysis the 
promoters of H3K4me3 and bivalent/H3K27me3hi genes were used for which a 
normal distribution of H3K4me3 levels could be established. Furthermore, for 
H3K27me3 analysis the promoters of bivalent/H3K27me3hi genes were used for 
which a normal distribution of H3K27me3 levels could be established. The mean 
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and standard deviation of  total number of sequencing tags for all the promoters 
that were included in the normal distribution was computed. The z-score for each 
promoter was obtained using the following formula in Microsoft Office Excel: z-
scorepromoter = (x – mean)  ⁄∕ standard deviation 
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3. CML stem cells share the characteristics of both 
stem cells and proliferative cells at the gene 
expression level 
3.1 Abstract 
In order to understand the phenotype of CML stem cells (LSCs), studying their 
gene expression profile is essential to identify the genes and pathways that are 
involved in malignant transformation as well as the genes and pathways that 
maintain their stem cell-like phenotype. However, this aim could only be achieved 
by first understanding normal haemopoiesis and the pathways regulating HSC 
maintenance as well as the mechanisms involved in the differentiation of early 
haemopoietic progenitors. Therefore, in this Chapter, the genome-wide gene 
expression profiles of HSCs, LSCs, normal haemopoietic progenitors (HPCs,) and 
CML progenitor cells (LPCs) were determined using Affymetrix technology. 13 
biological pathways were identified to be associated with the HSC identity, which 
included TGF-β   signalling, Wnt signalling, chemokines and cytokines signalling, 
and several novel neurotransmitter signalling pathways. Furthermore, it was 
demonstrated that the HSC identity pathways retained their expression levels in 
LSCs, whereas several pathways associated with proliferative capacity were 
upregulated in LSCs. Therefore, LSCs shared similarities with both  HSCs and 
HPCs at the level of biological pathways. Furthermore, the exit from stem cell 
compartment in CML was associated with the loss of HSC identity pathways and 
acquisition of further proliferative capacities. It was also revealed that a global 
programming regulate gene expression changes at the genome-wide level in both 
normal and CML cells. Consequently, this global programming controls gene 
expression changes at many biological pathways, as was also observed in the 
HSC identity pathways. However, LPCs were found to be more effective in 
downregulating the genes in the HSC identity pathways than their normal 
counterparts. Thus, it can be argued that the CML cells implement this global 
programming in a different manner from their normal counterparts.       
3.2 Introduction 
As described in Chapter 1, transcriptomics is the science of defining and 
quantifying all the various transcripts present in a cell, or population of cells, 
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including mRNAs, non-coding RNAs (ncRNAs) and small RNAs. Studying the 
complete set of transcripts in a cell and their levels is a crucial step in 
understanding molecular phenotype and functions of cells and tissues. The 
knowledge of transcriptomics is required for identifying the mechanisms involved 
in development and disease. The study of transcriptome has been made possible 
through development of various technologies which were described in Table 1.1. 
The work presented in this Chapter is generated by the Affymetrix microarrays 
which use a hybridisation-based approach. A brief summary of Affymetrix 
microarray platform and the downstream bioinformatics analyses that were used in 
this work is presented below. 
Several studies have investigated the gene expression signatures of HSCs in 
human systems. These studies have helped identifying the mechanisms involved 
in HSC self-renewal and quiescence (Sections 1.6.4 and 1.6.5). In one study, the 
genome-wide gene expression analysis of human foetal HSCs (Lin- CD34+ CD38-), 
murine foetal HSCs (Lin- AA4.1+ c-Kit+ Sca-1+) and murine adult HSCs (Lin- c-Kit+ 
Sca-1+) were analysed using Affymetrix arrays (Ivanova et al., 2002). The 
comparison of gene expression signatures between these three cell types 
identified evolutionarily conserved genes that may have a crucial role in HSC 
maintenance. Intriguingly, these HSC maintenance genes were shown to be 
predominantly associated with, signalling ligands and cell surface receptors, 
intracellular signalling, adhesion molecules and transcription factors. This 
signature included several important genes associated with TGF-β, Wnt and Notch 
signalling pathways, such as BMP8, frizzled 4 (FZD4), TCF3, and jagged 2 
(JAG2), which could be important in the maintenance of HSCs (Section 1.6.4). 
Furthermore, the homeobox family of transcription factors, particularly HOXA5, 
HOXA10, HOXA2 and HOXB4, were also identified in this signature (Ivanova et 
al., 2002). HOXA10 and HOXB4 were reported to have an important role in HSC 
self-renewal (Magnusson et al., 2007, Sauvageau et al., 1995). On the contrary, 
the gene expression signature of early progenitors (Lin- CD34+ CD38+ in human or 
Lin- c-Kit+ Sca-1- in mouse) was significantly enriched for cell cycle-associated 
genes, DNA repair mechanisms and protein synthesis and metabolism. The 
observation was in agreement with the proliferative capacities of these populations 
(Ivanova et al., 2002). The gene expression signatures of adult human HSCs were 
first described by isolating the Lin- CD34+ CD38- population from BM, PB, and cord 
blood using Affymetrix arrays (Georgantas et al., 2004). Genes that were 
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significantly upregulated in HSC populations relative to the differentiated 
haemopoietic cells (Lin+ CD34+ CD38+) in all three tissues were described as HSC 
signature. The HSC signature was significantly enriched for signalling proteins as 
well as transcription factors, such as CEBPB, GATA3, HLF, HOXA3, HOXB6, 
KLF2, KLF4, RBPMS, and MECOM (MDS1 and EVI1 complex) (Georgantas et al., 
2004). These two studies reported gene expression signatures of human HSCs for 
the first time and both highlighted the importance of signalling pathways and the 
HOX family of transcription factors in these signatures. The importance of 
signalling pathways in the maintenance of adult HSCs was also shown in mouse 
(Park et al., 2002, Ramalho-Santos et al., 2002).  
A global analysis of gene expression signatures have been performed recently in 
human HSCs (CD34+ CD38-), lineage progenitors and terminally differentiated 
haemopoietic cells using Affymetrix arrays (Novershtern et al., 2011). This report 
has identified a subset of genes that are predominantly expressed in HSCs and 
early progenitors. This gene cluster comprises several transcription factors, such 
as GATA2, HOXA9, HOXA10 and MEIS1, as well as cell surface markers, such as 
CD34 and KIT. These genes were also expressed in early myeloid progenitors. 
However, their expression was suppressed after the branching of GMPs and 
MEPs and also in lymphoid branch (Novershtern et al., 2011). This HSC gene 
expression signature was used as a validation tool for the work presented in this 
Chapter. 
There have been a number of studies investigating the gene expression of CP 
CML in recent years. Several reports have conducted their gene expression 
analyses in order to identify biomarkers for disease progression, response to TKIs 
and prognosis (McWeeney et al., 2010, Oehler et al., 2009, Radich et al., 2006). 
However, they did not address the differences between CML cells and their normal 
counterparts and more importantly the underlying gene expression signature that 
defines the LSC compartment. Three studies have attempted to answer these 
questions which are reviewed in this Section.  
The first study investigated the gene expression signatures of CD34+ cells isolated 
from the BM of CML patients and normal individuals using customised cDNA 
arrays covering 1,185 genes (Kronenwett et al., 2005). This study identified 158 
genes that were significantly misregulated in CML relative to normal. This gene 
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signature showed an upregulation in the genes associated with proliferation and 
cell cycle progression, such as CDK4 and cell division cycle 25C (CDC25C), as 
well as downstream effectors of BCR-ABL1, such as RAS family and JAK2. On the 
contrary, the gene expression levels of two CDKIs, CDKN1A/p21 and 
CDKN2D/p19, were significantly downregulated in CD34+ CML cells. Additionally, 
several chemokine- and cytokine-related genes were also significantly 
downregulated in CML cells, such as IL10, chemokine (C-X-C motif) receptor 4 
(CXCR4), platelet-derived growth factor-α (PDGFA) and G-CSF receptor (CSF3R). 
This study also investigated the gene expression differences between the CML 
CD34+ cells isolated from BM and PB, which identified no significant differential 
expression between the two populations. However, the CML cells isolated from 
either BM or PB were closely related to the normal CD34+ cells that were isolated 
from BM at the gene expression level. Intriguingly, this report showed a significant 
upregulation of neurotransmitter receptors on CD34+ CML cells, which include 
adenosine A1 receptor (ADORA1), opioid μ1 receptor (OPRM1) and chloride 
channel 1A (CLNS1A). This finding was combined with immunofluorescence 
analysis of various neurotransmitter receptors on the surface of CD34+ CML cells. 
The results demonstrated an upregulation of GABA-B, serotonin 1F, corticotropin-
releasing hormone (CRH) receptor, adenosine A1 and A2B receptors, opioid μ1 
and κ1 receptors, and orexin receptor 1 and 2 (Kronenwett et al., 2005). The 
observation was in agreement with an earlier report demonstrating the expression 
of the above neurotransmitter receptors on the surface of HSCs (CD34+ CD38-) 
which were diminished in the CD34+ CD38+ progenitor cells and were completely 
absent in terminally differentiated cells (Steidl et al., 2004).  
In another study, the gene expression signature of non-dividing (G0) CD34+ CML 
cells were reported using Affymetrix arrays (Graham et al., 2007). This study 
showed a small differential expression between the CML G0 and dividing 
populations, whereas the normal CD34+ cells in G0 were significantly segregated 
from their dividing counterparts. This analysis also identified a large subset of 
significantly misregulated genes in CML G0 relative to normal G0. The significantly 
upregulated genes in CML G0 relative to their normal counterparts were mainly 
associated with cell cycle progression and CDK activities, DNA replication and 
mitosis, whereas the significantly downregulated genes were mainly associated 
with chemokine activity and antigen presentation. These observations were in 
agreement with the above study. However, the differential expression analysis 
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between CML G0 and dividing populations revealed a significant upregulation in 
chemokine activity in the quiescent compartment. This study identified several 
chemokine ligands, such as CCL19, CXCL3, CXCL12, CXCL13, which were 
significantly upregulated in the quiescent population of CML and suggested a role 
for the chemokines in the maintenance of LSCs. 
Gene expression signatures of BM LSCs (CD34+ CD38-) cells were also 
established in comparison with three myeloid progenitors in CML, which include 
CMPs, GMPs and MEPs (Bruns et al., 2009). This study also indicated a 
significant degree of similarity between the gene expression signatures of LSCs 
and CMPs. Furthermore, the differential expression analysis between LSCs and 
HSCs demonstrated a significant downregulation of several cell adhesion proteins 
and chemokine receptors, such as CXCR4 and cadherin 2 (CDH2) and it was 
suggested that this downregulation could explain the inherent defective adhesion 
and migratory capacities of LSCs. Additionally, several stem cell self-renewal 
promoting transcription factors were also significantly downregulated in LSCs, 
such as PTEN and FLT3. Therefore, the report suggested a possible explanation 
for the reduced self-renewal and quiescence capacities of LSCs (Section 1.7.3).  
Overall, the above studies indicated a proliferative-like gene expression signature 
for LSCs which was associated with elevated levels of cell cycle regulators and 
reduced levels of adhesion proteins and stem cell regulators relative to their 
normal counterparts. Additionally, an important role for the chemokine ligands and 
receptors was suggested in LSCs, although their levels were significantly reduced 
relative to their normal counterparts. Intriguingly, one study suggested a role for 
neurotransmitter regulation of LSCs similar to HSCs (reviewed in Section 1.6.4.7). 
However, all these studies only reported a small subset of genes and their 
association with biological processes which tend to be broad descriptions. They 
did not investigate the interaction between the misregulated genes in the context 
of biological pathways which provide a better understanding of CML biology. 
Moreover, the gene expression signatures were reported without considering the 
role epigenetic regulation that was shown to be responsible for lineage priming in 
haemopoietic development (Section 1.6.7). Therefore, the work presented in this 
Chapter is going to address the impact of misregulated genes in LSCs in the 
context of biological pathways. Subsequently, the role of chromatin modifications 
in transcriptional regulation of LSCs will be investigated in Chapter 5. 
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3.3 Methods 
3.3.1 The Affymetrix GeneChip expression arrays 
Typically, fluorescently-labelled complementary DNAs (cDNAs) are hybridised 
onto customised or commercial high-density oligonucleotide microarrays. Genomic 
tiling microarrays, described in Chapter 4, with whole genome coverage at high 
density were initially used for high resolution mapping (ranging from several base 
pairs to ~100 bp) of transcribed regions (Bertone et al., 2004). However, the 
emergence of commercial platforms such as Affymetrix GeneChips revolutionised 
this technology by producing high resolution arrays with a genome-wide coverage. 
Affymetrix GeneChip microarrays were first constructed by adapting 
semiconductor technology using quartz wafer and the photolithographic process 
(McGall and Christians, 2002). The Affymetrix GeneChip expression array system 
is a one-colour microarray system. In a one-colour array, control and experimental 
samples are hybridised onto different arrays, labelled with the same fluorescent 
dye. The one-colour design provides flexibility when comparing multiple different 
samples from the same platform (Russell et al., 2009). The GeneChip arrays are 
mainly classified into Whole-Genome 3′ in vitro transcription (IVT) arrays and 
Whole-Transcript (WT) Exon/Gene arrays (Figure 3.1).  
 
Figure   3.1: Comparison between the design of Affymetrix arrays and genomic tiling arrays. 
The spread of the oligonucleotide probes (black bars) across the gene body is demonstrated for 
different types of arrays used for gene expression analysis.  
The 3′ IVT arrays were the first generation of commercial arrays using probes 
designed against the 3′-end of each gene to estimate the expression of the entire 
gene (Dalma-Weiszhausz et al., 2006). This technology required 3′-oligo(dT) 
cDNA synthesis and labelling procedure. However, transcripts with unknown 3′-
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ends, which were non-polyadenylated, had alternative polyadenylation sites, or 
were truncated, could not be analysed by this approach. Therefore, due to the 
above limitations and the presence of a large number of splice variants, the next 
generation of Affymetrix arrays - the WT Gene/Exon arrays - were designed which 
allowed the analysis of alternative splicing as well as transcripts with undefined 3′-
ends, truncations, or degradation products (Dalma-Weiszhausz et al., 2006). WT 
arrays have replaced oligo(dT) cDNA synthesis used for 3′   IVT   arrays   with   a  
random priming approach. To perform hybridisation, total RNA or mRNA extracted 
from the cell or tissues of interest is first reverse-transcribed using a T7-promoter 
random primer to generate double-stranded cDNA. The cDNA then undergoes an 
in vitro transcription reaction in the presence of T7 RNA polymerase and 
biotinylated ribonucleotides to generate biotin-labelled complementary RNAs 
(cRNAs). The biotinylated cRNAs are fragmented (to optimise target-probe 
hybridisation kinetics) and hybridised onto the probe array. The hybridised probe 
array is stained with a streptavidin phycoerythrin (PE) conjugate and scanned. The 
PE conjugate is excited by laser and emits fluorescence for detection (Dalma-
Weiszhausz et al., 2006) (Figure 3.2). 
Human WT Gene arrays were specifically used for the work presented in this 
Chapter. Human WT Gene arrays cover 28,869 annotated genes (University of 
California Santa Cruz (UCSC) hg18 and National Centre for Biotechnology 
Information (NCBI) build 36 annotations). The oligonucleotide probes used in WT 
Gene array design are perfect match (PM) probes with a complete 
complementarity to the target sequence and the background noise is analysed 
using a set of 20,000 generic background probes. Each gene is represented by an 
average of 26 25-mer probes positioned across the exons which provides a more 
accurate and complete profiling of gene expression than the 3′  IVT  arrays  (Russell 
et al., 2009).  
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Figure   3.2: Schematic overview of cDNA synthesis for Affymetrix WT Gene/Exon arrays. 
The overall work-flow of RNA-to-cDNA preparation for the Affymetrix WT arrays is illustrated. cDNA 
synthesis is performed in two cycles initiated by random priming. This process results in generation 
of biotinylated sense DNA targets that are required for hybridisation on Affymetrix arrays. T7: T7 
RNA polymerase; UDG: uracil-DNA glycosylase; APE1: apurinic/apyrimidinic endonuclease.  
Despite the high-throughput advantage of the hybridisation-based approaches, 
they suffer from several limitations. These include dependency on the existing 
knowledge of genomic sequence and annotation, cross-hybridisation which could 
result in high background, and limited dynamic range of detection as dictated by 
the signal saturation and background (Wang et al., 2009). Furthermore, 
comparison between experiments requires complicated normalisation approaches 
and experiments performed on different array platforms could not be directly 
compared owing to differences in the array or probe design (Wang et al., 2009). 
These limitations resulted in the development of sequence based approaches 
(Table 1.1), such as RNA-sequencing (RNA-seq), which offer a high-throughput 
and unbiased analysis of all types of transcripts. Nevertheless, these approaches 
require large amounts of RNA which cannot be obtained from small adult stem cell 
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populations. Therefore, these approaches could not be employed for the analysis 
of the gene expression signatures in HSCs and LSCs in this work.  
3.3.2 Affymetrix data analysis 
3.3.2.1 Data pre-processing 
Data pre-processing is a crucial step prior to downstream statistical analysis or 
data clustering. Pre-processing largely consists of various data normalisation 
steps to adjust for the systematic errors as a result of experimental variation as 
opposed to real biological differences (Russell et al., 2009). The major steps of 
data normalisation are: (i) probe summarisation which merges intensities from 
multiple probes that correspond to a gene to generate a single value for each 
gene; (ii) background correction which   is  a   ‘within-array’  normalisation  procedure  
to   account   for   background   levels;;   (iii)   normalisation   which   is   a   ‘between-array’  
normalisation that accounts for intensity variations between multiple arrays. 
A. Probe summarisation – As mentioned earlier, the WT Gene arrays are 
designed based on PM probes and a probe set is defined as a set of probes for a 
given gene. Robust Multi-array Averages (RMA) and GeneChip RMA (GCRMA) 
are the two methods that have been introduced for the probe summarisation of PM 
probe sets (Irizarry et al., 2003). In RMA approach, the observed signal is 
regarded as a measure of true expression in addition to a probe-specific affinity 
factor. The output is comprised of log transformed intensities which is fitted to 
Tukey’s  median  polish  model (Irizarry et al., 2003).  
B. Background correction – Background noise is a common artefact of any 
microarray technology and Affymetrix arrays are not an exception. The 
background level should be determined and corrected prior to any further 
evaluation of the signals. The noise in Affymetrix arrays could be caused by the 
scanning device, non-specific binding of labelled DNA to the surface of arrays, 
artefacts of labelling, or other imperfections in array design. The background 
correction should be accurate as otherwise true signals might be mistakenly 
removed in the process (Russell et al., 2009). As mentioned earlier, a set of 
20,000 generic background probes are designed on WT Gene arrays. These 
generic probes are used in a global background correction method performed in 
RMA algorithm (Russell et al., 2009). 
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C. Normalisation – ‘Between-array’   normalisation   is   also   important   to   maintain  
the ability to compare results generated on different arrays. The RMA method 
uses a quantile normalisation approach which assumes the same amount of RNA 
is hybridised to identical arrays and therefore, expects an identical overall intensity 
distribution. In other words, RMA normalisation works by making the intensity 
distribution of multiple arrays identical (Irizarry et al., 2003).  
3.3.2.2 Differential expression analysis  
A powerful differential expression analysis requires a powerful experimental 
design. In other words, microarray experiments should be designed to contain an 
appropriate number of biological replicates in a cost efficient manner. Previous 
studies using microarrays for gene expression analysis suggested an experimental 
design which contains a minimum, but not an optimum, of five biological replicates 
per condition group providing that only two groups of conditions are to be 
compared (Allison et al., 2006, Pavlidis et al., 2003). Biological replicates would 
allow evaluation of biological differences between two groups as well as 
measuring the variability within each group. However, technical replicates can be 
substituted if the number of samples is limited or the cost of obtaining another 
sample is more than the cost of an array (Allison et al., 2006).  
Another important step in the analysis of differential expression is the hypothesis 
test required for making statistical decisions on whether a gene is differentially 
expressed. Four types of possible outcomes are predicted for a pair of 
hypotheses, two of which are regarded as correct decisions: when a differential 
gene expression value is not significant (p-value above the threshold) and there 
are no gene expression differences, and when the difference is statistically 
significant (p-value below the threshold) and there is a change of expression. The 
other   two   outcomes   are   known   as   ‘inferential   errors’:   type   1   errors   or   false  
positives, when p-value is significant but there is no change of gene expression, 
and type 2 errors or false negatives, when the p-value is not significant but there is 
a change of expression. Power of the test is indicated by the probability of not 
making false negative errors, whereas the confidence is defined by the probability 
of not obtaining false positive errors (Russell et al., 2009, Tsai et al., 2003).  
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Fold change can be used as a sole measure of gene expression differences; 
however, it is deemed statistically inadequate as the variance and confidence 
levels cannot be measured. Therefore, using fold change cutoffs regardless of the 
variance or sample size, results in increased false positive rates (Allison et al., 
2006). In order to tackle this issue statistical tests are performed on many 
transcripts to verify the candidates that show expression differences based on the 
p-value (Allison et al, 2005; Russell et al, 2009). False discovery rate (FDR) 
control methods, such as Benjamini-Hochberg (BH) correction (Benjamini and 
Hochberg, 1995),  are common statistical tests in microarray analysis. 
3.3.2.3 Principal component analysis (PCA) 
PCA is a class of unsupervised methods which do not require prior knowledge of 
potential gene expression differences. PCA algorithm converts a set of potentially 
correlated variables, such as gene expression, into a set of values of linearly 
uncorrelated types known as principal components (PCs). In the gene expression 
model, PCs are employed for visualisation purposes by reducing the 
dimensionality of expression data and filtering noise. PCA analysis results in the 
identification of gene or sample clusters with similar expression patterns (Russell 
et al., 2009).   
3.3.2.4 Data mining  
In order to convert the differences in gene expression into meaningful biological 
clusters, different tools have been developed to divide differentially expressed 
genes based on their biological function, molecular characteristics, or cellular 
location amongst others. These variants are referred to as the GO terms. 
PANTHER database (www.pantherdb.org) (Thomas et al., 2003) provides 
integrated GO analysis tools, which are used for biological pathways analyses in 
this Chapter.   
3.3.2.5 Validation of microarray data 
FDR control is not very stringent in detecting false positive errors to allow the 
discovery of gene expression differences, particularly in the absence of large 
numbers of biological replicates. These false positive signals could be due to the 
cross-hybridisation or hybridisation artefacts. Furthermore, the limited intensity 
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range of the spots on the array does not reflect true fold change differences, but 
as a factor of normalised intensity relative to the other spots and arrays in the 
experiment. Therefore, it has been recommended to use RT-PCR for validation of 
the observed gene expression differences. RT-PCR provides a better measure of 
quantitative differences in gene expression levels between two experimental 
conditions or samples. Furthermore, the false positive signals can be identified by 
designing gene-specific RT-PCR primers (Rajeevan et al., 2001, Rockett and 
Hellmann, 2004).  
The microarray data can also be compared with information available in literature. 
An agreement between the microarray analysis and data from other sources 
provides confidence in the identified biological processes. Taking the analysis in 
this Chapter as an example, gene expression analysis of HSCs and CML cells 
have been previously reported (reviewed below). If there is an overlap between 
the observed gene expression signatures in this Chapter and the previous reports, 
it could be suggested that the observed results are likely to be meaningful.        
3.4 Aims of the Chapter 
The gene expression patterns of CML cells versus their normal counterparts will 
be investigated. 
1. To purify normal and CML cell populations based on the CD34 and CD38 
cell surface markers by FACS. 
2. To derive gene expression profiles of HSCs (CD34+ CD38-), LSCs (CD34+ 
CD38-), HPCs (CD34+ CD38+) and LPCs (CD34+ CD38+).  
3. To identify the genes and pathways involved in the maintenance of HSCs. 
4.  To identify the genes and pathways involved in the proliferation of HPCs.  
5. To identify the genes and pathways, which are uniquely affected in CML. 
6. To determine whether the pathways identified in 4, 5 and 6 change in their 
levels of expression as LSCs become LPCs.  
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Results 
3.5 Overall strategy 
HSCs (CD34+ CD38-), LSCs (CD34+ CD38-), HPCs (CD34+ CD38+) and LPCs 
(CD34+ CD38+) were isolated by FACS from non-CML (Ph-) (n=3) and chronic 
phase CML (Ph+) (n=3) samples. Total RNA was extracted followed by cDNA 
synthesis, labelling and hybridisation on Affymetrix WT Gene arrays. After pre-
processing the raw image data, significant gene expression differences between 
each cell type were deduced. Gene expression profiles were used in PCA analysis 
to cluster the datasets according to the similarities and differences between 
different cell types. Differential expression was used to identify the significant 
biological pathways associated with each transition using the PANTHER 
database. Putative pathways involved in maintaining HSC quiescent and self-
renewal (HSC identity) or those involved in proliferation (HPC identity) were 
identified by comparing the gene expression profiles of HSCs to those of HPCs. 
Furthermore, CML identity pathways were identified as the pathways which 
showed expression changes uniquely in in the CML cells. The expression levels of 
HSC identity and HPC identity pathways were analysed in LSCs and LPCs to 
establish the links between the stem cell phenotype of LSCs and the pathways 
which control it, as well as the changes in these pathways that are required for 
LSCs to become proliferative progenitors.  
3.6 Isolation of HSCs, LSCs, HPCs, and LPCs 
HSCs and HPCs were purified from G-CSF-mobilised PB samples of a healthy 
donor and two non-Hodgkin lymphoma patients. Non-Hodgkin lymphoma is a 
haematological malignancy that affects lymphoid branch of haemopoiesis and 
abnormalities have not been reported for their HSC compartment. Therefore, 
these samples were referred  to  as   ‘non-CML’   in  this  work.  LSCs  and  LPCs  were  
purified from the PB samples of three CP CML patients. The CD34+ populations 
from these patients were assessed for the presence of Ph chromosome by FISH 
technique at the time of sample collection (Table 3.1; Dr. Mhairi Copland, 
unpublished data). All CML samples were >96% Ph+. 
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HSCs and LSCs were defined as cell populations expressing CD34 cell surface 
antigen in the absence of CD38 antigen and therefore, referred to as CD34+ CD38- 
population, whereas HPCs and LPCs were identified by expression of both CD34 
and CD38 molecules on their cell surface and therefore, referred to as CD34+ 
CD38+ population. The CD34+ CD38- population was previously reported to be 
~100 folds more enriched for engraftable HSCs than the CD34+ CD38+ population 
(Bhatia et al., 1997, Larochelle et al., 1996). The Ph+ LTC-IC CML cells were also 
significantly associated with the CD34+ CD38- population (Petzer et al., 1996). 
However, as discussed in Section 1.7.3, cytogenetic analysis was required for 
further characterisation of sorted LSCs and LPCs. (Table 3.1; Dr. Mhairi Copland, 
unpublished data).  
The isolation of CD34+ CD38- and CD34+ CD38+ subpopulations was achieved by 
FACS using antibodies against CD34 and CD38 antigens (Figure 3.3). The 
proportion of stem cell compartment varied between samples, although non-CML 
individuals showed significantly larger stem compartment than the CML samples. 
This could be associated with the G-CSF mobilisation that released HSCs from 
their BM niche. FISH analysis for the Ph chromosome in the sorted LSCs showed 
that >89% of the cells were Ph+ (Table 3.1, Dr. Mhairi Copland, unpublished data).  
 
Table   3.1: Molecular characteristics of the HSCs, LSCs, HPCs, and LPCs used in this study. 
The phenotype and the percentage of Ph+ cells measured by FISH are reported for the samples 
used in this study. The percentage of Ph+ cells reported for the bulk CD34+ compartment was 
obtained at the time of collection from newly diagnosed patient. The percentage of Ph+ reported for 
CD34+ CD38- population was obtained after cell sorting. Data was not available for the post-sort 
LSC2 sample, although the CML2 CD34+ population was significantly Ph+ (Dr. Mhairi Copland, 
unpublished data).  
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Figure   3.3: Isolation of HSCs, LSCs, HPCs, and LPCs by FACS-sorting. 
Dot plots represent FACS profiles of non-CML (n=3) and CML (n=3) samples. (A, B) Cell sorting 
was performed on the CD34+-enriched in the three non-CML and CML1 samples, whereas 
unenriched mononuclear cells were used for CML2 and CML2 samples. (A) The live cell population 
was identified by using the side scatter (SSC) and forward scatter (FSC) parameters. The 
percentage of live cells is shown. (B) The CD34 and CD38 gates were adjusted based on the 
isotype controls. The percentage of live cells in CD34+ CD38- and CD34+ CD38+ populations are 
shown. (C) The HSCs and LSCs were isolated by the presence of CD34 (x-axis) and the absence 
of CD38 (y-axis) cell surface antigens. (D) The HPCs and LPCs were isolated by the presence of 
both CD34 and CD38 markers. The post-sort plots demonstrate the purity of samples in each case 
as represented by the percentage of cells in each gate. (E) The distinction between cell surface 
CD38 expression in isolated CD34+ CD38- (blue line) and CD34+ CD38+ (red line) cells is shown as 
histograms representing the CD38 intensity on the x-axis with the cell count on the y-axis.  
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3.7 RNA extraction for Affymetrix hybridisations 
Total RNA was extracted from the isolated HSCs, LSCs, HPCs, and LPCs, as 
described in Chapter 2. For HSCs and LSCs, two technical replicates per sample 
were obtained by FACS purification of two separate aliquots of each sample at 
independent time points. In total, six RNA samples were generated for each of 
HSC and LSC cell types. For HPCs and LPCs, three RNA samples were purified 
for each individual and were subsequently divided into two technical replicates. 
The quality and integrity of purified DNase-treated RNA samples were investigated 
using the Agilent Bioanalyzer prior to cDNA synthesis for Affymetrix hybridisation 
(Figure 3.4). RNA integrity was calculated by the RNA integrity number (RIN) 
which assigns a value between 1 and 10. RIN of 1 indicates complete degradation 
and 10 complete integrity of RNA samples. The RIN values of 8 or above are 
recommended for the Affymetrix hybridisations.  
 
Figure   3.4: Bioanalyzer quality control of purified total RNA. 
The Bioanalyzer gel results for the total RNA samples purified from HSC, LSC, HPC, and LPC 
samples. Two major bands are detectable in each lane which belong to 28s (top) and 18s rRNAs 
(bottom). Moreover, no significant genomic DNA or protein contamination was detected in any of 
the samples. Ladder and the bp ruler can be seen on the left side. The integrity of RNA samples 
were measured by the RIN tool. RIN values of above 8.0 are considered as acceptable for 
Affymetrix hybridisation.  
The Bioanalyzer gel analysis showed no major contamination of genomic DNA or 
proteins and only two bands could be significantly detected for all samples which 
belonged to 28s and 18s rRNAs (Figure 3.4). Furthermore, all RNA samples 
showed an RIN of 8 or above and therefore, passed the required integrity 
threshold for Affymetrix hybridisation.    
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3.8 Affymetrix hybridisation and pre-processing of data 
cDNA synthesis and labelling, using the random priming approach described 
earlier, was performed and the samples were hybridised onto Affymetrix human 
GeneChip WT Gene arrays (HuGene-1_0-st-v1). The raw image data (.CEL files) 
were obtained and the pre-processing of data was achieved by RMA probe 
summarisation and background correction, and quantile normalisation in the 
aroma.affymetrix package of Bioconductor, as described in Chapter 2. RNA 
degradation, Normalised Unscaled Standard Error (NUSE), and Relative Log 
Expression (RLE plots) were generated to check the quality of the hybridisation 
and to identify potential outlier datasets (Figure 3.5). 
 
Figure   3.5: Affymetrix pre-processing quality control (QC) plots. 
(A) RNA degradation plots which show the mean intensity of probes (y-axis) as laid down from 5′ to 
3′ in an average transcript (x-axis). The RNA degradation plots demonstrate higher intensity of 
probes at the 5′ end with a gradual decline towards the 3′ end. Furthermore, the slope of the plots 
are in agreement. (B) NUSE plot in which the medians of box plots are expected to align close to 
1.00 (y-axis). (C) RLE plot in which the medians of box plots are expected to align at M=0 (y-axis).  
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RNA degradation plot is a visualisation tool to inspect the quality of hybridisation 
across the probes in an average gene as laid down from 5′ to 3′.  The RNA is 
degraded from the 5′-end and therefore, intact RNAs at the time of hybridisation 
show higher probe intensity at the 5′-end with a gradual decline towards the 3′-
end. Furthermore, the arrays that show a different slope relative to others are 
normally regarded as outlier. In this case, all the arrays showed a similar slope in 
RNA   degradation   plots   with   higher   intensities   at   5′-end and lower intensities 
towards   the  3′-end (Figure 3.5A). Therefore, the expression differences between 
the samples would not be due to significant quality variations of the hybridised 
material. NUSE and RLE plots were used as the next line of QC after pre-
processing. NUSE is calculated by standardising the standard error of the 
estimated expression value for each probe set in order to obtain a median 
standard error for each array which is close to 1.00. The median of standard error 
for each array in this study was observed to be close to 1.00 (Figure 3.5B). RLE 
plots are generated by calculating log-scale estimates for the expression of each 
probe set on each array. Furthermore, it is presumed that the number of 
differentially expressed genes between datasets are relatively few and therefore, 
the box plot representing each array is expected to centre close to 0. All the 
hybridised arrays in this work were shown to be aligned at 0 (Figure 3.5C). 
Therefore, the hybridised arrays passed the QC tests and can be used for the 
downstream PCA and differential expression analyses.  
3.9 PCA clustering of the gene expression datasets 
In order to demonstrate the relationship between the gene expression profiles of 
CML cells and their normal counterparts, three-dimensional (3D) PCA plots were 
generated from the preprocessed microarray datasets (Figure 3.6). PCA method is 
typically employed for visualisation purposes by reducing the dimensionality of 
expression data and filtering noise. Unlike hierarchical clustering, the clustering 
decisions are not made locally in the PCA approach and the relationship between 
different data sets can be re-evaluated at a later stage in a 3D environment 
(Russell et al., 2009).  
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Figure   3.6: PCA clustering of the gene expression datasets. 
3D PCA clustering of the preprocessed gene expression datasets is shown from two different 
angles. The relationship between the gene expression signature of the four cell can be observed. 
HSCs (green circles), HPCs (red circles), LSCs (blue circles), and LPCs (yellow circles) are 
labelled with regards to their sample number (Table 3.1).  
The 3D PCA clustering demonstrated that there is a considerable heterogeneity in 
the LSC population (Figure 3.6, blue circles). The LSC1 sample was found in close 
proximity to their normal counterparts (Figure 3.6, green circles), whereas LSC2 
and LSC3 samples were in the close proximity of LPCs (Figure 3.6, yellow circles). 
Intriguingly, the distance between LSCs and HSCs in the 3D environment was 
similar to the distance between HSCs and HPCs (Figure 3.6, red circles), although 
LSCs and HPCs did not overlap. These observations indicated that the gene 
expression signature of LSCs was located between the gene expression profiles of 
HSCs and LPCs. Therefore, LSCs could be expected to demonstrate the 
intermediate characteristics of both cell type, or in other words, less primitive but 
more proliferative than their normal counterparts. The observations were also in 
agreement with the reported similarities between the gene expression signature of 
LSCs and early myeloid progenitors (Bruns et al, 2009; reviewed in Section 3.1.4).  
The LPCs, on the other hand, were more homogenous and discrete than LSCs. 
Furthermore, LPCs were observed in the proximity of their normal counterparts, 
HPCs. This observation was in agreement with the proliferative capacities of both 
cell types. However, LPCs and HPCs did not overlap which indicated distinct gene 
expression profiles between the two progenitor cell types. Furthermore, LPCs and 
HPCs were the two most completely segregated cell populations in the 3D PCA 
plot. Therefore, it could be expected that LPCs and HSCs demonstrate the largest 
number of gene expression differences amongst all the possible comparisons.  
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These global observations at the level of gene expression profiles showed 
interesting characteristics for LSCs and LPCs relative to their normal counterparts. 
However, the relationship between the gene expression signatures of CML cells 
and their normal counterparts needs further investigation by analysing differential 
expression and the biological pathways that were affected by the changes of gene 
expression between cell types.  
3.10 Analysis of differential gene expression 
Four types of differential gene expression analysis were performed. First 
comparison was performed between HPCs and HSCs in order to identify the 
genes that are associated with the HSC identity and the proliferative HPC identity. 
Second comparison was performed between LSCs and HSCs to distinguish the 
similarities that LSCs share with the HSC and HPC identities. This comparison 
was also required in order to identify the unique gene expression changes that 
occur during LSC formation which define the CML identity. Third comparison was 
performed between LPCs and LSCs in order to investigate gene expression 
differences that promoted exit from the stem cell compartment which define LPCs 
characteristics. Fourth comparison was performed between LPCs and HSCs in 
order to establish the overall gene expression differences that occurred in the 
course of LPC development from HSCs. The fourth comparison can also be used 
to establish the similarities and differences that the formation of LPCs from HSCs 
share with normal differentiation to HPCs.     
Statistically significant gene expression differences in each comparison were 
deduced using the limma package in Bioconductor with BH FDR control adjusted 
at 0.05 confidence threshold, as described in Chapter 2. The hg18 RefSeq 
annotation was used to annotate the significantly differentially expressed 
Affymetrix probe sets. The total number of significantly upregulated or 
downregulated genes in each of the above comparisons is shown in Table 3.2. 
Chapter 3  129 
  
 
Table   3.2: Total number of significant gene expression differences in the four comparisons. 
The total number of significantly (p<0.05) upregulated (red) and downregulated (green) genes is 
indicated for each of the studied comparisons. 
The first comparison which was performed between HPCs and HSCs identified 
4,489 significantly differentially expressed genes (p<0.05). 60% of the gene 
expression changes (n=2,612) in this comparison were in favour of upregulation 
which could be potentially associated with the proliferative characteristics of HPCs. 
Furthermore, the significantly downregulated genes (n=1,877) could be potential 
regulators of HSC identity or the genes whose expression were no longer required 
in HPCs. The second comparison which was performed between LSCs and HSCs 
identified 3,628 significantly differentially expressed genes, 55% of which 
(n=1,996) were associated with significant upregulation and 45% of them were 
significantly downregulated in LSCs (n=1,632). The third comparison was 
performed between LPCs and LSCs which identified 3,221 significantly 
differentially expressed genes. 73% of the gene expression differences (n=2,336) 
in this comparison was linked to upregulation, whereas only 27% of changes were 
in a downward direction indicating a large tendency for gene upregulation to 
promote exit from the stem cell compartment. The fourth comparison which was 
performed between LPCs and HSCs identified 9,055 significantly differentially 
expressed genes. 55% of the changes (n=4,948) were linked to upregulation and 
45% of the changes (n=4,107) were associated with downregulation. This 
observation indicated that although the gene expression changes during LPC 
formation from LSCs are largely skewed towards upregulation, the gene 
expression differences between LPCs and HSCs were not skewed and resembled 
that pattern that was observed between HPCs and HSCs. The comparison 
between LPCs and HSCs identified the largest subset of gene expression 
differences amongst the four comparisons which was in agreement with earlier 
observations of 3D PCA clustering (Figure 3.6). However, the sum of total number 
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of changes between LSCs and HSCs as well as LPCs and LSCs was 6,849 which 
only accounted for 75% of the overall changes between HSCs and LPCs. The 
results could propose that a subset of genes accumulated non-significant gene 
expression changes in the HSC-to-LSC and LSC-to-LPC transitions which became 
significant gene expression differences in the overall comparison between HSCs 
and LPCs.   
The above results demonstrated significant number of changes in both upward 
and downward directions in each of the studied comparisons. However, the 
relationship between the significant expression changes in one comparison and 
the gene expression changes in other comparisons was not revealed. In order to 
address that the expression changes (both significant and non-significant) of all 
the annotated genes in all four comparisons were plotted as heatmaps (Figure 
3.7Ai). Furthermore, heaptmaps were also generated for the genes that were only 
significantly differentially expressed in each of the comparisons (Figure 3.7Aii).  
The heatmap of all the expression changes which included both significant and 
non-significant changes in the four comparisons revealed that the direction of gene 
expression changes in different comparisons was concordant (Figure 3.7Ai). 
However, the magnitude of gene expression change and their significance level in 
different comparisons were not the same. In other words the genes that were 
downregulated in HPCs relative to HSCs were also predominantly associated with 
downregulation in other comparisons. Similar observation was also made for the 
upregulation events. Furthermore, the heatmap that was generated for the 
significant gene expression changes, which were a subset of the genes from the 
previous heatmap, showed a concordance in the direction of significant gene 
expression changes in other comparisons if the expression change was also 
significant (Figure 3.7Aii). Both heatmaps provided evidence for the earlier 
suggestion that the accumulation of non-significant gene expression changes 
during HSC-to-LSC and LSC-to-LPC transitions could result in significant gene 
expression changes in the overall comparison between HSCs and LPCs. 
Furthermore, the heatmap for significant gene expression changes (Figure 3.7Aii) 
also demonstrated a concordance in the direction of gene expression changes 
between HSC-to-HPC and HSC-to-LPC transitions. This could propose similar 
changes in the gene expression signature of HSCs in the course of differentiation 
to HPCs and leukaemic transformation to LPCs. This was further investigated by 
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analysing the overlap between the significant gene expression differences in HSC-
to-HPC transition and the other three comparisons involving LSCs and LPCs 
(Figure 3.7B).         
 
Figure   3.7: The direction of gene expression differences in the four studied comparisons is 
concordant.   
(A) The heatmaps represent the genome-wide expression differences observed in each of the 
studied comparisons. (i) All expression changes that include both significant and non-significant 
and (ii) the significant (p<0.05) expression changes are depicted. The green bars indicate 
downregulation events and the red bars indicate upregulation events. (B) Venn diagrams represent 
the overlap between the significantly up- and downregulated genes (p<0.05) in the HSC-to-HPC 
transition and the HSC-to-LSC, LSC-to-LPC, and HSC-to-LPC comparisons. The number of 
significantly downregulated genes are shown in green circles, whereas the number of upregulated 
genes is represented in the red circles. The small Venn diagrams in between represent the 
discordant changes between the comparisons. Both heatmaps and Venn diagrams demonstrate a 
concordance in the direction of gene expression changes despite differences in their magnitude 
and significance.   
The Venn diagrams highlighted earlier observations in heatmaps that the direction 
of gene expression changes were concordant in the four studied comparisons 
(Figure 3.7B). 78% of the genes that were significantly downregulated in HPCs 
relative to HSCs were also significantly downregulated in LPCs relative to HSCs. 
Furthermore, 87% of the significantly upregulated genes in HPCs relative to HSCs 
were also significantly upregulated in LPCs relative to HSCs. This observation 
demonstrated that the majority of the genes that were significantly differentially 
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expressed in the course of normal differentiation were also differentially expressed 
during LPC formation which can be associated with the proliferative status of both 
cell types. However, 65% of significantly downregulated and 55% of significantly 
upregulated genes between HSCs and LPCs were observed uniquely in this 
comparison. These gene expression differences, therefore, could be linked to the 
CML identity of LPCs.  
The gene expression differences in the HSC-to-LSC and LSC-to-LPC transitions 
did not demonstrate similar degree of overlap with the gene expression differences 
between HSCs and HPCs (Figure 3.7B). 42% of the genes that were significantly 
downregulated in LSCs were also significantly downregulated in HPCs relative to 
HSCs. Moreover, 64% of the genes that were significantly upregulated in LSCs 
were also upregulated in HPCs relative to HSCs. These observations indicated 
that the gene expression signature of LSCs share similarities with HPCs, in 
particular with respect to the upregulation events.  
Furthermore, 40% of the significantly downregulated and 52% of significantly 
upregulated genes between LPCs and LSCs were also significantly downregulated 
and upregulated in HPCs relative to HSCs, respectively (Figure 3.7B). This 
observation indicated that exit from stem cell compartment in CML shared 
similarities with exit from stem cell compartment in their normal counterparts. 
Nevertheless, as the gene expression signatures of LSCs shared a lot in common 
with HPCs, as shown above, and also closely-related to LPCs, as indicated by 3D 
PCA clustering, fewer gene expression changes are required to promote the LPC 
formation.   
Overall, the key findings of the results presented in this section are summarised 
here. The direction of gene expression changes, both significant and non-
significant, in the four studied comparisons was concordant despite differences in 
their significance level and magnitude of change. In other words, a subset of 
genes in HSCs are only programmed to be downregulated or repressed upon 
leaving the stem cell compartment, whereas another subset of genes in HSCs are 
only programmed to be upregulated or activated upon leaving the stem cell 
compartment. This finding is in agreement with the lineage priming model which 
was reviewed in Section 1.6.5. Furthermore, the leukaemic transformation was not 
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able to abnormally upregulate or downregulate genes that were destined for 
downregulation or upregulation, respectively, during normal differentiation.  
Another finding of the above results indicated that the gene expression differences 
during LSC formation shared similarities with the expression changes during HPC 
differentiation. The transition from LSC to LPC also shared similarities with the 
HPC differentiation but to a lower level. This could provide further evidence that 
LSCs share similarities with the progenitor cells.         
3.11 Validation of the identified gene expression 
differences by real-time PCR (RT-PCR) 
The validation of gene expression differences observed by the Affymetrix 
hybridisation is a crucial step due to the presence of false positive discoveries as a 
result of cross-hybridisation or other labelling and array artefacts, as described 
earlier. Furthermore, due to the limited variance in the spot intensities as well as 
the normalisation processes, the fold expression differences reported by the 
arrays could be under- or over-estimates in some cases (Rajeevan et al., 2001).  
A total of 77 genes were selected from significantly (p<0.05) differentially 
expressed genes between LSCs and HSCs that were identified by the Affymetrix 
analysis – 44 upregulated and 33 downregulated in LSCs. The genes were 
selected from three pathways that were of special interest to this research group, 
which include TGF-β   signalling   pathway, PI3K signalling pathway and the 
intracellular signalling downstream of BCR-ABL1 oncoprotein. TaqMan 384-well 
micro fluidic cards were designed using 18S rRNA, GAPDH, and RPLP0 as 
housekeeping genes. Each RT-PCR assay was performed in triplicate for each 
LSC sample and an RNA pool of HSC samples that were hybridised on the 
Affymetrix arrays, as described in Chapter 2. The absolute gene expression values 
were quantified for each probe relative to the average Ct values of the 
housekeeping genes and subsequently the log2 fold change differences were 
calculated using the HSC expression levels as the calibrator (Figure 3.8). 17 
genes failed to demonstrate significant differential expression between LSCs and 
HSCs reported by Affymetrix. Therefore, 78% of the reported differences could be 
successfully validated by RT-PCR, which was greater than the previously reported 
success rate of 71% (Rajeevan et al., 2001).    
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Figure   3.8: RT-PCR validation of differentially expressed genes identified by Affymetrix. 
77 differentially expressed genes as identified by Affymetrix analysis between LSCs and HSCs 
were chosen from which 44 were upregulated (red bars) and 33 were downregulated (green bars) 
in LSCs. The log2 fold enrichments (y-axis) were measured using the HSC expression levels as the 
calibrator. Each gene is represented with two sets of data; HSC log2 fold expression which is set to 
0 for all the samples (baseline) and LSC log2 fold expression which is represented at the height of 
the bars. The error bars show the confidence intervals at 95% and in the absence of overlap 
between the error bars of HSC and LSC data points the differential expression was called 
significant and therefore, passed the validation step. The grey bars and the genes marked with 
asterisks failed the validation (n=17).  
3.12 Identification of genes and pathways important for 
the maintenance of HSCs and their progression to the 
proliferative state 
The implication of the identified gene expression differences in the context of 
biological pathways was investigated for each of the studied comparisons. The 
comparison between HPCs and HSCs identified 1,877 genes that were 
significantly downregulated in HPCs, which could be associated with the 
maintenance of HSCs. However, before analysing the biological pathways that 
were significantly associated with this subset of genes, the expression levels of 
several known HSC maintenance genes were investigated as an extra validation 
level. A recently published dataset identified 830 genes that were significantly 
upregulated in human HSCs relative to all the known haemopoietic progenitors 
and terminally differentiated haemopoietic lineage cells (Novershtern et al., 2011; 
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Section 3.1.3). A comparison was made between this published dataset and the 
HSC upregulated gene set from this study which identified 135 genes in common. 
The common gene set included several known HSC maintenance transcription 
factors and cell surface receptors (Section 3.1.3) including FLT3, GATA3, HLF, 
HOXA2, HOXA4, HOXA5, HOXA9, HOXB2, HOXB5, MECOM, MEIS1, NANOG, 
RBPMS, and SOCS2 (Figure 3.9). 
 
Figure   3.9: Several known HSC maintenance transcription factors are upregulated in HSCs 
relative to HPCs. 
The log2 fold change (y-axis) of gene expression in HSCs relative to HPCs was extracted from the 
significantly differentially expressed genes identified by Affymetrix analysis (p<0.05).  
The significant gene expression differences between HSCs and HPCs were used 
to identify the biological pathways that were significantly upregulated or 
downregulated in this comparison (Table 3.3). Pathway analysis was performed 
using PANTHER database tool (Section 3.1.2.4). The list of significantly 
differentially expressed genes and their fold change differential expression values 
was used as an input. The statistical tool then created a distribution of values for 
the input data set, which is then used as a reference for distribution. Subsequently, 
the input data set was divided into functional categories that comprise biological 
pathways, and the distribution of values in each group was calculated and 
compared against the reference distribution. The probability of obtaining a random 
distribution from the reference distribution in each category was measured by the 
Mann-Whitney Rank-Sum test (U-test) (Clark et al, 2003; Thomas et al, 2006). The 
output data was represented as p-values associated with the direction of shift for 
the distribution of values in each group relative to the reference distribution. The 
categories with non-random distribution were associated with small and significant 
p-values.  
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Table   3.3: Pathways significantly upregulated in HSCs or HPCs. 
The table summarises a list of pathways showing a significant (p<0.05) shift of distribution in the 
HSC or HPC direction relative to the overall distribution. The number of genes affected in each 
pathway and the calculated p-values (U-test) are also shown. The pathways are ranked based on 
their significance in terms of up-regulation or down-regulation in HSCs or HPCs respectively.   
Thirteen biological pathways showed significantly higher expression in HSCs 
relative to HPCs. Conversely, nineteen pathways were significantly upregulated in 
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HPCs relative to HSCs. Intriguingly, all the 13 pathways that were downregulated 
upon commitment to HPCs were involved in cell signalling, including Wnt, platelet-
derived growth factor (PDGF), endothelin, TGF-β,   interleukins,   and   inflammation 
mediated by chemokines and cytokines signalling pathways. Furthermore, several 
neurotransmitter signalling pathways were also downregulated in HPCs, which 
included histamine via H1 receptor, serotonin via 5HT2 receptors, acetylcholine 
via muscarinic receptors 1 and 3, oxytocin, thyrotropin-releasing hormone (TRH), 
catecholamines via α-adrenergic receptors, and angiotensin II signalling pathways. 
The importance of Wnt, TGF-β, chemokines and cytokines signalling pathways in 
the maintenance of self-renewal and quiescence of HSCs have been previously 
reported (reviewed in section 1.6.4) (Reya et al., 2003, Sitnicka et al., 1996, Steidl 
et al., 2004). Furthermore, neurotransmitter receptors have also been reported on 
the cell surface of HSCs which were downregulated in the course of differentiation 
(Steidl et al., 2004; Section 1.6.4.7). These 13 pathways were, therefore, referred 
to as the HSC identity pathways.  
Conversely the pathways upregulated in HPCs were associated with cellular 
metabolism, DNA replication, ubiquitin proteasome pathway, transcriptional 
regulation, p53 induction and regulation, and cell cycle. The upregulation of these 
pathways was in agreement with the proliferative nature of HPCs and therefore, 
were referred to as the HPC identity pathways. These pathways were also shown 
to be upregulated in the CD34+ CD38+ population relative to the CD34+ CD38- 
population in previous studies (Georgantas et al., 2004, Ivanova et al., 2002).  
The identification of previously reported biological pathways that regulate HSC and 
HPC identities could confirm that appropriate cell populations were purified and 
the differential expression analyses were performed accurately to reflect true and 
significant biological differences.     
3.13  LSCs share similarities with both HSCs and HPCs at 
the pathway level.  
The significant gene expression differences between HSCs and LSCs were also 
subjected to pathway analysis in order to identify the similarities and differences 
between HSCs and LSCs at the pathway level (Table 3.4). 
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Table   3.4: Pathways significantly upregulated or downregulated in LSCs relative to HSCs. 
The table summarises a list of pathways showing a significant (p<0.05) shift of distribution in a 
positive (LSC) or negative (HSC) direction relative to the overall distribution. The number of genes 
affected in each pathway and the calculated p-values (U-test) are also shown. The pathways are 
ranked based on their significance in each direction. 
Endothelin signalling was the only HSC identity pathway that was significantly 
downregulated in LSCs, whereas the remaining 12 HSC identity pathways were 
not significantly down- or upregulated in LSCs. These pathways include TGF-β, 
Wnt, PDGF, chemokine and cytokine, interleukins and several neurotransmitter 
signalling pathways (Section 3.10). Therefore, the HSC identity pathways were 
expressed at similar levels in both HSCs and LSCs, which may propose their 
function in LSC maintenance. The role of TGF-β and Wnt signalling pathways in 
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the maintenance of quiescence and self-renewal capacities of LSCs were reported 
previously (Section 1.7.6) (Naka et al., 2010, Zhao et al., 2007). Conversely, two 
reports showed significant downregulation of several chemokine ligands and 
receptors in LSCs relative to their normal counterparts (Bruns et al., 2009, Graham 
et al., 2007). However, this was not in agreement with the above findings that 
showed no significant change of expression in the chemokine and cytokine 
signalling pathway between HSCs and LSCs. Furthermore, several 
neurotransmitter receptors were also reported to be expressed on the surface of 
LSCs (Kronenwett et al., 2005), although the reported receptors were not 
associated with the neurotransmitter pathways that were identified above.  
Twenty pathways were significantly upregulated in LSCs relative to HSCs, 12 of 
which were involved with the HPC identity (Section 3.10). These included ubiquitin 
proteasome pathway, cell cycle, DNA replication, p53 induction and several 
metabolic pathways. This observation was in agreement with the previous reports 
that showed the upregulation of cell cycle and DNA replication genes in LSCs 
relative to their normal counterparts (Graham et al., 2007, Kronenwett et al., 
2005). 
In addition to the pathways that were associated with the HSC and HPC identities, 
several other biological pathways were also identified to be significantly 
misregulated between HSCs and LSCs. Toll-like receptor signalling and T-cell 
activation pathways showed a significant downregulation in LSCs, whereas 
integrin signalling, blood coagulation, cytoskeletal regulation by Rho GTPase, and 
apoptosis signalling were upregulated in LSCs. Therefore, these pathways could 
be associated with the CML identity.     
LSCs, therefore, share similarities with both HSCs and HPCs at the pathway level. 
The shared similarities with HPCs was expected from the overlap between the 
gene expression differences that observed in the HSC-to-HPC and HSC-to-LSC 
transitions (Figure 3.7B). The persistent activity of the HSC identity pathways in 
LSCs could provide further evidence for the stem cell features of LSCs such as 
self-renewal and quiescence despite the upregulation of many proliferative 
pathways. 
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3.14 LPCs show a significant loss of HSC identity.  
The significantly differentially expressed genes between LSCs and LPCs were 
analysed at the pathway level to identify the pathways that were significantly 
down- or upregulated in the course of LSC commitment to LPCs (Table 3.5). 
Table   3.5: Pathways significantly upregulated or downregulated in LPCs relative to LSCs. 
The table summarises a list of pathways showing a significant (p<0.05) shift of distribution in a 
positive (LPC) or negative (LSC) direction relative to the overall distribution. The number of genes 
affected in each pathway and the calculated p-values (U-test) are also shown. The pathways are 
ranked based on their significance in each direction. The HSC identity pathways are highlighted in 
green.  
Eight HSC identity pathways were shown to be significantly downregulated in 
LPCs. These included Wnt, TGF-β, PDGF, interleukin, and inflammation via 
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chemokine and cytokine signalling pathways, as well as serotonin signalling via 
5HT2 receptors, oxytocin, and TRH signalling pathways. The downregulation of 
these pathways in the transition from LSCs to LPCs provides a second line of 
evidence that they may be important in maintaining the stem cell phenotype of 
LSCs. However, four HSC identity pathways did not show a significant up- or 
downregulation in LPCs, which include α-adrenergic receptor signalling, 
muscarinic acetylcholine receptors 1 and 3 signalling, histamine H1 receptor 
signalling and angiotensin II receptor signalling pathways. Therefore, it can be 
argued that these pathways may confer a less mature phenotype to LPCs. 
Furthermore, three pathways associated with the HPC identity were upregulated in 
LPCs. These included DNA replication, the cell cycle, and de novo pyrimidine 
biosynthesis. These three pathways had also been upregulated in LSCs relative to 
HSCs, but were upregulated even further in the transition from LSCs to LPCs. 
Thus, the upregulation of these three pathways may also constitute key 
determinants in the transition from LSCs to LPCs.  
Additionally, pathways involved in angiogenesis, blood coagulation, RAS pathway, 
heterotrimeric Gα protein signalling, integrin, cadherin, vascular endothelial growth 
factor (VEGF), JAK/STAT, FGF, epidermal growth factor (EGF), PI3K, and 
nicotinic acetylcholine signalling were uniquely downregulated in the transition 
from LSCs to LPCs. Therefore, these pathways could also be involved with the 
CML identity, since they were not associated with any significant changes during 
normal haemopoiesis.  
Therefore, the results indicate that the exit from stem cell compartment in CML is 
associated with the loss of HSC identity in addition to acquiring further proliferative 
capacities by upregulating the pathways involved in cell cycle and DNA replication.  
Overall, the three sets of pathway analyses described above identified three major 
classes of pathways, including HSC identity, HPC identity, and CML identity 
(Figure 3.10). The HSC identity pathways could be involved in the regulation of 
self-renewal and quiescence, whereas the HPC identity pathways were associated 
with proliferation mechanisms. The CML identity pathways could be linked to 
proliferation, differentiation, survival, cell-cell contact, migration, and 
vascularisation. 
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Figure   3.10: Pathways significantly affected during normal commitment and leukaemic 
transformations. 
The schematic diagram shows pathways significantly (p<0.05) associated with HPC identity (red 
boxes), CML identity (black boxes), and HSC identity (green boxes). The significant up- and 
downregulation of pathways in each transition are marked with (+) and (-) signs, respectively. The 
pathways that were not significantly affected in a transition are connected by a straight line. 5HT, 5-
hydroxytryptamine (serotonin); Musc., muscarinic; R., receptor; reg., regulation. 
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The above observations were further strengthen by investigating the biological 
pathways that were significantly up- or downregulated by the significant gene 
expression changes between HSCs and LPCs (Table 3.6). This analysis would 
allow expression levels of pathways to be measured accurately between the cell 
types. 
  
Table   3.6: Pathways significantly upregulated or downregulated in LPCs relative to HSCs. 
The table summarises a list of pathways showing a significant (p<0.05) shift of distribution in a 
positive (LPC) or negative (HSC) direction relative to the overall distribution. The number of genes 
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affected in each pathway and the calculated p-values (U-test) are also shown. The pathways are 
ranked based on their significance in each direction. The HSC identity pathways are highlighted in 
green.  
The results showed that the formation of LPCs from HSCs was associated with 
significant downregulation of HSC identity pathways and the acquisition of 
proliferative capacities, which was in agreement with the earlier pathway analysis 
between LPCs and LSCs.  
3.15 Analysis of expression changes of the genes in the 
HSC identity pathways 
In order to further understand the fate of HSC identity pathways in LSCs and 
LPCs, their relative expression levels in the four cell types were established by 
performing pathway analysis for all the possible comparisons between the four cell 
types (Figure 3.11).  
 
Figure   3.11: The expression levels of stem cell maintenance pathways in the four cell types. 
The expression levels of stem cell maintenance pathways were analysed in the four cell types in 
relation to each other. The pathways were categorised into four major classes based on the 
similarities in their expression level in the four cell types. The horizontal grey lines indicate 
significance levels (p<0.05). The error bars represent the 95% confidence intervals and the 
significant differences are assigned in the absence of overlap between the error bars. 
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The HSC identity pathways were by definition significantly downregulated in HPCs 
relative to HSCs. By performing pathway analysis in all possible comparisons 
between the four cell types the expression levels of each pathway in each cell type 
with relation to the other cell types could be distinguished. From 13 HSC identity 
pathways the expression levels of two pathways could not be reliably established 
between the four cell types, which include PDGF signalling and histamine H1 
receptor signalling pathways. The fate of remaining 11 HSC identity pathways in 
LSCs and LPCs could be classified into four major classes (Figure 3.11).  
Type I pathways included Wnt, serotonin via 5HT2 receptors, oxytocin, and TRH 
signalling pathways which demonstrated a non-significant downregulation in LSCs 
with further significant downregulation in the progenitor cells with LPCs 
representing the lowest expression levels of all. Type II pathways, which included 
TGF-β, PDGF, interleukins, and inflammation mediated by chemokine and 
cytokine signalling, exhibited a non-significant upregulation in LSCs, but were 
significantly downregulated upon commitment to LPCs. However, their expression 
level in LPCs was not significantly lower than HSCs which indicated a higher level 
of activity for these pathways in LPCs compared to their normal counterparts, 
HPCs. Type III pathways included α-adrenergic receptors signalling, muscarinic 
acetylcholine receptors 1 and 3 signalling, and angiotensin II signalling pathways. 
These pathways showed a non-significant downregulation in both LSCs and LPCs 
relative to HSCs. Therefore, their expression level in CML cells was in an 
intermediated state between HSCs and HPCs. Type IV category included 
endothelin signalling pathway that showed a uniform significant downregulation in 
HPCs, LSCs, and LPCs relative to HSCs.  
The results indicated that the type I and type II HSC identity pathways showed no 
significant differential expression between LSCs and HSCs, but were significantly 
downregulated upon commitment to LPCs. Thus, it was plausible to associate 
them with the maintenance of stem cell-like features in LSCs. Additionally, type III 
pathways were not significantly different between LSCs and LPCs relative to 
HSCs. As a result, these pathways may confer a less mature phenotype to LPCs. 
Similar to the earlier analysis that was performed for the genome-wide expression 
changes in the four studied comparisons, the gene expression differences of the 
genes in the HSC identity pathways were also examined in each comparison. In 
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total, 845 genes were associated with the 13 HSC identity pathways. Heatmaps 
were generated for all the gene expression changes, including both significant and 
non-significant changes, as well as the significant gene expression changes in 
order to investigate the concordance between the direction of gene expression 
changes between the four comparisons (Figure 3.12A). Similar to the earlier 
observations at the genome-wide level the direction of gene expression changes 
was concordant between the four comparisons despite differences in their 
significance level and their magnitude of change. This could suggest that the 
genes in the HSC identity pathway could be under a global gene regulation 
programme upon the exit from stem cell compartment. Furthermore, the numbers 
of significantly up- and downregulated genes in the HSC identity pathways in each 
comparison were identified and the overlap between the significant changes 
during normal commitment and the leukaemic transformations was established 
(Figure 3.12B). The significant gene expression changes in the HSC identity 
pathways identified 88 upregulated and 103 downregulated genes in the HSC-to-
HPC transition. This indicated a preference towards downregulation, which could 
be expected from the nature of these pathways that were significantly 
downregulated in HPCs. Furthermore, the gene expression changes of the HSC 
identity pathways in the HSC-to-LSC transition were balanced between up- and 
downregulation with 76 and 79 genes, respectively.  
The same analysis in the LSC-to-LPC transition identified 57 significantly 
upregulated genes as opposed to 46 significantly downregulated genes. This 
indicated a preference towards the upregulation events, although fewer genes 
were significantly changed relative to the other transitions. However, when the 
overall comparison was made between HSCs and LPCs, 188 genes were 
identified to be significantly downregulated which was slightly higher than 181 
significantly upregulated genes. Therefore, the preference towards downregulation 
was restored similar to the normal commitment. Nevertheless, the number of 
significantly affected genes were doubled in either directions relative to the HSC-
to-HPC transition. Furthermore, 80% (n=70) of the genes that were significantly 
upregulated in HPCs were also significantly upregulated in LPCs relative to HSCs; 
and 70% (n=73) of the significantly downregulated genes in HPCs were also 
significantly downregulated in LPCs relative to HSCs. These observations 
indicated that the downregulation of HSC identity pathways in LPCs was mediated 
by suppressing more genes in these pathways than HPCs.    
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Figure   3.12: The significant expression changes of the genes in the stem cell pathways. 
(A) The heatmaps represent the expression differences observed for the genes in the HSC identity 
pathways in each of the studied comparisons. (i) All expression changes (n=845) that include both 
significant and non-significant and (ii) the significant (p<0.05) expression changes are depicted. 
The green bars indicate downregulation events and the red bars indicate upregulation events. (B) 
The number of significantly (p<0.05) upregulated (red bars) and downregulated genes in the HSC 
identity pathways in each of the studied comparisons. The overlap between the significant changes 
in the HSC-to-HPC transition and the other three leukaemic transformations is shown as darker 
overlaid red and green bars. The total number of gene expression differences in each transition is 
also indicated on top of each bar.  
Overall, it can be argued that the genes in the HSC identity pathways were 
regulated by a global programme upon the exit from HSC compartment, which 
may be similar to the global programming that regulate genome-wide gene 
expression changes. However, the scope of transcriptional repression in the genes 
of the HSC identity pathways was a lot bigger during LPC formation compared to 
the normal development. This could suggest potential differences in the global 
programming between CML cells and their normal counterparts.      
3.16 Discussion 
The work presented in this Chapter showed the gene expression patterns of CML 
cells and their normal counterparts. Furthermore, the study of biological pathways 
that were significantly up- or downregulated during normal commitment and 
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leukaemic transitions could help the understanding of underlying biology in the 
maintenance of LSCs and their exit from stem cell compartment during LPC 
formation. The key findings of this Chapter are discussed below. 
3.16.1 LSCs share similarities with both HSCs and HPCs. 
The PCA clustering of the expression profiles of the four studied cell types, 
demonstrated that LSCs were located between HSCs and LPCs. Moroever, the 
distance between LSCs and HSCs in the 3D environment was similar to the 
distance between HSCs and HPCs, although LSCs and HPCs were not 
overlapping. This observation provided the first line of evidence that LSCs and 
HSCs do not completely match with regards to their gene expression profiles and 
demonstrate similarities to the progenitor cell types, HPCs and LPCs. The second 
line of evidence was obtained from the analysis of genome-wide gene expression 
differences. The majority of significant changes between HSCs and LSCs were 
also found to be significantly changing between HSCs and HPCs. This observation 
provided further evidence that LSCs share similarities at the level of gene 
expression differences with HPCs. The third line of evidence was obtained from 
the pathway analysis performed for the significantly differentially expressed genes 
between HSCs and LSCs. The pathway analysis identified 12 HSC identity 
pathways to be expressed at similar levels between HSCs and LSCs. 
Furthermore, 12 HPC identity pathway were also significantly upregulated in LSCs 
relative to HSCs. This observation provided evidence at the pathway level that 
LSCs share similarities with both HSCs and HPCs. 
Previous gene expression analysis of LSCs and CML progenitors also 
demonstrated significant similarities between LSCs and the progenitor cells based 
on the gene expression differences (Bruns et al., 2009, Graham et al., 2007). 
These studies identified fewer expression differences between LSCs and the early 
progenitors in CML than LSCs and their normal counterparts. However, these 
studies only investigated the significant gene expression differences between cell 
types without providing further evidence on the similarities at the level of biological 
pathways. Furthermore, it was reported that the genes associated with DNA 
replication, cell cycle and mitosis were significantly upregulated in LSCs relative to 
HSCs (Graham et al., 2007, Kronenwett et al., 2005), which was in agreement with 
the observations in this Chapter.  
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The observations in this Chapter were also in agreement with the phenotype of 
LSCs as reported by several studies. LSCs have been shown to reside in the G0 
cell cycle compartment and exhibited stem cell properties both in vitro and in vivo 
(Holyoake et al., 1999). Nevertheless, LSCs were demonstrated to exit quiescence 
state more readily than HSCs (Traycoff et al., 1998) and also exhibited reduced 
self-renewal capacities as shown by the LTC-IC assays (Udomsakdi et al, 1992). 
Furthermore, unlike their normal counterparts, LSCs demonstrate a growth factor-
independent survival mechanism as a result of abnormal proliferative capacities 
(Bedi et al., 1994, Strife et al., 1988). These observations provide further evidence 
that show LSCs share similarities with both stem cell compartment and 
proliferative cells. 
3.16.2 LPCs show a significant loss of HSC identity. 
The pathway analysis for the genes that were significantly differentially expressed 
between LSCs and LPCs identified eight HSC identity pathways to be significantly 
downregulated in LPCs. However, only three proliferative pathway associated with 
HPC identity was significantly upregulated, such as cell cycle and DNA replication. 
This finding was further strengthened by performing pathway analysis between the 
genes that were significantly differentially expressed between HSCs and LPCs, 
which confirmed the above findings. Therefore, the exit from stem cell 
compartment in CML is mediated by the loss of pathways associated with stem 
cell maintenance such as Wnt, TGF-β and chemokine and cytokine signalling as 
well as acquiring more proliferative capacities. It can be argued that the HSC 
identity pathways block the derive of upregulated proliferative pathways in LSCs 
and upon their downregulation LSCs will start to proliferate and differentiate. 
However, It can be conversely argued that the derive for the exit from stem cell 
compartment in CML was mediated by the upregulation of the three upregulated 
proliferative pathways in LPCs or a combination of both.   
In addition to the downregulation of eight HSC identity pathways, the expression of 
four HSC identity pathways remained unchanged between LSCs and LPCs. The 
persistent activity of pathways associated with stem cell maintenance could confer 
a less mature phenotype to LPCs.    
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3.16.3 The role of HSC identity pathways in the maintenance of 
LSCs 
TGF-β and Wnt signalling pathways, which are the master regulators of HSC 
quiescence and self-renewal (Reya et al., 2003, Sitnicka et al., 1996), retained 
their expression levels in LSCs. These pathways were significantly downregulated 
in LPCs, which provide further evidence for their role in the maintenance of stem 
cell features in LSCs.  
The role of TGF-β   signalling   in   the  maintenance  of   LSCs  was   recently   reported  
(Naka et al., 2010). The activated TGF-β  signalling   in  LSCs  was  shown   to  block  
the phosphorylation and, consequently, activation of the AKT protein despite BCR-
ABL1 expression. As a result, FOXO3A transcription factor was not degraded and 
induced quiescence in LSCs. This would further highlight the possible interactions 
between the stem cell maintenance pathways and the upregulated proliferative 
pathways in LSCs. As mentioned earlier, one argument for the exit from stem cell 
maintenance could indicate an important role for the loss of HSC identity pathways 
that would release the block on the proliferative pathways to induce proliferation 
and the formation of LPCs.  
Furthermore, the role of Wnt signalling in LSC maintenance has also been 
reported   in   recent   studies.   The   loss   of   β-catenin in the murine models of CML 
resulted in reduced self-renewal capacities of LSCs and increased the survival 
rate of the mice (Zhao et al., 2007). Increased activity of Wnt signalling have also 
been reported in the case of self-renewing GMPs during blast crisis (Jamieson et 
al., 2004). Therefore, the downregulation of Wnt signalling in LPCs could indicate 
their importance in self-renewal regulation of LSCs. 
The results in this Chapter also showed that the chemokine and cytokine signalling 
pathway retained its expression level in LSCs, but was subsequently 
downregulated in LPCs. However, previous reports suggested significant 
downregulation of the genes associated with chemokine ligands and receptors in 
LSCs relative to HSCs (Graham et al., 2007, Kronenwett et al., 2005). The 
expression levels of these genes were subsequently downregulated in the dividing 
CML population (Graham et al., 2007). These analyses were performed at the 
gene level and the expression changes of various members of the pathway were 
not taken into consideration. Therefore, although individual genes in each pathway 
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may be significantly up- or downregulated but such changes may not necessarily 
result in a significant expression change of the whole pathway. 
3.16.4 Neurotransmitters signalling pathways may have a role 
in the maintenance of stem cell features in LSCs.  
In addition to TGF-β  and  Wnt  signalling  whose  roles   in   the  maintenance  of  stem  
cells have been elucidated, several neurotransmitter signalling pathways were 
also found to be associated with the HSC identity. These pathways included 
acetylcholine, adrenergic (epinephrine and norepinephrine), serotonin, histamine, 
angiotensin II, oxytocin, and TRH signalling pathways. The neurotransmitter 
signalling pathways also maintained their expression level in LSCs, which could 
imply their role in the maintenance of LSCs. Subsequently, in the course of LPC 
development serotonin, oxytocin and TRH signalling pathways were significantly 
downregulated. However, acetylcholine, adrenergic, histamine H1 and angiotensin 
II signalling pathways were the only HSC identity pathways that did not show a 
significant downregulation in LPCs relative LSCs. This could suggest their role in 
conferring a less mature phenotype to LPCs in comparison to their normal 
counterparts. 
The BM has been shown to be substantially innervated in close proximity to 
arterial smooth muscle cells, although no direct contact between HSCs and nerves 
has been reported (Mignini et al., 2003). The functional link between HSCs and 
neurons was established through observation of neurotransmitter receptors on 
these cell types, including dopamine, adrenergic, opioid, serotonin, adenosine, 
orexins, tachykinins, GABA-B, VIP, CRH, somatostatin, and angiotensin II 
receptors (Kalinkovich et al., 2009, Steidl et al., 2004). These neurotransmitter 
receptors were shown to be subsequently downregulated in the course of 
differentiation (Steidl et al., 2004). These observations was in agreement with the 
pathway analysis performed between HSCs and HPCs.  
Furthermore, similar neurotransmitter pathways were also identified on the surface 
of CML CD34+ cells which were expressed at higher levels relative to their normal 
counterparts (Kronenwett et al., 2005). Although the observation of 
neurotransmitter receptors on the surface of CML cells was in agreement with the 
findings of this work, they did not identify the same type of receptors. 
Chapter 3  152 
Recent studies have reported the roles of neurotransmitter signalling in the 
maintenance of HSCs through interactions with other stem cell maintenance 
pathways. For instance, adrenergic receptors were identified on the surface of 
murine LSK population (Muthu et al., 2007) as well as human HSCs (CD34+ CD38-
) (Spiegel et al., 2007). Furthermore, stimulation of adrenergic signalling pathway 
in human HSCs induced BM repopulation via activating the canonical Wnt 
signalling pathway (Spiegel et al, 2007). A recent report also suggested that 
norepinephrine induces the production of HSCs from their haemogenic 
endothelium precursors in AGM; thus, providing compelling evidence on the role of 
neurotransmitters in the formation of HSCs (Fitch et al., 2012). Serotonin 
receptors, in particular the  5HT2 type, were demonstrated to induce expansion of 
primitive cord blood CD34+ cells in response to serotonin. This in turn enhanced 
their engraftment potential after transplantation into NOD/scid mice (Yang et al., 
2007). Additionally, the nonmyelinating Schwann cells, which are a subset of the 
neural cells in BM niche, were shown to be required for the activation of the latent 
form of TGF-β and therefore, indirectly maintain the quiescence of HSCs 
(Yamazaki et al., 2011). These evidence, therefore, provide further support for the 
role of neurotransmitters in the maintenance of HSCs directly or indirectly. 
However, the neurotransmitter signalling was also linked to the induction of HSC 
mobility and proliferation. Norepinephrine treatment of HSCs induced motility in 
response to both G-CSF and GM-CSF cytokines (Spiegel et al., 2007). 
Angiotensin II, was also demonstrated to be capable of stimulating the expansion 
of myeloid (CFU-GM) and erythroid (BFU-E) colonies through activation of 
angiotensin receptor II in immature human cord blood CD34+ cells (Peng et al., 
2005). Therefore, some may also play a role in mobilisation, maturation and 
proliferation of HSCs. This could be linked with the earlier observations in this 
Chapter that showed four neurotransmitter pathways retained their expression 
levels in LPCs similar to HSCs and LSCs. Thus, the role of neurotransmitters 
could be context-dependent. 
Despite discovering the neurotransmitter receptors, their role in leukaemia and 
particularly in the maintenance of LSCs has not been reported previously. Thus, 
the identification of these neurotransmitters signalling pathways in this Chapter 
suggest they may contribute to stem cell identity along with known pathways that 
promote self-renewal and quiescence. Such preliminary data requires further in 
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vitro and in vivo validation to elucidate the roles of these pathways in maintaining a 
stem cell phenotype. Therefore, the role of these identified neurotransmitters in the 
LSC maintenance is going to be analysed in vitro in Chapter 6.   
3.16.5 The CML identity pathways could be important in LSC 
maintenance 
Several biological pathways were identified to be significantly up- or 
downregulated in the HSC-to-LSC and LSC-to-LPC transitions which were not 
significantly changed during normal commitment. These pathways were, therefore, 
linked to the CML identity. Integrin signalling and the cytoskeletal regulation by 
Rho GTPases were two CML identity pathways that were significantly upregulated 
in LSCs relative to HSCs. Integrin signalling pathway was subsequently 
downregulated in LPCs. Therefore, these pathways may also contribute to the 
regulation of other aspects of stem cell maintenance such as adhesion and cell-
cell contact in the niche.  
It was reported that BCR-ABL expression enhances fibronectin (extracellular 
matrix) adhesion via integrin signalling mediated by VLA-4  (α4β1) and VLA-5  (α5β1) 
(Bazzoni et al., 1996, Fierro et al., 2008).  β1-integrin has been associated with the 
cell adhesion-mediated-drug resistance (CAM-DR) that causes resistance to anti-
leukaemic drugs (Hazlehurst et al., 2000, Tabe et al., 2007). The upregulation of 
β1-integrins in CML cells could, therefore, result in their adhesion to protected 
regions of bone marrow in order to escape chemotherapeutics (Fierro et al., 2008). 
Furthermore, Rho kinases (ROCKs) are regarded as oncogenes by increasing 
migration and reducing adhesion (Greenman et al., 2007). It has been recently 
shown that the inhibition of ROCK in CML cells results in growth arrest and 
apoptosis. The mechanism of ROCK activation in CML stem cells is thought to 
involve the activation of upstream RhoA protein by the BCR-ABL-phosphorylated 
PI3 kinases (Mali et al., 2011).  
The above observations are in agreement with the upregulation of integrin and 
Rho GTPase signalling pathways in LSCs and also their association with CML 
identity.  
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3.16.6 Genome-wide gene expression changes are globally 
regulated. 
The results in this Chapter showed that the direction of expression changes, both 
significant and non-significant, between the studied comparisons was in 
concordant. In other words, a subset of genes were programmed to be 
downregulated upon the exit from HSC compartment, whereas another subset of 
genes were programmed to be upregulated during this transition. Furthermore, the 
presence of BCR-ABL1 oncoprotein in CML cells did not seem to alter the 
direction of expression changes. Nevertheless, the gene expression changes were 
not in agreement in their significance level or their magnitude of change between 
the studied comparisons. These observations could indicate that a global 
programming regulates the gene expression changes at the genome-wide level. 
Therefore, this global programming could control many biological pathways. This 
was further investigated for the gene expression changes of the HSC identity 
pathways. The results revealed that the direction of changes in the genes of these 
pathways was also concordant between the studied comparisons. Therefore, the 
HSC identity pathways could also be regulated by this global programming. 
Furthermore, it was observed that LPCs can downregulate the genes in the stem 
cell identity pathways more efficiently than their normal counterparts. This key 
finding demonstrated that although these genes are globally regulated, there are 
potential differences between leukaemic cells and their normal counterparts in 
implementing this programme.  
These observations was in agreement with a recent report that demonstrated the 
role of epigenetic regulation in global programming of gene expression changes 
during haemopoiesis development (Cui et al., 2009). This report indicated that the 
subset of genes that were upregulated upon HSC differentiation were associated 
with accessible and open chromatin conformation in HSCs. Conversely, the subset 
of genes that were downregulated in the course of normal differentiation were 
associated with closed and inaccessible chromatin conformation in HSCs or 
acquired this chromatin conformation in the differentiated cells. Therefore, the 
report suggested that the genes that were upregulated or downregulated upon 
differentiation were epigenetically programmed in HSCs. Thus, the global 
programming of gene expression differences observed in this Chapter could be 
linked to such epigenetic programming mechanism.       
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3.16.7 Further improvements in studying gene expression 
signatures of LSCs 
The source of HSCs in this study was PB instead of BM and therefore, the 
observations could be biased towards the features of G-CSF mobilised stem cells 
as opposed to real HSC gene expression signatures. However, the differences 
between the transcriptomes of BM-derived CD34+ cells and G-CSF mobilised 
HSCs were studied previously (Steidl et al., 2002). This report showed that CD34+ 
cells in BM upregulated several cell cycle, DNA replication, and pro-apoptotic 
genes. Conversely, the mobilised HSCs showed elevated levels of self-renewal 
and differentiation inhibitor transcription factors such as GATA2. The cell adhesion 
proteins did not show a significant differential expression between the two 
populations, except CXCR4 which was highly expressed in the BM population. 
Furthermore, the BM-derived CD34+ populations showed more homogeneity than 
the mobilised HSCs (Steidl et al., 2002). Overall, the gene expression signatures 
of HSCs could vary in response to different environments and the events observed 
in PB may not fully reflect the signature of the HSCs in the BM niche. However, 
obtaining sufficient number of HSCs from BM samples is difficult.  
The CML and non-CML samples in this study were cultured prior to purification 
and gene expression analysis (Chapter 2). However, this in vitro culture lacks the 
major components of the BM niche, such as osteoblasts, stromal cells, nerves, 
and endothelium. These supporting cells in the niche are responsible for secretion 
of many cytokines, chemokines, and neurotransmitters, which in turn affect the 
gene expression signatures of the haemopoietic cells in the niche. However, under 
a non-BM microenvironment culture, all procedures were performed similarly in all 
cell populations. Therefore, the effect of external cues on their expression profiles 
should not be reflected in the observed differences we detected between 
populations.  
Overall, the statistical power of the analyses in this Chapter would be significantly 
increased using more biological replicates obtained from different patients, 
especially given the heterogeneity observed between LSC samples. This could 
potentially identify two subsets of LSCs with respect to their similarities to HSCs or 
progenitor cells.   
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Functional assays such as CFC and cell division tracking using CFSE dye will be 
required to monitor the effect of the novel pathways identified in the maintenance 
of LSCs (Chapter 6). This would further confirm the importance of the findings in 
this Chapter.  
3.17 Conclusion 
LSCs share similarities with both HSCs and HPCs at the level of gene expression  
differences and biological pathways. Therefore, LSCs have the characteristics of 
both stem cell compartment and the proliferative cells. Furthermore, the exit from 
stem cell compartment in CML is associated with the loss of HSC identity as well 
as acquiring further proliferative capacities. Several novel neurotransmitter 
signalling pathways have also been identified that potentially maintain stem cell 
characteristics of HSCs and LSCs. The genome-wide gene expression changes 
are globally regulated upon the exit from HSC compartment in both normal and 
CML cells. This global mechanism can also regulate the gene expression changes 
in many biological pathways as demonstrated for the HSC identity pathways. One 
of the major global mechanisms of gene regulation is epigenetic programming, 
which have been reported previously to have a key role in fate determination 
during normal haemopoiesis. Thus, the next Chapter investigated the role of 
epigenetic programming in the global gene expression regulation in both normal 
and CML cells. 
157 
4. Improvements of a low-cell ChIP method 
suitable for genome-wide analysis using 
microarrays or deep sequencing 
4.1 Abstract 
Chromatin immunoprecipitation in combination with high-throughput readouts is 
used routinely to study the epigenetic signatures of different cell types. However, 
the need for large numbers of cells (>106) per experiment has been a major 
limitation in studying rare primary cell populations. Since this thesis is focused at 
studying the epigenetic signatures of rare HSCs and LSCs, developing a low-cell 
ChIP method that could reproducibly generate genome-wide histone modification 
maps was a primary aim. This Chapter, therefore, demonstrates empirically 
validated adjustments to the ChIP procedure that allow it to be used to study 
histone modifications with as few as 10,000 cells in combination with genome-wide 
scale platforms including microarrays (ChIP-chip) and high throughput DNA 
sequencing (ChIP-seq). The low-cell ChIP method for a range of histone 
modifications was optimised initially in the context of murine embryonic stem cells 
and was subsequently tested using primary human HSCs. The results presented 
in this Chapter, demonstrate the successful application of ChIP method to small 
cell populations which can be robustly and reproducibly used in combination with 
downstream genome-wide readouts.     
4.2 Introduction 
Chromatin immunoprecipitation (ChIP) is a method of enriching for the DNA 
sequences which are associated with proteins in genomes. This method is 
powerful to identify in vivo protein-DNA interactions which are crucial for cellular 
processes such as DNA replication and repair, chromosomal stability, cell cycle 
succession, and epigenetic regulation through silencing and activating 
mechanisms. ChIP has been widely-used to study histones, transcription factors, 
and other protein binding sites (O'Neill and Turner, 1996, Orlando et al., 1997, 
Solomon and Varshavsky, 1985). Moreover, ChIP can be coupled to various 
downstream applications including PCR and qPCR, southern blot analysis 
(Orlando et al., 1997), western blot analysis (Wells and Farnham, 2002), cloning 
and sequencing (Loh et al., 2006), microarrays (ChIP-chip) (Hanlon and Lieb, 
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2004, Weinmann and Farnham, 2002), and high throughput DNA sequencing 
(ChIP-seq) (Barski et al., 2007). ChIP can be classified into two sub-types: 
crosslinked ChIP (X-ChIP) (Orlando et al., 1997) or native ChIP (N-ChIP) (O'Neill 
and Turner, 2003). In X-ChIP, DNA-bound protein complexes are usually 
reversibly crosslinked by formaldehyde and chromatin is then sheared by 
sonication to an approximate size range of 200-1000 bp, with an average length of 
500 bp. N-ChIP uses unfixed chromatin that can be fragmented mainly by 
nuclease digestion. For both sub-types, the fragmented chromatin is then 
incubated with antibodies specifically raised against the protein of interest and 
antibody-protein-DNA complexes are precipitated by agarose or paramagnetic 
beads coated with protein A/G followed by a series of washes. After crosslink 
reversal and digestion of proteins, the associated DNA fragments are purified by 
phenol-chloroform treatment. The X-ChIP approach is schematically illustrated in 
Figure 4.1.  
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Figure   4.1: ChIP and downstream applications. 
Schematic representation of ChIP steps and main downstream analysis approaches (coloured 
boxes). The concept of ChIP-chip is also illustrated. Red spots are indicative of lower levels of 
enriched DNA relative to input whereas the green spots show higher abundance of enriched DNA 
relative to input. Yellow spots are associated with array elements which have equal levels of 
enriched and input DNA.   
ChIP, like many other molecular biology methods, has certain steps in the 
procedure that require some adjustment depending on the context of the cells 
under study and/or the protein-DNA interaction of interest. These parameters are 
briefly discussed below: 
Amount of starting chromatin material – one of the major obstacles in ChIP is the 
requirement for large cell numbers as the starting material (~107-108 cells, ~200 
μg chromatin), which is mainly due to the loss of cells and DNA material during the 
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ChIP procedure, and overall ChIP inefficiency being relatively low (150 ng ChIP 
output) (Acevedo et al., 2007). Therefore, this requirement has hampered the 
study of rare cell populations, such as small primary stem cell populations from 
embryos and adult stem cells or small tissue biopsies, where the starting number 
of cells available is quite often less than 106 cells. However, there have been 
some recent improvements to the ChIP procedure which would allow such cell 
samples to be analysed (see section 3.1.3). 
Fixation – formaldehyde is the most commonly used fixation agent due to its ability 
to create biochemical bonds between molecules in close proximity (~2 angstroms) 
and fixation is readily reversible (Dedon et al., 1991). The length of formaldehyde 
treatment should be optimised to ensure an appropriate level of fixation. Histone 
proteins are known to crosslink faster than non-histone proteins (Das et al., 2004). 
As mentioned above, long formaldehyde treatment can complicate DNA 
fragmentation by sonication and mask the recognisable epitopes of the desired 
protein; therefore, reducing the ChIP yield and possibly biasing the sites that can 
be assayed. It is also reported that lysine residues are more likely to be fixed by 
formaldehyde (Orlando et al., 1997), therefore histone modifications involving a 
lysine residue can be affected in longer treatments.  
DNA fragmentation – the strength and duration of sonication are the major factors 
to be optimised in this step to ensure the fragmentation of chromatin to the desired 
size range. Nuclease digestion is an alternative approach which is largely 
applicable in N-ChIP assays. Nuclease digestion is more targeted, though it poses 
the risk of over-digestion and fragmentation to sub-optimal levels (O'Neill and 
Turner, 2003). It is also a relatively longer procedure than sonication.  
Pre-clearing – conventionally, the fragmented chromatin is pre-cleared prior to IP 
by using non-specific IgG antibody. Pre-clearing is believed to improve ChIP 
efficiency by removal of excess proteins, lipids, carbohydrates, and cellular debris 
present in the cell and nuclear lysate that may interfere with IP by sequestering the 
antibody or preventing antibody interaction with the right epitope (Becker, 1999). 
However, in low chromatin concentrations pre-clearing can potentially remove real 
protein-DNA  interactions  due  to  IgG’s  high  affinity  for  certain  epitopes.  
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Immunoprecipitation (IP) – Antibody quality is a key issue in any ChIP experiment 
as they determine the signal-to-noise ratio and the yield. Antibody specificity can 
be tested in vitro by western blotting and peptide competition assays for the 
epitope of interest (Suka et al., 2001). However, most of the antibodies used in 
ChIP assays are specifically developed to work under ChIP conditions and their 
specificity should be tested in vivo by verifying the genomic regions which are 
known or expected to be associated with the protein of interest (Spencer et al., 
2003). Commercially available ChIP antibodies are mainly affinity purified which 
will   reduce   the   risk   of   contamination   by   the   source   organism’s   sera   and   this  
eliminates the chance of generating background noise due to cross-reactivity. 
ChIP antibodies are available as either monoclonal or polyclonal. In the case of 
crosslinked ChIP, monoclonal antibodies may not be able to interact with the right 
epitope due to masking by the fixing agent and therefore, polyclonal antibodies are 
preferred as they are less limiting in their epitope recognition (Das et al., 2004). 
Furthermore, the optimum amount of antibody for maximum signal-to-noise ratio 
should be measured empirically through titration with the chromatin extract (Das et 
al., 2004). Antibody-to-chromatin ratio has to be appropriately adjusted to avoid 
non-specific interactions that would result in an elevated background noise in 
microarray and sequencing data.  
The antibody complexes are commonly captured by using agarose/Sepharose 
beads coated with proteins A and/or G. The A or G preference is determined by 
the class of immunoglobulin and the source organism in which that antibody is 
raised; for example, protein G has a higher affinity for the IgG class of antibodies 
from different species (Harlow and Lane, 1999). Agarose beads have a high 
binding capacity and the beads-to-antibody ratio should be optimised as in the 
case of low beads-to-antibody ratio, the beads would be become limiting, and 
many antibody-bound complexes would not be precipitated. Therefore, some 
important interactions would be lost that result in lower yield and sensitivity. To 
determine the appropriate levels of protein A/G-coated beads, the chromatin 
extract-antibody mixture should be incubated with different concentrations of 
protein A/G solution. Alternatively, magnetic beads have recently been introduced 
as a substitute to agarose beads and although these are more expensive, they 
speed up the IP process due to their ease of handling and are suggested to 
reduce background noise (O'Neill and Turner, 2003). 
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4.3 Methods 
4.3.1 Coupling ChIP to microarray hybridisation (ChIP-chip) 
Using microarrays to investigate the nature of ChIP-purified DNA fragments has 
advanced the ChIP application over the last decade. The initial studies involving 
ChIP-chip were reported on S. cerevisiae’s   transcription factor binding sites (Iyer 
et al., 2001, Lieb et al., 2001, Ren et al., 2000). For ChIP-chip assays, eluted ChIP 
DNA and non-immunoprecipitated input DNA are fluorescently labelled. After 
mixing the two samples, they are hybridised onto a microarray covered with 
oligonucleotide or PCR-amplified probes which may fully or partially cover the 
genome of interest. If the intensity of ChIP DNA signal exceeds the intensity of 
input on the array, the genomic region is regarded as a binding site of the protein 
of interest.  
Coverage, density, and resolution are three major parameters in characterising 
microarrays. Coverage simply refers to the proportion of the genome that is 
represented on the array. The array density is determined by the number of 
individual probes, known as features or elements, on the array which are usually 
PCR-amplified DNA sequences or oligonucleotides of different lengths. The 
resolution is defined as the length of the features and the length of the intervening 
genomic regions between them on the array; therefore, a high resolution 
microarray contains very few gaps between features and the features themselves 
represent relatively short (approx. 20-50 bp) DNA sequences. Tiling path arrays 
have the highest resolution as there is little or no genomic spacing between the 
features on the array. The former is made up of PCR-amplified sequences that are 
spotted onto a glass slide and due to technical limitations their density cannot 
exceed 30,000 features (Hudson and Snyder, 2006). Oligonucleotide arrays on the 
other hand are synthesised in situ through synthetic oligonucleotide chemistry 
(Chee et al., 1996) and therefore, can be found in much higher densities (>1 
million features). Thus, they are the ideal choice for studies requiring both high 
resolution and genome-wide coverage.  
The major concerns associated with analysis of microarray platforms include 
sensitive scanning and analysis, background noise subtraction, standard 
normalisation, and statistical issues with the data analysis (reviewed in Buck and 
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Lieb, 2004). Microarray experiments are commonly performed in replicates to 
distinguish the real biological signals from the background noise. There are 
several data analysis methods to analyse ChIP-chip data including median 
percentile rank, the single array error model, and a sliding-window method (Buck 
and Lieb, 2004).  
4.3.2 Coupling ChIP to deep sequencing (ChIP-seq) 
ChIP-purified DNA fragments can also be coupled to deep sequencing (ChIP-seq) 
using the next generation sequencing (NGS) platforms. The major advantages of 
ChIP-seq over ChIP-chip include (i) base pair resolution, (ii) less expensive for 
whole genome analysis, (iii) greater genome coverage as the only limitation is the 
alignability of sequenced tags, (iv) the absence of noise generated as a result of 
cross-hybridisations or labelling artefacts, (v) larger dynamic range as the 
enrichment levels are independent of signal intensities which are affected by 
saturation points, (vi) requirement for significantly lower amounts of starting 
material (~10 ng); (vii) less amplification for genome-wide analysis which can even 
be completely avoided in the case of single-molecule sequencing (Park, 2009).  
The ChIP-seq library is constructed from the immunoprecipitated DNA fragments 
that carry two adapter sequences at both ends. The PCR-amplified library is 
subjected to size selection in the ~200-300 bp range. The sequencing of ChIP 
DNA is normally performed from the 5′-end and is therefore, known as single-end 
(SE) sequencing. Nevertheless, it is possible to perform sequencing from both 
ends which is known as paired-end (PE) sequencing. The PE sequencing is 
advantageous in mapping the repetitive elements and long-range chromatin 
interactions (Fullwood and Ruan, 2009). Illumina Genome Analyzer is the most 
widely used NGS platform for the ChIP-seq studies, although other platforms such 
as  Life  Technologies’  SOLiD  and  Helicos  BioSciences’  HeliScope  have  also  been  
employed (Table 4.1) (Metzker, 2010, Park, 2009). The Illumina NGS platform was 
the only NGS technology available for ChIP-seq analysis in this study.  
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Table   4.1: The comparison of major NGS platforms. 
Major NGS platforms are listed with their template preparation and sequencing chemistries as well 
as their advantages and disadvantages and the types of biological applications which they can be 
employed (Metzker, 2010). emPCR, emulsion PCR. 
Illumina NGS platform requires amplified templates to be immobilised to a glass 
surface, known as the flow-cell. Clonal amplification of templates is necessary 
since most imaging systems are not designed to detect single fluorescent events. 
Illumina technology uses a solid-phase amplification approach in which forward 
and reverse primers are covalently attached to the flow-cell in very high density. 
After hybridisation of single-stranded template onto the flow-cell, each single-
molecule template is extended and forms a bridge with immediately adjacent 
primers, which are attached to the flow-cell (Bentley et al., 2008, Fedurco et al., 
2006). This bridge amplification leads to the formation of clusters which are 
spatially separated and therefore, allow 100-200 million of sequencing reactions to 
be performed simultaneously in a flow-cell. Size selection of the library around 200 
bp was found to generate clusters more efficiently to obtain an optimum number of 
clusters on the flow-cell. Illumina sequencing uses a four-colour cyclic reversible 
termination method which includes fluorescently-labelled nucleotide incorporation, 
fluorescence imaging, and cleavage (Bentley et al., 2008). Figure 4.2 
schematically illustrates the major steps in ChIP-seq library preparation for 
Illumina NGS platforms. 
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Figure   4.2: ChIP-seq library preparation for Illumina NGS platforms.  
Schematic diagram showing the major steps of ChIP-seq library preparation for Illumina Genome 
Analyzer platform.  
The requirement for 10 ng of starting material has made ChIP-seq a preferential 
method for studying abundant protein-DNA interactions in low cell number 
samples, as performing genome-wide studies using ChIP-chip demands whole-
genome amplifications to generate >2 μg of DNA per array which could also 
introduce PCR bias (Park, 2009).  
4.3.3 ChIP methods developed for study of small numbers of cells 
In order to overcome the requirement for large numbers of cells in ChIP several 
ChIP methods have been improved recently for the detection of DNA-protein 
interactions or epigenetic features in a starting population of as few as 100 cells. 
These methods, and their suitability in genome-wide applications, are summarised 
below (Table 4.2): 
1. Carrier ChIP (CChIP).   This   method   used   a   “carrier”   chromatin   from   a  
distantly related species which was mixed with the small numbers of the cell 
type of interest to drive the efficiency of the ChIP, facilitate DNA 
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precipitation and to increase the overall DNA yield. Large numbers of 
Drosophila cells (5x107 cells) were mixed with a small number of 
mammalian cells (100 - 1,000 cells). After mononuclease digestion of the 
isolated chromatin, histone modifications of interest were 
immunoprecipitated and the enriched DNA fragments were amplified using 
radioactively-labelled, species-specific PCR primers followed by 
phoshphorimaging to visualise the small quantities of enriched DNA (O'Neill 
et al., 2006). CChIP was used to study the active and repressive histone 
marks in cells isolated from the mouse blastocyst. The presence of 
Drosophila chromatin in CChIP means that high throughput analysis of the 
resultant ChIP DNA is not possible due to cross-reactivity and sensitivity 
issues during microarray analysis, and the abundance of sequence reads 
from the carrier material in ChIP-seq.  
2. MicroChIP. MicroChIP was developed using as few as 10,000 cells to study 
genome-wide histone modifications and RNAPII binding sites in human 
cells using high-density oligonucleotide arrays (Acevedo et al., 2007). This 
method was developed by miniaturising the standard ChIP. microChIP did 
not require the use of foreign DNA as carrier chromatin and, therefore, 
could be used in ChIP-chip rather than being limited to the analysis of a few 
genomic loci. microChIP RNAPII ChIP-chip profiles over known gene 
promoters generated from 10,000 - 100,000 crosslinked cells were 
demonstrated to be highly reproducible between the microChIP 
bioreplicates and also could identify 70% of the promoters associated with 
RNAPII from a standard ChIP assay (107 cells) (Acevedo et al., 2007). The 
major drawback of this method was the requirement for whole-genome 
amplification of the ChIP DNA prior to microarray hybridisation which could 
introduce PCR amplification biases. In order to immunoprecipitate antibody 
complexes, Staphylococcus aureus protein-A expressing bacterial cells are 
used in combination with herring sperm DNA to reduce the risk of non-
specific interactions during IP (Acevedo et al., 2007). However, the 
abundance of sequence reads from the herring sperm DNA would be an 
issue for ChIP-seq. 
3. Q2ChIP and μChIP. This method allowed a rapid precipitation from ChIP 
using 100,000 cells as starting material to analyse both histone 
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modifications and transcription factor binding sites (Dahl and Collas, 2007). 
Similar to the microChIP method, Q2ChIP also required crosslinking and 
therefore, transcription factors and non-histone DNA binding proteins could 
be studied. The usage of paramagnetic beads, which speed up the IP step, 
and combining different steps of standard ChIP including reversal of 
crosslinking, protein digestion, and DNA elution into a single shorter (~2 
hrs) step, shortened the overall procedure. Reducing the number of steps 
and limited handling as well as increasing the antibody-to-chromatin ratio 
enhanced the ChIP efficiency and increased signal-to-noise ratio in ChIP 
with limited cell numbers. Q2ChIP was used to determine changes of 
histone methylations and acetylations in differentiating embryonic 
carcinoma cells through qPCR screens of developmentally regulated 
promoters (Dahl and Collas, 2007). Q2ChIP was improved with slight 
modifications and reintroduced as μChIP (Dahl and Collas, 2008) which 
offered an even faster approach (1 day) with fewer cell numbers (100 - 
1,000 cells as starting material) to study histone modifications and RNAPII 
binding sites. Furthermore, μChIP-enriched DNA could be amplified by 
whole-genome amplification kits in order to perform ChIP-chip assays 
(Collas, 2011). Although the Q2ChIP method was demonstrated to be 
reproducible and sensitive in identifying histone modification enrichments in 
comparison to a standard ChIP assay, this has yet to be reported for the 
μChIP method.   
4. MiniChIP. This method allowed investigation of histone modification 
enrichments from a range of 50,000 – 150,000 haemopoietic cells by 
miniaturising the standard protocol and the application of protein A-agarose 
beads in the presence of salmon sperm DNA (Attema et al., 2007). 
miniChIP’s   downstream   application   was   initially   limited   to   qPCR   screens;;  
however, recent improvements in the methodology through magnetic IP and 
whole-genome amplification have enabled miniChIP-chip assays from 
10,000 murine HSCs on promoter tiling arrays (Weishaupt and Attema, 
2010). miniChIP method has since been used in understanding the histone 
modification changes in the course of haemopoiesis and it was reported 
that approximately 40% of bivalent mouse promoters identified by 
miniChIP-chip in murine HSCs were also bivalent in multipotent human 
HSCs (CD133+ CD34+ CD38+) (Weishaupt et al., 2010).  
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5. Low-cell ChIP. It was reported that conventional ChIP with as few as 10,000 
cells could be coupled to microarray hybridisation by adjusting the antibody-
to-chromatin ratio and protein G-agarose beads concentration for several 
histone modifications (Dillon, PhD Thesis, 2008). The antibody-to-chromatin 
ratio was shown to be a key factor in generating reliable ChIP-chip data 
from 10,000 cells where antibody levels in the range of 0.5 – 5.0 μg 
produced the highest signal-to-noise ratio compared to the standard ChIP. 
Furthermore, reducing the concentration of protein G-agarose beads in 
ChIP with 100,000 cells showed an increase in signal-to-noise ratio. These 
results were obtained by aliquoting the chromatin that was prepared from 
108 cells and therefore, the effect of the above adjustments are yet to be 
confirmed with a starting chromatin preparation that contains low numbers 
of cells. Furthermore, demonstrating a reliable and reproducible ChIP-chip 
without the requirement for whole-genome amplification could provide a 
platform to develop a low-cell ChIP method that can be used for ChIP-seq.  
6. Nano-ChIP. Nano-ChIP is the latest ChIP method designed for small 
numbers of cells, in which histone modification maps were generated from 
as few as 10,000 mES cells and 20,000 mouse HSCs (Adli et al., 2010). 
Nano-ChIP was developed through miniaturising the conventional ChIP and 
required protein A-Sepharose beads for IP. Genome-wide histone 
modification maps was generated by nano-ChIP coupled to Illumina high 
throughput DNA sequencing (nano-ChIP-seq). The ChIP-seq library 
preparation was performed by random priming with a universal hairpin 
primer followed by 10-15 cycles of PCR amplification prior to a second 
round of PCR amplifications (18 cycles). The nano-ChIP-seq was 
demonstrated to identify 93% of the promoters marked with H3K4me3 in 
mES cells by standard ChIP-seq (Adli et al., 2010), despite the whole 
genome amplification of ChIP DNA which could potentially introduce PCR 
bias. Nano-ChIP-seq was also used to establish the epigenetic signatures 
of mouse HSCs and to identify the epigenetic changes involved in the 
course of HSCs development. The authors also emphasised the importance 
of antibody titration for small cell ChIP assays as well as establishing their 
sensitivity and efficiency with regards to the standard ChIP (Adli et al., 
2010). Moreover, the application of this method was only demonstrated with 
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a few histone modifications while its efficiency for RNAPII and transcription 
factors has yet to be reported.  
       
Table   4.2: ChIP methods designed for samples with limited cell numbers.  
All the methods published to date with their major downstream applications and their advantages 
and disadvantages.  
4.4 Aims of the Chapter 
In order to obtain whole genome epigenetic profiles of both normal and leukaemic 
stem cell populations (Chapter 5), this Chapter focuses on further developing and 
improving the low-cell ChIP method developed previously in the laboratory of D. 
Vetrie (Dillon, PhD thesis, 2008) to address or overcome the following issues:  
(i) ChIP from as few as 100,000 cells as starting material (or 10,000 cells/IP),  
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(ii) applicable to all genome-wide applications including ChIP-chip and ChIP-
seq,  
(iii) no requirement for whole genome amplification,  
(iv) no contaminating source of carrier DNA,  
(v) high signal-to-noise ratio,  
(vi) reproducible between replicates and comparable to conventional ChIP 
profiles, and  
(vii) high sensitivity in identifying relevant genomic elements such as 
promoters.  
To these ends, the aims of the work presented in this Chapter are as follows: 
1. To establish the parameters required for generating histone modification 
maps from 10,000 cells using genome-wide applications such as ChIP-chip 
in the context of mES cells.   
2. To assess the sensitivity of the improved low-cell ChIP method coupled to 
deep sequencing (ChIP-seq) for detecting the histone modification 
enrichment at the relevant genomic features such as promoters. 
Results 
4.5 Overall strategy 
A number of steps in the ChIP procedure were examined as a means of optimising 
a low-cell ChIP procedure for looking at histone modification patterns in the mouse 
genome (Figure 4.3). These included: 
1. the amount of antibody per IP condition,  
2. the requirement for both a cell lysis and a nuclear lysis step, 
Chapter 4  171 
3. the effect of chromatin pre-clearing. 
Previous work in this laboratory had demonstrated that adjusting antibody levels 
(Dillon, PhD thesis, 2008) were important to obtaining the highest signal-to-noise 
ratio. Others had also adopted a low cell ChIP approach by performing a single 
cell and nuclear lysis step or by removing the pre-clearing step (Dahl and Collas, 
2008, Weishaupt and Attema, 2010). All conventional ChIP was performed using 
107 cells per IP condition derived from a chromatin preparation for 108 cells. All 
low-cell ChIP assays were performed using 104 cells per IP condition derived from 
a chromatin preparation for 105 cells.  
In order to benchmark the performance of low cell ChIP against ChIP performed in 
the conventional way, it was necessary to compare results from a cell system 
which could provide large numbers of cells – aliquots of which could be used for 
conventional ChIP or for low-cell ChIP. mES cells (E14 clone) were chosen as 
they can be readily grown under experimental conditions and produce large cell 
populations in a short period of time. Additionally, their histone modification maps 
have been generated previously (Mikkelsen et al., 2007).  
ChIP-chip was primarily used to assess the optimisation of the low-cell ChIP 
method. A mouse tiling path microarray was used in the present study to facilitate 
the development of a low-cell ChIP method. This array was designed to span 
regions of the mouse genome which corresponded to regions analysed in the 
human genome in the pilot phase of the ENCODE project (Birney et al., 2007). 
6,448 PCR products (average size 1 kb) were spotted in triplicate to produce an 
array which represented 0.25% of the mouse genome (~8.5 Mb), and covered 12 
different genomic regions (Table 4.3). This array used a spotting chemistry which 
utilised PCR-amplified single-stranded DNA features that were covalently attached 
to a glass surface through their 5′-aminolink modifications. This spotting chemistry 
had been previous demonstrated to provide high sensitivity in array-based ChIP 
assays and other applications (Dhami et al., 2005).  
Chapter 4  172 
 
Table   4.3: Description of the mouse tiling path array regions.  
The genomic coordinates (mm7 build) of 12 regions that are printed in triplicates on mouse tiling 
path arrays, which make up to approximately 8.5 Mb (~0.25%) of the mouse genome. These 
regions are orthologs of the biologically important human regions that were chosen for the 
ENCODE pilot project. 
Additionally, the murine comparative studies between conventional and low-cell 
ChIP were also converted to ChIP-sequencing readouts. This would allow the 
robustness of low-cell ChIP to be tested independently of array-based methods 
and in a readout similar to that which would be used to examine histone 
modification patterns in both normal and leukaemic cells later in this thesis 
(Chapter 5).  
Optimisation of low-cell ChIP was based on assessing the ability of the assays to 
detect biologically meaningful data in a reproducible way. These assessments 
were based on the following analyses: 
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a. Sensitivity measurements: Sensitivity was measured in a number of ways. 
Firstly, the ability of low-cell  ChIP   to   obtain   “peaks”   or   “blocks”   of   histone  
modifications across biologically meaningful features, such as gene 
promoters, or gene bodies, was assessed using the BLOCs algorithm 
(Pauler et al., 2009), ChIPOTle (Buck et al., 2005), SICER (Zang et al., 
2009), or BayesPeak (Spyrou et a.l, 2009). BLOCs algorithm can identify 
broad local enrichments of histone modifications which are larger than 5 kb 
in breadth, typically for modifications such as H3K27me3. Additionally, the 
ChIPOTle and SICER algorithms were also used to identify histone 
modification peaks. ChIPOTle was designed to identify peaks in ChIP-chip 
data, whereas SICER and BayesPeak were designed for peaks found in 
ChIP-seq datasets. Collectively these algorithms were used to compare the 
“peaks”   or   “blocks”   identified   in   histone   modification   patterns   when  
comparing conventional ChIP with low-cell ChIP.  
b. Specificity measurements: the BLOCs and ChIPOTle analyses were also 
used to examine the number of novel  enrichment   “blocks”  or   “peaks”   that  
were identified by the low-cell ChIP assays. The novel islands could be a 
result of high background noise levels that were classified as real 
enrichments (false positives) or the rare events taking place in a subset of 
cells in the larger population.   
c. Reproducibility measurements: This was measured between histone 
modification profiles generated using conventional ChIP and low-cell ChIP; 
for instance, H3K4me3 conventional ChIP versus H3K4me3 low-cell ChIP; 
and between different bioreplicates assaying the same histone modification 
using low-cell ChIP; for instance, between two H3K4me3 low-cell ChIP 
bioreplicates.   Spearman’s   rank   correlation   coefficient   was   used   for   this  
analysis. These coefficients range from between -1 to +1. Values which 
approach +1 between two samples show a high positive correlation.  
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Figure   4.3: Overall strategy in improving the low-cell ChIP method. 
Low-cell ChIP-chip was performed with 10,000 cells/IP and compared against the ChIP-chip 
profiles from the standard ChIP using 107 cells/IP. The ChIP steps boxed in red were modified or 
adjusted during optimisation. The sensitivity, specificity and reproducibility of low-cell ChIP were 
measured upon applying these adjustments. After optimising the low-cell ChIP on microarrays, the 
method was coupled to deep sequencing (ChIP-seq) and the sensitivity of the genome-wide 
approach was investigated.  
4.6 Quality control assessment of ChIP material 
Each ChIP assay performed as part of the study described in this Chapter was 
subjected to several quality control (QC) assessments prior to ChIP-chip or ChIP-
seq analyses. These included (i) gel electrophoresis of purified ChIP DNAs, (ii) 
ChIP-qPCR to demonstrate that the ChIP material contained histone modification 
enrichments for genomic loci used as positive controls, (iii) gel electrophoresis of 
purified Cy-3 labelled ChIP prior to hybridisation onto microarrays along with Cy-5 
labelled input DNA. Examples of these QC assessments are shown in Figures   
4.4 and 4.5. 
Typically, as shown in Figure 4.4, DNA smears for ChIP DNA purified from 
conventional ChIP were visible when subjected to gel electrophoresis. However, 
DNA smears from low-cell ChIP purified DNAs were not visible. Nevertheless, 
ChIP-qPCR analysis of gene promoters showed that there was enrichment for the 
histone modification of interest in DNAs derived from either conventional ChIP or 
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low-cell ChIP. The low-cell ChIP showed a similar pattern of enrichment at these 
loci, although the fold enrichment levels were lower relative to the conventional 
ChIP assay. Therefore, although the DNA smear could not be detected by gel 
electrophoresis, it could be shown at the level of qPCR that the IP had worked in 
low-cell ChIP, albeit at a lower efficiency.   
 
Figure   4.4: Gel electrophoresis of purified ChIP DNA and qPCR screens for quality control. 
(A) Agarose gel electrophoresis of purified conventional and low-cell ChIP DNA. Lane 1 = 1 kb 
DNA marker ladder; lane 2 = H3K4me3 conventional ChIP, lane 3 = H3K4me3 low-cell ChIP. DNA 
smear is visible in conventional ChIP (lane 2) ranging from 200 bp to 1 kb which shows the 
efficiency of the sonication regime. The electrophoresis was performed on 1% agarose 1x TBE 
gels and visualised with SYBR Safe DNA gel stain (Invitrogen). (B) ChIP-qPCR screens of the 
genomic loci known to be associated with the histone modification of interest for low-cell ChIP 
quality control. The H3K4me3 conventional and low-cell ChIP-qPCR results are shown here with 
four positive control designed at the promoters of active genes, including Tal1/Scl, Oct4, Nasp, and 
Rps16; and two negative control primer pairs designed at the promoters of repressed genes, 
including Exo1 and Myo10. The height of the bars shows the Log2 fold enrichment relative to the 
negative control enrichments. The error bars represent 95% confidence intervals.   
Despite the relatively low recovery of DNA from low-cell ChIP (Figure 4.4), labelled 
DNA fragments were observed as a smear when subjected to agarose gel 
electrophoresis. These smears showed similar size distributions as labelled 
material derived from conventional ChIP (Figure 4.5), although there did appear to 
be less material in labelled samples obtained from low-cell ChIP (see lane 3 in 
Figure 4.5).  
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Figure   4.5: Gel electrophoresis of fluorescently labelled ChIP and input DNA. 
Left: Gel electrophoresis of Cy3-labelled ChIP DNA samples. Lane 1 = 1 kb DNA marker ladder; 
lane 2 = H3K27me3 conventional ChIP; lane 3 = H3K27me3 low-cell ChIP. Labelling reactions 
have worked with similar efficiency in both conventional and low-cell ChIP assays, as DNA smears 
are visible in both cases (lanes 2 and 3). Majority of labelled DNA can be seen in the size range of 
85-150 bp which is an outcome of random priming amplification. Right: Gel electrophoresis of Cy5-
labelled input DNA. Lane 4 = 1 kb DNA marker ladder; lane 5 = input DNA for conventional ChIP; 
lane 6 = input DNA for low-cell ChIP. Input DNA is required as a reference in ChIP-chip assays 
which is directly purified from an unenriched sonicated chromatin source that is used for the ChIP 
assays. The labelling has worked with similar efficiency to the ChIP samples. The brighter intensity 
of DNA smears in ChIP samples (left) is due to the biochemical reaction between SYBR Safe gel 
stain and the Cy3 dyes. The electrophoresis was performed on 1% agarose 1x TBE gels and 
visualised with SYBR Safe DNA gel stain. 
4.6.1 Examining the effect of antibody levels on low-cell ChIP 
4.6.1.1 Titration of the anti-H3K27me3 antibody in low-cell ChIP 
As previously reported, titrating antibody levels is a key factor in improving signal-
to-noise levels and increasing the ChIP efficiency (Dillon, PhD thesis, 2008). It had 
been reported for H3K4me3 and H3 acetylation that antibody levels between 0.5 
and 5.0 μg per IP produce the highest signal-to-noise ratio on average (Dillon, 
PhD thesis, 2008). Therefore, a serial dilution of antibodies at 5.0, 1.0, and 0.5μg 
was performed with low-cell ChIP using 10,000 cells/IP. These were benchmarked 
against conventional ChIP which was performed using an optimised 10.0 μg of 
antibody per IP (Dhami et al., 2010, Dillon, 2008). In every other respect, the low-
cell ChIP antibody titration experiments were performed under the same 
conditions as the conventional ChIP with changes in antibody levels as the only 
variable.  
The histone modification H3K27me3 is associated with repressed loci. This 
histone mark appears as either enrichment peaks at the promoters of repressed or 
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poised genes (Bernstein et al., 2006, Bracken et al., 2006), or large blocks of 
enrichments covering between 10 – 140 kb spanning entire genes or gene clusters 
as observed in the case of mammalian HOX gene clusters (Ringrose, 2007). The 
anti-H3K27me3 antibody used here was a polyclonal antibody raised in rabbit 
which was reported previously in genome-wide ChIP applications (Pan et al., 
2007, Zhao et al., 2007). The antibody titration was performed with low-cell ChIP 
assays and these were used in ChIP-chip assays with the mouse tiling array 
(described in section 4.3) as the readout. Figure 4.6 shows ChIP-chip histone 
modification profiles from four different regions of the mouse genome that were 
chosen to represent the overall variation in histone modification enrichments that 
were observed in these experiments. 
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Figure   4.6: Anti-H3K27me3 antibody titration. 
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
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order:  (A)  10.0  μg  H3K27me3  conventional  ChIP;;  (B)  5.0  μg;;  (C)  1.0  μg  and  (D)  0.5  μg  H3K27me3 
low-cell ChIP. The black horizontal bars on top of each track show the significantly enriched 
domains identified by the BLOCs algorithm. The bottom track shows the RefSeq genes (Pruitt et 
al., 2007) with transcriptional orientation indicated by arrows. The ChIP-chip data is displayed in 
the four intervening tracks as the ratio of ChIP sample fluorescence to input DNA fluorescence. 
Each black vertical bar is the enrichment measured at a single array element with the relative log2 
fold enrichments represented at the height of the bar. The scale and the chromosome coordinates 
are demonstrated on top of each panel.  
When compared against the results of conventional ChIP across all 12 murine 
regions represented on the tiling path array, low-cell H3K27me3 ChIP performed 
with 5.0 μg   of   antibody   showed   the   highest   Spearman’s   correlation   coefficient  
(0.74). 1.0 μg and 0.5 μg of antibody showed coefficients of 0.66 and 0.07 
respectively.  Using  the  BLOCs  algorithm,  36  H3K27me3  “blocks”  or  “islands”  were  
identified significantly above the background in conventional ChIP-chip from 
which, 19 islands were also recognised in the 5.0 μg low-cell ChIP condition. 
However, low-cell ChIP with 1.0 μg of antibody could identify 16 of these 36 
islands, whereas 0.5 μg could distinguish only 5 of 36. On the other hand, 0.5 μg 
and 1.0 μg of antibody identified 18 and eight novel islands, respectively, whereas 
5.0 μg of antibody located only three novel domains. The novel islands could be a 
result of high background noise levels that were classified as real enrichments 
(false positives) or the rare events taking place in a subset of cells in the larger 
population. All of this data, when taken together, suggested that  the low-cell ChIP-
chip data derived from IPs which used 5.0 μg of anti-H3K27me3 antibody showed 
the highest degree of similarity to  the results of conventional ChIP. This provided 
a first line of evidence that H3K27me3 antibody levels used in IPs were a key 
determinant of IP efficiency in low-cell ChIP. 
4.6.1.2 Titration of the anti-H3K4me3 antibody in low-cell ChIP 
The histone modification H3K4me3 is prevalent in open chromatin regions and the 
promoters of active or poised genes (Barski et al., 2007, Bernstein et al., 2006). 
The anti-H3K4me3 antibody used here was a polyclonal antibody raised in rabbits 
which had been used extensively in genome-wide studies (Bernstein et al., 2006, 
Santos-Rosa et al., 2002). Similar to those experiments described above, the 
antibody levels of the anti-H3K4me3 antibody was titrated in low-cell ChIP 
experiments and the resultant ChIP material hybridised to murine tiling path 
arrays. The conventional and low-cell ChIP-chip profiles that were derived across 
four different regions of the mouse genome are shown in Figure 4.7. 
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Figure   4.7: Anti-H3K4me3 antibody titration. 
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
order:  (A)  10.0  μg  H3K4me3  conventional  ChIP;;  (B)  5.0  μg;;  (C)  1.0  μg;;  and  (D)  0.5  μg  H3K4me3 
low-cell ChIP. The black bars on top of each track show the significantly enriched peaks identified 
by ChIPOTle. The bottom track shows the RefSeq genes (Pruitt et al., 2007) with transcriptional 
orientation indicated by arrows. The ChIP-chip data is displayed in the four intervening tracks as 
the ratio of ChIP sample fluorescence to input DNA fluorescence. Each black vertical bar is the 
enrichment measured at a single array element with the relative log2 fold enrichments represented 
at the height of the bar. The scale and the chromosome coordinates are demonstrated on top of 
each panel. 
When compared against the results of conventional ChIP across all 12 murine 
regions represented on the tiling path array, low-cell H3K4me3 ChIP performed 
with 5.0 μg   of   antibody   showed   the   highest   Spearman’s   correlation   coefficient  
(0.35). 1.0 μg and 0.5 μg of antibody showed coefficients of 0.22 and 0.26 
respectively. Using the ChIPOTle analysis,   462   H3K4me3   enrichment   “peaks”  
were identified significantly above the background in conventional ChIP-chip from 
which, 64 peaks were also recognised in the 5.0 μg low-cell ChIP condition. 
However, low-cell ChIP with 1.0 μg of antibody could identify 13 of these 462 
peaks, whereas 0.5 μg could distinguish only 10 of 462. On the other hand, 0.5 μg 
and 1.0 μg of antibody identified 28 and 35 novel peaks, respectively. However, 
5.0 μg of antibody located 43 novel peaks. The novel peaks could be a result of 
high background noise levels that were classified as real enrichments (false 
positives) or the rare events taking place in a subset of cells in the larger 
population. All of this data, when taken together, suggested that  the low-cell ChIP-
chip data derived from IPs which used 5.0 μg of anti-H3K4me3 antibody showed 
the highest degree of similarity to  the results of conventional ChIP. This provided 
a first line of evidence that H3K4me3 antibody levels used in IPs were a key 
determinant of IP efficiency in low-cell ChIP. 
Overall, the antibody titration was proved to be important in improving the low-cell 
ChIP sensitivity where 5.0 μg of anti-H3K4me3 and anti-H3K27me3 antibodies 
were shown to reproduce the conventional ChIP better than the other 
concentrations within the titration range.    
4.6.2 Examining the effect of simultaneous cell and nuclear lysis 
on low-cell ChIP 
The conventional ChIP protocol is comprised of an initial cell lysis step, which 
disrupts the cell membrane while maintaining the cell nuclei intact. Once the nuclei 
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are isolated, a second lysis step is then used to disrupt the nuclear membrane. 
This two-step approach facilitates the removal of proteins, lipids, and 
carbohydrates present in the cytoplasm from the intact nuclei – thus removing 
potential non-specific targets which could bind antibody during IP and thus 
affecting ChIP efficiency. However, simultaneous cell and nuclear lysis was 
employed in various low-cell ChIP methods with small cell numbers in order to 
minimise handling steps during ChIP and thus maximising the chromatin recovery 
and yield (Acevedo et al., 2007, Dahl and Collas, 2008, Weishaupt and Attema, 
2010).  
Therefore, the effect of simultaneous cell and nuclear lysis was tested under the 
low-cell ChIP conditions and was compared to conventional ChIP, which employed 
a two-step lysis, to determine the improvement in the efficiency of the assays. 
Low-cell ChIP was performed with anti-H3K4me3 and anti-H3K27me3 antibodies 
at 5.0 μg. The only variable between the low-cell ChIP conditions were the cell and 
nuclear lysis step that was performed either in two sequential steps or 
simultaneously. The resultant low-cell ChIP material was hybridised onto the 
murine tiling path array and the results compared to those obtained for 
conventional ChIP for these two histone modifications (Figures 4.8 and 4.9).  
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Figure   4.8: The effect of simultaneous cell and nuclear lysis on low-cell H3K27me3 ChIP.  
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
order:   (A)   10.0   μg  H3K27me3   conventional  ChIP;;   (B)   two-step lysis; and (C) simultaneous lysis 
H3K27me3 low-cell ChIP. The black horizontal bars on top of each track show the significantly 
enriched domains identified by the BLOCs algorithm. The bottom track shows the RefSeq genes 
(Pruitt et al., 2007) with transcriptional orientation indicated by arrows. The ChIP-chip data is 
displayed in the three intervening tracks as the ratio of ChIP sample fluorescence to input DNA 
fluorescence. Each black vertical bar is the enrichment measured at a single array element with the 
relative log2 fold enrichments represented at the height of the bar. The scale and the chromosome 
coordinates are represented on top of each panel. 
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Figure   4.9: effect of simultaneous cell and nuclear lysis on low-cell H3K4me3 ChIP. 
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
order:   (A)   10.0   μg   H3K4me3 conventional ChIP; (B) two-step lysis; and (C) simultaneous lysis 
H3K4me3 low-cell ChIP. The black bars on top of each track show the significantly enriched peaks 
identified by ChIPOTle. The bottom track shows the RefSeq genes (Pruitt et al., 2007) with 
transcriptional orientation indicated by arrows. The ChIP-chip data is displayed in the three 
intervening tracks as the ratio of ChIP sample fluorescence to input DNA fluorescence. Each black 
vertical bar is the enrichment measured at a single array element with the relative log2 fold 
enrichments represented at the height of the bar. The scale and the chromosome coordinates are 
demonstrated on top of each panel. 
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When compared against the results of conventional ChIP across all 12 murine 
regions represented on the tiling path array, low-cell H3K27me3 ChIP performed 
with   simultaneous   cell   and   nuclear   lysis   showed   higher   Spearman’s   correlation  
coefficient (0.82) than the two-step lysis (0.74) (Figure 4.8). Using the BLOCs 
algorithm, simultaneous cell and nuclear lysis low-cell H3K27me3 ChIP could 
identify 29 of the 36 islands identified in the conventional assay. Furthermore, low-
cell H3K27me3 ChIP with simultaneous cell and nuclear lysis identified four novel 
domains. The novel peaks could be a result of high background noise levels that 
were classified as real enrichments (false positives) or the rare events taking place 
in a subset of cells in the larger population. All of this data, when taken together, 
suggested that the H3K27me3 low-cell ChIP-chip data derived from IPs with 
simultaneous cell and nuclear lysis showed higher degree of similarity to  the 
results of conventional ChIP and improved sensitivity in comparison to the two-
step lysis approach. 
Moreover, low-cell H3K4me3 ChIP performed with simultaneous cell and nuclear 
lysis   showed   higher   Spearman’s   correlation   coefficient   (0.37)   than   the   two-step 
lysis (0.35) in comparison to the conventional ChIP assay across all 12 murine 
regions represented on the tiling path array (Figure 4.9). Simultaneous cell and 
nuclear lysis low-cell H3K4me3 ChIP could identify 31 of the 462 peaks identified 
in the conventional assay as determined by ChIPOTle. Furthermore, low-cell 
H3K4me3 ChIP with simultaneous cell and nuclear lysis identified 37 novel peaks. 
The novel peaks could be a result of high background noise levels that were 
classified as real enrichments (false positives) or the rare events taking place in a 
subset of cells in the larger population. All of this data, when taken together, 
suggested that the H3K4me3 low-cell ChIP-chip data derived from IPs with 
simultaneous cell and nuclear lysis showed slightly higher degree of similarity to 
the results of conventional ChIP. Although the sensitivity of low-cell H3K4me3 
ChIP was not improved using simultaneous cell and nuclear lysis, its specificity 
was increased in comparison to the two-step lysis approach.  
Overall, although simultaneous cell and nuclear lysis was not detrimental to low-
cell ChIP, it minimised the handling of cells which may improve yields. Therefore, 
simultaneous cell and nuclear lysis would present an improvement in terms of 
simplifying the method. 
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4.6.3 Analysing the effect of pre-clearing on low-cell ChIP 
The pre-clearing step is conventionally performed prior to IP step to increase the 
ChIP efficiency, as described earlier (section 4.1.1). However, some ChIP 
protocols suggested removing this step when dealing with small cell numbers to 
minimise the loss of DNA-protein complexes as a result of non-specific IgG 
interaction in low chromatin concentration conditions (Dahl and Collas, 2008, 
Weishaupt and Attema, 2010).  
In order to test the effect of pre-clearing on low-cell ChIP, pre-cleared (PC) and 
non-pre-cleared (NPC) conditions were examined and the low-cell ChIP assays 
were performed with 5.0 μg of antibody and simultaneous cell and nuclear lysis. 
Therefore, the only variable in these assays was the pre-clearing step. The 
resultant low-cell ChIP material was hybridised onto the murine tiling path array 
and the results compared to those obtained for conventional ChIP for these two 
histone modifications (Figures 4.10 and 4.11). 
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Figure   4.10: The effect of pre-clearing on low-cell H3K27me3 ChIP. 
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
order:  (A)  10.0  μg  H3K27me3  conventional  ChIP;;  (B)  NPC;;  and  (C)  PC H3K27me3 low-cell ChIP. 
The black horizontal bars on top of each track show the significantly enriched domains identified by 
the BLOCs algorithm. The bottom track shows the RefSeq genes (Pruitt et al., 2007) with 
transcriptional orientation indicated by arrows. The ChIP-chip data is displayed in the three 
intervening tracks as the ratio of ChIP sample fluorescence to input DNA fluorescence. Each black 
vertical bar is the enrichment measured at a single array element with the relative log2 fold 
enrichments represented at the height of the bar. The scale and the chromosome coordinates are 
represented on top of each panel. 
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Figure   4.11: The effect of pre-clearing on low-cell H3K4me3 ChIP. 
Screenshot views of the UCSC genome browser (Kuhn et al., 2007) of four different regions 
represented on the mouse arrays. For each region the ChIP-chip profiles are shown in the following 
order:   (A)  10.0  μg  H3K4me3  conventional  ChIP;;   (B)  PC H3K4me3 low-cell ChIP; and (C) NPC;. 
The black bars on top of each track show the significantly enriched peaks identified by ChIPOTle. 
The bottom track shows the RefSeq genes (Pruitt et al., 2007) with transcriptional orientation 
indicated by arrows. The ChIP-chip data is displayed in the three intervening tracks as the ratio of 
ChIP sample fluorescence to input DNA fluorescence. Each black vertical bar is the enrichment 
measured at a single array element with the relative log2 fold enrichments represented at the height 
of the bar. The scale and the chromosome coordinates are demonstrated on top of each panel. 
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When compared against the results of conventional ChIP across all 12 murine 
regions represented on the tiling path array, low-cell H3K27me3 ChIP performed 
under  the  NPC  condition  showed  higher  Spearman’s  correlation  coefficient  (0.86)  
than the assay under the PC condition (0.82) (Figure 4.10). Using the BLOCs 
algorithm, low-cell H3K27me3 ChIP under the NPC condition could identify 29 of 
the 36 islands identified in the conventional assay. Furthermore, low-cell 
H3K27me3 ChIP under the NPC condition identified five novel domains. The novel 
peaks could be a result of high background noise levels that were classified as 
real enrichments (false positives) or the rare events taking place in a subset of 
cells in the larger population. All of this data, when taken together, suggested that 
the H3K27me3 low-cell ChIP-chip data derived from IPs under the NPC condition 
showed higher degree of similarity to  the results of conventional ChIP. However, 
the level of sensitivity and specificity did not show further improvements. 
Moreover, low-cell H3K4me3 ChIP performed under the NPC conditions showed 
higher   Spearman’s   correlation   coefficient   (0.54)   than   the   assay   under   the   PC  
condition (0.37) in comparison to the conventional ChIP assay across all 12 
murine regions represented on the tiling path array (Figure 4.11). H3K4me3 ChIP 
under the NPC condition could identify 94 of the 462 peaks identified in the 
conventional assay as determined by ChIPOTle. Furthermore, low-cell H3K4me3 
ChIP under the NPC condition identified 29 novel peaks. All of this data, when 
taken together, suggested that the H3K4me3 low-cell ChIP-chip data derived from 
IPs under the NPC condition showed higher degree of similarity to the results of 
conventional ChIP. Furthermore, the sensitivity and the specificity of low-cell 
H3K4me3 ChIP was considerably improved under the NPC condition in 
comparison to the assays performed under the PC condition.  
Overall, H3K4me3 and H3K27me3 low-cell ChIP under NPC conditions showed 
higher degree of similarity to the conventional ChIP-chip results, in addition to the 
noticeable improvements of sensitivity and specificity in the case of low-cell 
H3K4me3 ChIP.  
4.6.4 Summary of optimisation of low-cell ChIP 
The low-cell ChIP method showed a noticeable improvement by adjusting the 
antibody-to-chromatin ratio, performing simultaneous cell and nuclear lysis, and 
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excluding the pre-clearing step. This improvement was demonstrated by the 
increase in statistical correlation with the conventional method (reproducibility), 
improved sensitivity which was shown by the number of islands or peaks identified 
significantly above background that were overlapping with the results of 
conventional ChIP assays, and improved specificity by showing the reduced 
numbers of novel peaks or islands identified significantly above background. Table 
4.4 summarises the findings for each optimisation step. 
 
Table   4.4: Summary of statistical tests performed for each optimisation step. 
The values highlighted in green show the antibody concentration that produced highest statistical 
correlation and overlapping number of islands or peaks with the conventional ChIP. The values 
highlighted in red represent the optimisation steps that showed an improved statistical correlation, 
sensitivity (number of islands or peaks identified with BLOCs or ChIPOTle, respectively), and 
specificity (number of novel islands or peaks identified with BLOCs or ChIPOTle, respectively) in 
low-cell ChIP assays performed with 5.0 μg of antibody. All the correlation coefficients were highly 
significant (p-value=0). 
The low-cell ChIP assays performed with anti-H3K27me3 antibody demonstrated 
higher statistical correlation with the conventional assay, noticeably better 
sensitivity and specificity in comparison with the low-cell ChIP assays performed 
with the anti-H3K4me3 antibody. Therefore, the efficiency of low-cell ChIP is 
largely determined by the sensitivity and specificity of the antibody under the low-
cell conditions.  
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4.6.5 Investigating the reproducibility of the improved low-cell 
ChIP  across bioreplicates 
In order to determine the reproducibility of low-cell ChIP across bioreplicates that 
were obtained from different chromatin preparations, low-cell H3K4me3 and 
H3K27me3 ChIP assays were performed under the improved conditions for two 
bioreplicates. Similarly conventional H3K4me3 and H3K27me3 ChIP assays were 
performed for two bioreplicates. The resultant ChIP material was hybridised to 
murine tiling path arrays. The conventional and low-cell ChIP-chip profiles that 
were derived across four different regions of the mouse genome are shown in 
Appendix 5. 
The comparison of two low-cell H3K27me3 ChIP bioreplicates across all 12 
murine regions represented on the tiling path array, showed a significantly high 
Spearman’s  correlation  coefficient   (0.87)   (Table  4.5).  Similarly   the  comparison  of  
two low-cell  H3K4me3 ChIP bioreplicates across all 12 murine regions 
represented on the tiling path array, also demonstrated a significantly high 
Spearman’s  correlation  coefficient  (0.  73).     
Furthermore,  the  Spearman’s  correlation  coefficient  between  the  two  conventional  
H3K27me3 ChIP assays across all 12 murine regions represented on the tiling 
path   array,   showed   a   significantly   high   Spearman’s   correlation coefficient (0.83) 
(Table 4.5). Additionally, the comparison of two conventional H3K4me3 ChIP 
assays across all 12 murine regions represented on the tiling path array also 
demonstrated  a  significantly  high  Spearman’s  correlation  coefficient  (0.84).   
The above results, therefore, indicated that the low-cell ChIP assays 
reproducibility between the bioreplicates obtained from different chromatin 
preparations was comparable to the degree of similarity observed between the 
bioreplicates in the conventional ChIP assays.   
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Table   4.5: Statistical correlation between the bioreplicates in low-cell and conventional ChIP 
assays. 
Highly significant (p-value=0)   positive   Spearman’s   rank   correlations   between   the   bioreplicates 
indicate a high reproducibility rate within low-cell ChIP assays. The observed correlation values 
between bioreplicates of conventional ChIP were also presented to show the level of reproducibility 
and the degree of variation within the ChIP assays.  
4.7 Analysing the performance of low-cell ChIP coupled 
to deep sequencing (low-cell ChIP-seq) 
ChIP-chip analysis using the mouse microarray was used to improve the low-cell 
ChIP conditions and to characterise the antibody levels in a smaller scale genomic 
platform, which covered only 0.25% of the mouse genome. However, a thorough 
analysis of genome-wide distribution of histone modifications was mainly possible 
by ChIP-seq. Except for the nano-ChIP method which has been recently reported 
in association with Illumina deep sequencing platform (Adli et al., 2010), no other 
ChIP assays designed for the small cell numbers were reported in this context. 
Therefore, to investigate the performance of low-cell ChIP-seq method, 
sequencing libraries were prepared for both conventional and low-cell H3K4me3 
and H3K27me3 ChIP assays, as described in Chapter 2.   
The sensitivity of low-cell ChIP-seq was examined by investigating the overlap of 
identified enrichment peaks by low-cell ChIP-seq with the ones identified by 
conventional ChIP-seq.  The  promoters  of   the   ‘on’  genes   (n=12,677),  which  were  
defined as the top 50% of expressed genes in the mES genome (E14 clone), were 
searched for the presence of H3K4me3 enrichment domains using BayesPeak 
algorithm. The total number of uniquely aligned sequencing reads in conventional 
H3K4me3 ChIP-seq was 2.5 times greater than the low-cell H3K4me3 ChIP-seq. 
Therefore, in order to reduce a potential bias towards the conventional ChIP-seq 
which had the bigger library size, random sampling of equivalent to low-cell ChIP-
seq library size was performed on the conventional ChIP-seq library. On average 
10,718   peaks  were   identified   at   the   promoters   of   the   ‘on’   genes   by   the   random  
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sampling of conventional ChIP-seq library from which 64% could be identified at 
these promoters by the low-cell ChIP-seq (Table 4.6).  
To evaluate the performance of low-cell H3K27me3 ChIP-seq data, the promoters 
of bivalent genes (n=2,706) reported in mES cells (Mikkelsen et al, 2007) were 
used as a reference to search for enrichment peaks by SICER algorithm. The total 
number of uniquely aligned sequencing reads in low-cell H3K27me3 ChIP-seq 
was 1.2 times greater than the conventional H3K27me3 ChIP-seq. Therefore, in 
order to reduce a potential bias towards the low-cell ChIP-seq which had the 
bigger library size, random sampling of equivalent to conventional ChIP-seq library 
size was performed on the low-cell ChIP-seq library. On average 2,145 peaks 
were identified at the promoters of the bivalent genes by the conventional ChIP-
seq library from which 80% could be identified at these promoters by the low-cell 
ChIP-seq (Table 4.6). 
The above observations indicated that the low-cell H3K4me3 and H3K27me3 
ChIP-seq assays demonstrated a large degree of overlap with the conventional 
H3K4me3 and H3K27me3 ChIP-seq assays in terms of identifying biologically 
important features such as active or bivalent promoters, respectively. Low-cell 
H3K4me3 ChIP-seq assays, in particular, demonstrated a noticeably improved 
sensitivity when compared to the earlier observations in the low-cell H3K4me3 
ChIP-chip assays.  
 
Table   4.6: The comparison of low-cell and conventional ChIP-seq in mES cells. 
ChIP-seq analyses for H3K4me3 and H3K27me3 in mES cells are summarised. The total number 
of uniquely aligned sequencing reads marked with the asterisks specifies the bigger library size for 
each histone modification which was used for the random sampling of equivalent to the size of 
smaller library. Random sampling was performed three times and the average number of islands 
was used to measure the percentage of overlap between the low-cell and conventional ChIP-seq 
assays.  
Chapter 4  200 
4.8 Discussion 
4.8.1 Improvements to low-cell ChIP method 
The focus of this Chapter was to develop a sensitive and reproducible ChIP assay 
that can use as few as 10,000 cells through modifying various steps of the 
conventional ChIP. Adjustments in three steps of conventional ChIP assay 
resulted in increased reproducibility, sensitivity and specificity of low-cell ChIP. 
The adjusted steps included (i) antibody titration, (ii) simultaneous cell and nuclear 
lysis, and (iii) omitting the pre-clearing step.  
The amount of antibody used in low-cell ChIP assays was shown to be an 
important factor in improving the sensitivity and specificity of the low-cell ChIP 
assays for both H3K4me3 and H3K27me3 antibodies. This was due to the 
reduced chromatin amounts in low-cell ChIP assays. It was demonstrated that 5 
μg of anti-H3K4me3 and anti-H3K27me3 antibodies can reproduce the 
conventional ChIP-chip profiles more efficiently than the lower tested amounts of 
antibodies. Additionally, 5 μg of anti-H3K27me3 antibody increased both sensitivity 
and specificity of low-cell ChIP, whereas 5 μg of anti-H3K4me3 antibody could 
increase the sensitivity but not specificity. Therefore, it was noticeable that the 
optimal antibody to chromatin ratio could be assay-specific as H3K4me3 antibody 
performed less efficiently under the low-cell ChIP conditions than the H3K27me3 
antibody under similar conditions based on the microarray readouts. 
Furthermore, performing low-cell ChIP assays with simultaneous cell and nuclear 
lysis as opposed to the conventional two-step cell and nuclear lysis increased the 
low-cell ChIP efficiency in reproducing the conventional ChIP-chip profiles. This 
adjustment also increase the sensitivity of low-cell H3K27me3 and the specificity 
of low-cell H3K4me3 ChIP assays. Therefore, minimising the handling of cells 
during low-cell ChIP as a result of simultaneous cell and nuclear lysis would 
simplify the ChIP method and improve the low-cell ChIP readouts on microarrays. 
Chromatin pre-clearing prior to IP during conventional ChIP assays may improve 
ChIP efficiency by removal of excess proteins and cellular debris present in the 
cell and nuclear lysate that may sequester the antibody or may prevent antibody 
interaction with the right epitope. However, when using reduced chromatin 
amounts in low-cell ChIP assays, the pre-clearing step may result in the removal 
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of real DNA-protein interactions and in turn true signals as a result of non-specific 
interactions with IgG. Consequently, by omitting from the low-cell ChIP assays, 
their sensitivity and specificity were improved for both H3K4me3 and H3K27me3 
assays. Furthermore, low-cell ChIP was a lot more efficient to reproduce the 
conventional ChIP-chip profiled in the absence of pre-clearing step. 
The improved low-cell ChIP was coupled to deep sequencing to investigate the 
sensitivity of low-cell ChIP assays at the genome-wide level in identifying 
biologically important features such as promoters. The low-cell H3K27me3 ChIP-
seq assay could identify 80% of the H3K27me3 peaks that were also identified by 
the conventional H3K27me3 ChIP-seq at the bivalent promoters in mES cells. This 
was in agreement with the percentage of conventional H3K27me3 ChIP-chip 
peaks that were identified significantly above background by the low-cell 
H3K27me3 ChIP-chip (80%). Furthermore, the low-cell H3K4me3 ChIP-seq assay 
could identify 64% of the H3K4me3 peaks that were also located by the 
conventional H3K4me3 ChIP-seq   assay   at   the   promoters   of   ‘on’   genes in mES 
cells. This was significantly higher than the percentage of conventional H3K4me3 
ChIP-chip peaks that were identified significantly above background by the low-cell 
H3K4me3 ChIP-chip (20%). The differences between the microarray and 
sequencing readouts could be associated with the absence of noise generated as 
a result of cross-hybridisations or labelling artefacts in the sequencing assays. 
Additionally, the requirement for significantly lower amounts of starting material for 
sequencing could suggest a more suitable readout for the low-cell ChIP assays. 
Furthermore, the sequencing results were not limited in their coverage, which can 
introduce bias in the microarray analyses as a result of variation in the association 
between the protein of interest and the regions presented on the arrays.         
4.8.2 Comparison of low-cell ChIP method with other related ChIP 
methods 
The advantages of this improved method over the previously reported ChIP 
assays designed for the small number of cells (Table 4.2) are discussed briefly 
below. The improved low-cell ChIP method presented in this Chapter could be 
coupled to genome-wide applications such as microarray and sequencing in the 
absence of whole genome PCR amplifications that could introduce bias to the 
results. Conversely, CChIP and Q2ChIP were reported mainly in association with 
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qPCR readouts and genome-wide application of these methods were not reported 
(Dahl and Collas, 2007, O'Neill et al., 2006). Moreover, microChIP, miniChIP and 
μChIP that could be coupled with the microarray analyses required genome-wide 
amplification of ChIP-purified DNA prior to array hybridisations (Acevedo et al., 
2007, Collas, 2011, Weishaupt and Attema, 2010).  
Furthermore, the improved low-cell ChIP method presented in this Chapter did not 
require carried DNA or chromatin   from  other   species,   such  as  CChIP   (O’Neill   et  
al., 2006) and microChIP methods (Acevedo et al., 2007), to increase the yield 
and efficiency of the ChIP assays with small cell numbers. The abundance of 
sequence reads from foreign DNA material would be an issue for ChIP-seq.  
In a more recent method, nano-ChIP-seq (Adli et al., 2010), ChIP-purified DNA 
from 10,000 mES cells was coupled to Illumina deep sequencing. This method 
also demonstrated the importance of antibody titration in increasing the efficiency 
of ChIP assays using small cells numbers. The ChIP-purified DNA by nan-ChIP 
was subjected to four cycles of random priming that required specialised random 
hairpin primers. Subsequently, the hairpin primers were subjected to restriction 
digestion and PCR amplification for 10-15 cycles prior to preparation of Illumina 
sequencing libraries, which require an extra 18-cycles of amplification. Random 
priming method could reduce the bias generated by the whole-genome 
amplification methods since the template DNA fragment could give rise to 
amplified fragments varying in size and sequence. Consequently, this would 
increase the complexity of the ChIP purified DNA library before PCR 
amplifications. Nano-ChIP-seq H3K4me3 was shown to identify 93% of the 
enriched promoters by the conventional ChIP-seq  with the true positive rate of 68-
83% and the true negative rate of 90% as reported by the receiver operating 
characteristic (ROC) curve (Adli et al., 2010). However, the improved low-cell ChIP 
method presented in this Chapter could be coupled to Illumina sequencing with a 
comparable level of sensitivity in the absence of universal hairpin primers and 
extra 10-15 rounds of amplification. Consequently, the improved low-cell ChIP 
method is simpler, but as sensitive as the nano-ChIP-seq approach. 
The improved low-cell ChIP method is a lengthy procedure that could last four 
days. Conversely, μChIP method is a rapid approach as the whole procedure can 
be done in a day (Dahl and Collas, 2008). The μChIP method was developed by 
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combining different steps of conventional ChIP including reversal of crosslinking, 
protein digestion, and DNA elution into a single shorter (~2 hrs) step as well as 
using paramagnetic beads which speed up the IP step.  
4.8.3 Further improvements of low-cell ChIP 
Low-cell ChIP method can be further improved through implementing other 
adjustments. Although the handling of small cell numbers has been significantly 
improved by performing the fixation and sonication in small tubes with only one-
step cell and nuclear lysis, replacing the probe sonication with waterbath 
sonication could significantly reduce the loss of material, cross-contamination, and 
non-uniform sonication bias. Besides, optimisation of the sonication regime is 
essential to maintain an optimised size range for the DNA fragments at 200-500 
bp as smaller and larger DNA fragments could affect the downstream applications.  
The improved low-cell ChIP method was not tested for the transcription factors 
and less abundant chromatin-bound proteins. Non-histone proteins can be difficult 
to ChIP under low-cell number ChIP conditions due to the reduced signal levels 
which are lost in the background noise. The concentration and incubation of the 
fixing agent should be optimised for such assays and antibody levels should be 
titrated in a wider range covering lower concentrations. Nevertheless, microChIP, 
Q2ChIP and μChIP methods reported non-histone protein ChIP assays, 
particularly for RNAPII, which were mainly limited to qPCR readouts (Q2ChIP and 
μChIP) (Dahl and Collas, 2007, Dahl and Collas, 2008) or required whole-genome 
amplifications for microarray analysis (Acevedo et al., 2007).  
Nevertheless, low-cell ChIP assays with poor outcome could result from inefficient 
antibodies at the low-cell conditions due to the high antibody-to-chromatin ratio. 
Therefore, antibodies from different organisms or reactive against different 
epitopes can be tested. Moreover, N-ChIP could be substituted when the epitopes 
are feared to be masked by the fixation agent, although this would largely limit the 
application of low-cell ChIP to histone proteins. Finally, the usage of magnetic 
beads instead of agarose beads may have an impact on the efficiency of low-cell 
ChIP by increasing the affinity for the antibody-protein-DNA complexes and can 
also reduce the length of low-cell ChIP procedure. 
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4.9 Conclusion 
The work presented in this Chapter described the improvements to a low-cell ChIP 
method (Dillon, PhD thesis, 2008) to generate reproducible and sensitive genome-
wide histone modification maps from as low as 10,000 cells using ChIP-chip and 
ChIP-seq. These improvements were made to several steps of the conventional 
ChIP including (i) antibody titration, (ii) simultaneous cell and nuclear lysis, and (iii) 
omitting the pre-clearing step. This method can be used for identification of 
genome-wide histone modifications in primary samples with limited cell numbers 
such as HSCs whose epigenetic signature could not be established otherwise by 
ChIP-seq. In Chapter 5 the application of low-cell ChIP method to the primary 
human HSCs and CML stem cells was demonstrated to investigate the genome-
wide distribution of histone modifications that would shed light on the underlying 
epigenetic mechanisms that are potentially important in the maintenance of LSCs. 
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5. Abnormal epigenetic programming in CML cells 
modulate gene expression patterns. 
5.1 Abstract 
The role of chromatin modifications in regulating gene expression has been widely 
investigated in the course of normal development and tumourigenesis (reviewed in 
Section 1.5). However, due to the limitations of working with rare adult stem cell 
populations such links have not yet been established in the context of cancer stem 
cells. Therefore, in this Chapter, the genome-wide distribution of histone 
modifications in LSCs was investigated using the low-cell ChIP-seq approach and 
compared to the histone modification profiles of HSCs, HPCs, and LPCs. It was 
shown that the HSC identity pathways (Chapter 3) were significantly associated 
with the bivalent class of promoters. Furthermore, it was demonstrated that an 
epigenetic reprogramming, which was associated with gene expression changes 
in CML cells, was initiated during LSC formation. Consequently, CML cells were 
shown to be more dependent on Polycomb proteins for modulating expression 
patterns in a different manner than that found in HPCs.  
5.2 Introduction  
There have been few studies investigating the genome-wide chromatin 
modifications in leukaemia. One studied investigated the genome-wide distribution 
of activation histone mark, H3K9 acetylation, in three cases of AML and two cases 
of Ph+ ALL (Figueroa et al., 2008). The histone modification maps were combined 
with genome-wide DNA methylation and gene expression analysis. This study 
demonstrated an inverse relationship between promoter DNA methylation and 
H3K9 acetylation, which was found at the promoters of active genes. This report 
also suggested that the integration of H3K9 acetylation maps and gene expression 
profiles could increase the number of identified significantly differentially regulated 
genes between ALL and AML samples. Furthermore, the integration of gene 
expression signatures and chromatin modifications improved the identification of 
differentially regulated biological pathways in AML relative to ALL. This study 
showed that the integration of epigenetic analysis and gene expression profiles 
could enhance the identification of many novel genes and pathways that would 
have been missed with a less comprehensive approach.  
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MLL, one of the catalytic subunits of TrxG complex, is linked to chromosomal 
translocations that are found in 70% of the childhood leukaemias (Krivtsov and 
Armstrong, 2007). The MLL-rearranged leukaemias are shown to have different 
gene expression profiles than both ALL and AML leukaemias (Armstrong et al., 
2002), which in indicative of a unique global programming in these cancers. In 
order to investigate the changes of chromatin conformation in MLL-rearranged 
leukaemias, a knock-in model of MLL-AF4 fusion oncogene have been developed 
(Krivtsov et al., 2008). The downstream targets of this fusion protein, such as 
HoxA9, RUNX1, ETV6 and RUNX2, showed significant increase of H3K79me2 
histone modification, which is associated with transcribed genes. Genome-wide 
analysis of H3K79me2 in leukaemia cells identified ~1,200 gene promoters that 
were significantly associated with H3K29me2 marks compared to normal pre-B 
cells. Similar observations were also made in the cases of human MLL-rearranged 
ALL. Therefore, it was suggested that the MLL-AF4 fusion oncoprotein abnormally 
recruited DOT1L, H3K79 methyltransferase, to their target genes which resulted in 
their abnormal activation. Furthermore, similar association with DOT1L was also 
observed in the cases of MLL fusion proteins with AF9, AF10 and MLLT1 (Krivtsov 
et al., 2008) Interestingly, it was previously reported that the introduction of MLL-
AF9 fusion oncoprotein to the haemopoietic progenitor cells could induce the 
formation of LSCs. This was associated with global reprogramming of gene 
expression which in turn caused increased self-renewal activity (Krivtsov et al., 
2006). This finding, therefore, indirectly links the formation of LSCs from progenitor 
cells to the changes in chromatin structure (Krivtsov and Armstrong, 2007). 
The role of PRC2 complex and in particular EZH2 in haematological malignancies 
have also been studied in recent years. Several reports have identified somatic 
mutations in EZH2 in several lymphoid or myeloid leukaemias. For instance, a 
gain-of-function mutation in the catalytic SET domain of EZH2 is found in 
association with diffuse large B-cell lymphoma. This observation suggested an 
oncogenic role for EZH2 (Morin et al., 2010, Sneeringer et al., 2010). However, 
loss-of-function mutations in EZH2 were also identified in T-ALL (Ntziachristos et 
al., 2012) and myeloid malignancies (Ernst et al., 2010). These observations, 
therefore, propose a tumour-suppressive role for EZH2. Consequently, the 
function of EZH2 as an oncogene or tumour-suppressor can be context-dependent 
which is determined by the haemopoietic lineage.  
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In addition to the identified mutations in EZH2, the overexpression of EZH2 is also 
reported in myeloid malignancies and AML (Grubach et al., 2008, Xu et al., 2011). 
A recent report showed that the EZH2 knockout in AML cells results in the 
differentiation of AML cells and blocks the progression of the disease (Tanaka et 
al., 2012). In this study, deletion of EZH2 in AML cells inhibited cell cycle 
progression and induced apoptosis, although their proliferative capacities were not 
affected. The EZH2-depleted AML cells failed to engraft immunodeficient mice as 
a result of significant reduction in the number of AML stem cells. Therefore, it was 
suggested that EZH2 was required for the maintenance of LSCs, especially 
against environmental stresses. The deletion of EZH2 was associated with 
significant reduction of H3K27me3 histone modifications, although many gene 
promoters maintained their H3K27me3 levels (Tanaka et al., 2012). This was 
linked to the potential role of EZH1 in partially complementing EZH2 similar to its 
role in normal HSCs, where EZH1 is the dominant catalytic subunit of PRC2 
complex (Mochizuki-Kashio et al., 2011). The loss of EZH2 in normal HSCs did not 
affect their self-renewal capacities (Mochizuki-Kashio et al., 2011), but the loss of 
EZH2 in AML cells significantly impaired the self-renewal capacities of LSCs, 
suggesting that the AML cells are highly-dependent on EZH2 function (Tanaka et 
al., 2012). This report also showed that EZH2 targets were associated with 
differentiation and cell-fate determination in AML cells. Thus, EZH2 potentially 
reinforces the LSC compartment in AML by blocking differentiation mechanisms 
(Tanaka et al., 2012).  
Overall, the above studies on the role of chromatin modifications in 
leukaemogenesis were performed on the bulk of leukaemia cells. The genome-
wide analysis of chromatin modifications in leukaemia stem cells have not been 
performed to date due to the technical limitations with ChIP method, as discussed 
in Chapter 4. However, in order to understand the early events in global epigenetic 
programming during leukaemic transformation the analysis of chromatin structure 
in LSCs is crucial. Therefore, the development of the low-cell ChIP method 
(Chapter 4) could help elucidating the histone modification maps of LSCs in CML. 
These histone modifications can be further interpreted in association with the gene 
expression profiles that were established in Chapter 3 for a comprehensive 
analysis of differentially regulated genes and pathways in LSCs and LPCs.  
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5.3 Methods  
As described in Chapter 4, ChIP-purified DNA fragments can be coupled to 
various downstream applications such as qPCR, microarrays (ChIP-chip), and 
deep sequencing (ChIP-seq). The advantages of ChIP-seq over other approaches 
can be summarised as higher resolution, enhanced coverage, fewer artefacts, and 
a greater dynamic range. Genome-wide histone modification profiling using ChIP-
seq was first reported in human T cells (Barski et al., 2007) which used the 
Illumina/Solexa 1G platform to generate approximately 8 million tags per sample. 
ChIP-seq technology was also used in profiling histone modifications in mES cells 
and differentiated cells (Mikkelsen et al., 2007). 
The requirement for 10 ng of starting material has made ChIP-seq a preferential 
method for studying abundant protein-DNA interactions in low cell number 
samples, as performing genome-wide studies using ChIP-chip demands whole-
genome amplifications to generate >2 μg of DNA per array which could also 
introduce PCR bias (Park, 2009). Nonetheless, the amount of purified DNA in low-
cell ChIP cannot be accurately quantified by NanoDrop and is estimated to be at 
picogramic quantities. Conventional ChIP-seq library preparation method requires 
at least 10 ng of DNA for the generation of high complexity libraries that can 
produce an optimum number of clusters and as a result can generate high quality 
and reliable sequencing data. On the contrary, a low complexity template, in the 
case of template quantities below 10 ng, poses various challenges that should be 
addressed in advance to reliably obtain and interpret the sequencing data. The 
challenges include (i) the presence of contaminating DNA material that can affect 
the sequencing even in the smallest amounts, and (ii) generation of PCR product 
duplicates which have previously been reported to reach up to 60% of the 
sequences (Quail et al., 2008).  
The ChIP-seq technology also has certain limitations such as the sequencing 
errors that arise towards the end of each read (Minoche et al., 2011), or a bias 
towards GC-rich fragments caused by the amplification steps during ChIP-seq 
library preparation or during sequencing (Hillier et al., 2008, Quail et al., 2008). 
The cluster generation in Illumina platforms is an important step in determining the 
quality of output data, where too little sample will result in very few tags and too 
much sample results in the generation of clusters too close to one another which 
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reduces the data quality (Park, 2009). New improvements of the Illumina 
sequencing technology allow generation of 75 or 106 bp sequence reads to 
increase the alignability and therefore, specificity at a lower cost. However, it was 
shown that the gain in unique alignments declines after ~35 bp and is marginal 
beyond 70-100 bp (Nix et al., 2008).    
The depth of sequencing is defined as the number of sequenced fragments in a 
ChIP-seq experiment. Initially, 4-6 million reads were generated per each 
sequenced sample; however, with the recent improvements of the NGS platforms 
the depth of sequencing has increased to 20-30 million reads per lane (Park, 
2009). The depth of sequencing is subjective and largely dictated by the chromatin 
binding pattern of the protein of interest. For instance, in the case of histone 
modifications larger numbers of reads are required due to the greater genome 
coverage. It was demonstrated in a recent study that the number of protein binding 
sites detected increases steadily by increasing the depth of sequencing 
(Kharchenko et al., 2008). However, this report showed that the sequencing depth 
can  reach  a  ‘saturation  point’  after  which  additional  reads  will  not  identify  any  new  
binding sites. 
It has been reported that open chromatin regions associated with promoters and 
regulatory domains of expressed genes are fragmented more frequently by 
sonication. Therefore, the sequencing library could be biased towards the open 
chromatin regions as a result of non-uniform sonication (Auerbach et al., 2009). 
Repeat sequences could also confer aligning difficulties which results in their 
exclusion from the library of sequenced reads. As a result, a control sample could 
be sequenced such as input DNA or non-specific IP using a non-specific IgG 
antibody. By using the input DNA the biases causes by non-uniform fragmentation  
and PCR amplification could be corrected (Park, 2009). 
Aligning the sequenced reads in ChIP-seq datasets should take into account the 
mismatches resulting from the sequencing errors, single-nucleotide 
polymorphisms (SNPs), and other potential differences between the sequenced 
genome and the reference genome. Several algorithms for aligning have been 
developed which include Eland by Illumina, Mapping and Assembly with Qualities 
(MAQ) (Li et al., 2008), and Bowtie, which is a very fast aligner based on a file 
compression algorithm (Langmead et al., 2009). Many mapping pipelines discard 
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non-unique tags, which are mapped to more than one genomic location (multiple 
hits), and only report the number of unique alignments to the reference genome; 
however, stringent mapping pipelines have been recently introduced for aligning 
the repetitive elements (Day et al., 2010).  
After identifying the uniquely aligned DNA fragments, the statistically significantly 
enriched   genomic   regions   relative   to   the   control   can   be   identified   by   the   ‘peak  
calling’   algorithms.   Enriched   regions   of   different   types   can   be   found,   such   as  
sharp, broad, and mixed. Sharp peaks are largely associated with histone 
modifications or chromatin-binding proteins at regulatory elements and the broad 
regions are mainly found across repressed or transcribed domains. Earlier peak 
calling algorithms (Kharchenko et al., 2008, Mikkelsen et al., 2007, Rozowsky et 
al., 2009) were mainly designed to identify the sharp peaks, whereas the broad 
peaks were located by merging the adjacent peaks post hoc. Overall, an ideal 
peak calling algorithm should take into account the strand-specific pattern at any 
binding location, correct for the local variation shown by input DNA, adjust for 
sequence alignability, and measure the expected ratio of incorrectly discovered 
sites to those that are found to be significant by the FDR. Validation of a large set 
of sites by qPCR can be used to measure the accuracy of a peak caller (Park, 
2009, Storey and Tibshirani, 2003).  
In order to identify the overlap between the identified peaks between multiple 
samples or to discover the overlap between different protein binding sites and a 
defined genomic feature, such as a regulatory element, the extracted signals from 
peak callers are compared. Furthermore, by calculating the number of events that 
are close enough between multiple datasets, overlapping regions could be 
identified. This complex downstream analysis has several limitations which include 
a bias towards the peak-calling step and the empirical threshold values used to 
distinguish between real signal and noise, and complexity of comparing datasets 
with different binding patterns, such as sharp (H3K4me3) or broad enrichments 
(H3K27me3), where peak calling is more difficult. Therefore, to facilitate qualitative 
and quantitative comparisons between multiple ChIP-seq datasets at a reference 
set of genomic sites, seqMINER k-means clustering tool was developed that 
requires uniquely aligned tags to compute a density array over a defined window 
around the reference coordinates. Furthermore, the density array is normalised 
linearly in each sample to correct for inter-sample variations in sequencing depth. 
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The normalised values are used for the clustering step and graphically 
represented through heatmaps (Ye et al., 2011). 
In this Chapter, the sequenced tags were aligned to the reference human genome 
(RefSeq hg18 build) using the Bowtie algorithm. Subsequently, the unique 
alignments were clustered in seqMINER at the annotated gene promoters in all 
four cell types for H3K4me3 and H3K27me3 histone modifications. The subgroups 
of genes associated with distinct histone modification patterns were isolated for 
further investigations, such as pathway analysis using the PANTHER database.         
5.4 Aims of the Chapter 
The patterns of histone modifications and their relationship to gene expression 
profiles will be examined in this Chapter. 
1. To establish the genome-wide signatures of H3K4me3 and H3K27me3 
histone modifications at the annotated gene promoters in HSCs, HPCs, 
LSCs and LPCs by low-cell ChIP-seq.  
2. To identify the epigenetic mechanisms that regulate HSC and HPC identity 
pathways in normal and leukaemic cell types.  
3. To establish the link between observed expression changes and the 
underlying epigenetic programming in normal and leukaemic cell types. 
4. To investigate the gene expression levels of chromatin modifiers that add or 
remove H3K4me3 and H3K27me3 to try and account for the differences in 
histone modification levels between normal and leukaemic cell types. 
Results  
5.5 Overall strategy 
Initially, the conventional ChIP-seq method was optimised for the low-cell ChIP 
assays. The low-cell ChIP-seq method was used to generate histone modification 
patterns of HSCs and LSCs, while the conventional ChIP-seq method was used in 
the case of LPCs. The histone modification patterns of HPCs was obtained from 
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publicly available dataset (Cui et al., 2009). In order to identify the epigenetic 
differences between CML cells and their normal counterparts the promoter histone 
modification signatures in each cell type were identified and characterised. 
Subsequently, the relationship between the promoter signatures and the pathways 
that were identified to regulate stem cell maintenance and proliferation was 
established. Finally, the changes in promoter signatures were investigated in 
response to changes in gene expression between the cell types.  
5.6 Optimisation of low-cell ChIP-seq library preparation 
Initially, the low-cell ChIP was employed to investigate the distribution of H3K4me3 
and H3K27me3 marks in the HSC1 sample. The ChIP-purified DNA was 
subsequently coupled to deep sequencing (ChIP-seq) using the Illumina Genome 
Analyzer platform. The ChIP-seq libraries were generated using the original 
Illumina method in which library size-selection was performed prior to PCR 
amplification. After aligning the sequencing reads to the reference human genome, 
only 9% of the reads could be aligned (Figure 5.1). Conversely, 63% of the 
sequencing reads were aligned to the mouse genome and the rest (28%) were 
associated with an unknown source (Figure 5.1). Further analysis of non-
mappable reads that were aligning to the mouse genome demonstrated that the 
contaminating reads were evenly distributed across the mouse genome at a low 
tag density with no bias for specific gene features. Therefore, the source of 
contaminating sequences was mouse genomic DNA.  
Moreover, from the 9% of sequencing reads that were aligned to the human 
genome, only two thirds of them (6% of total reads) could be aligned uniquely to 
one location in the genome (Figure 5.1). The rest of the reads constituted 
repetitive sequences that could not be uniquely aligned. Furthermore, two thirds of 
the uniquely aligned reads (4% of total reads) were found to be PCR duplicates 
which could not be reliably used in downstream analysis (Figure 5.1).  
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Figure   5.1: Contaminating mouse genomic DNA and PCR duplicates affect the quality of 
low-cell ChIP-seq output.  
Top: table shows the number of sequencing reads obtained from low-cell ChIP-seq assays using in 
which gel size selection was performed prior to PCR amplification. Table also indicates the number 
of sequencing reads that were aligned to human genome, the number of multiple hits, the number 
of unique alignments, the number of PCR duplicates, and the number of non-mappable sequencing 
reads aligning to mouse genomic DNA or with an unknown source. Bottom: the average results 
from the two low-cell ChIP-assays are illustrated as a pie chart. The average total number of 
sequencing reads was ~25 million, 63% of which was aligned to the mouse genome and only 9% 
could be aligned to the human genome. A third of the sequencing reads (3% of total reads) that 
aligned to the human genome were multiple hits that comprised repetitive sequences. Two thirds of 
the uniquely aligned reads (4% of total reads) were also derived from PCR duplicates.   
The mouse genomic DNA contamination could have been introduced as a result of 
cross contamination by using a probe sonicator, or by using contaminated ChIP 
reagents. In order to tackle this issue, a separate probe sonicator was used for the 
human samples and all the ChIP reagents were renewed and kept separate from 
mouse genomic DNA samples. Furthermore, in order to ensure that the above 
measures could successfully eliminate the mouse genomic DNA contamination, 
qPCR primers were designed at multiple mouse genomic sites which did not show 
sequence homology with the human genome. The contamination level was 
monitored at two stages; first, after the purification of ChIP DNA and second, after 
the preparation of ChIP-seq libraries (Figure 5.2B). After the ChIP-qPCR the 
percentage ratio of mouse DNA to the human DNA was measured to determine 
the level of contamination in each sample. For human ChIP amplifications a region 
of genome enriched with the histone modification of interest was chosen based on 
the previously reported histone modification enrichments at the TAL1/SCL locus 
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(Dhami et al., 2010). The sequenced libraries did not exceed 5% mouse genomic 
contamination before and after library preparations as shown for the typical 
examples in Figure 5.2B. The templates or the PCR-amplified libraries that had 
more than 5% contamination were discarded before sequencing. 
Furthermore, the presence of a large proportion of PCR duplicates (up to 60%) 
was previously reported in libraries derived from low-complexity templates (Quail 
et al., 2008). Low-cell ChIP from 10,000 cells was estimated to generate ~30 pg of 
DNA (Acevedo et al., 2007). In the original Illumina ChIP-seq library preparation 
method, the adapter ligated ChIP-DNA were subjected to gel electrophoresis and 
size-selection at ~200bp. Therefore, by using small amounts of DNA as ChIP-seq 
library template, the size-selection step purifies even lower amounts of DNA, 
which is referred to as a low-complexity template. Consequently, during the PCR 
amplification of ChIP-seq library, the low-complexity template would leave the 
exponential phase in early cycles as there would be fewer number of template 
strands available. Therefore, PCR amplification of a low-complexity template 
would increase the incidence of PCR product duplicates. In order to tackle this 
issue, the adapter ligated low-cell ChIP template was directly PCR amplified 
without reducing it complexity further. Subsequently, the size selection was 
performed at 200-300 bp range (Figure 5.2A), which comprised 92 bp of ligated 
adapters and 108-208 bp of ChIP DNA insert. This would ensure the elimination of 
unincorporated adapters or adapter dimers from the sequencing library in addition 
to maintaining the optimum library size for cluster generation (reviewed in Section 
5.1.1). 
Through optimising the above steps and careful handling of the low-cell ChIP 
material during library preparation, the percentage of uniquely aligned sequencing 
reads to the human genome without PCR duplicates increased from 2% to 35% 
(Figure 5.2D). However, on average 40% of the sequencing reads could still not 
be aligned to the human genome due to the presence of contaminating DNA 
material or sequencing errors. The conventional ChIP-seq assays performed in 
Chapter 4 showed an average of ~10% non-mappable sequencing reads which 
could be due to the sequencing errors or the presence of primer dimers. 
Furthermore, ~10% of the total number of sequencing reads resulted from PCR 
duplicates (Figure 5.2C). Therefore, in comparison with the conventional ChIP-seq 
results, the low-cell ChIP-seq datasets demonstrated significantly reduced levels 
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of PCR duplicates, although the presence of non-mappable reads was still an 
issue. However, from an average total number of 30 million reads obtained from 
each low-cell ChIP-seq assay, 10.5 million sequencing reads (35%) could be 
uniquely aligned to the human genome, which could provide sufficient depth for 
performing downstream analyses.  
 
Figure   5.2: The optimised low-cell ChIP-seq method. 
(A) Typical examples of gel electrophoresis of PCR-amplified ChIP-seq libraries for two histone 
modifications H3K4me3 and H3K27me3. The ChIP-seq libraries were found to be in the range of 
100 bp – 1 kb with the majority of DNA fragments at the 100-400 bp range. The <100 bp bands 
represent un-incorporated primers and adapters. Size selection was performed at 200-300 bp, 
shown by the red lines. First lane in each gel shows the 1 kb DNA ladder. The electrophoresis was 
performed on 2% 1X TAE buffer agarose gels and visualised by ethidium bromide staining. (B) 
Typical examples showing the percentage ratio of mouse genomic DNA to the human ChIP DNA 
as measured by performing qPCR at various mouse genomic regions. The percentage of DNA 
contamination was below 5% before and after the ChIP-seq library preparation. (C) The 
percentages of non-mappable reads (blue), multiple alignments (red), unique alignments (green), 
and PCR duplicates (purple) on average in conventional ChIP-seq, and (D) low-cell ChIP-seq 
datasets from an average 30 million sequencing reads.   
5.7 Genome-wide mapping of H3K4me3 and H3K27me3 
in HSCs, HPCs, LSCs, and LPCs 
H3K4me3 and H3K27me3 are well-studied in the context of gene promoters and 
predicting the transcriptional activity of their marked loci (Barski et al, 2007). 
Furthermore, these histone modifications are associated with bivalent promoters 
which have an important role during development (Azuara et al., 2006; Bernstein 
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et al., 2006; Section 1.5.4.6). Therefore, it was important to understand their role in 
gene expression regulation in the course of leukaemic transformations.  
After the optimisation of the low-cell ChIP-seq method, the genome-wide 
distribution of H3K4me3 and H3K27me3 histone modifications were studied in 
HSCs and LSCs using ~10,000 cells/IP. The histone modification maps for LPCs 
were generated by conventional ChIP-seq assays since the cell numbers were not 
limiting (~100,000 cells/IP). The epigenetic profiles were obtained from the same 
samples and cell populations that were used to analyse the genome-wide gene 
expression profiles in Chapter 3. However, the histone modification maps for the 
HPCs were obtained from the previously published conventional ChIP-seq 
datasets that were generated from a pool of normal HPCs (CD133+ CD34+ CD38+) 
(Cui et al., 2009). After aligning the sequencing reads to the human genome, the 
unique alignments without PCR duplicates (Table 5.1) were used to cluster all the 
annotated promoters (n=33,626) in the human genome (RefSeq hg18 build) by 
seqMINER. The promoters were defined as 2.5 kb regions upstream and 2.5 kb 
regions downstream of the TSSs. The clusters were generated graphically through 
heatmaps (Figure 5.3).  
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Table   5.1: The number of aligned sequencing reads obtained from H3K4me3 and H3K27me3 
ChIP-seq assays in HSCs, LSCs, LPCs and HPCs. 
The total number of sequencing reads, the number of sequencing reads aligned to the human 
genome, the number of unique alignments without PCR duplicates and the number of multiple hits 
are listed for each ChIP-seq assay. HSCs and LSCs were subjected to low-cell ChIP-seq, whereas 
HPCs and LPCs were subjected to the conventional ChIP-seq. ‡  The  ChIP-seq datasets for HPCs 
were obtained from publicly available database (Cui et al., 2009) and the number of unique 
alignments   without   duplicates   could   be   reported.   †   The   results   obtained   by   merging   two  
independent low-cell ChIP-seq datasets.  
5.8 defining H3K4me3 and H3K27me3 epigenetic 
signatures for promoters 
The seqMINER clustering identified three classes of promoters based on the 
H3K4me3 and H3K27me3 signatures. These three classes of promoters included 
(i) H3K4me3, (ii) bivalent (H3K4me3 and H3K27me3), and (iii) neither histone 
modifications (Figure 5.3). Subsequently, further clustering of the neither 
modification category resulted in the separation of two subclasses of H3K27me3hi 
promoters and promoters that harboured neither modifications. Therefore, in total 
four classes of promoters were distinguished, including (i) H3K4me3, (ii) bivalent, 
(iii) H3K27me3hi, and (iv) neither modifications (Figure 5.3). Furthermore, these 
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clusters were generated by clustering all three bioreplicates for each cell type 
together as opposed to clustering on a sample by sample basis. 
 
Figure   5.3: Clustering heatmaps and composite plots of H3K4me3 and H3K27me3 
distribution at the annotated promoters. 
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Top: the seqMINER-generated heatmaps demonstrate the distribution of H3K4me3 and 
H3K27me3 histone modifications at the promoters of the annotated transcripts in the human 
genome (RefSeq hg18 build) in HPCs, HSCs, LSCs, and LPCs. Each heatmap represents six 
lanes illustrating H3K4me3 followed by H3K27me3 in three biological replicates (patient samples), 
except the HPCs for which data was obtained from previously published datasets (Cui et al, 2009) 
comprising only one pooled sample. Heatmaps could identify three major classes which include 
H3K4me3, bivalent (H3K4me3 and H3K27me3), and H3K27me3hi or neither modifications 
promoters. Further sub-clustering of the latter resulted in two separate classes of H3K27me3hi and 
neither modifications promoters. Bottom: the composite plots for each major class are shown for 
each cell type based on the normalised averaged number of tags across the 5 kb region centred at 
the TSSs for H3K4me3 (blue line) and H3K27me3 (red line). The x-axes show the average 
genomic coordinates where the orientation of transcription is shown by an arrow and the position of 
the TSSs is marked by vertical dotted lines. The y-axes show the number of tags per million at 
each genomic location. 
The meta-gene profiles, which are referred to as composite plots in this Chapter, 
were created for each class of promoters that were defined by clustering. The 
composite plots were generated by allocating 100 bins across the defined 
promoters – 2.5 kb upstream and 2.5 kb downstream of TSSs – and computing 
the normalised averaged number of sequencing reads, which are also referred to 
as tags, per bin in all the genes represented in a promoter class. The final 
composite plots showed an average of three bioreplicates in each cell type except 
for the HPCs which represented only one pair of datasets (Figure 5.3). These 
composite plots, therefore, represent an average distribution of histone 
modifications across an average promoter in a promoter class. The H3K4me3 
promoters in all cell types were associated with significantly high enrichment levels 
of H3K4me3 right after the TSS, which could be located by a noticeable dip as a 
result of nucleosomal depletion (Bernstein et al., 2004, Lee et al., 2004). The 
difference between the tag density at the TSSs of H3K4me3 promoters in HPCs 
and LPCs with HSCs and LSCs is a result of different ChIP efficiencies. This 
phenomenon was demonstrated in Chapter 4 which showed higher enrichment 
levels for H3K4me3 in conventional ChIP-seq assays compared to the low-cell 
ChIP-seq assays. Therefore, the differences are observed here is not due to the 
biological differences between the progenitor samples and their stem cell 
compartment, but mainly due to the differences between low-cell and conventional 
ChIP-seq assays.  
The bivalent class was distinguished by the presence of appreciable levels of both 
H3K4me3 and H3K27me3 marks at the promoters. The enrichment levels of 
H3K4me3 were much lower at the bivalent promoters but featuring a nucleosomal 
depletion dip at the TSS immediately followed by a downstream peak similar to the 
H3K4me3 promoters. The H3K27me3 enrichment pattern at bivalent promoters in 
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HSCs, LSCs, and LPCs highly resembled that of H3K4me3, with a dip at the TSS 
followed by a downstream peak, but featured a broader distribution in HPCs as 
noticed by a wider dip at the TSS and the absence of downstream enrichment 
peak. The H3K27me3hi promoters showed the most varied patterns between the 
four cell types, but all displayed higher levels of H3K27me3 than H3K4me3 
forming peaks at the TSSs with further extension of enrichment blocks over the 
gene bodies, which distinguished this class of promoters from the bivalent class. 
Neither modifications category showed barely detectable levels for both histone 
modifications which formed very small peaks of enrichment over the TSSs. This 
class of promoters, primarily devoid of H3K4me3 or H3K27me3, is associated with 
DNA methylation (Meissner et al., 2008). These four classes of promoters were 
also previously reported in genome-wide histone modification analyses of normal 
haemopoietic cells (Cui et al., 2009, Weishaupt et al., 2010). Therefore, the results 
presented above were in agreement with the previously reported histone 
modification signatures at the gene promoters.  
Since the HPC profiles were obtained from previously published datasets (Cui et 
al., 2009), a comparison between the number of bivalent genes identified by 
seqMINER in this section and the previously reported SICER analysis was 
performed (Figure 5.4). The seqMINER clustering identified 2,766 bivalent 
promoters whereas the SICER results indicated 2,602 promoters. 1,660 promoters 
were found in the overlap which comprised of approximately 65% of the previously 
reported promoters by SICER, whereas 942 promoters were only recognised as 
bivalent by SICER and instead 1,106 bivalent promoters were only identified as 
bivalent by seqMINER. The discrepancy could be explained by the SICER 
approach in which the H3K4me3 and H3K27me3 profiles were analysed 
independent of each other. Therefore, a bias towards the peak calling step could 
be expected as the broad H3K27me3 domains could be more difficult to 
distinguish as enrichment peaks in a given window (Zang et al., 2009). 
Conversely, seqMINER generated the clusters for both H3K4me3 and H3K27me3 
marks simultaneously (Ye et al., 2011). Furthermore, different studies use different 
empirical threshold values to distinguish between real signal and noise.  
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Figure   5.4: The comparison between the number of bivalent promoters identified by 
seqMINER with the published SICER analysis in HPCs. 
seqMINER analysis identified 2,766 bivalent promoters in HPCs (blue circle), whereas the reported 
SICER analysis (green circle) identified 2,602 bivalent promoters in the same dataset. Both 
analyses agreed on 1,660 promoters. However, seqMINER identified 1,106 promoters that were 
not recognised by SICER and 942 promoters were only identified as bivalent by SICER. 
5.9 The association of different promoter class with gene 
expression levels 
It has been previously shown that each of these promoter classes is associated 
with different levels of transcription of their relevant gene loci (Mikkelsen et al., 
2007). In order to confirm similar association between the promoter classes 
identified by seqMINER and the expression levels of their relevant loci, the 
average RMA (gene expression) values for the genes in each promoter category 
were extracted for each cell type from the Affymetrix datasets. The spread of RMA 
levels in each promoter class was reported as box plots (Figure 5.5). 
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Figure   5.5: The relationship between each epigenetic category and the gene expression in 
each cell type. 
Box plots represent the spread of the gene expression (RMA) values in each epigenetic category in 
each cell type. The whiskers represent 5-95 percentile with the medians shown as horizontal lines. 
The y-axes show the RMA values (gene expression) and the x-axes show different epigenetic 
categories. The p-values were calculated using unpaired, two-tailed t-test with 95% confidence 
intervals comparing the average RMA values between two compartments and p<0.05 was 
considered to be significant.  
The box plots showed that the genes in H3K4me3 compartment were associated 
with a significantly higher average of expression values (p<0.0001) than the other 
three compartments in all cell types (Figure 5.5). This was in agreement with 
previous reports which showed a positive correlation between the H3K4me3 
enrichments at the promoters and the transcriptional activity of the associated 
gene (Barski et al., 2007, Kim et al., 2005). On the other hand, bivalent promoters 
were associated with low transcriptional activity in four cell types (Figure 5.5) 
despite H3K4me3 enrichments, indicating that the repressive impact of PcG 
proteins at these promoters is dominant over the activity of TrxG proteins. 
Furthermore, the H3K27me3hi promoters, which are also regulated by PcG 
proteins, were associated with low gene expression levels (Figure 5.5). These 
promoters could be categorised as bivalent promoters with a higher H3K27me3 
enrichments than H3K4me3, as observed in their composite plots (Figure 5.3). 
The similarities in the range of gene expression levels in both bivalent and 
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H3K27me3hi promoters could suggest similar transcriptional regulation 
programming mediated by the PcG proteins. The relationship between bivalent 
and H3K27me3hi promoters and low or repressed transcriptional activities was in 
agreement with previous reports (Boyer et al., 2006, Lee et al., 2006, Mikkelsen et 
al., 2007). The neither modification promoter category was also associated with 
repressed loci. However, the absence of PcG binding to these promoters could 
indicate a broader range of gene expression levels, as was observed with the 
spread of the box plots (Figure 5.5). However, previous reports indicated that up to 
80% of these promoters can be associated with DNA methylation in ES cells 
(Meissner et al., 2008), which could explain for their repressed gene expression 
status. Overall, the gene expression levels associated with each promoter class in 
each of the four cell types were in agreement with previous reports, suggesting 
that the clusters were generated accurately. 
5.10 Validation of ChIP-seq data by ChIP-qPCR 
Prior to performing further analysis on the ChIP-seq datasets, the observed 
histone modification signatures were validated using ChIP-qPCR approach, as 
described in Chapter 2. A panel of 67 promoters representing different promoter 
classes were selected. The gene promoters were selected from three pathways 
that were of special interest to this research group, which include TGF-β  signalling  
pathway, PI3K signalling pathway and the intracellular signalling downstream of 
BCR-ABL1 oncoprotein. The validation panel was comprised of 49 putative 
H3K4me3 promoters, 13 putative bivalent promoters, and five putative 
H3K27me3hi or neither-modifications promoters in HSCs (Figure 5.6) as defined by 
seqMINER clustering. The qPCR results were represented as the log2 fold 
enrichment levels of H3K4me3 or H3K27me3 enrichments at the tested promoters 
relative to the median of H3K4me3 and H3K27me3 enrichments of negative 
control regions, which were selected as intergenic regions within the TAL1/SCL 
locus (Dhami et al., 2010). Figure 5.6 demonstrates the average of the log2 fold 
enrichments for each tested promoter as measured for all three HSC bioreplicates. 
The criteria used for passing the validation step were as follows: H3K4me3 
promoters to be associated with significantly positive H3K4me3 enrichment and 
significantly negative enrichment of H3K27me3, bivalent promoters to be 
associated with significantly positive enrichment for both H3K4me3 and 
H3K27me3, and the promoters with H3K27me3hi or neither modifications with only 
Chapter 5  224 
significantly positive H3K27me3 enrichment or significantly negative enrichment 
for both marks, respectively. A total of 9 promoters failed to validate by ChIP-
qPCR (marked by asterisks in Figure 5.6) and therefore, the validation rate of the 
ChIP-seq dataset was 87% suggesting a high confidence in sequencing and 
clustering results.  
 
Figure   5.6: Validation of ChIP-seq datasets by ChIP-qPCR in HSCs. 
A panel of 67 gene promoters from H3K4me3, bivalent, and H3K27me3 or neither-modifications 
categories were selected for validation by qPCR in HSCs. The height of the bars (y-axis) shows the 
log2 fold enrichment levels relative to the median of negative control enrichments averaged from 
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three individual samples. The positive log2 fold enrichments indicate the presence of an enrichment 
and the negative values indicate their absence. The error bars show the standard error of mean. 
The H3K4me3 and H3K27me3 enrichments which passed the validation are illustrated as red and 
green bars, respectively, whereas the H3K4me3 and H3K27me3 enrichments which could not be 
validated are displayed as black and grey bars, respectively. The promoters which did not pass the 
validation step are marked with asterisks (n=9).    
5.11 CML cells show elevated levels of bivalent 
promoters 
As discussed in Section 5.7, the H3K27me3hi category of promoters is a subset of 
the bivalent class with higher H3K27me3 levels than H3K4me3 levels. Therefore, 
The genes identified in these two categories in all four cell types were collectively 
referred to as bivalent/H3K27me3hi class of promoters. Previous reports have 
indicated that the pluripotent cells, such as ES cells, are associated with a large 
number of bivalent genes, which are significantly reduced in the course of 
differentiation (Mikkelsen et al., 2007). A large subset of bivalent promoters have 
also been reported in HSCs, whereas the more differentiated cell types, such as 
MEPs and T cells, are associated with fewer bivalent promoters (Cui et al., 2009, 
Weishaupt et al., 2010). Therefore, less mature cell types are associated with a 
large number of bivalent promoters. Consequently, the number of transcripts and 
genes associated with each promoter class in each cell type was investigated 
(Figure 5.7). 
 
Figure   5.7: Number of transcripts or genes in different promoter categories in each cell type. 
The number of transcripts or genes associated with H3K4me3 (red), bivalent/H3K27me3hi (yellow), 
and neither histone modifications (black) are shown in each cell type as a bar chart (top) and a 
table (below). 
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The number of bivalent/H3K27me3hi promoters showed a 20% drop in HPCs 
(n=5,050) relative to HSCs (n=6,248). However, the number of 
bivalent/H3K27me3hi promoters was elevated by approximately 10% in LSCs 
(n=6,847) and LPCs (n=6,788) relative to HSCs. The observation in HPCs was in 
agreement with the expected reduction of bivalent/H3K27me3hi promoters in the 
course of differentiation. Furthermore, the observation of large number of 
bivalent/H3K27me3hi promoters in LSCs could be expected due to their stem cell 
phenotype. However, the elevated levels of bivalent/H3K27me3hi promoters were 
not in agreement with the progenitor status of LSCs. Consequently, the fate of 
many bivalent promoters were still undecided in LPCs which may confer a less 
mature phenotype to LPCs relative to their normal counterparts. Thus, it is 
plausible to propose profound differences in epigenetic programming between 
LPCs and HPCs.     
5.12 Bivalent promoters are significantly enriched for the 
stem cell pathways  
In order to understand the role of each promoter class in the regulation of 
biological pathways, the genes that were associated with each promoter category 
in each cell type were subjected to pathway analysis using PANTHER database. 
The pathway analysis was performed by providing a reference list that contained 
all the annotated genes in the RefSeq hg18 database (n=21,733). This reference 
list was divided into genes groups that constitute different biological pathways. 
Subsequently, the list of genes in each promoter class was provided as an input 
list, which was divided into similar categories of biological pathways. The input list 
was then compared against the reference list and a binomial test was applied to 
statistically determine how significantly a group of genes was over- or under-
represented in the input list relative to the reference (Mi et al., 2010). The 
pathways that were significantly over-represented in a promoter class were 
assigned +1 values and the pathways that were significantly under-represented 
were assigned -1 values. The pathways that were not significantly over- or under-
represented in a promoter class in a cell types were assigned 0 values. 
Furthermore, these values were used in a k-means clustering approach in order to 
group subset of pathways based on similarities in the epigenetic signatures of their 
promoters (Figure 5.8).  
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Figure   5.8: Clustering of the pathways significantly associated with each promoter class in 
the four cell types. 
Pathways that were found to be significantly under- or over-represented in at least one promoter 
class in a cell type were clustered using a k-means clustering approach. Four major clusters of 
pathways were identified as labelled on the right. The name of each pathway is represented on the 
left. A black box indicates over-represented, grey box indicates expected representation and light 
grey box indicates under-represented in a particular promoter class. The pathways that were 
shown to be significantly downregulated or upregulated at the level of expression between the cell 
types (Chapter 3) were represented by green and red arrows, respectively, which indicate the 
orientation of the expression change. The pathways that were shown to be associated with HPC 
identity (orange boxes), CML identity (black boxes), and HSC identity (green boxes) (as defined in 
Chapter 3) are also indicated.  
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The clustering of significantly under- or over-represented pathways in each 
promoter class in four cell types identified four classes of pathways based on 
similarities in the epigenetic signatures of their promoters. The identified classes 
included H3K4me3-enriched, bivalent/H3K27me3hi-enriched, neither 
modifications-enriched, and the orphans. The classes were labelled according to 
the pathways over-representation in a particular promoter class in the four cell 
types.  
The H3K4me3-enriched class was characterised by the pathways that were pre-
dominantly over-represented in the H3K4me3 compartment in the four cell and 
were under-represented in the bivalent/H3K27me3hi or neither modifications 
categories dependent on the cell type. Intriguingly, 10 out of 11 HPC identity 
pathways which were associated with proliferative capacities, as identified in 
Chapter 3, were significantly enriched with this class of promoters. These included 
transcriptional regulation by bZIP proteins, the ubiquitin proteasome pathway, the 
p53 pathway and its regulatory feedback loops, the cell cycle, the TCA cycle, and 
DNA replication. Furthermore, six out of 15 CML identity pathways were also 
found to be enriched in this category, including apoptosis signalling, RAS pathway, 
EGF receptor signalling, JAK/STAT signalling, Toll-like receptor signalling, and T-
cell activation mechanism. The pathways classified in this category were largely 
associated with upregulation between cell types, as indicated by red arrows in 
Figure 5.8. Therefore, it can be suggested that the H3K4me3 promoters have a 
predisposition for upregulation.  
The bivalent/H3K27me3hi-enriched category was comprised of the pathways that 
were only over-represented in the bivalent/H3K27me3hi promoter class in a cell 
type or becoming significantly over-represented during the transition to the 
progenitor states (HPCs or LPCs). Interestingly, nine out of 12 HSC identity 
pathways, identified in Chapter 3, were found in this category, which included Wnt 
and TGF-β signalling as well as α-adrenergic receptor, serotonin 5HT2 receptors, 
acetylcholine muscarinic receptors 1 and 3, histamine H1 receptor, oxytocin 
receptor, TRH receptor and endothelin signalling pathways. Furthermore, seven 
out of 15 CML identity pathways were also found in this category, including 
angiogenesis, integrin signalling, cadherin signalling, heterotrimeric Gα-protein 
signalling, and PI3K pathway. The pathways identified in these two categories 
were largely associated with downregulation events between cell types, as 
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indicated by green arrows in Figure 5.8. Therefore, it can be suggested that the 
bivalent/H3K27me3hi promoters have a predisposition for downregulation. 
The neither modifications-enriched pathways were defined as the pathways mainly 
over-represented in the neither modifications promoter class, such as the 
chemokine/cytokine-mediated inflammation signalling, which was linked to the 
HSC identity, and the blood coagulation, which was linked to the CML identity,  
pathways. The orphans, on the other hand, included the pathways which did not 
share a common epigenetic signature between the four cell types. The orphans 
included several metabolic pathways as well as notch signalling, hedgehog 
signalling, and angiotensin II receptor signalling pathways. 
The above observation indicated that the genes with bivalent promoters were 
significantly enriched for the HSC identity pathways, which were proposed to have 
a role in the maintenance of stem cell features (Chapter 3). However, 40 pathways 
were identified in the bivalent/H3K27me3hi categories (Figure 5.8) from which only 
16 pathways were demonstrated to be associated with the HSC or CML identities 
at the level of expression. Therefore, it is plausible to suggest that the other 
pathways that were not associated with a significant change of expression were 
also capable of using similar transcriptional regulation mechanisms during normal 
differentiation and leukaemic transformations and, consequently, might have a role 
in the maintenance of stem cell phenotype in both HSCs and LSCs.  
5.13 Gene expression changes of bivalent genes and 
bivalent-enriched pathways are skewed towards 
upregulation in LSCs. 
In order to elucidate the role of epigenetic programming in transcriptional 
regulation of different epigenetic classes of biological pathways (Figure 5.8), the 
significant genome-wide gene expression changes associated with each promoter 
class were studied in the following transitions: (i) HSCs to HPCs, (ii) HSCs to 
LSCs, (iii) LSCs to LPCs, and (iv) HSCs to LPCs (Figure 5.9). 
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Figure   5.9: The association between each promoter class and genome-wide gene 
expression changes in the four studied transitions. 
The gene expression changes associated with each promoter class during each transition are 
illustrated as pie charts. The status of the genes in the cell of origin in each transition is shown on 
the left with their potential outcomes in the new cell type. The number of significantly upregulated 
(red) and downregulated (green) genes are also shown. (A) Genes that were associated with 
H3K4me3 promoters in the cell of origin; (B) genes that were associated with bivalent/H3K27me3hi 
promoters;  and (C) genes that were associated with neither modifications.  
The genes that were associated with H3K4me3 compartment in the cell of origin in 
each of the above transitions were associated with upregulation of gene 
expression more profoundly than the downregulation events (Figure 5.9A). 
However, the activating capacity of H3K4me3 promoters were reduced to 60% in 
the HSC-to-LSC transition in comparison to the normal differentiation (70%). 
Furthermore, LPCs regained the activating capacity similar to HPCs. This was in 
agreement with our earlier observation at the level of pathways, which showed that 
that the H3K4me3 promoters have a predisposition for upregulation (Section 5.10). 
Therefore, these findings further strengthen the requirement for the HPC identity 
pathways, which are associated with proliferation, to be enriched for the H3K4me3 
promoters in order to be upregulated upon leaving the HSC compartment. 
Conversely, the gene promoters that were associated with neither modifications in 
the cell of origin in each of the above transitions favoured significant 
downregulation of gene expression over upregulation events (Figure 5.9C).  
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Furthermore, bivalent/H3K27me3hi genes were associated with significant 
downregulation of gene expression more profoundly than the upregulation events 
in the HSC-to-HPC, LSC-to-LPC, and HSC-to-LPC transitions (Figure 5.9B). This 
observation was in agreement with the results at the pathway level which indicated 
that bivalent promoters have a predisposition for downregulation (Section 5.10). 
However, the HSC-to-LSC transition was linked to a skewed tendency for bivalent 
genes to be upregulated. The importance of this finding was in connection with the 
significant association between the bivalent promoters and the HSC identity 
pathways, which may have a role in the maintenance of stem cell features. 
Therefore, the tendency for downregulation in bivalent promoters during HSC-to-
HPC, LSC-to-LPC, and HSC-to-LPC was in agreement with the significant 
downregulation of the HSC identity pathways in above transitions. However, the 
bivalent promoters are abnormally programmed during HSC-to-LSC transition 
which could have an impact in the regulation of the bivalent/H3K27me3hi pathways 
in these cells. In order to further investigate the transcriptional regulation of the 
bivalent/H3K27me3hi pathways in each of the above transitions, the number of 
significantly upregulated and downregulated genes in these pathways were 
analysed (Figure 5.10). 
 
Figure   5.10: The analysis of significant expression changes for the genes of 
bivalent/H3K27me3hi pathways in the four studied transitions. 
The number of significantly (p<0.05) upregulated (red bars) and downregulated genes in the 
bivalent/H3K27me3hi pathways in each of the studied transitions. The overlap between the 
significant changes in the HSC-to-HPC transition and the other three leukaemic transformations is 
shown as darker overlaid red and green bars. The total number of gene expression differences in 
each transition is also indicated on top of each bar.  
The significant expression changes of the genes in the bivalent/H3K27me3hi 
pathways during the HSC-to-HPC transition were balanced between upregulation 
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and downregulation events. However, the gene expression changes in these 
pathways were skewed towards upregulation in the HSC-to-LSC transition. This 
was in agreement with the earlier observations that indicated a tendency towards 
upregulation for the bivalent/H3K27me3hi genes in this transition. Therefore, it is 
plausible to suggest a different epigenetic programming for the 
bivalent/H3K27me3hi genes and pathways that is associated with reduced 
repressive potential and increased activation or upregulation capacities.  
LPCs, on the other hand, demonstrated a tendency towards downregulation of the 
genes in bivalent/H3K27me3hi pathways, suggesting that the epigenetic 
programming is more efficient in downregulating genes in this cell type.     
5.14 Changes in H3K4me3 and H3K27me3 levels regulate 
the transcriptional activity of bivalent promoters in 
CML cells 
The fate of the majority of genes associated with bivalent/H3K27me3hi promoters 
was shown to be repression in the course of normal differentiation (Figure 5.9). 
However, during the HSC-to-LSC transition these promoters behaved differently 
with regards to the transcriptional regulation of their controlled loci (Figure 5.9). 
Therefore, it was important to examine whether these promoters were linked to a 
different epigenetic programming in LSCs and LPCs relative to their normal 
counterparts. Consequently, the levels of H3K4me3 and H3K27me3 histone 
modifications in 1 kb upstream and 1 kb downstream of TSSs of all bivalent genes 
in the four cell types were investigated. This was achieved by computing the total 
number of sequencing reads for both H3K4me3 and H3K27me3 marks at all the 
annotated promoters across a 2 kb window centred at their TSSs. The obtained 
values for each promoter were normalised against the total number of uniquely 
aligned reads without PCR duplicates for each of the H3K4me3 and H3K27me3 
datasets in individual bioreplicates. Subsequently, the normalised H3K4me3 
values were z-scored across the H3K4me3 and bivalent/H3K27me3hi promoters 
for which this enrichment could be associated with a normal distribution. 
Furthermore, the normalised H3K27me3 values were z-scored for the 
bivalent/H3K27me3hi promoters for which this enrichment was found to be 
normally distributed. Z-scoring was performed to normalise against differences in 
ChIP-seq efficiency between bioreplicates and between cell types. The results 
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were presented as the median of z-scored values of all the bioreplicates for each 
cell type, except HPCs that were associated with only one dataset.       
In order to establish the differences in the levels of H3K4me3 and H3K27me3 at 
the bivalent promoters between LSCs/LPCs and their normal counterparts, the 
levels of these histone marks were initially examined at the promoters of a control 
gene set (n=200). This control gene set was defined as the bivalent genes that 
were not associated with significant differential expression between the four cell 
types. Furthermore, these genes were chosen based on their matched expression 
levels in HSCs with the significantly differentially expressed bivalent genes (Figure 
5.11A). Therefore, the relationship between cell types with regards to the 
H3K4me3 and H3K27me3 levels at the control promoters was used as the 
baseline.   
In order to establish the changes in the levels of H3K4me3 and H3K27me3 at the 
bivalent promoters during HPC commitment and leukaemic transformations, two 
subsets of genes were investigated. First, the bivalent genes that were 
significantly downregulated in HPCs and LSCs/LPCs relative to HSCs (n=182) 
and; second, the bivalent genes that were significantly upregulated in HPCs and 
LSC/LPCs relative to HSCs (n=138). The first subset of genes, which were 
downregulated upon leaving the HSC compartment, showed a significant increase 
in the levels of H3K27me3 repressive mark at the LSC promoters (Figure 5.11B). 
However, the H3K27me3 levels in HPCs remained significantly unchanged relative 
to HSCs. Similarly, the levels of H3K27me3 remained significantly unchanged 
between LSCs and LPCs. On the contrary, the changes of H3K4me3 levels at 
these promoters were not significantly different from the baseline changes (Figure 
5.11B). Therefore, the significantly downregulated bivalent genes in LSCs/LPCs 
use a different epigenetic regulation from HPCs which is mediated by increasing 
the levels of H3K27me3 repressive marks in LSCs. 
The analysis of second subset of genes that were upregulated in HPCs and 
LSCs/LPCs showed that the changes of H3K4me3 and H3K27me3 levels were not 
different from the baseline changes in both HPCs and LSCs (Figure 5.11C). 
However, LPCs demonstrated a significant reduction in the levels of H3K27me3 
levels relative to HSCs, in the absence of a significant change of H3K4me3 levels. 
Therefore, the significantly upregulated bivalent genes in LSCs/LPCs use a 
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different epigenetic regulation from HPCs which is mediated by reducing the levels 
of H3K27me3 repressive marks in LPCs. 
Overall, the bivalent genes that are differentially expressed upon leaving HSC 
compartment are associated with gains and losses of H3K27me3 in LSCs and 
LPCs, which are not observed in HPCs.   
 
Figure   5.11: Regulation of H3K4me3 and H3K27me3 levels at the promoters of bivalent 
genes in the four cell types.  
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The average total number of sequenced tags for H3K4me3 and H3K27me3 marks over a 2 kb 
region centred at the TSS of all bivalent genes in the four cell types were computed and z-scored. 
The histograms demonstrate the z-scored levels of H3K4me3 (green) and H3K27me3 (red) at the 
promoters of (A) non-changing matched control bivalent gene set, (B) significantly downregulated 
bivalent genes in common between HPCs and LSCs/LPCs, and (C) ) significantly upregulated 
bivalent genes in common between HPCs and LSCs/LPCs. The average expression levels of the 
genes investigated in each category were also expressed as RMA values. The error bars indicate 
standard error of mean. * p<0.05; ** p<0.01; *** p<0.0001. P-values were calculated by unpaired 
two-tailed t-test. 
The above results indicated a different usage of H3K4me3 and H3K27me3 histone 
marks at the promoters of bivalent genes in LSCs/LPCs relative to their normal 
counterparts. However, these results did not indicate at what stage during 
leukaemic transformations the abnormal epigenetic programming was initiated. 
Therefore, the differentially expressed bivalent genes were examined during the 
HSC-to-LSC transition, referred to as type I changes, and during the LSC-to-LPC 
transition, referred to as type II changes (Figure 5.12A).  
The type I significantly downregulated genes were associated with a significant 
increase in the levels of the repressive H3K27me3 marks and a significant 
reduction in the levels of the activating H3K4me3 marks (Figure 5.12B). 
Furthermore, the type I significantly upregulated genes showed a significant 
increase in the levels of H3K4me3, in the absence of a significant change in the 
levels of H3K27me3 (5.13C). Therefore, the type I differentially expressed genes 
were associated with the changes of both H3K4me3 and H3K27me3 marks in 
LSCs. Conversely, type II significantly downregulated and upregulated genes were 
not associated with a significant change of H3K4me3 and H3K27me3 levels 
between LSCs and LPCs (5.13D-E) relative to the observed baseline changes 
(5.12A). 
Thus, the above results indicated that the abnormal epigenetic programming was 
initiated during the HSC-to-LSC transition. Furthermore, differential expression of 
bivalent genes in LSCs/LPCs was associated with the changes of both H3K4me3 
and H3K27me3 histone marks, suggesting an abnormal mechanism of action for 
both PcG and TrxG complexes in LSCs/LPCs. Therefore, the expression levels of 
these protein complexes were investigated in the four cell types (Section 5.14). 
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Figure   5.12: Regulation of H3K4me3 and H3K27me3 levels at the promoters of bivalent 
genes differentially expressed in CML cells. 
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(A) The differentially expressed bivalent genes in LSCs/LPCs were examined during HSC-to-LSC 
transition (type I) and LSC-to-LPC transition (type II). (B-E) The histograms demonstrate the z-
scored levels of H3K4me3 (green) and H3K27me3 (red) at the promoters of (B) type I significantly 
downregulated changes, (C) type I significantly upregulated changes, (D) type II significantly 
downregulated changes, and (E) type II significantly upregulated changes. The average expression 
levels of the genes investigated in each category were also expressed as RMA values. The error 
bars indicate standard error of mean. * p<0.05; ** p<0.01; *** p<0.0001. P-values were calculated 
by unpaired two-tailed t-test.   
5.15  Gain and loss of bivalency are associated with 
significant differential expression in CML cells 
In the previous Section it was established that the gains and losses of H3K27me3 
at the bivalent/H3K27me3hi promoters were associated with significant differential 
expression in LSCs/LPCs, whereas this mechanism was not observed in during 
normal differentiation. Consequently, these findings suggested that the resolution 
of bivalent promoters to H3K4me3 by losing H3K27me3 marks or conversion of 
H3K4me3 promoters to bivalent by gaining H3K27me3 marks could have a 
significant impact on transcriptional regulation in CML. This was further 
investigated by demonstrating the significant gene expression changes (ΔRMA 
values) that were associated with the above epigenetic changes during four 
transitions, including (i) HSC-to-HPC, (ii) HSC-to-LSC, (iii) LSC-to-LPC, and (iv) 
HSC-to-LPC (Figure 5.13). 
 
Figure   5.13: The effects of gain and loss of bivalency on transcriptional regulation during 
normal differentiation and leukaemic transformations. 
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Box plots represent the spread of the gene expression changes (ΔRMA) as a result of the gain and 
loss of bivalency in the four transitions. The whiskers represent 5-95 percentile with the medians 
shown as horizontal black lines and the average values shown as horizontal red lines. The y-axes 
show the ΔRMA values (gene expression differences) and the x-axes show the type of epigenetic 
change. The p-values were calculated using unpaired, two-tailed t-test comparing the average 
ΔRMA values between the classes of epigenetic changes. The p<0.05 was considered to be 
significant and highlighted red for a significant upregulation or green for a significant 
downregulation.   
The resolution of bivalency to H3K4me3 and the gain of bivalency from the 
H3K4me3 compartment were not associated with a significant differential 
expression in the HSC-to-HPC transition (Figure 5.13). However, the bivalency 
resolution to H3K4me3 was associated with a significant upregulation of gene 
expression during HSC-to-LSC and HSC-to-LPC transitions. Furthermore, the gain 
of bivalency from H3K4me3 compartment was associated with a significant 
downregulation during all leukaemic transformations, including HSC-to-LSC, LSC-
to-LPC, and HSC-to-LPC transitions.  
Therefore, the above observations were in agreement with the unique association 
between the gains and losses of H3K27me3 in transcriptional regulation in LSCs 
and LPCs that were not observed with their normal counterparts. Thus, a profound 
role for the PcG proteins can be suggested in CML cells.    
5.16 The chromatin modifiers are misregulated in 
leukaemic cells. 
Various lines of evidence presented in previous Sections demonstrated that the 
bivalent/H3K27me3hi promoters were differentially regulated in LSCs/LPCs. 
Consequently, it was important to investigate the abnormalities in the function of 
chromatin modifiers that regulate bivalent/H3K27me3hi promoters in CML cells and 
their normal counterparts. H3K4me3 and H3K27me3 marks are added to the 
histone tails by TrxG and PcG PRC2 complexes, respectively. Furthermore, the 
removal of these histone modifications is mediated by KDM proteins (Section 
1.5.4.5).  
The abnormalities in the function of these protein complexes could be mediated by 
the abnormal expression of various members of the above protein complexes. 
Therefore, their gene expression levels (RMA values) were extracted from the 
Affymetrix datasets. Furthermore, differential expression analyses were performed 
between the four cell types for all possible comparisons. The gene expression 
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differences between all four cell types and the gene expression levels for 
individual genes in these complexes were plotted (Figures 5.14 – 5.16). 
5.16.1 PcG PRC2 members are misregulated in CML. 
The bivalent/H3K27me3hi promoters in LSCs showed a loss of repressive power, 
as the majority of gene expression changes were associated with upregulation. 
Nevertheless, the bivalent/H3K27me3hi promoters in LPCs demonstrated the 
regaining of this repressive power. Furthermore, differential expression of bivalent 
genes in CML cells was associated with significant gains and losses of H3K27me3 
levels. Similarly the gain and loss of bivalency in CML cells were also 
demonstrated significant differential expression. The above observations 
suggested that the PcG PRC2 complex could be misregulated in CML cells.  
Interestingly, the two catalytic subunits of PcG PRC2 complex, EZH1 and EZH2, 
were found to be significantly misregulated in both LSCs and LPCs (Figure 5.14). 
EZH1 was significantly downregulated in LSCs and LPCs relative to both HSCs 
and HPCs, whereas EZH2 was significantly upregulated in LSCs and LPCs 
relative to HSCs and HPCs, respectively. EZH1 levels were significantly higher 
than EZH2 in HSCs, as indicated by their RMA levels. This was in agreement with 
previous reports indicating EZH1 as the dominant catalytic subunit of PRC2 HSCs 
(Mochizuki-Kashio et al., 2011). In the course of normal differentiation, significant 
downregulation of EZH1 and upregulation of EZH2, resulted in similar mRNA 
levels for both proteins in HPCs. However, both LSCs and LPCs demonstrated 
significantly higher levels of EZH2 than EZH1. Although the EZH1 levels remained 
significantly unchanged between LSCs and LPCs, the EZH2 levels were 
significantly elevated in LPCs than LSCs.  
Therefore, the observed loss of repressive capacity of the bivalent/H3K27me3hi 
promoters in LSCs is likely to be associated with the significant downregulation of 
EZH1, whereas the regaining of repressive capacity in these promoters could be 
linked to the higher levels of EZH2.  
In addition to the catalytic subunits, another PRC2 subunit, SUZ12, which is 
important in activating the catalytic subunits (Pasini et al., 2004), was also 
abnormally upregulated in LSCs and LPCs (Figure 5.14). RBBP7 and PHF19, 
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which are associated with chromatin recruitment of PRC2 (Nekrasov et al., 2007, 
Song et al., 2008), were also upregulated in LSCs. Furthermore, RBBP4 and 
RBBP7 were upregulated abnormally in LPCs, whereas MTF2, which is another 
recruitment factor, was significantly downregulated in LPCs. JARID2, PHF19, and 
PHF1 were also significantly differentially expressed in LPCs relative to HSCs, but 
their levels were not significantly different from HPCs and therefore, could be 
mainly associated with the proliferative capacities of progenitor cells. Overall, the 
abnormal regulation of non-catalytic subunits of PRC2 could have an additional 
effect on the function of PRC2 complex and its recruitment to the target loci.    
 
Figure   5.14: Gene expression levels of the PcG PRC2 complex members in the four cell 
types. 
The gene expression levels were extracted from the Affymetrix datasets for each cell type and the 
significant expression changes were calculated using the HSC expression levels as the calibrator. 
Left: the gene expression differences are shown schematically between the four cell types. 
horizontal lines indicate the significance levels (p<0.05) and the error bars represent the 95% 
confidence intervals. Right: the raw RMA values are represented for the genes that showed 
significant differential expression in at least one pair-wise comparison. The error bars indicate the 
95% confidence intervals.  
5.16.2 TrxG complex members are misregulated in CML. 
In addition to the changes of H3K27me3 levels, H3K4me3 levels were also 
significantly altered at the promoters of differentially expressed bivalent genes in 
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CML cells. Therefore, the expression levels of TrxG complex members were 
investigated in the four cell types (Figure 5.15). MLL and ASH1L were the catalytic 
subunits that were significantly abnormally downregulated in LSCs. Furthermore, 
MLL2 and SETD1A were the catalytic subunits that were significantly abnormally 
downregulated and upregulated in LPCs, respectively. However, LPCs also 
showed significant downregulation of MLL, MLL3, and ASH1L relative to HSCs 
similar to HPCs (Figure 5.15), which could be associated with the proliferative 
capacities of progenitor cells.  
The effect of MLL and ASH1L reduction in LSCs could imply a reduction in 
H3K4me3 levels which was observed in the case of significantly downregulated 
bivalent genes in LSCs (Figure 5.12B). Furthermore, significantly lower levels of 
H3K4me3 at the promoters of the control bivalent gene set in LPCs, which was 
also observed in the case of HPCs (Figure 5.11A), could be due to the significant 
downregulation of MLL, MLL2, MLL3, and ASH1L catalytic subunits in LPCs.  
In addition to the catalytic subunits of TrxG complex, several accessory proteins, 
which are involved in recruiting and activating the complex, were also 
misregulated in leukaemic cells (Figure 5.15). PAXIP1 and WDR5 were 
significantly abnormally upregulated and NCOA6 was significantly abnormally 
downregulated in LSCs. Furthermore, ASH2L, CXXC1, DPY30, HCFC1, PAXIP1, 
RBBP5, and WDR5 were significantly abnormally upregulated in LPCs. The 
upregulation of TrxG accessory proteins in CML cells could potentially increase 
the assembly, catalytic activity, and recruitment of TrxG complex to certain target 
loci.   
Chapter 5  242 
 
Figure   5.15: Gene expression levels of the TrxG complex members in the four cell types. 
The gene expression levels were extracted from the Affymetrix datasets for each cell type and the 
significant expression changes were calculated using the HSC expression levels as the calibrator. 
Top: the gene expression differences are shown schematically between the four cell types. 
horizontal lines indicate the significance levels (p<0.05) and the error bars represent the 95% 
confidence intervals. Bottom: the raw RMA values are represented for the genes that showed 
significant differential expression in at least one pair-wise comparison. The error bars indicate the 
95% confidence intervals. 
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5.16.3 H3K4 demethylases are misregulated in CML. 
As mentioned earlier, changes in the levels of H3K4me3 and H3K27me3 is a net 
outcome of the chromatin modifiers that are involved in adding and removing 
these histone marks. TrxG and PcG PRC2 complexes are involved with 
incorporating histone methylation, whereas KDM proteins are required for their 
removal (reviewed in Section 1.5.4.5). Consequently, the gene expression levels 
of the KDMs were established in the four cell types. Interestingly, the expression 
levels of H3K27 demethylases, KDM6A and KDM6B, were not significantly 
different between the four cell types (Figure 5.16). This could indicate that the 
losses of H3K27me3 levels at the promoters of bivalent/H3K27me3hi promoters in 
CML cells were not directly linked to abnormalities in the expression levels of 
H3K27 KDMs.  
On the other hand, H3K4 demethylases were shown to be misregulated in CML 
cells (Figure 5.16). KDM5B was the only H3K4 demethylase that was significantly 
abnormally downregulated in LSCs. Furthermore, KDM5A and KDM5B were also 
abnormally downregulated in LPCs. The reduced expression of H3K4 
demethylases could result in increased levels of H3K4me3. However, LSCs and 
LPCs did not show an impairment in removing H3K4me3 marks at the promoters 
of bivalent/H3K27me3hi genes (Figure 5.12). Moreover, KDM1A was the only 
H3K4 demethylase that was significantly upregulated in LPCs. The increased 
levels of KDM1A in LPCs could potentially neutralise the effect of KDM5A and 
KDM5B downregulation. Overall, the effect of abnormalities in the levels of H3K4 
KDMs on the epigenetic regulation of bivalent/H3K27me3hi promoters could be 
part of an integrated network of abnormalities involving both PcG PRC2 and TrxG 
complex proteins.   
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Figure   5.16: Gene expression levels of the KDM proteins in the four cell types. 
The gene expression levels were extracted from the Affymetrix datasets for each cell type and the 
significant expression changes were calculated using the HSC expression levels as the calibrator. 
Top: the gene expression differences are shown schematically between the four cell types. 
horizontal lines indicate the significance levels (p<0.05) and the error bars represent the 95% 
confidence intervals. Bottom: the raw RMA values are represented for the genes that showed 
significant differential expression in at least one pair-wise comparison. The error bars indicate the 
95% confidence intervals.  
Overall, several subunits of the PcG PRC2 and TrxG complexes as well as H3K4 
demethylases were misregulated in CML cells. These abnormalities could be 
linked with the abnormal regulation of bivalent/H3K27me3hi promoters in CML 
cells. However, the significant changes in mRNA levels are not sufficient on their 
own to provide mechanistic links between the abnormal regulation of these 
promoters and the abnormalities in the function of chromatin modifiers. Therefore, 
further analysis is required to establish the changes in the protein levels of 
misregulated chromatin modifiers in addition to elucidating their target specificity 
by ChIP assays in CML cells and their normal counterparts.    
5.17 Discussion 
The work described in this Chapter characterised the histone modification 
signatures of a cancer stem cell for the first time using the developed low-cell ChIP 
method in combination with deep sequencing. The analysis of global H3K4me3 
and H3K27me3 distributions in HSCs, HPCs, LSCs, and LPCs resulted in the 
identification of three major promoter classes based on their epigenetic signatures, 
including H3K4me3, bivalent/H3K27me3hi, and neither modifications. The 
H3K4me3 promoters were significantly enriched for the HPC identity pathways, 
while the bivalent/H3K27me3hi promoters were significantly enriched for the HSC 
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identity pathways. Furthermore, the epigenetic mechanisms associated with the 
regulation of bivalent/H3K27me3hi promoters in CML cells and their normal 
counterparts were investigated. The major findings of this Chapter are discussed 
below.    
5.17.1 LSCs and LPCs showed elevated number of 
bivalent/H3K27me3hi promoters 
The clustering of all annotated promoters in the human genome identified three 
major classes of promoters based on the H3K4me3 and H3K27me3 enrichments 
in all four cell types, including H3K4me3, bivalent/H3K27me3hi, and neither 
modifications. The genes identified in the H3K4me3 promoter class were 
demonstrated to be expressed at significantly higher levels with a more dynamic 
range than the other categories. The bivalent/H3K27me3hi and neither 
modifications categories were associated with low expressed and repressed 
genes, while the bivalent/H3K27me3hi promoters showed the least dynamic range 
of expression. In the course of normal differentiation, HPCs demonstrated 20% 
reduction in the number of bivalent/H3K27me3hi promoters relative to HSCs. 
However, the number of bivalent/H3K27me3hi promoters was increased in LSCs 
and LPCs.      
Bivalent promoters were initially reported in association with the developmentally 
regulated genes in ES cells and were found to be expressed at very low levels 
(Azuara et al., 2006, Bernstein et al., 2006, Guenther et al., 2007, Stock et al., 
2007). Bivalent promoters were demonstrated to be kept at a poised state which 
can provide plasticity for transcriptional regulation in the course of development 
and differentiation (Mikkelsen et al., 2007). The same study also established that 
very few novel bivalent promoters were formed in the course of normal 
differentiation, which was in agreement with the observations in this chapter. The 
pluripotency factors whose function was no longer required in differentiated cells 
were demonstrated to be associated with the progressive resolution of their 
bivalent promoters to H3K27me3 (Cui et al., 2009, Mikkelsen et al., 2007, Mohn et 
al., 2008). Therefore, observing more bivalent bivalent/H3K27me3hi promoters in 
CML cells could imply that LSCs and particularly LPCs maintain a less mature 
phenotype relative to HPCs by keeping a large set of developmentally regulated 
genes poised for longer. 
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Previous reports also supported the identification of other promoter classes, for 
instance H3K4me3 histone modifications were found as sharp peaks over the 
active promoters (Barski et al., 2007, Guenther et al., 2007, Kim et al., 2005). 
Furthermore, the promoters that were not associated with neither H3K4me3 or 
H3K27me3 histone modifications were reported to be located in the CpG poor 
regions which were largely found in association with DNA methylation and were 
therefore transcriptionally silenced (Fouse et al., 2008, Meissner et al., 2008).  
5.17.2 Bivalent/H3K27me3hi genes are enriched for the HSC 
identity pathways 
A cluster of 40 biological pathways were identified which were significantly 
associated with bivalent/H3K27me3hi promoters in the four cell types. Intriguingly, 
9 HSC identity and 7 CML identity pathways were found in this category, which 
were all significantly downregulated at the expression level upon commitment to 
HPCs and/or LPCs. Furthermore, the HPC identity pathways were significantly 
associated with the H3K4me3 promoters in the four cell types. These pathways 
were significantly upregulated upon leaving the HSC compartment. 
The analysis of genome-wide significant differential expression associated with 
each class of promoters, demonstrated that 70% of H3K4me3 promoters were 
associated with the upregulation of expression during normal differentiation. 
Although the upregulation events was favoured to downregulation during HSC-to-
LSC transition, the proportion of upregulated genes were reduced to 60%, 
suggesting a decrease in the activating capacity of these promoters in LSCs. 
However, this activating capacity was restored in LPCs. Consequently, the HPC 
identity pathways, which are linked to proliferation, are required to be associated 
with H3K4me3 promoters in order to be upregulated upon leaving the HSC 
compartment.  
Conversely, the bivalent/H3K27me3hi promoters were mainly associated with 
downregulation of gene expression during normal differentiation. This was in 
agreement with the observed link between these promoters and the HSC identity 
pathways that potentially regulate stem cell maintenance. However, the repressive 
capacity of these promoters was shifted towards activation and upregulation 
during HSC-to-LSC transitions. LPCs demonstrated a regain of repressive 
capacity for these promoters. Therefore, the above observation suggested that 
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there are fundamental differences in the epigenetic regulation of bivalent 
promoters in LSCs. 
Intriguingly, the gene expression changes of the bivalent/H3K27me3hi-enriched 
pathways were also skewed towards activation and upregulation in the HSC-to-
LSC transition. However, the number of downregulated genes were higher than 
the upregulated events in LPCs. Therefore, these results indirectly suggest a 
different epigenetic programming in LSCs and LPCs in the regulation of HSC 
identity pathways from their normal counterparts.  
5.17.3 The Polycomb target genes are regulated differently in 
CML cells.  
The analysis of the bivalent/H3K27me3hi genes that were significantly differentially 
expressed in both HPCs and CML cells upon leaving the HSC compartment, 
revealed that the changes of H3K27me3 levels at these promoters are associated 
with significant up- or downregulation events more profoundly in CML cells. 
Significantly downregulated bivalent/H3K27me3hi genes demonstrated a 
significant increase in the H3K27me3 levels at their promoters in LSCs. 
Additionally, the H3K4me3 levels were significantly reduced at the promoters of 
these genes in LSCs. The results demonstrated a crosstalk between the two 
histone modifications at the promoters of the repressed bivalent/H3K27me3hi 
genes during HSC-to-LSC transition. Intriguingly, the levels of H3K4me3 and 
H3K27me3 marks at the promoters of differentially expressed 
bivalent/H3K27me3hi genes in the LSC-to-LPC transition were not significantly 
altered, suggesting other mechanisms of gene regulation are potentially involved 
in this transition. Thus, it is plausible to suggest that the different epigenetic 
programming at the bivalent/H3K27me3hi promoters in CML is initiated during the 
HSC-to-LSC transition. 
Furthermore, it was demonstrated that resolution of bivalency to H3K4me3 and the 
conversion of H3K4me3 promoters to bivalent during leukaemic transformations 
were linked to significant upregulation and downregulation of gene expression, 
respectively. This phenomenon was not observed in the case of normal 
differentiation. A recent study that investigated the mechanism of gene repression 
during normal development showed that the repressed genes in differentiated cells 
were associated with the expansion of H3K27me3 marks over to the gene bodies 
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(Hawkins et al., 2010). This study also demonstrated the repressed promoters 
were positively correlated with the gain of H3K9me3 marks at their promoters, 
suggesting two different mechanisms involved in suppression of developmentally 
regulated promoters during normal differentiation.  
However, the gains and losses of H3K27me3 at the promoters are linked with 
significant changes of gene expression in CML cells. Thus, the Polycomb PRC2 
complex in CML cells have a more profound role in transcriptional regulation at the 
gene promoters than their normal counterparts.   
5.17.4 Several members of PcG PRC2, TrxG and KDM 
complexes are misregulated in leukaemic cells. 
The results presented in this Chapter indicated a unique epigenetic programming 
of bivalent/H3K27me3hi genes in CML cells which involved the usage of H3K4me3 
and H3K27me3 levels at their promoters to regulate their transcriptional activity. 
Therefore, the differences in the epigenetic programming of these two histone 
modifications between HPCs and CML cells could indicate a different mechanism 
of function for the protein complexes responsible for the addition and removal of 
these histone modifications, which include PcG PRC2 and TrxG complexes as 
well as KDM proteins.   
5.17.4.1 Abnormalities in the levels of PcG PRC2 members 
Analysis of the gene expression levels of the PcG PRC2 members in the four cell 
types, demonstrated profound differences in the levels of two catalytic subunits, 
EZH1 and EZH2, between normal and leukaemic cell types. Both LSCs and LPCs 
displayed significant downregulation of EZH1, which was the more expressed 
catalytic subunit in HSCs, and significant upregulation of EZH2. The levels of 
EZH1 and EZH2 were significantly imbalanced in both LSCs and LPCs, whereas 
HPCs showed similar expression levels for both proteins. The loss of EZH1 in 
LSCs could explain the loss of repressive capacity in bivalent/H3K27me3hi 
promoters. However, significant upregulation of EZH2 in LPCs relative to LSCs 
could provide evidence for the regaining of repressive capacity in the 
bivalent/H3K27me3hi promoters. Furthermore, several other PRC2 subunits were 
also upregulated in LSCs and LPCs that could be important in targeting and 
assembly of the catalytic subunits at the Polycomb target. Overall, the 
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abnormalities at the gene expression levels of PRC2 members may explain the 
epigenetic reprogramming in CML cells that exploit the H3K27me3 levels at the 
gene promoters more efficiently in order to transcriptionally silence or activate 
genes.   
Previous reports indicated that PRC2-deficient ES cells were impaired in their 
differentiation and lineage commitment and therefore, the role of PRC2 in fate 
determination processes was to inactivate the pluripotency-specific factors 
(Chamberlain et al., 2008, Pasini et al., 2007, Shen et al., 2008). The observed 
role of EZH2 in ES cells could explain its upregulation in the course of normal 
differentiation, but whether leukaemic cells also exploit the PRC2 complex in the 
same fashion is not known. However, in a recent study, the deletion of EZH2 was 
linked to the differentiation of AML cells, indicating an oncogenic role for EZH2 in 
AML (Tanaka et al., 2012). The EZH2 double knock-out AML mice exhibited 
increased apoptosis but maintained their proliferative activity. However, the AML 
LSCs were found to be significantly affected and showed impaired function in 
serial transplantation assays. This study showed that the EZH2 activity resulted in 
the maintenance of LSCs through blocking differentiation mechanisms. Therefore, 
it was suggested that LSCs were more dependent on EZH2 function than the 
normal HSCs (Tanaka et al., 2012). Recent studies also provided evidence for the 
role of bivalent promoters during cancer in which these promoters showed a 
higher tendency for becoming abnormally hypermethylated (Rodriguez et al., 
2008, Widschwendter et al., 2007). It was suggested that bivalent promoters in 
adult stem cells were more likely to gain DNA methylation which could result in the 
formation of self-renewing tumour cells that exhibit reduced differentiation 
capacities (Widschwendter et al., 2007). 
Based on the observations in this chapter and the role of EZH2 during normal 
differentiation and AML formation, a model of action for EZH2 can be proposed in 
CML. LSCs could be more dependent on the EZH2 function that their normal 
counterparts as a result of significant downregulation of EZH1. However, the exit 
from stem cell compartment in CML is potentially mediated by the increased 
activity of EZH2 that could in turn repress bivalent/H3K27me3hi promoters many of 
which associated with the HSC identity. Although the suppression of the HSC 
identity pathways in LSCs is potentially a key event in initiating the development of 
LPCs, as discussed in Chapter 3, the elevated levels of bivalent/H3K27me3hi 
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genes in LPCs could be indicative of their less differentiated phenotype than their 
normal counterparts. However, the link between EZH2 upregulation and the 
suppression of differentiation-related genes could not be directly verified in this 
Chapter. Thus, it is plausible to hypothesise a model in which the abnormal 
epigenetic programme in LSCs is initiated by the loss of EZH1, but the exit from 
stem cell compartment in LPCs is mediated by the increase in the EZH2 levels.    
5.17.4.2 Abnormalities in the levels of TrxG members 
Analysis of the TrxG complex also identified several misregulated members in 
CML cells. MLL and ASH1L catalytic subunits were found to be significantly 
downregulated in LSCs. MLL protein has been reported to have an important role 
in the resolution of bivalency to H3K4me3 promoters by recruiting H3K27 
demethylases (Agger et al., 2007, Lee et al., 2007). One study demonstrated an 
increase in H3K27me3 levels at the bivalent promoters in MLL knock-out neural 
stem cells (Lim et al., 2009). Therefore, the downregulation of MLL in LSCs could 
potentially explain the significant increase in H3K27me3 levels and decrease in 
H3K4me3 levels at the promoters of repressed bivalent/H3K27me3hi genes.  
Furthermore, ASH1L was also reported to indirectly counteract PRC2 function as a 
result of H3K36 methylation (Yuan et al., 2011). Therefore, the significant 
downregulation of ASH1L in LSCs could result in an increase in the levels of 
H3K27me3 in certain loci.   
In addition to the downregulation of catalytic subunits of TrxG complex, several 
accessory subunits were significantly abnormally upregulated in leukaemic cells. It 
was reported that the stability, the catalytic activity and the recruitment of the 
H3K4 methyltransferases were largely dependent on their core subunits (Dou et 
al., 2006). Therefore, the abnormalities in the levels of these proteins in CML cells 
could result in abnormalities in target specification and the activity of catalytic 
subunits in a complex manner. Consequently, in order to better elucidate the 
impact of above abnormalities, the binding sites of the misregulated subunits 
should be investigated in vivo in CML cells.  
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5.17.4.3 Abnormalities in the levels of H3K4 demethylases 
The regulation of H3K4me3 in CML cells could be more complicated as several 
H3K4 demethylases were found to be misregulated in LSCs and LPCs. KDM5A 
and KDM5B which were significantly downregulated in leukaemic cells were 
previously reported to be associated with bivalent promoters. KDM5A, in 
particular, was shown to be recruited by PRC2 complex to the target genes and 
causing bivalency resolution to H3K27me3 (Pasini et al., 2008). Furthermore, 
KDM5B was also identified at the TSSs of bivalent genes and its depletion 
resulted in a global increase of H3K4me3 (Schmitz et al., 2011). KDM5B was 
found to share many PRC2 targets, although a direct interaction between PRC2 
and KDM5B was not detected. Thus, the reduction in the levels of KDM5A and 
KDM5B in leukaemic cells could result in an increase in the levels of H3K4me3 at 
bivalent promoters. Although a global increase in the levels of H3K4me3 was not 
observed at the bivalent/H3K27me3hi promoters in LSCs and LPCs, the 
upregulated bivalent/H3K27me3hi genes in LSCs demonstrated increased levels of 
H3K4me3. Therefore, these promoters could be the specific target of these KDMs. 
Furthermore, the loss of repressive power at the bivalent/H3K27me3hi promoters 
in LSCs and their shift towards gene activation could also be induced by the 
reduced expression of KDM5B in LSCs. 
Nevertheless, KDM1A, which is known to be a key player in stem cell maintenance 
by controlling the H3K4me3 levels at bivalent promoters (Adamo et al., 2011), was 
significantly upregulated in LPCs. Therefore, it is plausible to suggest that LPCs 
compensate for the depletion of KDM5A and KDM5B by upregulating the 
expression of KDM1A. Consequently, this could also contribute to the regaining of 
repressive capacity at the bivalent/H3K27me3hi promoters in LPCs.  
5.18 Conclusion 
The work presented in this Chapter demonstrated histone modification signatures 
of a cancer stem cell for the first time. It also provided crucial evidence that the 
HSC identity pathways, which potentially regulate stem cell maintenance, were 
significantly associated with the bivalent/H3K27me3hi genes. Furthermore, the 
bivalent/H3K27me3hi promoters in LSCs showed reduced repressive capacities 
which were restored in LPCs. The results indicated abnormal epigenetic 
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programming in CML cells, which was initiated during the HSC-to-LSC transition. 
The differential expression of bivalent/H3K27me3hi genes in CML cells was 
associated with significant changes of H3K27me3 and H3K4me3 levels at their 
promoters. This mechanism was profoundly different from their normal 
counterparts. The significant reduction in EZH1 levels in LSCs was suggested to 
be the underlying mechanism for the loss of repressive capacity in 
bivalent/H3K27me3hi genes, whereas the significant increase in EZH2 levels could 
explain the regaining of this repressive capacity. Furthermore, abnormalities in the 
levels of TrxG complex members and H3K4 demethylases could have further 
impact in the regulation of bivalent/H3K27me3hi promoters and the significant 
changes in the levels of H3K4me3 marks. Overall, there is a global epigenetic 
reprogramming in CML cells which have a significant impact on transcriptional 
regulation in these cells which can be linked to the differences observed in terms 
of global regulation of gene expression changes in Chapter 3. 
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6. Neurotransmitter signalling pathways maintain 
stem cell features of CML stem cells 
6.1 Abstract 
In Chapter 3 of this thesis, genome-wide gene expression analysis implicated 
several novel neurotransmitter pathways in the maintenance of HSCs. These 
pathways exhibited similar expression levels in LSCs when compared to HSCs – 
suggesting that they also played a role in the stem cell phenotype of LSCs. This 
Chapter investigates the roles that neurotransmitters may have in maintaining the 
LSC phenotype. Acetylcholine, norepinephrine, serotonin, histamine, and 
glutamate were added to cultures of CML stem cells and their effects on 
quiescence and the ability to maintain a primitive stem cell phenotype in replating 
assays were measured. Neurotransmitter signalling pathways also show a large 
overlap with heterotrimeric G protein core signalling pathways – and the ability of 
neurotransmitters to modulate these pathways was also tested. The in vitro 
functional assays performed in this Chapter demonstrated that LSCs respond to 
these neuroactive molecules through cell cycle arrest as well as increasing their 
self-renewal capacity as observed in replating assays. These observations were 
found to be independent of apoptosis or toxicity-induced cell cycle arrest. 
Furthermore, the activity of neurotransmitter signalling pathways was 
demonstrated to be associated with the activation of genes of heterotrimeric G 
protein signalling pathways and the upregulation of cell cycle inhibitors such as 
ID1 and p21/CDKN1A which are important in the maintenance of the quiescent 
stem cell phenotype.    
6.2 Introduction 
Neuropeptides such as acetylcholine, catecholamines, serotonin, glutamate, 
histamine, endothelin, and angiotensin II stimulate various cellular functions 
through activating their respective G protein-coupled receptors GPCRs. In addition 
to neurotransmission, the GPCRs are associated with numerous other 
physiological functions such as immune response, hormone release, cardiac and 
smooth muscle contraction, and blood pressure. They are also linked to many 
human diseases and are reported to be direct or indirect targets of 50-60% of all 
current drugs (Pierce et al., 2002). Misregulation and malfunction of GPCRs have 
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been found during cancer progression and metastasis. The tumour cells were 
shown to abnormally exploit GPCRs to evade immune surveillance, proliferate 
autonomously, invade the surrounding tissues and metastasise to other organs, 
and enhance their uptake of oxygen and nutrients. The abnormal overexpression 
of GPCRs and/or activating mutations of G proteins are the major events causing 
the overt activation of GPCR signalling in tumours which could be further 
increased by the release of ligands produced by tumours themselves or their 
stromal microenvironment. Therefore, abnormal GPCR function in cancer provides 
opportunities for developing novel chemotherapeutic targets (Dorsam and Gutkind, 
2007).   
The GPCRs are a transmembrane protein family comprised of approximately 
1,000 members which all share a conserved 7-transmembrane domain structure. 
The GPCRs undergo a conformational change in their transmembrane and 
intracellular domains upon binding to their ligands which results in interaction with 
heterotrimeric G proteins. This change of conformation converts the GPCRs into 
guanine nucleotide exchange factors (GEFs) for the α subunits of heterotrimeric G 
proteins, promoting guanosine triphosphate (GTP) binding by facilitating the 
release of guanosine diphophate (GDP) and therefore, activating G proteins. The 
activated α   subunit   in   conjunction   with   β   and   γ subunits will bind various 
downstream effectors to mediate a variety of cellular responses. The α subunits of 
G proteins are found in multiple subtypes such as Gαi/o, Gαs, Gαq, and Gα12/13. The 
downstream effectors also vary dependent on the Gα  subtype,  including  adenylyl  
cyclase,   phospholipase   Cβ   (PLCβ),   and   Rho-GEF. The effectors directly or via 
second messengers such as cyclic adenosine monophosphate (AMP), 
diacylglycerol (DAG), and inositol-1,4,5-triphosphate (Ins(1,4,5)P3) regulate 
downstream effectors, including protein kinase A (PKA) and protein kinase C 
(PKC).   After   dissociation   of   heterotrimeric   G   proteins,   the   βγ   subunits   can  
modulate  other  downstream  effectors  such  as  PLCβ  and  ion  channels   (Ritter and 
Hall, 2009) (Figure 6.1). Table 6.1 demonstrates the association between different 
GPCRs  and  α subunit families and their reported mechanisms of action.  
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Figure   6.1: The mechanism of heterotrimeric G protein activation and downstream effectors 
by the ligand-bound GPCRs. 
Schematic diagram depicts the mechanism of heterotrimeric G protein activation upon binding the 
agonist to the 7-transmembrane GPCRs. The GPCR activation results in the substitution of GDP 
with GTP in the α subunit of heterotrimeric G proteins. Different subtypes of α   subunit   (yellow  
circles) are linked with the activation or inhibition of different downstream effectors (green boxes) 
which in turn activate another set of downstream effectors (red boxes) directly or via the second 
messenger   system   (blue   boxes).   The   dissociated   βγ   subunits,   upon   agonist   binding,   are   also  
capable  of  activating  downstream  effectors  through  PLCβ  or  activating  the  ion  channels  in  the  cell  
membrane. 
 
Table   6.1: The α subunit families and their mechanism of action. 
The four major α subunit families αi/o, αs, αq, α12/13 are listed along with less frequent α subunit 
families associated with olfactory receptors (αolf) and rhodopsin (αt). The mechanism of action of 
each family and their associated GPCRs are also listed. The last column shows the gene names of 
the α subunits in each family (Ritter and Hall, 2009).  
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The ligand-bound GPCRs can also become phosphorylated as a result of 
interaction with GPCR kinases (GRKs). Upon phosphorylation, GPCRs limit their 
interaction with G proteins and increase their association with the scaffold proteins 
known as arrestins which inhibit G protein-mediated GPCR signalling (Reiter and 
Lefkowitz, 2006). Activation of arrestins could enhance the endocytosis of active 
GPCRs by clathrin-coated pits to regulate the desensitisation and resensitisation 
of GPCRs (Hanyaloglu and von Zastrow, 2008) (Figure 6.2). The internalised 
arrestin-bound GPCRs could activate distinct signalling pathways via arrestin 
proteins such as MAPK and ERK pathways. Recent reports indicate that different 
agonists have preferences for arrestin-mediated GPCR signalling over the G 
protein-mediated signalling pathways, or vice versa (Urban et al., 2007). 
 
Figure   6.2: Arrestin-mediated desensitisation and resensitisation of activated GPCRs. 
Activated GPCRs can be phosphorylated by GRKs that in turn favour arrestins over heterotrimeric 
G proteins in a process known as desensitisation. The association of arrestins results in 
internalisation of GPCRs via clathrin-coated pits and endocytosis of GPCRs. The internalised 
GPCRs can be recycled and re-presented to the cellular membrane in a process known as 
resensitisation or targeted to lysosomes for degradation. Furthermore, the arrestin-bound 
internalised GPCRs can activate several other intracellular pathways such as MAPK or ERK via 
arrestin proteins. 
The link between abnormal activation of neurotransmitter receptors and tumour 
progression was established in early studies, including serotonin and acetylcholine 
GPCRs (Gutkind et al., 1991, Julius et al., 1989). Furthermore, the abnormal 
activation of endothelin receptors and angiotensin II receptors was identified in 
prostate cancer and found to be associated with high levels of the ligands in 
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plasma (Daaka, 2004). The antagonists of these receptors caused growth arrest in 
prostate tumour cells both in vitro and in vivo (Daaka, 2004). The activation of 
neuropeptide GPCRs in some cases results in the activation of PKC via Gαq 
subunit (Heasley, 2001). However, further investigations showed that 
neuropeptide signalling can trigger activation of ERK, MAPK, and Rho GTPases 
(Marinissen et al., 2001). Therefore, activation of neuropeptide receptors via 
autocrine and/or paracrine routes stimulates an interconnected network of 
intracellular pathways that lead to the survival and/or proliferation of tumour cells 
(Dorsam and Gutkind, 2007).  
Despite the suggested role of neuropeptide signalling via heterotrimeric G proteins 
in cancer progression, their function in the maintenance of cancer stem cells has 
not been studied to date. The work presented in previous chapters, however, 
provided compelling in vitro evidence regarding involvement of several 
neuropeptides in the maintenance of LSCs, at both the epigenetic and gene 
expression levels; and these neuropeptides are also likely to be associated with 
HSC maintenance. Therefore, the work presented in this Chapter was to further 
investigate the role of neurotransmitter signalling pathways in stem-cell 
maintenance in the context of LSCs in the presence of stromal cells that partially 
mimic the bone marrow microenvironment in vitro.  
6.3 Aims of the Chapter 
1. To determine whether neuropeptides are capable of promoting stem cell 
features of LSCs, including quiescence and self-renewal.  
2. To begin to understand the relationships between neuropeptides, stem cell 
features of LSCs and intracellular signalling pathways linked via 
heterotrimeric G-proteins.  
Results 
6.4 Overall strategy 
Flow-cytometry isolated primary LSCs (CD34+ CD38-) were first stained with CFSE 
and then cocultured in vitro in the presence of mouse OP9-GFP stromal cells. 
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Mouse OP9 cells were used as the stromal support as they have previously been 
shown to successfully induce differentiation of mouse and human ES cells into 
haemopoietic cells, including CD34+ cells (Kodama et al., 1994, Vodyanik et al., 
2005). OP9 cells were shown to promote haemopoiesis by specifically promoting 
the survival and proliferation of primitive and clonogenic CD34+ cells, but not the 
mature CD34- population (Ji et al., 2008); therefore, providing a unique in vitro 
microenvironmental support that promotes haemopoiesis in a similar hierarchical 
manner to the bone marrow niche.   
Acetylcholine, norepinephrine, serotonin, L-glutamate and histamine 
neuropeptides were added to the coculture in independent assays on day 0, 
alongside untreated control. After 72 hrs, the GFP- CML cells were isolated from 
the GFP+ stromal cells by FACS in each condition, and the progression of cells 
through divisions (CFSE) was investigated. Furthermore, after 72 hrs the CD34+ 
CD38- CML cells were isolated and cultured in semi-solid methylcellulose-based 
medium to analyse the colony forming potential (CFC assay) of the treated and 
untreated cells as indicators of haemopoietic cell growth and differentiation. 
Subsequently, replating assays were performed using the colonies obtained from 
the CFC assays to investigate the self-renewal capacities of CML cells in the 
presence and absence of each neurotransmitter. The CD34+ CD38- CML cells 
which demonstrated an enhanced self-renewal and/or quiescence in the presence 
of each neurotransmitter were analysed further at the level of gene expression to 
identify the activity of downstream heterotrimeric G protein signalling pathway and 
various cell cycle regulators (Figure 6.3). 
 
Figure   6.3: The overall strategy in functional validation of novel neurotransmitter signalling 
pathways in the context of CML stem cells. 
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The schematic diagram shows the major steps in the functional validation of several neuropeptides 
in the maintenance of LSC features such as quiescence and self-renewal, as well as their effect on 
cell growth and proliferation after 72 hrs of treatment in the presence of agonists. Gene expression 
signatures of several downstream effectors were investigated to validate the intracellular activity of 
neurotransmitter signalling pathways.  
6.5 Heterotrimeric  Gα  protein  signalling  pathway  shows  
HSC-like epigenetic signature in LSCs  
The gene expression analysis in Chapter 3 revealed that the expression levels of 
12 HSC identity pathways did not change significantly between HSCs and LSCs, 
suggesting potential roles for these pathways in the maintenance of stem cell 
features in LSCs. Furthermore, it was also important to identify the pathways that 
showed an HSC-like epigenetic signature in LSCs, which in turn may have a role 
in the maintenance of stem cell features of LSCs. Therefore, the genes that 
showed similar epigenetic signature in both HSCs and LSCs, but were associated 
with a different epigenetic signature in HPCs were identified (Figure 6.4A). 
Intriguingly, the bivalent/H3K27me3hi genes demonstrated the largest number of 
genes that were associated with an HSC-like signature in LSCs. Subsequently, 
pathway analysis was performed for the genes with HSC-like epigenetic signature 
using PANTHER database, similar to the pathways analyses performed for 
different promoter classes in Chapter 5. This analysis identified 18 biological 
pathways that were significantly (p<0.05) associated with the genes that showed 
HSC-like epigenetic signature in LSCs (Figure 6.4B). The top two most 
significantly over-represented pathways in this list were the heterotrimeric G 
protein-mediated  signalling  via  Gαi,  Gαs, Gαq and Gαo subunits. Additionally, Wnt 
signalling, cadherin signalling, glutamate signalling via ionotropic and metabotropic 
receptors, acetylcholine signalling via muscarinic and nicotinic receptors, 
endothelin signalling, and GABA-B receptor signalling were also found to be over-
represented in this list. This analysis identified several new signalling pathways 
mainly associated with neurotransmitters that could be potentially involved in the 
maintenance of stem cell features in LSCs.   
Furthermore, since the heterotrimeric Gα protein signalling pathways were the 
most over-represented pathway in the above analysis, the overlap between the 
genes in these pathways and other signalling pathways were investigated (Figure 
6.4C). As was expected, many neurotransmitter signalling pathways showed a 
large overlap with the heterotrimeric Gα protein signalling, suggesting that the Gα 
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protein signalling serves as downstream effector of these neurotransmitters. 
Seven neurotransmitter HSC identity pathways that were identified at the level of 
gene expression (Chapter 3) were shown to have a large overlap with the 
heterotrimeric Gα protein signalling pathways, including serotonin signalling via 
5HT2 receptors, histamine signalling via H1 receptor, α-adrenergic receptors 
signalling, acetylcholine signalling via muscarinic receptors 1 and 3, angiotensin II, 
oxytocin, and TRH signalling pathways (Figure 6.4C).  
Overall, the above results demonstrated a noticeable overlap between the 
pathways that were identified at the level of gene expression and epigenetics 
which could be associated with the maintenance of stem cell features in LSCs. 
Additionally, through epigenetic analysis several novel neurotransmitter signalling 
pathways were identified, such as glutamate signalling pathways, which may also 
be important in the maintenance of stem cell like features in LSCs. Therefore, in 
order to verify whether this comprehensive study, which combined gene 
expression and epigenetic analyses, could identify novel signalling pathways that 
control LSC maintenance, the role of serotonin, acetylcholine, catecholamines (α-
adrenergic receptors), histamine, and glutamate signalling pathways were 
investigated in vitro (Section 6.5). 
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Figure   6.4: Pathways that showed HSC-like epigenetic signature in LSCs. 
(A) The histogram shows the number of transcripts (y-axis) which have a similar epigenetic 
signature in both HSCs and LSCs (right), but have a different epigenetic signature in HPCs (left). 
The fates of the genes that did not show similar epigenetic signatures in HPCs are also indicated. 
The bivalent/H3K27me3hi genes demonstrated highest number of transcripts with HSC-like 
epigenetic signature in LSCs, which were resolved to neither modifications or H3K4me3 in HPCs. 
(B) The pathways that were significantly over-represented for the genes associated with the HSC-
like epigenetic signature in LSCs. The heterotrimeric (Ht3) Gα protein signalling pathways were the 
top two hits (highlighted in red). (C) The pathways that showed a large degree of overlap (black 
bars) with the Ht3 Gα protein signalling pathways. The HSC identity pathway are marked with 
asterisks. The total number of genes in each pathway is also represented (y-axis).   
6.6 Investigating the role of neurotransmitters in 
maintenance of stem cell features in LSCs  
The role of neurotransmitters in the maintenance of LSCs was investigated in vitro, 
as described in Chapter 2. Briefly, confluent cultures of GFP-tagged OP9 mouse 
stromal cells were established in collagen-coated plates and the flow cytometry-
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isolated primary LSCs (CD34+ CD38- population) from three different patient 
samples (bioreplicates) were cocultured in the presence or absence of each 
neuropeptide agonist for 72 hrs. The CD34+ GFP- CML cells were subsequently 
isolated from the GFP+ OP9 cells by flow cytometry (Figure 6.6) and the effect of 
neuropeptides on cell division progression, colony forming potential, and self-
renewal capacities upon replating assays were assessed in comparison to the no-
drug control (NDC). Furthermore, CD34+ CD38- CML cells were isolated in each 
condition to investigate the gene expression levels of the heterotrimeric Gα protein 
signalling pathway as further confirmation of the activity of neurotransmitter 
signalling and their effect on cell cycle regulation.  
 
Figure   6.5: The flow-cytometry isolation of CML cells from the OP9-GFP stromal cells after 
72 hrs of coculture. 
The live CML cells were initially separated from the OP9 stromal cells based on their smaller size 
(left). Subsequently, the contaminating GFP-tagged OP9 cells were filtered out by excluding the 
GFP+ (FITC+) cells. The GFP- CML cells were then used for the downstream analysis.  
The concentration of each neuropeptide agonist was chosen based on previously 
reported results using primary cells, although some of the agonists were not 
reported in the context of haemopoietic cells and therefore, the choice of 
concentration was made based on the best physiological response in other 
tissues. To induce muscarinic acetylcholine receptors, the acetylcholine agonist 
was applied at 100nM (Al-Zi'abi et al., 2009). For induction of α-adrenergic 
receptors, norepinephrine was used at 1μM (Spiegel et al., 2007). 5HT2 type 
receptors were stimulated by applying serotonin at 5μM (Ebrahimkhani et al., 
2011). L-glutamate was used as an agonist which triggers both ionotropic and 
metabotropic type receptors at 10μM (Porras and Stutzin, 2011). Histamine, which 
is capable of activating all histamine receptors, was administered at 100μM 
(Szukiewicz et al., 2009).  
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6.6.1 The effect of neurotransmitters on LSC quiescence 
The effects of neurotransmitters on the maintenance of quiescence and the 
regulation of cell division were measured by using CFSE intracellular fluorescence 
dye, as described in Chapter 2, and evaluating the number of cell divisions that the 
cells underwent after 72 hrs in comparison with the no drug control (NDC) (Figure 
6.7). 
 
 
Figure   6.6: Analysis of cell division progression (CFSE) in the presence of 
neurotransmitters. 
(A) Histograms representing the intensity of CFSE after 72 hrs in the presence or absence of 
agonists in three different CML samples. The dotted red line represents the intensity of CFSE in the 
colcemid-treated sample which indicates the position of the undivided populations. The no-agonist 
control (NDC) is shown in blue. The arrow indicates the shift in the fluorescence intensity (x-axis) of 
LSCs upon neurotransmitter treatments relative to NDC. (B) The percentage recoveries of CD34+ 
cells in undivided and each cell division were normalised against the percentage of CD34+ recovery 
in the NDC condition. (C) The total percentage recovery of the CD34+ CD38- input cells was 
normalised against the total percentage recovery of input in the NDC condition. The data represent 
the average of three bioreplicates and the error bars indicate the standard error of mean. The non-
overlapping error bars from each condition with the NDC value were assigned significant. ACH, 
acetylcholine; NEPI, norepinephrine; 5HT, serotonin; GLU, L-glutamate; HIS, histamine. 
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The fluorescence intensity of undivided populations was determined by the 
intensity of the colcemid-treated CFSE+ LSCs which were blocked in their cell 
division progression by colcemid (Figure 6.7A). Intriguingly, the effect of 
neurotransmitters on the progression of cell division varied between CML samples 
due to the potential heterogeneity between LSC populations. The first bioreplicate 
showed a considerable shift towards the undivided population in the presence of 
neurotransmitters, whereas the other two bioreplicates only showed small shifts in 
the presence of agonists, possibly due to their less proliferative characteristics as 
could be observed by their distance from the undivided population.    
When the results of all three bioreplicates were analysed together, the percentage 
of CD34+ cells in the undivided population was only marginally higher than NDC, in 
the presence of ACH, NEPI, 5HT, and HIS (Figure 6.7B). The percentage of 
CD34+ cells was noticeably higher in the first and second divisions of all 
neurotransmitter conditions as compared to NDC. Furthermore, 5HT, GLU, and 
HIS showed noticeable reduction of cells in the fourth and fifth divisions, in 
addition to ACH treatment which also showed a noticeable reduction of cells in the 
fifth division as compared to NDC. Any effect of NEPI treatment did not noticeably 
affect the percentage of CD34+ cells in the third, fourth, and fifth divisions. The 
observed differences in the presence of agonists were not due to noticeable 
increases or decreases in the total percentage of recovered input cells (CD34+ 
CD38-) with respect to the NDC condition (Figure 6.7C); thus, excluding toxicity of 
the agonists at the administered concentrations as an explanation for the 
noticeable changes detected. The above observations suggested that the 
neurotransmitter treatments resulted in reduced cell division progression and 
induced quiescence as the percentage of CD34+ cells was increased in earlier 
divisions and dropped at later divisions, particularly in the case of ACH, 5HT, GLU, 
and HIS. NEPI treatment, on the other hand, only increased the percentage of 
cells in the undivided population and the first two divisions without noticeably 
affecting later divisions.  
6.6.2 The effect of neurotransmitters on colony forming potential 
and self-renewal 
CFC assays were established after 72 hrs of treatment with agonists or NDC on a 
semi-solid methylcellulose medium. The total number of colonies generated after 
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10 days was counted under a microscope and the effect of each condition on 
increasing or decreasing colony forming potentials of LSCs was evaluated relative 
to NDC (Figure 6.9A). Furthermore, 50 colonies were plucked at random and 
replated onto a semi-solid methylcellulose medium to investigate their self-renewal 
capacities. The total number of colonies and their type in each condition were 
analysed under a microscope after 10 days and compared to NDC (Figure 6.9B-
D). 
NEPI was the only neuropeptide that significantly increased the total number of 
colonies in the CFC assays relative to NDC (Figure 6.9A). On the contrary, HIS 
was the only neurotransmitter that significantly reduced the colony forming 
potential of LSCs. Any changes under the other agonists did not achieve 
significance. ACH, NEPI, and 5HT enhanced the self-renewal capacities of LSCs 
as measured by the significantly increased number of colonies during replating 
assays (Figure 6.9B). NEPI was the only neuropeptide to significantly increase 
both granulocytic (CFU-GM) and erythroid (CFU/BFU-E) types of colonies, 
whereas ACH and 5HT treatments resulted only in the significant increase of 
erythroid colonies (Figure 6.9C-D). GLU treatment also caused a marginally 
significant increase in the number of erythroid colonies post-replating. 
Furthermore, the types of observed colonies in the ACH, 5HT, and NEPI 
treatments were bulkier and larger, which were indicative of more primitive types 
of colonies, than the types of colonies observed in the presence of GLU, HIS, or 
NDC (Figure 6.9E). The above results indicated a potential role in the self-renewal 
maintenance of LSCs for ACH, 5HT, and NEPI. 
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Figure   6.7: Investigating the colony-forming potential and self-renewal capacities of LSCs 
upon treatment with neurotransmitters. 
(A) Averaged normalised total number of colonies generated in the CFC assays under each 
condition relative to NDC, which were obtained from three independent assays. The average total 
number of colonies in each condition was: NDC (n=144), ACH (n=181), NEPI (n=212), 5HT 
(n=155), GLU (n=147), HIS (n=134) (B) Averaged normalised total number of colonies post-
replating from three independent assays. The average total number of colonies in each condition 
was: NDC (n=42), ACH (n=52), NEPI (n=60), 5HT (n=47), GLU (n=40), HIS (n=42). (C) Averaged 
normalised total number of granulocytic colonies (CFU-GM) post-replating from three independent 
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assays. The average number of CFU-GM colonies in each condition was: NDC (n=26), ACH 
(n=32), NEPI (n=39), 5HT (n=27), GLU (n=22), HIS (n=27). (D) Averaged normalised total number 
of erythroid colonies (CFU/BFU-E) post-replating from three independent assays. The average 
number of CFU/BFU-E colonies in each condition was: NDC (n=14), ACH (n=19), NEPI (n=17), 
5HT (n=19), GLU (n=16), HIS (n=13). The error bars indicate standard error of mean. The error 
bars which did not overlap with the NDC value were assigned significant and marked with 
asterisks. (E) The post-replating colonies in each condition as observed under microscope (4X 
magnification). Two colonies are shown for each condition from two independent assays. The 
larger and bulkier that can be observed in the case of ACH, NEPI, and 5HT contained both CFU-
GM and CFU-E colonies (CFU-GEMM), whereas the NDC, GLU, and HIS colonies were mainly 
associated with the smaller type of colonies of either CFU-GM or CFU-E.  
6.6.3 The effect of neurotransmitters on the activation of 
heterotrimeric G protein signalling pathway 
The effect of neurotransmitter treatment on the activation of heterotrimeric G 
protein-mediated signalling pathway as well as their unique downstream effectors 
was investigated by TaqMan RT-PCR performed on the Fluidigm gene expression 
platform, as described in Chapter 2. ACH, NEPI and 5HT neurotransmitters 
noticeably enhanced the self-renewal capacity of LSCs. Consequently, in order to 
further elucidate the mechanism of self-renewal and quiescence induction by 
these neurotransmitters the differential expression of the genes in the 
heterotrimeric G protein signalling pathway and several cell cycle regulators were 
analysed in CD34+ CD38- CML cells treated with ACH, NEPI or 5HT and 
compared to NDC (Figure 6.10).  
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Figure   6.8: Gene expression analysis of the core heterotrimeric G protein signalling 
pathway in response to neurotransmitter treatments. 
This histograms demonstrate the log2 fold change of expression for the genes in the heterotrimeric 
G protein signalling pathway and cell cycle and apoptotic regulators in the presence of (A) ACH, 
(B) NEPI, and (C) 5HT relative to NDC. The error bars indicate the standard error of mean. The 
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error bars which were not overlapping with the x-axis were considered as significant. (D) The 
schematic representation of the activated (red) and repressed (green) genes in each condition. The 
grey boxes indicate no significant change relative to NDC. (E) The proposed model of 
heterotrimeric G protein core activation by neurotransmitters which resulted in the upregulation of 
ID1 and p21/CDKN1A genes in LSCs.  
The gene expression analysis of core G protein signalling pathway (Figure 6.10) 
showed that ACH treatment induced the expression of 18 genes out of 25 tested 
genes in this pathway (72%), including the muscarinic cholinergic receptor 3 
(CHRM3). Furthermore, NEPI induced the expression of 13 genes (52%) in the G 
protein signalling pathway, including alpha-2a adrenergic (ADRA2A) and beta-2 
adrenergic (ADRB2) receptors. ACH and NEPI induced the expression of several 
PKC subunits such as PRKCE and PRKCH as well as the cAMP-dependent 
protein kinase catalytic subunit alpha (PRKACA), which is downstream of cAMP 
second messenger. However, NEPI treatment showed the specific activation of 
PLCβ (PLCB1) while ACH treatment specifically activated PLCγ genes, PLCG1 
and PLCG2, which indicated a preferential usage of the downstream effectors by 
these neuropeptides. On the contrary, the 5HT treatment resulted largely in the 
repression of G protein core pathway by silencing eight genes (32%) as opposed 
to activating only two genes. PRKACA, PRKCH, and PLCG2 showed significant 
downregulation upon 5HT treatment, whereas the other PLC and PKC genes did 
not change significantly, which suggested a mechanism of action for 5HT 
independent of PKA and PKC activation.  
ACH, NEPI, and 5HT treatment resulted in the upregulation of p21/CDKN1A and 
ID1, which are important in the maintenance of self-renewal and quiescence in 
HSCs (Cheng et al., 2000, Perry et al., 2007). Therefore, it was plausible to 
deduce a common mechanism of action for these neurotransmitters in conferring 
stem cell-like phenotype to LSCs. Additionally, NEPI upregulated p27/CDKN1B, 
another cell cycle inhibitor important in HSC maintenance (Dao et al., 1998), and 
downregulated CCND1, which promotes the cell cycle progression.  
The above observations led to a model (Figure 6.10E) in which ACH and NEPI 
activate the core heterotrimeric G proteins which in turn result in the activation of 
p21/CDKN1A and ID1 genes that maintain the stem cell phenotype of LSCs, as 
shown by their induced quiescence and self-renewal capacities. However, while 
this model supports the data obtained from the expression analysis, the 
mechanism by which this occurs could not be elucidated. 
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6.7 Discussion 
Several novel neurotransmitter pathways with potential role in the maintenance of 
stem cell features in LSC were identified in this study at the level of gene 
expression and epigenetics. These neurotransmitters included ACH, NEPI, 5HT, 
HIS, and GLU. In this Chapter the role of these neurotransmitters in the regulation 
of LSCs self-renewal and quiescence was investigated in vitro in the presence of 
stromal cells. It was demonstrated that these neurotransmitters reduced the cell 
division progression rate of LSCs and subtly increased the number of cells in G0 
compartment in comparison to untreated condition. Furthermore, ACH, NEPI and 
5HT treatments increased the self-renewal capacities of LSCs as observed in 
replating assays. The gene expression analyses of LSCs treated with ACH and 
NEPI showed significant upregulation of several genes in the heterotrimeric Gα 
protein signalling pathway as well as cell cycle regulators p21/CDKN1A and ID1. 
6.7.1 Neurotransmitters appear to reduce the cell division 
progression rate of LSCs 
The above results, therefore, suggest a potential role for the studied 
neurotransmitters in reducing cell division progression rate. Ideally with the 
heterogeneity observed in terms of response further samples should be analysed 
and an attempt made to uncover any features of individual samples or patients 
that may make them more or less susceptible to neurotransmitter signalling.  
Although the above results indicated that CML cells could progress, albeit at a 
slower rate, through cell division even in the presence of neurotransmitters, the 
self-renewing or differentiating nature of these divisions was not investigated here 
but would be very interesting to explore. Numb, a protein that can be inherited 
asymmetrically during differentiation, was used in a recent CML study and it was 
demonstrated that the low expression levels of Numb were associated with the 
more primitive cell types, whereas its upregulation was associated with 
differentiation mechanisms (Ito et al., 2010). To further investigate the influence of 
neurotransmitters on the ratio of self-renewing to differentiating cell divisions, the 
presence of membrane-bound Numb could be investigated during agonist 
treatments by immunofluorescence assays and compared to the NDC condition. 
However, due to the limited number of LSCs per condition and time constraints 
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immunofluorescence staining was not performed in parallel with the other 
downstream assays in this body of work.    
6.7.2 ACH, NEPI, and 5HT appear to increase the self-renewal 
capacities of LSCs 
ACH, NEPI, and 5HT agonists caused significant increases in the total number of 
colonies post replating which indicated their potential role in the maintenance of 
LSCs self-renewal. NEPI was the only neuropeptide to significantly increase both 
granulocytic (CFU-GM) and erythroid (CFU/BFU-E) types of colonies after 
replating, whereas ACH and 5HT significantly induced differentiation towards 
erythroid colonies.  
Previous studies provided evidence for the role of adrenergic signalling pathways 
in haemopoiesis. In a study by Fonesca et al, an increased level of erythropoiesis 
was observed upon treatment of BM MNCs in vitro with NEPI at 100 nM, whereas 
higher concentrations (>1 mM) completely blocked erythropoiesis (Fonseca et al., 
2005). Furthermore, stimulation of adrenergic signalling pathway by NEPI in 
human HSCs induced BM repopulation via activating the canonical Wnt signalling 
pathway (Spiegel et al., 2007). Overall, the role of neurotransmitters in the 
maintenance of stem cell features in HSCs have not been fully elucidated and the 
work presented in this Chapter was the first reported account of neurotransmitters 
in enhancing self-renewal of LSCs.   
It should also be noted that the regulation of haemopoiesis by neurotransmitters 
potentially involves a complex interconnected network of direct and indirect 
mechanisms as the neurotransmitter receptors are identified on both haemopoietic 
cells and stromal cells in the niche. For example, α1a-adrenergic receptors were 
found on the surface of BM stromal cells, while α2-adrenergic receptors were 
found on the surface of both MNCs and stromal cells (Pereira et al., 2003). 
Therefore, the presence of neurotransmitter receptors could be investigated on the 
surface of OP9 cells in the future.  
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6.7.3 ACH and NEPI activate the core G protein signalling 
pathway in LSCs 
The expression analysis of the genes in the heterotrimeric G protein signalling 
pathway upon neurotransmitter treatments revealed the activation of the G protein 
signalling pathway in response to ACH and NEPI, whereas 5HT treatment induced 
repression of the genes in this pathway. ACH and NEPI activated several PKA, 
PKC, and PLC genes, therefore, suggesting an activation mechanism via Gαs and 
Gαq subunits. α- and β- adrenergic receptors as well as muscarinic receptors 1 and 
3 mediate their function via Gαs and Gαq subunits (Table 6.1). There was also 
evidence for upregulation of α- and β- adrenergic receptors in NEPI treatment and 
muscarinic receptor 3 in ACH treatment, which could suggest a role for these 
receptors in the maintenance of LSCs. 5HT treatment, on the contrary, reduced 
the expression of PKA, PKC, and PLC genes, except PLCG2, which could be 
linked to the activation of Gαi/o subunits as a result of stimulation of 5HT1 and/or 
5HT5 receptors (Table 6.1). ACH, NEPI, and 5HT agonists induced the expression 
of p21/CDKN1A and ID1 genes that are important quiescence and self-renewal 
markers (Cheng et al., 2000, Perry et al., 2007). The gene expression analysis 
could, therefore, explain the observed CFSE and replating assays results in which 
ACH NEPI, and 5HT induced quiescence and self-renewal of LSCs.  
6.7.4 Further functional validation of neurotransmitter 
involvement in LSC maintenance  
The results presented in this Chapter were obtained in ex vivo experiments which 
only partially mimicked the bone marrow niche. However, further in vivo functional 
validation is required where the effect of physiologically secreted neurotransmitters 
could be reverted by the administration of antagonists to the above 
neurotransmitter pathways. Furthermore, the biological impact of 
neurotransmitters is mediated in a dose- and gradient-dependent manner which 
could oscillate in response to various stimuli such as stress, which could not be 
fully simulated in vitro (Kalinkovich et al., 2009). However, only NEPI was used at 
concentrations that were validated previously in the context of haemopoietic cells, 
whereas the other agonists were used at concentrations that showed a 
physiological response in other human tissues. Therefore, some of the observed 
effects could be a result of over- or under-exposure to the agonists which could be 
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overcome in the future by testing different concentrations and/or replenishing the 
agonists at different intervals.  
As mentioned earlier, various neurotransmitter receptors were also identified on 
the surface of stromal cells which could be stimulated upon treatment and result in 
the release of various factors that could indirectly regulate the stem cell features of 
LSCs. Therefore, to further understand the effect of stromal cells in the context of 
neurotransmitter stimulation, genome-wide gene expression changes of OP9 cells 
could be investigated in the presence and absence of agonists. Furthermore, in 
order to elucidate the genes and the biological pathways that become activated in 
response to the neurotransmitter stimulus, genome-wide gene expression analysis 
of the treated LSCs should be performed.  
Although the gene expression and epigenetics analyses identified neurotransmitter 
signalling via specific receptors, the functional validation was performed with the 
generic physiological ligand that could stimulate various receptors and potentially 
lead to the activation of different intracellular pathways. Nevertheless, after the 
initial round of functional validation by the generic agonists, more specific 
biochemical compounds could be used to trigger the specific receptors. A recent 
study investigated the role of neurotransmitter receptors in brain cancer stem cells 
by testing 1,267 chemical compounds that could specifically block or activate 
these receptors (Diamandis et al., 2007). This study demonstrated that dopamine 
and acetylcholine antagonists as well as an opioid agonist have profound impact 
on inducing apoptosis in brain cancer stem cells.     
In this Chapter, the effect of neurotransmitters on the major features of stem cell 
maintenance, such as quiescence, self-renewal, haemopoietic growth and 
proliferation were examined, whereas the other aspects of stem cell life cycle 
including motility, migration, and repopulation capacities upon engraftment were 
not evaluated. The migration potentials of LSCs upon neuropeptide treatments 
could be investigated by transwell migration assays (Aiuti et al., 1997) in which 
cells are placed in a small chambers above permeable membranes and the media 
containing the agonists are placed below the membranes. Subsequently the 
number of cells that pass through the membranes in an overnight incubation 
period are counted as a measure of induced motility. A recent study demonstrated 
that NEPI treatment can induce HSCs motility in response to both G-CSF and GM-
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CSF cytokines (Spiegel et al., 2007). Finally, the enhance self-renewal capacity 
and repopulation potential of LSCs upon treatment with neurotransmitters could be 
investigated in vivo by using NOD/scid mice. 
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7. Summary and Future work 
7.1 Summary  
Understanding the underlying mechanisms conferring a stem cell-like phenotype 
to LSCs is one of the major questions to be addressed in leukaemia biology in 
order to determine novel strategies required for more effective therapeutics that 
can eradicate the disease. The study of LSC biology is of significant importance in 
CML as the tumour initiating population is insensitive to the current TKIs due to the 
function of BCR-ABL1-independent mechanisms, which could involve epigenetic 
aberrations that give rise to a persistent leukaemic phenotype. Nevertheless, an 
enhanced understanding of CML biology will not be possible without unravelling 
the essential mechanisms involved in the maintenance of HSCs and their lineage 
commitment. Therefore, the aim of the work presented in this thesis was to obtain 
a global view of the epigenetic programming that is responsible for the gene 
expression signatures of LSCs and the expression changes required for the exit 
from the stem cell compartment. The analysis of genome-wide histone 
modification patterns required the development of a robust and reproducible ChIP-
seq method for profiling small primary stem cell populations.  
The work presented in this thesis showed the potential role of HSC identity 
pathways in regulating the stem cell features of LSCs, whose subsequent 
downregulation triggers the progression to the more proliferative states. These 
pathways are significantly enriched for bivalent/H3K27me3hi promoters which were 
found to be abnormally regulated at the epigenetic level in CML cells which could 
be due to the abnormal function of the chromatin modifying machinery. 
Nevertheless, the underlying mechanisms resulting in the misregulation of 
chromatin modifiers could not be established. These results provide a unique 
window of opportunity to epigenetically target LSCs and also to identify new 
targets in some of the newly identified neurotransmitter signalling pathways that 
enhanced the stem cell features of LSCs in vitro. 
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7.2 Future work 
7.2.1 Identifying the EZH1/2 and KDMs targets 
To better understand the mechanism of EZH2 suppression in normal and 
leukaemic cells as well as the role of EZH1-EZH2 imbalance in the context of 
LSCs, their gene promoter targets should be investigated in the four cell types to 
elucidate: (i) the genes and the pathways that are specifically targeted by EZH1 or 
EZH2 and whether there is an overlap between the targets, (ii) whether the loss of 
EZH1 in LSCs can be compensated by EZH2 and how the expression levels of 
EZH1 targets are affected, (iii) the genes that are targeted by EZH2 upon exit from 
the stem cell compartment in LPCs, (iv) the similarities and differences between 
EZH2 targets in LPCs and HPCs and whether EZH2 functions differently in the 
context of leukaemic cells compared to normal cells. It was previously reported in 
embryonic carcinoma cells that EZH1 and EZH2 share many targets in addition to 
their unique targets (Margueron et al., 2008). The analysis of EZH1/2 targets can 
be achieved by ChIP-seq, although the low-cell ChIP-seq assays for non-histone 
proteins that bind DNA less frequently require further improvements, such as 
antibody titrations and adjusting the fixation step. 
On the other hand, abnormalities in the levels of H3K4 demethylases were 
suggested to have an impact on the loss of repressive capacity of 
bivalent/H3K27me3hi promoters in LSCs (Chapter 5). Therefore, in order to further 
understand the role of H3K4 demethylases in abnormal regulation of 
bivalent/H3K27me3hi promoters in LSCs, the identification of their target genes is 
crucial. Therefore, their global enrichment patterns should be established in HPCs 
to identify their binding sites and to compare their profiles in LSCs and LPCs to 
understand the effect of their downregulation in the leukaemic cells. Furthermore, 
although KDM1A is linked to H3K4me1/2 marks (Mosammaparast and Shi, 2010) 
it was also found to be enriched at the bivalent promoters and its loss resulted in 
abnormalities in the H3K4me3 levels (Adamo et al., 2011). Therefore, its 
upregulation in LPCs could suggest a potential compensating mechanism in the 
event of KDM5A and KDM5B downregulation. In order to distinguish the potential 
links between KDM1A upregulation and KDM5A/5B downregulation, the global 
binding sites of KDM1A in LPCs and HPCs should be investigated to identify the 
overlaps with KDM5A and KDM5B targets, and to establish a preferential use for 
Chapter 7  277 
KDM1A in LPCs that may not be the case in their normal counterparts. ChIP-seq 
assays should be used for identification of the KDM targets, although the low-cell 
ChIP-seq assays require further improvements as mentioned above.  
Furthermore, in order to distinguish between EZH2-dependent and –independent 
H3K4 demethylation, the overlap between KDMs and EZH2 targets should be 
investigated from the ChIP-seq analyses. Co-immunoprecipitation assays should 
be used to determine a direct association between the H3K4 KDMs and EZH2-
PRC2 complex to confirm the EZH2-dependent route, in both normal and 
leukaemic cell types, as LSCs and LPCs could have adopted different 
mechanisms in KDMs recruitment. KDM5A was the only H3K4 KDM that is shown 
to be directly recruited by the EZH2-PRC2 complex in mES cells (Pasini et al., 
2008), which may or may not be the case in haemopoietic cells. 
7.2.2 The underlying events responsible for the deregulation of 
PRC2 complex 
The abnormalities in the levels of PRC2 complex members could be the result of 
BCR-ABL1-dependent or –independent factors, or a combination of both. The 
downregulation of EZH1 and upregulation of EZH2 could represent events 
preceding the 9;22 translocation in HSCs, or could be mediated by BCR-ABL1 
indirectly, as PRC2 members are regulated at the transcriptional level. In order to 
test the first hypothesis, one copy of the EZH1 gene should be conditionally 
knocked out in murine HSCs. If a CML-like phenotype was observed, deregulation 
of the PRC2 complex is independent of BCR-ABL1 and potentially precedes the 
9;22 translocation, otherwise the abnormalities are most likely driven by BCR-
ABL1 expression. Furthermore, the same model could be used to investigate 
expression levels of EZH2 and other PRC2 members, such as SUZ12, to elucidate 
whether the upregulation of EZH2 in LSCs is part of a feedback mechanism that is 
initiated upon downregulation of EZH1, or whether the two events are regulated 
independently. To test the BCR-ABL1-dependent mechanism, the expression 
levels of PRC2 complex members should be analysed upon BCR-ABL1 
knockdown by lentiviral shRNA transduction in LSCs. The downregulation of EZH2 
and/or upregulation of EZH1 would then indicate a BCR-ABL1-dependent 
mechanism.   
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The expression of PRC2 members, other than  EZH1, was shown to be 
upregulated in many cancers by the upregulation of E2F transcription factors 
(Bracken et al., 2003). E2F1 levels are reported to be significantly upregulated in 
CML cells (Mohty et al., 2007, Stewart et al., 1995) and therefore, the upregulation 
of EZH2 could be mediated by the increased levels of E2F1 in a BCR-ABL1-
dependent manner. This hypothesis could be further investigated by the lentiviral 
shRNA knockdown of E2F1 in CD34+ CML cells and by observing the effect on 
EZH2 and other PRC2 members. Nevertheless, murine models with E2F1, E2F2 
and E2F3 triple knockouts may represent better in vivo models due to partial 
redundancies amongst these proteins (Chong et al., 2009).  
Another recent study proposed a link between EZH2 upregulation in cancers and 
the downregulation of microRNA-101 (MIR101) (Varambally et al., 2008). To test 
whether the abnormal upregulation of EZH2 in CML is mediated by the same 
mechanism, the expression levels of MIR101 could be established in leukaemic 
cells relative to normal cells and in the case of a negative correlation with EZH2 
levels, the reintroduction of MIR101 into LSCs or LPCs may result in the 
downregulation of EZH2 and/or upregulation of EZH1. 
7.2.3 Targeting the EZH2-dependent LSCs 
A significant drop of EZH1 and an insufficient upregulation of EZH2 in LSCs 
indicated an imbalance between the two catalytic subunits in LSCs, which was 
suggested to be responsible for the abnormal epigenetic regulation of 
bivalent/H3K27me3hi promoters in these cells. Therefore, EZH2 is critically 
required in LSCs in order to maintain the levels of H3K27me3 in the absence of 
EZH1 at the promoters of bivalent/H3K27me3hi genes which were significantly 
associated with the HSC identity pathways. Conversely, EZH1 was shown to be 
the highly expressed catalytic subunit of PRC2 complex in HSCs as EZH2 was 
expressed at relatively low levels, which in turn provides a unique therapeutic 
window to block EZH2 in LSCs. 3-Deazaneplanocin A (DZNep) is an anti-EZH2 
agent that is currently under investigation as an anti-cancer therapeutic (Tan et al., 
2007). 
A recent study demonstrated interesting effects of DZNep on AML cells as it 
induced apoptosis in primary CD34+ cells, alone or in combination with an HDAC 
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inhibitor, Panobinostat, although the more primitive CD34+ CD38- population was 
insensitive to DZNep alone. However, the pro-apoptotic effect of DZNep was not 
observed with normal CD34+ cells (Fiskus et al., 2009). Although this study failed 
to demonstrate the expression levels of EZH2 in AML cells relative to normal, it 
suggested drug specificity towards AML versus normal progenitor cells, which was 
associated with a global decrease in the levels of EZH2 and H3K27me3 and an 
increase in the levels of CDKIs p16, p21, and p27. Therefore, treating CML LSCs 
or LPCs with DZNep could have four potential outcomes: (i) induced apoptosis in 
more proliferative cells as shown in AML (Fiskus et al., 2009); (ii) increased activity 
of the stem cell programme as EZH2 is required for the exit from a non-dividing 
state by suppressing the pluripotency factors as previously reported (Margueron et 
al., 2008, Shen et al., 2008); (iii) induced differentiation as recently reported in the 
case of AML where EZH2 overexpression was associated with suppression of 
differentiation mechanisms (Tanaka et al., 2012); or (iv) have no effect due to the 
redundancy between EZH1 and EZH2 and potential compensation by EZH1 upon 
EZH2 inhibition. However, the latter is less likely to happen since the EZH1 levels 
was observed to be at low levels in LSCs and the inhibition of EZH2 is unlikely to 
result in adequate compensation by EZH1. The effect of DZNep on LSCs can be 
examined in vitro by evaluating cell division progression, apoptosis, colony forming 
potentials, and self-renewal capacities upon replating in the presence and 
absence of drug, in parallel to studies on normal stem cell controls. Furthermore, 
the effect of DZNep treatment on the global epigenome changes could be 
monitored by ChIP-seq analysis of H3K4me3 and H3K27me3 marks in 
combination with genome-wide gene expression analysis. 
7.2.4 Using epigenetic biomarkers in diagnosis, prognosis, and 
therapeutic response of CML 
The identification of abnormalities in several members of PcG, TrxG, and KDM 
families of chromatin modifiers could be used as epigenetic biomarkers in CML 
diagnosis, prognosis and patient response to TKI therapy. The reported 
abnormalities were only based on the observations in three chronic phase patients 
using Affymetrix technology. In order to employ such biomarkers in the clinical 
context the expression of these genes should be analysed in more chronic phase 
patients upon diagnosis as well as in patients in advanced phases of the disease, 
such as blast crisis, using more sensitive RT-PCR-based approaches. Moreover, 
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changes in the expression levels of these chromatin modifiers could be evaluated 
during TKI therapy and after achieving remission to monitor the response to TKIs 
and potentially as markers of disease recurrence.  
The overall levels and the global enrichment patterns of H3K27me3 could also be 
used as epigenetic biomarkers, since CML cells showed significant changes in the 
levels of H3K27me3 at the promoters to alter transcriptional activity of controlled 
loci. The global levels of histone modifications have recently been reported as 
prognostic tools in several cancers (Seligson et al., 2009) and in particular the loss 
of H3K27me3 marks is associated with poor prognosis in pancreatic, breast, and 
ovarian cancers (Wei et al., 2008).  
7.2.5 Further validation of the role of neurotransmitters in LSCs 
maintenance  
The results presented in Chapter 6 confirmed the role of ACH, NEPI and 5HT in 
the maintenance of LSCs in the presence of stromal cells in vitro. Although the 
overall expression levels of these pathways were not significantly different 
between HSCs and LSCs, the expression levels of some of the receptors in these 
pathways could be significantly misregulated in LSCs, which can be identified from 
the Affymetrix analyses and further validation by RT-PCR-based methods. 
Moreover, the presence of these receptors at the cell surface of LSCs can be 
validated by flow cytometry using indirect immunofluorescence staining with 
primary antibodies against specific receptors followed by the secondary staining 
with rhodamine-conjugated antibodies (Kronenwett et al., 2005, Steidl et al., 
2004). By comparing the immunofluorescence levels of HSCs and LSCs, the 
receptors which are presented at higher levels on the cell surface of LSCs can be 
distinguished to design specific antagonists which block the in vivo activation of 
these receptors and potentially inhibit maintenance of stem cell features by 
neurotransmitter signalling pathways.      
The effects of these neurotransmitters are dose- and gradient-dependent that can 
only be regulated physiologically. Furthermore, the secretion of neurotransmitters 
in the niche can also indirectly control the stem cell features of LSCs by controlling 
the secretion of various cytokines and extracellular signals by the cells in the BM 
niche (Pereira et al., 2003). Therefore, the role of neurotransmitters in LSC 
maintenance can only be fully elucidated in vivo. The receptors that are uniquely 
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upregulated in LSCs could be knocked down by the lentiviral shRNA transduction 
system followed by engraftment of LSCs into NOD-scid mice to measure their 
effect on LSC survival, proliferation, and repopulation capacities in comparison to 
a control population. The receptors that show a significant change of phenotype 
upon knockdown could be used to develop antagonists which in turn provide new 
therapeutic approaches.  
7.3 Final thoughts  
The work presented in this thesis describes the chromatin landscape of cancer 
stem cells for the first time, which was only made possible by the development of a 
ChIP-seq method that can be applied to small primary cell populations. The 
observations contained here can open new therapeutic windows using epigenetic 
targets as well as the neurotransmitter signalling pathways, which are shown for 
the first time to be important in the context of leukaemia biology. The low-cell 
ChIP-seq method developed in this thesis can be used to study the distribution of 
other histone modifications to unravel other regulatory elements, such as 
enhancers and potentially transcription factor binding sites in LSCs. Finally, the 
outcomes of this thesis will contribute significantly towards developing new 
therapeutics that eliminate cancer stem cells and eventually improving the life 
expectancy of cancer sufferers. 
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Appendix 1 
List of the TaqMan probes used to design the TaqMan Micro Fluidic cards 
(Chapter 3) 
 
 * Catalogue of TaqMan gene expression assays available from Applied Biosystems website 
(http://bioinfo.appliedbiosystems.com/genome-database/gene-expression.html) 
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Appendix 2 
List of the TaqMan probes used for the Fluidigm analysis (Chapter 6) 
 
*Catalogue of TaqMan gene expression assays available from Applied Biosystems website 
(http://bioinfo.appliedbiosystems.com/genome-database/gene-expression.html) 
Appendix 3 
Sequences of primer pairs used for the mouse contamination screen 
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Appendix 4 
Sequences of primer pairs used in the qPCR validation of ChIP-seq datasets 
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†  H3K4me3  ChIP  negative  controls. 
‡  H3K27me3  ChIP  negative  controls. 
* H3K4me3/H3K27me3 ChIP negative controls. 
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Appendix 5 
 
A. Conventional H3K27me3 ChIP-chip bioreplicates 
B. Low-cell H3K27me3 ChIP-chip bioreplicates 
C. Conventional H3K4me3 ChIP-chip bioreplicates 
D. Low-cell H3K4me3 ChIP-chip bioreplicates 
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